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ABSTRACT 
This. thesis examines the role of respiratory bacterial and viral infection in the natural 
history of Chronic Obstructive Pulmonary Disease. The rationale for this study is 
based upon previous data demonstrating that airway bacterial colonisation is common 
in stable COPD and that bacterial and viral pathogens are commonly detected at 
exacerbations. 
The methods used have involved the careful characterisation and clinical follow up of 
a cohort of patients with moderate to severe COPD in the stable state and at 
exacerbation. Sampling of airway and systemic compartments enabled the detection 
of respiratory pathogens and quantification of inflammation. Comparisons between 
clinical indices and evidence of infection were performed to determine the 
relationships between bacterial and viral infections and disease outcomes including 
lung function decline and exacerbation severity. 
The findings confirmed that lower airway bacterial colonisation is common in stable 
COPD and is associated with airway inflammation. They demonstrated for the first 
time a relationship between the degree of bacterial carriage and the rate of disease 
progression. This study has also described novel evidence for persistence of 
respiratory syncytial virus in the lower airway and associations with inflammation and 
lung function decline and impaired anti-viral immune responses. The combined role 
of human rhinoviral and bacterial infection at exacerbation has been studied and 
factors influencing responses to exacerbation therapy determined with the importance 
of early initiation of treatment identified. 
The findings in this thesis indicate that both viral and bacterial pathogens may play an 
important role in the natural history of COPD and are therefore targets for potentially 
novel interventions. This work suggests that viral and bacterial infections and their 
interactions play an important role in modulating airway inflammation in stable 
disease and at exacerbation thus impacting on both disease progression and 
exacerbation severity. This work has provided a rationale for future investigation into 
the mechanisms underlying susceptibility to infection in this important disease. 
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INTRODUCTION 
CHAPTER I 
INTRODUCTION 
1.1 INTRODUCTION 
Chronic Obstructive Pulmonary Disease (COPD) occupies a unique position 
i1i the epidemiology of major diseases at the beginning of this century. It is the only 
common cause of death that is currently increasing in prevalence (Murray 1996, 
NVHO 1998). 
The World Health Organisation has ranked COPD as the twelfth most 
prevalent disease worldwide and the sixth most common cause of mortality. The 
NVHO predicts that by 2020 COPD will rise to be the fifth most prevalent disease and 
tile third most common cause of death. COPD is not only a major cause of mortality 
but causes extensive disability and is expected to become the fifth most important 
cause of disability adjusted life years (DALYS) by 2020 (WHO 1998). This trend has 
obvious major, current and future implications for both patients and healthcare 
providers alike. 
COPD is characterised by the development of airway inflammation in 
jresponse to long term inhalation of noxious gases, primarily tobacco smoke in 
susceptible individuals. This results in the development and progression of airways 
obstruction which can eventually lead to persistent symptoms, reduced functional 
status, susceptibility to exacerbations and to early mortality (WHO 1998, ATS 1995). 
18 
j[NTRODUCTION 
-Whilst cigarette smoking has been identified as the most important factor in the 
aetiology of COPD it remains uncertain why only a proportion of smokers go on to 
, develop the disease. 
The pathology of COPD is a combination of a number of processes, namely 
the development of chronic bronchitis, emphysema and small airways obstruction or 
-bronchiolitis. Chronic bronchitis is due to inflammation of the proximal airways 
(;;.. 4mm in diameter) leading to mucus gland hypertrophy and proliferation, mucus 
Ilyper-secretion and epithelial cell disruption, all of which contribute to an 
, crivironment where bacterial sterility of the airway, which is the normal finding 
in 
1, jealthy lungs cannot be maintained (Hogg 2005). 
Another key pathological entity in the syndrome which is termed COPD is 
Crophyserna. This term describes the destruction of lung tissue distal to the smallest 
t1ronchiole and was first described by Laennec in the early I 9th century following 
study of postmortem lungs. Emphysema itself is not a uniform condition and 
pathologically can be divided into centri-lobular, the commonest type in COPD 
characterised by dilatation of the bronchiole, and pan-lobular seen more often in 
olpha-l-antitrypsin deficiency. Emphysema can itself lead to airways obstruction due 
to the loss of lung elasticity contributing to narrowing and closure of small airways 
leading to gas trapping and hyperinflation (Strachan 1995). 
Recent pathological studies have highlighted that a key site of inflammation in 
t1le lungs of subjects with COPD is the small airway (Hogg 2004). Here 
concentrations of inflammatory cells have been described and it has been postulated 
tlIat this phenomenon is linked to the role of chronic airway infection. 
The mechanisms which determine whether an individual is susceptible to the 
C , 
ffects of tobacco smoke and the extent to which they develop bronchitis or 
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emphysema are not known. The underlying genetic susceptibility to the inflammatory 
effects of inhaled noxious substances is under study and is likely to prove complex 
and multi-factorial. To date, the role of genotype in COPD, outside the context of 
alpha- I -antitrypsin deficiency, remains poorly understood and furthermore knowledge 
of how prolonged exposure to environmental factors affects the epigenetics of 
individuals at the organ, cellular, DNA or RNA level remains similarly incomplete. 
Determining what drives the heterogeneity in phenotype between individuals with 
COPD, which may either be host specific and pre-determined or modulated by the 
presence of other environmental factors such as respiratory pathogens, is a vital 
process in understanding this disease, and a fundamental step in identifying new 
therapeutic targets in this highly complex and prevalent disease. 
1.2. HISTORICAI, PERSPECTIVE 
COPD is a modern, umbrella term for a disease state characterised by the 
presence of airflow obstruction due to either the conditions chronic bronchitis or 
emphysema or both (GOLD 1998, ATS 1995, NICE 2004). 
Chronic bronchitis has been recognised as a common disease since the early 
twentieth century. The prevalence of this condition predates the expansion of cigarette 
smoking in the general population in the UK. Indeed for many years chronic 
bronchitis was termed the 'English Disease' and the effects of ubiquitous cigarette 
smoking and environmental pollution seen in UK cities after the Second World War 
culminated in the excessive morbidity and mortality seen in the London smog of 1952 
(Davis 2002). This was a major spur to the epidemiological study of chronic 
bronchitis was being recognised as an important disease. 
20 
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Chronic Bronchitis was one of the first conditions to be defined for the 
purposes of epidemiological research, by the MRC in 1960, leading to the 
standardised diagnostic criteria of 'chronic productive cough for at least three months 
of the year for at least two years' (MRC 1965). The presence or absence of the 
symptom of exertional dyspnoea further characterised the diagnosis to either simple 
or obstructive bronchitis. It is only therefore in the last forty years that COPD has 
been defined, studied and also recognised as disease of major importance. 
1.3 EPIDEMIOLOGY AND RISK FACTORS 
1.3.1 DISEASE DEFINITIONS AND PHENOTYPES 
The recorded prevalence of any condition is dependent on the accepted 
definition of that disease. The prevalence of a condition such as COPD which covers 
a spectrum of clinical and pathological presentations rather than a discrete and easily 
classified disease entity (Figure 1.1) has been difficult to determine without 
Standardisation of the diagnosis. COPD has been defined using both clinical and 
spirometric criteria. 
Since the earliest consensus definition was made in the 1960's, there has been 
an evolution of the definition of COPD. More recent versions have included reference 
to both the characteristic obstructive lung function and to the progressive deterioration 
is lung function seen in this condition (GOLD 1998, ATS 1995, NICE 2004). 
In 1995 the European Respiratory Society (ERS) consensus statement defined 
COPD as 'a disorder characterized by reduced maximum expiratory flow and slow 
emptying of the lungs; features of which do not change markedly over several 
Vionths. Most of the airflow limitation is due to varying combinations of airways 
21 
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disease and emphysema; the relative contribution of the two processes is difficult to 
define in vivo. ' (Siafakas 1995). 
In comparison also in 1995, the American Thoracic society (ATS) published a 
comparable disease definition 'COPD is a disease state characterised by the presence 
of airflow obstruction due to chronic bronchitis or emphysema; the airflow 
obstruction is generally progressive, may be accompanied by airways hyperreactivity 
and may be partially reversible. ' (ATS 1995). This definition includes the term 
'chronic bronchitis' which has lead to some confusion. Reports of longitudinal studies 
have shown that mucus hypersecretion and progressive airflow deterioration whilst 
both related to smoking have distinct natural histories. Hypersecretion can occur in 
the absence of airflow limitation (Fletcher 1976, Vestbo 2002), whilst other work has 
demonstrated a link between chronic sputum production and subsequent decline in 
lung function (Vestbo 1996). Whether this association is only an epiphenomenon with 
sputum production and faster FEV, decline both independently associated with 
increased airway inflammation, or whether excess sputum production could have 
direct effects on lung function decline remains undetermined and is further discussed 
later in this introduction. 
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FIGURE 1.1 DIAGRAMMATic REPRESENTATION OF COMPONENTS OF COPD AND 
OBSTRUCTIVE AIRWAYS DISEASE. 
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1.3.2 IMPACT OF DISEASE DEFINITIONS ON THE PREVALENCE OF COPQ 
The criteria for the diagnosis of COPD had not been established 
internationally until recently. Various organisations had established their own 
spirometric diagnostic criteria for the disease. This point is important to the work 
discussed in this thesis, as not only will differences in definitions affect the recorded 
prevalence of the disease but also the interpretation of data from clinical studies that 
examine the role of infection or inflammation in disease pathogenesis. 
An Italian study illustrates the dependence of observed COPD prevalence 
upon the diagnostic criteria used. 1 727 Patients were assessed using the ERS and 
ATS criteria for COPD. See Table 1.1 (Viegi 2000). This illustrates that the 
prevalence of COPD within any population is dependent on the spirometric criteria 
used for diagnosis and underlines the importance a worldwide standardised diagnosis 
of COPD. 
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In 2000 the global initiative on obstructive lung disease (GOLD) consensus 
was formed. Its stated goals were to increase worldwide awareness of COPD and to 
work to decrease COPD related mortality and morbidity. The consensus definition of 
COPD was issued and is 'a disease state characterised by progressive development of 
airflow limitation that is not fully reversible. The airflow limitation is both 
progressive and associated with an abnormal inflammatory response to noxious 
particles or gases. '(GOLD 1998) 
'fABLE 1.1 IMPACT OF DIAGNOSTIC CRITERIA ON PREVALENCE OF AIRWAYS OBSTRUCTION IN A 
GENERAL POPULATION (Viegi 2000) 
CLINICAL ERS ATS 
AIRWAY OBSTRUCTION 28% 12.2% 57% 
MODERATE/SEVERE COPD 4.4% 3.6% 5.2% 
Diagnostic criteria; Clinical FEV, / FVC < 70% 
ERS FEV, / VC < 88% Predicted 
ATS FEV, / FVC < 75% 
The spirometric criteria for diagnosis were standardised; postbronchodilator 
fev, < 80% predicted, FEVI / FVC < 70% The GOLD consensus excludes reversible 
airflow limitation associated with bronchiectasis, cystic fibrosis, tuberculosis or 
asthma. The importance of the antecedence of smoking in COPD is not included in 
the definition above but many clinical investigators exclude neversmokers from their 
studies 
This international consensus definition has been updated by the ATS/ERS 
consensus published in 2004 (Celli 2004). Here the disease definition includes an 
optimistic opening statement and comments on the extra-pulmonary manifestations of 
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the disease; Thronic obstructive pulmonary disease (COPD) is a preventable and 
treatable disease state characterised by airflow limitation that is notfully reversible. 
The airflow limitation is usually progressive aml is associated with an abnormal 
inflanunatory response of the hings to noxious particles or gases, primarily caused by 
cigarette smoking. Although COPD affects the lungs, it also produces significant 
systemic consequences. ' In addition, this document rationalised the spirometric 
classification of disease severity including an at risk pre-disease category, and is 
comparable to previous GOLD staging criteria. See below: 
At Risk- FEVI >= 80% Predicted, FEVI/FVC >0.7 who smoke or who have 
exposure to pollutants, have cough sputum or dyspnoea. 
9 Mild COPD- FEVI >= 80% Predicted, FEVI/FVC < 0.7. 
e Moderate COPD- FEVI 50- 80% Predicted, FEV I /FVC < =0.7. 
* Severe COPD- FEVI 30-50% Predicted, FEVI/FVC <= 0.7. 
9 Very Severe COPD- FEVI <30% Predicted, FEVI/FVC < =0.7. 
However, use of the FEVI as the sole index of disease severity has been criticised 
and models which include measures of functional status and systemic manifestations 
of disease have been developed (Celli 2004). These are more useful as prognostic 
indicators than lung function alone and are likelY to become the framework for future 
consensus statements on estimating disease severity. 
1.3.3 STUDIES OF DISEASE PREVALENCE 
There are many ways of analysing the prevalence of a condition within a 
population. These include assessment of the clinical burden either in primary or 
secondary health care settings, crosssectional sampling studies, screening the "at risk" 
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population and correlating the prevalence of a major risk factor such as smoking to 
the likely disease prevalence. Each of these techniques can only approximate the true 
prevalence of a disease and has individual weaknesses and inaccuracies. However, it 
is apparent that in all studies COPD is of major importance and is increasing in 
prevalence in many countries (Anto 2001, Murray 1996, Feenstra 2001, Stang 2000). 
Despite the contribution of COPD to worldwide morbidity and mortality, 
there have been relatively few large population studies to assess the prevalence of the 
disease. Those that have been performed almost exclusively describe populations 
from industrialised countries and diagnostic definitions are often not standardised, 
making comparisons between studies problematical. 
NORTTI AMERICA 
The USA has collected more epidemiological data on COPD than most 
countries. The National Centre for Health Statistics published in its 1997 reported that 
Obstructive Lung Disease was responsible for more than 109 000 deaths in that year 
alone and estimated that 16 million US citizens have symptomatic COPD making it 
the fourth most common disease in the US at the time (NCHS 1998). 
A comparison between such national data and earlier, regional 
epidemiological studies gives an interesting insight into the changing prevalence of 
COPD over the last four decades. One such early prevalence study was performed in 
Berlin, New Hampshire and published in 1962 (Ferris 1962). This found the overall 
prevalence of 'Chronic non specific respiratory diseases' to be between 15.4 and 
39.1% in men dependent on location and between 15.2 and 20.9% in women. The 
large spread in the male population was felt to be due to the prevalent occupational 
risk factors in different locations. The prevalence of irreversible airways obstruction 
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60% predicted), representative of COPD ranged from 3.1 to 21.7% in men and 6.2 
to 13.9% in women. Other studies were less influenced by pollution or occupational 
risk factors; in Tecumseh, Michigan in a study of 9000 men and women, 14% of adult 
men and 8% of adult women had chronic bronchitis, COPD or both (Higgins 1984). 
A study from a population at altitude, Glenwood Springs, Colorado published in 1971 
found that 17% of men had symptoms of dyspnoea, cough, expectoration or wheeze 
and 13% had COPD with an FEVI/ FVC ratio less than 60%. In women, the 
prevalence of chronic bronchitis (10%) and COPD (4%) was lower, reflecting the 
gender differences in smoking behaviour (Mueller 197 1). 
The third National Health and Nutrition Examination Survey (NHANES III) 
is a large, national, US study including 20 050 adults which ran from 1988-1994 and 
included data on lung function, previous respiratory diagnoses and responses to a 
comprehensive questionnaire on respiratory symptoms. Data on 16 084 patients was 
analysed and characterised by gender and race. An umbrella diagnosis of Obstructive 
lung disease (OLD) (chronic bronchitis emphysema or asthma) was used and defined 
accor ing to spirometric criteria of an FEVI/FVC ratio less than 70% and an FEV, of 
less than 80% predicted (low lung function) (NHANES 1998, Petty 2000 ). 
The overall prevalence of low lung function was 6.8% and 10% in the 
population over 45 years. Overall, 8.5% reported some degree of obstructive lung 
disease, when analysed for smoking behaviour the rate was 12.5% of current smokers, 
9.4% of former smokers, 6.1% of pipe or cigar smokers and 5.8% of never smokers. 
The prevalence of OLD increased with increasing age and was higher in whites than 
blacks. There was considerable overlap between asthma and COPD with a number of 
patients reported both conditions, this group having lower lung function and more 
respiratory symptoms. 
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The study's authors report the most interesting finding as the marked under- 
diagnosis of OLD in the study population; 63.3% of the subjects with documented 
low lung function had no prior or current diagnosis of OLD. This was most marked in 
those with mild to moderate disease. 
These studies suggest that COPD is highly prevalent in the US and 
furthermore diagnosed cases may represent only a small proportion of those who have 
early to moderate disease (Mannino 2000, Petty 2000). Numerous authors have 
concluded that spirometric screening of the at risk population i. e. smokers may 
identify the true disease prevalence and allow early intervention and appropriate 
resource allocation and may also help to identify which factors may predispose 
smokers to the development of the disease. 
EUROPE 
Since 1995 when the European Respiratory Society published its consensus 
statement on COPD (Siafakas 1995) there has been renewed drive to improve 
awareness of COPD in Europe and improve the problem of underdiagnosis which is 
apparent on both sides of the Atlantic (Rennard 2002). 
To this end the IBERPOC Project (Estudio Epiderniologico de le EPOC en 
Espana) was carried out in 1997.4 035 randomly selected 40 to 69 year olds in Spain. 
The prevalence of smoking was 26% current and 24% ex smokers, whilst the 
prevalence of COPD defined by the ERS spirometric criteria was 9.1 % overall, 15.8% 
in males and 5.5% in Females (Sobradillo 1999). 
The majority of COPD cases were in the older age group, approximately half 
being between 60 and 69 years old. Again the proportion of patients with a positive 
spirometric diagnosis during the study who had previously been identified with 
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COPD was very low at 2.3%. The failure to diagnose COPD was not because patients 
were experiencing few symptoms. There was a high prevalence of reported cough 
(13.5%), sputum expectoration (10.7%), exertional dyspnoea (10.4%) and wheezing 
(40.2%) in this population. 
A high prevalence of respiratory symptoms in mild or 'pre-clinical' COPD 
was demonstrated by the findings of the European Respiratory Society study on 
COPD (EUROSCOP) (Yernault 1992). The study was a three year placebo controlled 
double blind trial to investigate the effect of inhaled corticosteroids on lung function 
decline. The 1 277 patients, all smokers, (mean age 52,74% men) were mainly 
recruited by media advertising rather than from a clinic population. The mean FEVI 
was 77% predicted with an obstructive ratio of 62% and very little reversibility to 
inhaled beta-agonists. More than 75% of patients with pre-clinical COPD reported 
respiratory symptoms. These data and current studies suggest that whilst there are 
some differences in COPD prevalence between European countries, the overall 
prevalence is high, and chronic symptoms and significant airflow obstruction are 
common findings at diagnosis. 
The history of COPD in the UK is different from many other industrialised 
nations. The prevalence of COPD has been very high in the UK throughout the last 
century and has actually declined over recent years. Historically the prevalence of 
smoking in the UK was much higher much earlier than elsewhere in Europe or the US 
(Pride 2002). The UK cohort of patients who had the highest smoking prevalence this 
century were those men bom in 1900-1910 and those women born 1920-1930. The 
survivors of this female group contribute to the current increase in COPD mortality 
seen in the female population whilst the majority of the male cohort would have 
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contributed to the peak prevalence of COPD seen some decades ago (Pride 2002, Doll 
2004). 
The only major UK study assessing lung function across a broad age range is 
the Health and Lifestyle Survey (Cox 1987). This study commenced in 1987 and 
assessed the lung function of 2484 men and 3063 women using turbine spirometry 
performed at the subject's home The subjects were a representative population 
sample and were aged 18-65 years. 10% of men and 11% of women overall 
demonstrated an FEV, two or more standard deviations below the predicted value for 
their age and height. The proportion with poor lung function increased with age 
particularly in smokers. The prevalence of COPD in these studies was high, and was 
related to tobacco usage and age demographics. However, a key feature was that 
social class, even when differences in tobacco usage are adjusted for, is an 
independent predictor of disease prevalence. This finding may suggest that 
environmental causes other than smoking are important in the development of COPD. 
THE REST OF THE WORLD 
The Global Burden of Disease Study conducted by the WHO and the World 
Bank estimated the worldwide prevalence of COPD to be 9.34/1,000 in men and 
7.33/1,000 in women in 1990 and this data is discussed in the GOLD consensus 
document (Murray 1996, WHO 2000). This document reminds us that such overall 
prevalence data considers all age groups and under estimates the true prevalence in 
older adults. Outside the developed world there is little data on COPD prevalence, 
however, the higher the per capita tobacco consumption the higher the prevalence of 
COPD. 
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Whilst there is evidence to suggest that the tobacco markets in the USA and 
Europe may have matured with consumption levels no longer rising, this is not the 
case in Third world economies where low levels of tobacco use is rapidly increasing. 
China, in particular, as an emerging economy already has a very high prevalence of 
smoking amongst males. Physician diagnosed COPD rates are high with 7.2% in men 
and 4.7% in women (Liu 1998, Xu 2005). These levels underestimate the true disease 
prevalence and even with a major smoking cessation initiative the future burden of 
COPD in this country alone will be enormous. 
There are differences in COPD prevalence and in related death rates between 
countries that may not be explained simply by the differences in tobacco 
consumption. There have been many theories to further explain these differences 
including genetics, pollution, climate, tobacco type and the frequency and nature of 
respiratory infections. However, mortality figures are dependent on local certification 
practices and awareness of particular conditions. The GOLD consensus aims to 
combat such difficulties in international comparisons, thus enabling improved 
epidemiological study which may uncover important genetic or geographic 
pre isposing factors more prevalent in certain populations. 
1.3.4 COPD ASSOCIATED MORTALITY, MORBIDITY AND HEALTH CARE COSTS 
Mortality data is almost universally collected in developed countries however 
the reliability of the diagnosis on death certificates is at best variable and often 
incomplete. Furthermore, the interpretation of this data and its relationship to COPD 
is difficult. The analysis of the certified cause of death alone does not allow for other 
clinically important conditions which have contributed to but are not the primary 
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cause of mortality. This is especially true when considering a chronic and disabling 
condition such as COPD. 
The ICD9 classification system which is intemationally recognised does not 
have a specific code for COPD. ICD9 codes 490-496 (unspecified bronchitis 490, 
chronic bronchitis 491, emphysema 492, asthma 493 etc. ) cover airways obstruction 
and have been analysed as a means of assessing mortality related to COPD. 
A review comparing ICD 9 coded mortality data for different countries found 
death rates from codes 490 - 496 to be highest in the UK, Australia, and Eastern 
Europe and lowest in Southern Europe, Scandinavia and Japan. Published figures for 
the UK 1992 reveal 6.4% of male deaths and 3.9% of female deaths to be certified as 
due to these coded diseases (NHSE 1996). 
When all contributing causes of death are considered the number of cases 
with chronic respiratory disease involvement is high. Analysis of multiple cause 
mortality from US national figures indicates that 8.2% of deaths had a coding for 
obstructive lung disease however less than half (43%) of these cases had COPD as the 
registered cause of death (NHLBI 1998). Mortality from COPD is underestimated, but 
even when considering current figures it is ranked as the sixth most important 
worldwide cause of death as is predicted by the WHO to rank third within twenty 
years (Feenstra 200 1, Murray 1996). 
Due to the chronic and progressive nature of COPD, it is an important cause of 
long term symptoms. In more severe disease these can limit functional capacity, 
impair health related quality of life and incur considerable health care costs. The costs 
of COPD care have been estimated in a number of countries and have been estimated 
to total $1.9 billion per year (Pauwels 2004). However the additional costs due to 
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disability, lost working days (up to 24 million dollars per year) and reduced 
productivity were estimated to be an additional $3 billion. 
The majority of COPD related costs are incurred by patients with more severe 
disease with a significant proportion of outpatient costs incurred by the provision of 
long-term oxygen therapy in the community (Guest 1999) and a similarly significant 
proportion of inpatient expenditure incurred in treating patients with severe 
exacerbations (Oostenbrink 2004). Therefore identification of factors which may 
modify progression to severe disease and the incidence and severity of exacerbations 
may have a major impact on the health care resources required by patients with 
COPD. 
All studies of COPD related costs are likely to underestimate the true 
economic impact of the disease, as patient care by family members of patients with 
chronic and severe disease is not usually included but is often significant, particularly 
in countries with less developed health care services. 
1.3.5 RiSK FACTORS FOR TIIE DEVELOPMENT OF COPD 
SMOKING PREVALENCE; THE RELATIONSHIP TO COPD PREVALENCE 
Consideration of the epidemiology of COPD illustrates the difficulties of 
direct and accurate estimation of the disease prevalence due to problems inherent in 
detecting the disease in its early stages. This is particularly true in non-industrialised 
countries where access to spirometry is limited, symptoms due to other respiratory 
disease are common and health resource utilisation data underestimates true 
prevalence. 
As cigarette smoking has been identified as the most important determinant of 
the pathogenesis of COPD, with age of starting smoking, and pack year history 
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predictive of COPD mortality. Therefore a model using smoking prevalence to 
estimate that of COPD would be a useful epidemiological tool. It is commonly quoted 
that 10 to 15% of smokers go on to develop COPD. This figure is taken from cross 
sectional US national data and Fletcher and Peto's seminal longitudinal work which is 
discussed later in this chapter (Fletcher 1976). However, a smoking model using up to 
date diagnostic criteria and validated against US prevalence data (NHANES III) was 
published by Stang et al. This study postulates that in current smokers 40 years old the 
true prevalence of COPD is 17% rising to 43% at age 75 upwards, with a higher 
prevalence in females for any given age (Stang 2000). If these figures are correct, 
these data confirm that the number of people diagnosed with COPD is only a small 
proportion of the actual number of people who have the disease. Furthermore any 
prevalence data must be qualified by the age of the population it describes. 
If the links to cigarette smoking and the development of COPD are 
incontrovertible the effects of smoking cessation on the course of the disease are less 
well described. However a longitudinal key study with a5 year follow up of over 
5000 patients 'The Lung Health Study', has described the benefits of smoking 
cessation in slowing disease progression, with sustained smoking cessation achieving 
the largest benefit (Anthonisen 1994). The effects of a reduction rather than a 
cessation in smoking are less marked with some benefits on lung function but little 
effects on symptoms seen in patients who reduce but do not stop daily tobacco use 
(Simmons 2005). This may suggest that once airway obstruction develops smoking 
cessation may not entirely limit disease progression, therefore factors which 
contribute to worsening lung function after cessation may be important. 
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GENETICS AND EPIGENEnCS 
The most conclusive proof that genetic factors play a role in the aetiology of 
smoking related airways obstruction comes from the model of alpha- I-antitrypsin 
(AIAT) deficiency. This autosomal recessive condition, first described in 1963 
(Eriksson 1963), is characterised by the development of early onset and rapidly 
progressive panacinar emphysema. MAT is a serpine protease inhibitor and its key 
role is to inhibit neutrophil elastase. The Z variant, most frequently associated with 
lung disease, results in normal mRNA and synthesis of antitrypsin, but only 15% is 
released into the circulation. The deficiency occurs because about 85% of synthesized 
AAT is blocked in the terminal secretory pathway of the hepatocyte (Lomas 2005, 
ATS 2003). 
The observed differences in the development of airway obstruction between 
individuals who develop COPD and have normal AAT levels suggests that 
differences in the extent of cigarette smoking account for onlY 15% of the observed 
variability in the development of airways disease in smokers (Bascom 1991). The role 
of genetic factors in the pathogenesis of COPD have also been suggested by 
association studies, with first degree relatives of patients with early onset COPD 
patients displaying a higher risk of developing COPD than controls matched for 
smoking behaviour (Silverman 1998). However, identification of polymorphisms 
associated with susceptibility for COPD has proved to be an elusive goal with 
inconsistent findings from one study to the next. Polymorphisms in matrix 
metalloproteinase genes may play a role in the pathogenesis of COPD. MMP I and 
MMP12 genes, but not MMP9, have been suggested to be related to smoking-related 
lung injury (Silverman 1998, McCloskey 2001, Sandford 2002). Whilst an association 
between an MMP9 (Minernatsu 200 1), IL- II (Klein 2004), TGF-beta I (Wu 2004), 
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polymorphisms and the development of COPD have been identified. However 
findings are rarely reproduced in different populations and further study is required. It 
is likely that multiple genes may be involved in determining susceptibility to the 
disease and that different gene expression patterns may explain the observed 
heterogeneity of clinical and pathological phenotypes. 
Epigenetics is the study of reversible changes in gene function or other 
controls of cell phenotype that occur without a change in DNA sequence. These non- 
coding changes occur in response to environmental factors, and may play a vital role 
in the development of diseases such as COPD. Whilst the long term effects of 
cigarette smoking have been described in terms of pathological and inflammatory 
changes, the way in which such exposure could lead to non-sequence modification of 
DNA and RNA expression and translation requires investigation. There is to date, 
some evidence that tobacco smoke exposure can lead to telomere shortening in a dose 
related fashion, suggesting important effects on nucleic acid conformation which may 
confer downstream effects on gene expression and hence phenotype or inflammatory 
profile (Morla 2006). A possible molecular mechanism by which cigarette smoke 
drives pro-inflammatory gene transcription and an inflammatory response in the lungs 
has been postulated following work in rats. Here, histone acetylation and de- 
acetylation, key steps in the regulation of the specificity and duration of gene 
transcription, were shown to be disrupted by smoke, resulting in excessive 
transcription of specific pro-inflammatory genes in the lungs (Marwick 2004). Further 
studies into the mechanisms underlying modification of gene expression and post- 
translational modification of protein products are required, especially with the advent 
of technologies which may provide new therapeutic opportunities to alter post 
translational genomic expression (Fire 1998). 
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ENVIRONMENTAL POLLUTION AND OCCUPATIONAL ExpoSURE 
Inhalation of particulate matter from environmental or occupational sources 
has been implicated as a risk factor for the development of COPD. Exposure to 
biomass smoke particularly in women has been identified with this disease in a 
number of population studies performed in different populations largely in non- 
developed countries (Amoli 1998, Pandey 1984, Perez-Padilla 1996, Smith 2000). 
Similarly exposure to occupational pollution is a risk factor for the development of 
airways obstruction and the effects are compounded by tobacco smoking (Kauffman 
1979). 
However, the contribution of outdoor pollution as an aetiological factor 
remains uncertain. Some studies have demonstrated a link (Tashkin 1994) however 
the effects are likely to be relatively inconsequential in comparison to inhalation of 
tobacco smoke. 
AIRWAY INFECTION 
The role of airway infection in the natural history of COPD is the key area of 
investigation for the studies described in this thesis and a discussion of the many 
studies into this is presented later in this introduction. The role that lung infections in 
early life may play in the later development of COPD is less well described. There is 
however, considerable epidemiological evidence that socioeconomic status is a risk 
factor for COPD. This link is likely to be multi-factorial and includes prenatal 
exposures, housing conditions, air pollution, environmental tobacco smoke, diet, in 
addition to possible infective factors such as frequent lower respiratory tract illnesses 
in childhood which associate with lower social class (Prescott 1999). There have been 
a number of studies which have found a relationship with lower respiratory tract 
infections in childhood and the development of subsequent COPD (Shaheen 1994, 
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Shaheen 1995). Whether these relationships reflect causality or an epiphenomenon 
due to the effects of low birth lung function, maternal smoking, respiratory tract 
infections and the development of subsequent wheeze or retardation of lung growth is 
uncertain. It is interesting to speculate on the possible mechanisms of these 
associations however evidence does exist that inflammatory episodes due to infections 
in early life predict the development of subsequent disease (Finch 2004). Whether this 
is due to long-term modulation of immune responses or even to persistence of 
infective pathogens remains uncertain. 
1.4 THE NATURAL HISTORY OF COPD 
1.4.1 LUNc; FUNCTION DECLINE 
Any clinician who has cared for patients with COPD will be aware of the 
progressive nature of the disease, and the majority of consensus definitions of COPD 
now allude to the progressive nature of lung function decline seen in the 
condition. The majority of patients are diagnosed in the fourth or fifth decade of life 
and are symptomatic at the time of diagnosis. In normal subjects lung function is 
maximal between 25 and 30 years of age with a gradual decline from then on with 
age. 
A landmark study published in the BMJ in 1976 by Fletcher and Peto was the 
first to describe the natural history of this decline in a suitably large population (792 
'healthy' males aged 30 to 59) based on 8 years of follow up. The well recognised 
curve is illustrated below (Fletcher 1976). 
The annual decline of FEV, in non-smokers was 25 ml and in smokers 50 ml 
per year. A subset population which exhibited an accelerated decline of 100ml per 
year developed significant symptomatic airways obstruction during the study. The 
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curve also demonstrates the possible effect of smoking cessation on the observed 
accelerated decline in lung function, suggesting a return to the rate of decline back to 
normal. This represents important evidence as to the benefits of smoking cessation at 
any stage of COPD. However, despite being recognised as an important study, the 
published curve relies largely on extrapolation at its extremes. 
FIGURE 1.2 THE FLETCHER-PETO CURVE OF HYPOTHETICAL DECLINE IN FEVI THE 
NATURAL HISTORY OF CHRONic BRONCHITIS AND EmPHYSEMA. 
Adapted from Oxford University Press 1976. 
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This is particularly important as the subjects' age and the deterioration in lung 
function becomes more marked. This section of the curve relies upon mathematical 
extension of the acquired data; the majority of patients were less than 60 on 
completion of the study and did not yet have severe airways obstruction. An accurate 
model of the changes in lung function at this clinically significant later phase of 
COPD is not yet available. 
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The annual rate of decline varies greatly between studies from as low as 7ml 
per year in the Six Cities Study (Xu 1992) to 91 mVyr in smokers in the Tucson 
population study (Lebowitz 1989). Some of these differences will be due to statistical 
noise created by simple variation in spirometry readings. The shorter the follow up 
period, the more likely this may mask any true effects as the 95% confidence interval 
for FEV, decline in an individual is 190ml, which is several years decline even in a 
population of smokers (Tweedale 1984). Hence, with annual spirometric readings, 
which has been the norm in larger studies, a follow-up period of at least 4 years is 
recommended (Pride 1995). 
It is believed that only certain individuals are susceptible to cigarette smoking 
and several years of accelerated lung function decline result in the spirometric 
impairment seen when COPD is diagnosed. If it is assumed that individual subjects 
tend to maintain their percentile ranking over time then an individual with an initially 
low FEV, will remain in the lower percentiles as his lung function declines a 
phenomenon known as tracking. 
An alternative theory is that lung function does not deteriorate significantly 
until damage to the airways has become very widespread. Thus due to the large 
functional reserve of the lungs, susceptible smokers might only develop an 
accelerated decline in FEV, after years of airway inflammation. Therefore until 
middle age, one would expect even susceptible subjects to exhibit normal annual 
changes in lung function. Techniques to assess changes in small airways more 
sensitively than spirometry are necessary to assess such early damage. 
Single breath nitrogen testing is such a technique. Indeed, ten year follow up 
data using this technique revealed that almost all patients who develop airways 
obstruction had abnormal nitrogen breath testing when there FEV, was still normal. 
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However the negative predictive value of this test was poor and as a technique it is 
less suitable for large population studies than spirometry (Buist 1988). Newer 
techniques such as high resolution CT scanning have yet to be evaluated in terms of 
longitudinal studies. 
1.4.2 'THE BRmsu HYPOTHESIS' 
In the 1950's and 1960's British respiratory researchers hypothesised that 
recurrent respiratory infections were the differentiating factor between those smokers 
who developed airways obstruction and those who did not, with the development of 
chronic bronchitis and hence innate immune defences a key stage in the process. The 
study by Fletcher and Peto (Fletcher 1976), found that chronic bronchitis (cough and 
sputum production, and episodes of acute bronchitis) as defined by the MRC (MRC 
1965), was not associated with the development of airways obstruction in a 
population of British workmen. They concluded that bronchitic symptoms were not 
related to disease progression in this patient group and these conclusions led to a 
change in emphasis for the role airway infection in the pathogenesis of COPD. 
The finding that uncomplicated chronic bronchitis does not predict 
development of subsequent COPD has been confirmed in a further study (Vestbo 
2002), however, an analysis involving patients with established airways disease has 
demonstrated that smokers with chronic bronchitis do develop airways obstruction 
more rapidly than those without these symptoms (Vestbo 1996). It is likely therefore 
that the role of mucus hypersecretion and its clinical correlate of chronic bronchitis in 
the development of airflow obstruction may vary depending on disease stage and 
potentially therefore on the prevalence of other factors which may upregulate the 
inflammatory response such as bacterial colonisation. 
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1.4.3 EXACERBAIIONS AND DiSEASE PROGRESSION 
Exacerbations of COPD can be defin'ed as 'an event in the natural course 
of the disease characterised by a change in the patients baseline dyspnoea, cough 
and/or sputum beyond day-to-day variability sufficient to warrant a change in 
management. ' (Celli 2004). These events have important consequences for patients 
and health care professionals alike, the key features of the aetiology and 
pathophysiology of these events are discussed later in this introductory chapter, 
however the evidence that exacerbations contribute to disease progression in COPD 4-1 
will be considered in this section. 
Analysis of data from the Lung Health Study (Kanner 2001) revealed that 
exacerbations were associated with an increased rate of decline in FEV, in current but 
not in ex-smokers. Data from our own group has confirmed that patients with more 
frequent exacerbations did have a decline their FEVI at a faster rate, irrespective of 
smoking status (Donaldson 2002). The key difference between these two studies was 
the severity of disease, witb a mean FEVI percent predicted of 78% in the LHS and 
38% in the East London Study. Airway inflarnmation, which is a key process in the 
development of progressive airflow limitation is greater in patients with more severe 
disease (O'Donnell 2004) and in smokers (Tanino 2002). Exacerbations are 
associated with increased levels of markers associated with (Bhowmik 2000) airway 
inflammation and this is the likely mechanism by which they accelerate FEV, decline. 
It is interesting to postulate that higher numbers of airway inflammatory cells in stable 
smoking and severe COPD patients potentiate a greater rise in inflammation at 
exacerbation with consequences for disease progression in these groups. 
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1.5 LOWER AIRWAY INFLAMMATION 
There is great heterogeneity in the pathology of COPD from one individual to 
the next with differing contributions from the key processes of chronic bronchitis, 
small airways disease and emphysema to the pattern of disease in a particular 
individual. What is common to all subjects with COPD however is the finding of 
pulmonary inflammation which has been demonstrated using biopsy, sputum, lavage 
and post mortern tissue studies (Maestrelli 1995, Thompson 1989, Hunninghake 1983, 
Hogg 2004, O'Donnell 2004). A number of pathological studies have described 
inflammatory profile associated with the development of airway obstruction -in 
COPD. However, the factors which determine the degree of the inflammatory 
response to inhaled noxious gases are not understood. 
Tobacco smoke inhalation affects ciliary function (Verra 1995) and may 
therefore impair mucous clearance from the airway, reducing the ability of the 
mucociliary escalator to remove particulates from the airway. Smoke inhalation also 
reduces the efficacy of the protective respiratory epithelial cell layer which may 
augment the overall acute inflammatory response due to facilitating the persistence of 
pat ogens in the lower airway (Qvarfordt 2000). 
Neutrophils, airway macrophages and mast cells are the key innate immune 
response cells which are involved in the initial phase of the immuno-inflammatory 
cascade. A number of studies have demonstrated increased numbers of neutrophils in 
the airways of patients with COPD compared to smokers who do not develop airway 
obstruction (O'Shaughnessy 1997, Baraldo 2004). Furthermore, experimental work 
has shown that a key product of activated neutrophils, neutrophil elastase can induce 
key pathological features representative of those seen in the COPD lung, including 
mucus hypersecretion, goblet cell metaplasia and the development of emphysema 
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(Sommerhoff 1990, Amitani 1991, Smallman 1984, Snider 1985, Hill 2000). Indeed 
work with animal models of smoke induced emphysema have demonstrated that 
alpha- I -anti-trypsin ameliorates the severity of changes suggesting not only a key role 
for neutrophil elastase in this process but also the importance of protease- antiprotease 
imbalance in the pathogenesis of COPD (Churg 2003). 
Another key cell in the innate defences of the lung is the macrophage, these 
are the most numerous cells present in the airway when sampled using bronchial or 
broncho-alveolar lavage. Macrophages are the key phagocytic cell and it is this 
process which is fundamental in orchestrating the innate immune response. 
Furthermore macrophage derived matrix-metalloproteases (MMPs) are important in 
the protease mediated epithelial and alveolar cell damage which contributes to the 
development of airways obstruction. Evidence for the importance of MMPs in the 
development of emphysema is available from in vitro studies. Mice without MMP12 
are not susceptible to the development of emphysema following cigarette smoke 
exposure (Hautamaki 1997). However it is likely that contributions from both 
macrophage and neutrophil are fundamental in the pathology of the disease; both 
NIMPs and neutrophils being required for matrix breakdown in models of emphysema 
via a TNF alpha mediated pathway (Hogg 2004, Dhami 2000, Finkelstein 1995). 
The role of eosinophils and their precursor; mast cells in the pathobiology of 
COPD is less certain. The evidence that eosinophils or ECP are elevated in COPD 
(Fujimoto 1999, Linden 1993, Lams 1998) or not (Di Stefano 1998, O'Shaughnessy 
1997, Lacoste 1993, Saetta 1999) depends or which part of the conflicting evidence 
base one reads. A study with more sophisticated approach than merely counting cell 
numbers has suggested that whilst eosinophil numbers may be higher in COPD the 
de ree of eosinophilic activation was no greater than that of normal controls (Rutgers 90 
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2000). An important clinical correlant of eosinophilc involvement in the pathology of 
COPD would be a link to steroid responsiveness. Generally, COPD is considered a 
Gsteroid resistant disease' when compared to asthma, a largely eosinophil mediated 
and steroid responsive disease. Indeed study subjects with greater eosinophil numbers 
have been shown to be more responsive to steroids (Fujimoto 1999, Chanez 1997, 
Pizzichini 1998) but whether this patient group represents a population with co- 
existent asthma or truly a subset of COPD remains uncertain. Similar controversy as 
to the role of mast cells exists and clearly further clinical and mechanistic studies are 
required in this area. 
Presentation of antigen allows activation of the adaptive immune response 
which itself is both apparent and abnormal in the COPD lung. Adaptive immune cells 
in regional pulmonary lymph nodes and in bronchial associated lung tissue (BALT) 
are activated by circulating antigen presenting cells and/or directly from the 
epithelium. An increase in T cells particularly CD8+ cells has been a finding in many 
(O'Shaugnessy 1997, Saetta 1999, Majo 2001, Hogg 2004) but not all studies of 
COPD airways, with higher numbers of CD4 + cells a less frequent finding. The exact 
role of CD8+ lymphocytes in the pathology of COPD is uncertain. They are an 
important component of the anti-viral immune response and can kill virally-infected 
ce s irectly by cytolysis or by the induction of apoptosis via the release of granzyme 
into the target cell (Abbas 2000). The presence of large numbers of CD8+ T cells in 
the airway of COPD patients has been linked to the possibility of a role for airway 
viral infection in the actiology of airway inflammation and obstruction. This is 
discussed further below. 
B lymphocytes may play an established role in maintaining airway immunity 
both through the production of mucosal IgA and through circulating Ig M and Ig G, 
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all of which can neutralise and opsonise microbial epitopes aiding phagocytosis by the 
innate immune system. Hogg's publication on small airway inflammation which 
showed greater numbers of not only T cells but also B cells in airways of patients with 
more severe disease suggests a role for this arm of the adaptive immune system in 
disease progression (Hogg 2004). 
The key site for development of airflow limitation are the small airways (Hogg 
2004) and it is here that airway inflammatory cells concentrate. At this site there has 
been shown to be a relationship between the number of cells in the lumen and the 
severity of COPD, in terms of airway obstruction (Hogg 2004, Yanai 1992). Indeed it 
has been postulated that mucus secretion and plugging of these small airways results 
is an important factor in the development of airways obstruction. 
A different and probably complementary mechanism in the development of 
airway obstruction is airway wall remodelling. Pathological studies have shown 
connective tissue deposition in the adventitia in severe disease (Matsuba 1989). This 
process of the small airways is seen in combination with local accumulation of BALT 
in more severe disease suggesting a role for infection in the development of this 
component of COPD (Hogg 2004). 
KEY INFLAMMATORY MARKERs ASSAYED IN THIS STUDY 
The cellular inflammatory response seen in the lungs of COPD patients is 
orchestrated by the production on an array of signalling peptides and proteins termed 
cyto ines an chemokines. The array of possible profiles is immense and this project 
which aims to determine the effects of airway infection in COPD has chosen a limited 
range of soluble mediators which when quantified reflect rather the overall degree of 
airway inflammation which may then be related to clinical and infective parameters. 
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IL-6 
IL-6 is a 26-kiloDalton cytokine with pleiotropic activity in a range of 
I 
systems. It is produced by a wide array of cells including lymphocytes, epithelial cells 
and macrophages. It is a key mediator in the acute-phase response (Geiger 1988) and 
is elevated in both acute (Chollet Martin 1996) and chronic inflammation (Ridderstad 
1991). IL-6 has been shown to be elevated in airway (Bucchioni 2003) and systemic 
(Debigare 2003) compartments in COPD and to rise further at exacerbation, 
particularly those associated with viral infection (Bhowmik 2000, Wedzicha 2000). 
IL-6 has been shown to augment antibody production and also to induce neutrophil 
deformability and sequestration to the lung (Suwa 2001) and therefore may play an 
important role in controlling the immune response to airway infection. 
IL-8 
Interleukin 8 is a chemokine produced by an array of cells including the 
airway epithelium, neutrophils, macrophages and lymphocytes (Pease 2002). The 
stimuli to IL-8 release include lipopolysaccharide, IL-lbeta and tumor necrosis factor- 
alpha. Regulation of the IL-8 production is under the control of nuclear factor kappaB 
IL-8 is a potent chernotactic agent for neutrophils and exerts its effects by binding 
with high affinity to two receptors on its cell surface, the chemokine receptors 
CXCR I and CXCR2. 
IL-8 is elevated in the COPD airway and the levels are higher in patients with 
more severe disease (Yamamoto 1997). Levels are also related to the degree of airway 
bacterial colonisation (Hill 2000) and rise during exacerbations (Aaron 2001, 
Fujimoto 2005, Wilkinson 2006). IL-8 is likely to play a key role in mediating the 
neutrophilic inflammatory responses which are key in the payhology of COPD. 
Myeloperoxidase (MPO). 
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Myeloperoxidase is a hemoprotein secreted during activation of neutrophils, 
which plays an important role in the immune defences by catalyzing the production of 
hypochloric acid (HOCI) which is toxic to pathogenic organisms which have been 
phagocytosed by the neutrophil. Levels are elevated in the airway of COPD patients 
and relate to disease severity and is a specific marker of neutrophil activation (Di 
Stefano 1998). It has been postulated that unregulated release of MPO may play a key 
role in driving oxidative stress which may be important in the development of airways 
obstruction (Drost 2005). 
Fibrinogen 
Fibrinogen is produced by hepatocytes in response to stimulation by systemic 
inflammatory cytokines chiefly interleukin 6 (IL-6) (Castell 1989, Gabay 1999). 
Elevated plasma fibrinogen is an established risk factor for coronary heart disease 
(Meade 1993, Ernst 1997, Salornaa 2002). It has been shown to be elevated in 
response to infection and during exacerbations of COPD (Wedzicha 2000) and 
therefore factors which modulate fibrinogen levels may also be important in the 
incidence of increased cardiovascular morbidity associated with COPD. 
1.6. COPD EXACFRBATIONS 
The natural history of COPD is characterised by sometimes frequent episodes 
of worsening symptoms and lung function termed exacerbations. These episodes are 
not only an important cause of morbidity and mortality (Guest 1999), but also are a 
frequent cause of physician consultation in primary and secondary care and a major 
cause of hospital admission (Garcia-Aymerich 2000, Pearson 1994). They also 
adversely affect health related quality of life (Seemungal 1998). 
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There remains no generally accepted definition of an exacerbation; however in 
recent years attempts to agree on a consensus definition have been made. Early 
definitions had largely been made in the context of clinical trials such as that used in 
the antibiotic trial by Anthonisen and colleagues of "At least two of increase in SOB, 
sputum purulence, sputum volume or any one above and one of: URTI, wheeze, 
cough, increase in respiratory or pulse rate" (Anthonisen 1987). Later definitions have 
been less specific; following a consensus meeting in 2000, a definition of "a sustained 
worsening of COPD patient's condition from stable state necessitating a change in 
regular medication" (Rodriguez-Roisin 2000)was proposed. However, this definition 
required health care utilisation to occur in order for an exacerbation to be diagnosed. 
This definition has been reworked against the background of clinical findings that 
COPD patients will often fail to report episodes of worsening symptoms and that 
these unreported episodes or exacerbations were similar in nature and severity to 
those that did receive additional therapy (Seemungal 1998, Seemungal 2000). 
Consequently, the consensus definition has evolved to "An exacerbation of COPD is 
an event in the natural course of the disease characterised by a change in the patient's 
baseline dyspnoea, cough and/or sputum beyond day-to-day variability sufficient to 
warrant a change in management. " (Celli 2004), which is widely but not universally 
accepted. 
The definition used in the context of a clinical study is required to be much 
more specific than the approaches of consensus statements above. The East London 
COPD group has used, since its inception, a symptom based definition based upon the 
original Anthonisen definition and is "the presence for at least two consecutive days of 
increase in any two "major" symptoms (dyspnoea, sputum purulence, sputum amount) 
or increase in one "major" and one "minor" symptom (wheeze, sore throat, cough, 
ý 
rc 
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symptoms of a common cold) (Seemungal 1998, Seemungal 2000, Bhowmik 2000). 
This definition has been validated against a number of important outcomes including 
health related quality of life (Seemungal 1998), rate of disease progression (Donaldson 
2002), airway (Bhowmik 2000) and systemic inflammatory changes (Wedzicha 2000). 
There have been a number of studies which have described the symptomatic, 
physiological and inflammatory changes which may occur during exacerbations of 
COPD. The first in depth description of the time course of symptoms during COPD 
exacerbations was published by our group in 2000. This analysis of 504 exacerbations in 
101 patients with moderate to severe COPD, this showed that there was a short 
prodrome before the onset of exacerbation associated with a deterioration in 
the symptoms of dyspnea, sore throat, cough, and symptoms of a common cold but 
not of lung function. Larger falls in PEFR were associated with symptoms of 
increased dyspnea colds , or increased wheeze . Median recovery times were 6 days 
for PEFR and 7 days for daily total symptom score. Recovery of PEFR to baseline 
values was complete in only 75.2% of exacerbations at 35 days. In the 404 
exacerbations where recovery of PEFR to baseline values was complete at 91 days, 
increased dyspnea and colds at onset of exacerbation were associated with prolonged 
recovery times (Seemungal 2000). 
A recent study in 20 patients demonstrated that acute exacerbations are 
associated with worsening airflow obstruction and lung hyperinflation. Reductions in 
dyspnoea following onset are associated with reductions in lung hyperinflation and 
consequent increase in expiratory flow rates (Parker 2005). However what determines 
the degree of deterioration in lung function at a given exacerbation or the modulation 
of recovery back to baseline is not understood. 
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It is also important to note that a not all symptomatic exacerbations, only 
49.6% in the Seemungal study, was actually reported to the investigators indicating 
that COPD patients often do not seek therapy for exacerbations which may have 
important consequences which have not been investigated. 
1.6.1. AIRWAY AND SYSTEMIC INFLAMMAIION AT EXACERBATION 
COPD exacerbations have been associated with heightened levels of airway 
and systemic inflammation (Hurst 2006). The variable nature of the findings of 
studies investigating the inflammatory changes at exacerbation highlights the 
heterogeneity of these events. Biopsy studies have confirmed greater numbers of 
inflammatory cells in subjects at exacerbation compared to stability. The role of the 
eosinophil remains controversial as there is evidence that airway mucosal eosinophil 
numbers rise significantly at exacerbation (Saetta 1994) although the nature of the 
eosinophils seen differs in terms of cytokine expression from those in the asthmatic 
airway (Saetta 1995). These biopsies also revealed evidence of neutrophilic airway 
inflammation along with increases in CD3+ T cells. There is also evidence that the 
degree of airway inflammation is directly related to both the severity of the 
exacerbation and of the underlying disease (Drost 2005). Studies of inflammation in 
our patient population with moderate to severe COPD using induced sputum failed to 
show a rise in sputum neutrophils at exacerbation, however soluble markers such as 
interleukin-8 did rise suggesting a contributory role for the airway epithelium in 
driving the inflammatory response (Bhowmik 2000). 
A link between the aetiology of an exacerbation and the inflammatory profile 
can be hypothesised from studies linking symptoms of putative viral infections such 
as cold symptoms to rises in IIL-6 (Bhowmik 2000) or the presence of purulent 
51 
INTRODUCTION 
sputum, higher isolation rates for bacterial pathogens and greater levels of LTB4 
(Gompertz 2001). 
A number of studies have also shown heightened levels of systemic 
inflammation at exacerbation. Work from our group has demonstrated rises in plasma 
fibrinogen at exacerbation (Wedzicha 2000) and patterns of systemic inflammation 
were seen to be related to possible infective aetiology, with a trend towards greater 
increases in systemic inflammation in virally associated exacerbations (Seemungal 
2001). 
Systemic inflammation at exacerbation may be an important part of the acute 
inflammatory response for a number of reasons. It is likely to be mechanistically 
linked to the muscular weakness associated with exacerbations with an association 
between systemic levels of CXCL8 and IGF-I and the development of peripheral 
muscle weakness in severe exacerbations (Spruit 2003). It may also contribute to the 
excessive cardiovascular morbidity associated with exacerbations (Sin 2003). 
1.6.2 BACTERIAL INFECTION AND EXACERBATION 
The hypothesis that airway infection may play an important role not only in 
the aetiology of exacerbations but also in the genesis and progression of airways 
obstruction has existed for a considerable time, indeed as a component of the original 
'British Hypothesis' discussed above. An association between the presence of airway 
pathogens and the occurrence of exacerbations has been established. However, despite 
the high incidence of these events, there is very little data available on how airway 
infection may modulate their severity or how different groups of pathogens may 
interact. It is also important to consider that a proportion of events diagnosed as 
exacerbations may be due to concurrent pathologies such as pulmonary emboli or 
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worsening of heart failure. The true incidence and indeed severity therefore of 
infective or inflammatory exacerbations may be affected by these additional 
aetiological factors. 
A number of studies have identified lower airway bacteria in sputum at 
exacerbations of COPD (Sethi 2000, Miravidles 1999, Monso 1995, Soler 1998). The 
most commonly identified organisms being Haentophilus influenzae, Streptococcus 
pneumoniae and Moraxella catarrhalis with isolation rates of potentially pathogenic 
organisms varying between 25 and 75%, and dependent on the severity of disease and 
the prevalence of smoking (Rosell. 2005, Monso 1995). 
The role of bacterial infection at exacerbation is complicated by the presence 
of bacteria colonising the lower airway in the stable state. Studies have shown 
however that the prevalence of potentially pathogenic organisms and that the airway 
bacterial load are higher at exacerbation than in the stable state (Monso 1995) which 
may strongly suggest but do not prove a role for bacteria in the aetiology of these 
events. Other work in this area has shown that the isolation of a bacterial pathogen at 
exacerbation was associated with the presence of sputum purulence which is itself a 
measure of neutrophilic inflammation, with 84% of subjects with purulent sputum and 
38% of those with mucoid sputum during an exacerbation cultured positive for a 
potentially pathogenic organism (Stockley 2000). Data from prospective studies 
which have assessed airway bacteria in the stable state and at subsequent exacerbation 
in the same patient are scant; one study which has followed a cohort of COPD 
patients wit regular sputum sampling and bacterial analysis (Sethi 2000) has shown 
that observed changes in strain of airway bacterial isolates, which were associated 
with increased risk of exacerbation. However, although strain changes were 
associated with a 2-fold increase in risk of exacerbation, only one third of strain 
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changes observed coincided with an exacerbation. Therefore, strain change may be 
one of many factors which trigger exacerbations but it is likely that other factors play 
a role in modulating their severity or response to therapy. 
The interplay between bacteria and host immune systems in COPD is 
complex. Whilst bacteria may colonise the lower airway in the stable state, due to 
defective host defences, there does appear to be an appropriate immune response to 
bacteria at exacerbation at least in terms of humoral mechanisms. Bakri and 
colleagues have shown that after exacerbation associated with Moraxella catarrhalis, 
new serum IgG antibodies and sputum IgA antibodies specific to the infecting strain 
developed after the majority of exacerbations (Bakri 2002). 
Whilst bacterial pathogens may trigger a percentage of exacerbations, they 
may also play a role in modulating their severity or response to therapy. Different 
species of isolate have a differential inflammatory effect in the airway; for example, 
Haeinophilus influenzae is associated with higher levels of airway inflammation than 
exacerbations not associated with this pathogen (Sethi 2000). Furthermore it is 
known that exacerbations are associated with higher airway bacterial loads (Monso 
1995) than the stable state but to what degree changes in load modulate inflammatory 
and physiological responses at exacerbation requires investigation. 
1.6.3 VIRAL INFECTIONS AND EXACERBATION 
The role that respiratory viral infections play in exacerbations has been 
discussed and studied for some time. The marked seasonality of exacerbations has 
been known to both clinician and epidemiologists alike and the association of peak 
exacerbation incidence with the winter epidemic of respiratory viral illnesses is well 
described (Donaldson 2006). 
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Early studies used viral culture and serology as methods of detection, but these 
are relatively insensitive and virus detection rates were consequently low (Gump 
1976, Buscho 1978, Smith 1980). Therefore these early studies tended to 
underestimate the true incidence of viral infection due to the insensitivity of detection 
techniques, particularly as human rhinovirus the most commonly detected viral 
pathogen in modem studies is fastidious and difficult to culture on common media 
(Tyrell 1970). With the advent of PCR and other molecular diagnostic techniques 
used in more recent studies much higher detection rates for common viral pathogens 
during COPD exacerbations have been reported. 
One of the first such studies using PCR was performed by our group 
(Seemungal 2001). This study confirmed that respiratory viruses can be detected by 
PCR in 39% of exacerbations with human rhinovirus the most commonly identified 
pathogen. This study used naso-pharyngeal sampling which has subsequently been 
shown to be a less sensitive technique than sputum analysis for detection of viruses 
(Seemungal 2000) suggesting the overall incidence of viral infection may be higher if 
the lower airway itself is sampled. The relative prevalence of viral pathogens detected 
is illustrated in Figure 1.3. 
These findings have been confirmed in a population of COPD patients 
admitted to hospital, with viral pathogens identified in 56% of patients using a 
combination of sputum and nasal lavage techniques (Rohde 2003). Very similar 
results to the Seemungal study were found in further study by Greenberg et al. in the 
US (Greenberg 2005). It is likely that even using sensitive PCR techniques that 
observed detection rates are underestimating the true incidence of viral infection. The 
incidence of common cold symptoms was 65% in the Seemungal study and detection 
rates for viruses commonly associated with colds was less than 40%. One reason for 
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this may be that patients do not present with exacerbations until the onset of lower 
airway symptoms and often some days past the onset of lower airway symptoms, 
therefore at a time when the peak viral load may have subsided. 
These studies of association between viral detection and exacerbations does 
not prove causality however additional evidence that viruses are important in the 
aetiology of these events comes from the finding that virally associated exacerbations 
are more severe than non virally associated exacerbations. This has been shown in 
terms of exacerbation recovery time (Seemungal 2000) and airway inflammation in 
terms of higher IL6 (Seemungal 2001). Recently exposure models of HRV infection in 
COPD patients have been developed (Mallia 2005). 
The evidence from studies which have focused on individual types of 
pathogens suggest that both bacteria and viruses may play a role in triggering and 
modulating the nature of COPD exacerbations; however, to date there have been very 
few studies which have looked at the combined effects of both type of pathogens in a 
particular individual at exacerbation. 
In the normal population there is an established association between 
respiratory viral infection and consequent or secondary bacterial infection (van der 
Sluijs 2004, Lowenberg 1975. ). The mechanisms for this association have been 
investigated and current evidence suggests that respiratory infection enables bacterial 
adherence to airway epithelial cells (Ishizuka 2003, Fainstain 1980). 
Early epidemiological data in populations of COPD patients has suggested a 
similar association between the incidence of viral and bacterial infection at 
exacerbations (Smith 1976). Considering that the rates of isolation of bacterial 
pathogens at exacerbation run from 40 to 70% and PCR detection rates of viral 
pathogens conservatively estimate the incidence of infection to be 40-50%, it is highly 
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probable that a significant proportion of exacerbations involve both types of pathogen. 
However, to date there has been no direct evidence of additive effects of viral and 
bacterial infections on airway inflammation or clinical outcomes in COPD. 
One study which has attempted to study the effects of bacteria and viruses 
only sampled (Aaron 2001) 14 exacerbations; furthermore, detection of either bacteria 
or viruses occurred in only 3 of these events which is at odds with the remainder of 
the literature on this topic suggesting inadequate sampling or detection techniques for 
these pathogens. Clearly, further work is required to determine the effects that 
combined bacterial and viral infection have on the airway in exacerbations of COPD 
and this is one focus for this study. 
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FIGURE 1.3 DETECTION RATES OF COMMON RESPIRATORY VIRAL PATHOGENS AT 
EXACERBATIONS OF COPD EXACERBATIONS FROM EAST LONDON COPD COHORT. 
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FIGURE 1.4 SEASONALITY OF EXACERBATIONS IN FIRST 5 YEARS OF EAST LONDON 
COPD COHORT STUDY. 
Y5 
f4 
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1.6.4 EXACERBATION THERAPY AND IMPROVING OUTCOMES 
Considering the spectrum of disease and the array of aetiologies that may 
trigger exacerbations or modulate their natural history it is no surprise that there is 
marked heterogeneity both in the clinical severity, and time course of these events 
(Seemungal 2000). Hence, predicting responses to prescribed therapy can be difficult. 
Whilst there have been a number of observational studies highlighting a potential role 
foe bacterial infection in the pathogenesis of exacerbations, the findings of antibiotic 
intervention studies are not consistently positive and the value of their use remains 
uncertain. Some controlled trials of antibiotics have shown benefit (Berry 1960, Pines 
1972) while others have not (Elmes 1965, Nicotra. 1982). A recent Cochrane review 
of eleven trials with 917 patients suggests "that in COPD exacerbations with 
increased cough and sputum purulence antibiotics, regardless of choice, reduce the 
risk of short-term mortality by 77%, decrease the risk of treatment failure by 53% and 
the risk of sputum purulence by 44%; with a small increase in the risk of 
diarrhoea. "(Ram 2006). Clearly if bacterial infection was the only factor in triggering 
exacerbations a more marked benefit of antibiotic therapy would be expected. These 
somewhat qualified conclusions as to the efficacy of antibiotics in this setting would 
suggest that although bacterial infection plays a role, other host and environmental 
factors may be important in modulating the occurrence and severity of exacerbations. 
Whilst current pharmacological therapies target the inflammation, infection 
and bronchoconstriction associated with exacerbations, their efficacy even in 
combination is limited and targeting therapies to presumed aetiologies of particular 
exacerbations remains largely a matter of clinical judgement. Furthermore the 
prescription of pharmacological treatments alone does not address the deleterious 
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effects on functional performance, psychological and social factors caused by 
exacerbation. 
Predicting outcome of exacerbations is therefore problematic, however 
patients with more severe disease at baseline are less likely to do well (Garcia- 
Aymerich 2001, Wouters 2004), particularly those with poor baseline functional 
capacity (Garcia-Aymerich 2003). Indeed, following severe (hypercapnic) 
exacerbations requiring hospital admission in over a third of patients may require 
mechanical ventilation, with an in-hospital mortality of over 10% (Connors 1996). 
Furthermore, the outcomes following admission remain poor with 80% of patients 
requiring inpatient management of a severe exacerbation readmitted within a year 
(Chu 2004). The outcome of less severe exacerbations managed in primary care is less 
well described. However, observational studies have revealed that a significant 
proportion of patients experiencing exacerbation symptoms fail to recover back to 
baseline levels (Seemungal 2000) and that poor outcomes are often related to failure 
to seek appropriate therapy (Wilkinson 2004). 
Despite recognition of the poor prognosis associated with COPD 
exacerbations requiring hospitalisation and attempts to summarise the evidence base 
in management guidelines, there are indications that appropriate standards of care for 
acute exacerbations are not met and simple assessments to identify at risk patients not 
completed (Roberts 2001). There is obviously considerable scope to improve 
management of COPD exacerbations, and thus to improve outcomes. It is possible 
that by careful observation of responses to currently standard therapy that factors 
which may predict response to treatment can be identified and hence future delivery 
of treatment improved. 
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1.7 AIRWAY INFECTION IN STABix DISEASE 
1.7.1 LOWER AIRWAY BACTERIAL COLONISAIION 
Despite the inhalation of many millions of pathogenic organisms each day the 
lower airway of healthy individuals is sterile. The mechanisms that protect the airway 
from infection are complex and include innate and adaptive defences. The production 
of mucus by the respiratory epithelium and its upward transportation by the cilial 
escalator both minimises the opportunity for bacterial adherence and removes 
pathogens and particulate matter from the lungs. Airway secretions contain a number 
of anti-bacterial agents such as lactoferrin and lysozyme which further embarrass 
pathogenic adhesion and growth (Boyton 2002). 
Hence any process which affects these host defences can lead to persistence of 
bacteria in the lower airway, leading to activation of the innate and adaptive immune 
responses which can lead to airway damage as can the direct effects of bacteria on the 
epithelium The integrity of the respiratory epithelium itself is vital to its protective 
role against infection. Bacteria can affect t6e airway epithelium directly and via the 
recruitment of neutrophils (Ras 1990, Noguera 2001) with release of excessive 
amounts of neutrophil derived proteases resulting in damage to airway epithelial cells 
(Wilson 1992). 
Tobacco smoking directly impairs the innate immune defences of the airway 
by a number of mechanisms including slowing the ciliary escalator both by long term 
effects on ciliary clearance (Stanley 1986) and by stimulating mucus hypersecretion 
which can lead to uncoupling of the surface layer of mucus from that being 
transported by cilia beneath. Cigarette smoke also excites inflammatory and oxidative 
responses which can damage the airway and lead to bacterial persistence (van der 
Vaart 2004). 
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Bacterial colonisation is a term used to describe the persistence of bacteria in 
the airway usually associated with a persisting weakness in airway defences. When 
colonisation. develops a balance is established between bacterial growth and airway 
immune defences, and bacteria may persist in significant numbers with a low grade, 
chronic inflammatory response. Studies of subjects with COPD have established that 
both this form of bacterial colonisation is a common phenomenon (Monso 1995, Soler 
1998) and that patients with more severe disease and active smokers are more at risk. 
The most commonly identified colonising bacteria in COPD patients are similar to 
those seen at exacerbation Haemophilus influenzae, Moraxella catarrhalis and 
Streptococcus pneumonia. These pathogens can exist in the lower airway in 
significant numbers (106-108 organisms mi") in the diseased lung, with the patient 
remaining 'clinically stable'. Their persistence is reliant both on pre-existing 
impairment of lung defences and pathogen specific mechanisms to prevent eradication 
such as paralysis of cilia (Wilson 1984). 
Studies using quantitative bacteriology have demonstrated a relationship 
between the airway bacterial load (number of bacteria per ml) and the degree of 
observed airway inflammation (Hill 2000, Patel 2002). This process of neutrophilic 
airway inflammation persists in COPD patients despite smoking cessation (Rutgers t:;, 
2000), and is heightened in patients with worse lung function (Stanescu 1996) and as 
bacterial colonisation is also more marked in patients with more severe disease 
(Zalacain 1999), a causal relationship has been suggested. Corroborative evidence 
comes from animal models of chronic bacterial infection in the lung which have 
shown changes characteristic of those seen in COPD with patterns of inflammatory 
cells, cytokine expression and pathological changes to both airways and alveoli 
mimicking those seen in humans with the disease (Vernooy 2002). With differential 
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pro- inflammatory effects by different bacterial species and indeed strains observed 
(Adler 1986). 
The 'vicious circle hypothesis' attempts to explain the proposed cyclical 
association between airway infection, subsequent inflammation epithelial cell and 
collateral lung tissue damage with further weakening of lung defenses with 
deleterious consequences on airway disease progression: see Figure 1.5 (Wilson 2002, 
Sethi 2001). 
The progression of the observed airway immune response from predominately 
innate in mild disease to adaptive in more severe disease (Hogg 2004) suggests that 
responses to airway colonisation may modulate the pattern of airway inflammation to 
a greater extent as the disease progresses. However, studies to date have been largely 
cross-sectional in nature and have failed to demonstrate a direct association between 
bacterial colonisation of the lower airway and disease progression. Furthermore, 
intervention studies involving antibiotic eradication of airway bacteria are required to 
determine to what degree the relationship between lower airway bacterial 
colonisation, airway inflammation and declining lung function in patients with COPD 
is causal. 
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FIGURE 1.5 SCHEMA'nc DIAGRAM OF THE 'Vicious CiRcLE HYPOTMESIS' 
ADAFMD FROM SETHI 2000. 
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1.7.2 CHRONic RESPIRATORY VIRAL INFECTION IN COPD 
The role of chronic respiratory viral infection in the pathobiology of COPD is 
less well established than that of bacteria. Whilst the effects of acute viral infections 
of the lower airway have been described at exacerbations of COPD, to what degree 
viruses persist in the lower airway when the subject with COPD is in the stable state 
and if present what their effects on the natural history of COPD are has yet to be 
described. 
There is a small body of evidence to suggest that 'chronic' viral infection may 
play an important role in COPD. There is some evidence that chronic airway infection 
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with adenovirus, may play a role in the development of airways obstruction, but 
studies have been cross- sectional in nature and relationships between viral infection 
and disease progression have not been demonstrated (Retamales 2001). Furthermore a 
role for RNA viruses in the pathogenesis of COPD has been little explored. However 
there is an established literature on the mechanisms underlying the persistence of 
RNA viruses in other disease states. The measles virus a member of the 
Pararmyxoviridae family can persistently infect neuronal. tissue and dendritic cells and 
can cause severe disease, such as sub acute sclerosing pan-encephalitis, several years 
after the acute infection (Litvak 1943, Rima 2005, Lamb 1996) 
Respiratory syncytial. virus (RSV) is a negative strand RNA virus, also of the 
Pararmyxoviridae family, but of the genus Pneumovirus. It is the major cause of acute 
lower respiratory tract infections in young children, where it occurs in winter 
epidemics, but is rarely identified in the summer (Gardner 1968, Glazer 1973). 
Human RSV has no animal reservoir and the source of these winter epidemics 
remains unknown. Recent studies have also identified RSV as an important pathogen 
in the elderly and in adults with cardiopulmonary disease (Falsey 2005, Falsey 1995, 
Falsey 1996, Walsh 1989). 
We have previously detected RSV in naso-pharyngeal samples from COPD 
patients in a cross sectional study (Seemungal 2001). Whilst the other commonly 
detected respiratory viral pathogens, such as human rhinovirus, were much more 
prevalent at exacerbation than in the stable state, RSV was detected at similar rates 
regardless of whether the patient was stable or having an exacerbation. (Seemungal 
2001) Using quantitative PCR, these findings have been confirmed in stable COPD 
patients and at exacerbation, with low viral loads identified in comparison to those 
seen in children with seasonal bronchiolitis (Borg 2003). However longitudinal 
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studies to determine whether RSV is able to persist in the lower airways of stable 
COPD patients are lacking and the clinical consequences of RSV persistence or that 
of other respiratory viruses have not been determined. 
CONCLUSION 
A number of studies of patients with COPD have identified a potential role for 
bacterial and viral infection in the aetiology of airway inflammation and exacerbation. 
The contribution of infective processes to disease progression or severity of 
exacerbations has not been fully described. The next chapter will surnmarise the 
specific aims of this study to investigate the role of airway infection in the natural 
history of COPD. 
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CHAPTER 2 
HYPOTHESIS AND STUDY Alms 
HYPOTHESIS 
revious studies of airway infection in COPD have identified that respiratory 
bacteria can commonly be found in the lower airway of COPD patients in the 
stable state and that the presence of bacteria are linked to airway inflammation. 
However studies to date have been largely cross-sectional in design and have not 
informed on the associations between bacterial colonisation and disease progression 
in COPD. Similarly the role of respiratory viruses in stable disease has not been 
elucidated. Furthermore whilst both bacterial and viral pathogens have been detected 
at exacerbation there are few data on how these pathogens modulate the nature and 
severity of exacerbations or what the impact of co-infection may be. 
Therefore the studies described in this thesis address the hypothesis that: 
In patients with COPD lower airway infection with bacterial and viral pathogens is a 
common phenomenon, both in the stable state and at exacerbation which has 
important patho-physiological effects on the airway and hence impacts upon the 
natural history and clinical outcome of the disease. 
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The specific aims of the study were: 
To prospectively determine the prevalence and chronicity of lower airway 
bacterial colonisation in a population of patients with stable COPD. 
* To determine the prevalence and chronicity of lower airway viral colonisation 
in a population of patients with stable COPD. 
* To determine the relationships between lower airway bacterial and viral 
infection on airway inflammation and disease progression in these patients. 
e To determine the relationships between lower airway infection and systemic 
inflammation. 
9 To determine the effects of lower airway bacterial and viral infection at 
exacerbations on the nature and severity of inflammation and clinical 
outcomes., 
The initial studies identified that respiratory syncytial virus could be identified 
in airway samples of a sub-population of COPD patients in the stable state. Data from 
acute infections in children suggested that RSV infection modulates the nature of the 
immune response to viral infection and we therefore investigated: 
11 The relationship between RSV detection and responses of peripheral blood 
mononuclear cells to viral stimulation in an ex-vivo assay. 
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The analysis of the effects of airway infection and inflammation on 
exacerbation outcomes suggested that the timing of presentation for exacerbation 
treatment may have important effects on the response to therapy. An analysis of the 
dataset from the East London COPD cohort was performed to determine: 
* The relationship between exacerbation reporting behaviour and clinical 
outcomes including exacerbation recovery, hospitalisation, and health related 
quality of life. 
The clinical and laboratory methods used to address these specific aims are 
addressed in the next chapter. 
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CHAPTER 3 
DESCRIPTION AND DISCUSSION OF 
METHODS USED 
3.1 INTRODUCTION 
In this chapter the methods used in the work contributing to this thesis are 
described. The methodology common to all aspects of the thesis are described in this 
chapter; clinical measurement, cohort follow up, sampling techniques, sample 
processing and detection of respiratory pathogens. The methodology peculiar to a 
particular sub-study will be described in the methods section of the appropriate 
chapter. The rationale for using the methods described and their limitations is 
discussed. 
3.2 ETHICAL APPROVAL 
The ethics committee of the East London and City Health Authority approved 
the studies described in this thesis. All patients gave their written, informed consent 
prior to recruitment into the study. 
3.3 PATIENT RECRUITMENT AND CHARACTERISATION 
Patients were recruited from the outpatients department of the London Chest 
Hospital in Bethnal Green, London, into the East London COPD cohort. This is a long 
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running cohort of patients with largely moderate to severe COPD which was first 
recruited in 1995. A rolling recruitment programme has been used to maintain cohort 
size. Patients were under the overall clinical supervision of the principle investigator 
of the research group Professor Wedzicha who co-supervised this work. 
Inclusion criteria for the study were as in previous East London cohort studies 
and first published in 1998 (Seemungal 1998): 
1. A history of COPD with an FEV, (forced expiratory volume in Is) less than 70% 
predicted for age, gender and height. 
History of reversibility to beta-2 agonist of less than 15% and/or less than 200 n-A 
(ATS Statement). 
3. A history of at least 10 pack years of tobacco smoking. 
Exclusion Criteria were: 
1. Patients were excluded who had a past history of asthma, 
2. A clinically significant history of bronchiectasis, 
3. A history of carcinoma of the bronchus. 
4. A history of significant respiratory disease other than COPD. 
5. They were also excluded if they were unable to complete diary cards. 
PATIENT CHARACTERISATION 
The initial assessment consisted of history, physical examination and 
assessment of physiological parameters. Patients were asked about their daily stable 
symptoms: dyspnoea, sputum production, cough and wheeze. Details were obtained 
of whether patients had a history of cardiovascular or respiratory disease other than 
COPD and the dose and frequency of use of all drug medications. Upon successful 
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recruitment each patient was given two identification labels: a study number and 4- 
letter code each of which was unique to that patient. 
SMOKING HISTORY 
Patients were classified as ex-smokers if they had not smoked in the past three 
months and as smokers if they smoked in the last three months. Where participants 
made their own cigarettes, half an ounce of tobacco was considered equal to one pack 
of commercial cigarettes (Jarad 1991). 
3.4 PATIENT FOLLOW UP AND CLINICAL MEASUREMENTS 
LUNG FUNCTION 
At recruitment baseline measurements were made of height, weight, FEVI, forced 
vital capacity (FVC) and peak expiratory flow rate (PEFR) by rolling sea] spirometer 
(Sensor Medic Corp, Yorba Linda, USA). Predicted values were assessed using 
equations which took into account age, sex and height (Cotes 1978). Lung function 
measurements on all patients were taken between 0930 and 1130 hours, At least three 
serial spirometry readings were taken at each visit and the best performance recorded. 
FEV, reversibility to 400 Vg inhaled salbutamol, and arterialised ear lobe blood gases 
(Pitkin, 1994) were also determined. Postero-anterior chest radiographs were assessed 
for evidence of other lung pathology. 
All patients were shown how to record on daily diary cards, PEFR (Mini-Wright peak 
flow meter, Clement Clarke International Ltd., Harlow, UK) measured indoors after their 
morning medication they recorded the best performance of three sequential readings. At 
recruitment patients were instructed how to record any increase over their chronic 
(stable) respiratory symptoms during the last 24 hours and to record these on their diary 
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card. These symptoms are classified into major and minor a symptom developed from 
the original work of Anthonisen (Anthonisen 1987) and fonn the basis of the validated 
symptom based diagnostic criteria for exacerbations used in all previous studies from the 
East London COPD group. These are as follows: 
(a) 'major' symptoms 
* increased dyspnoea, 
9 increased sputum purulence, 
* increased sputum amount 
'minor' symptoms 
9 nasal 'dischargekongestion, 
o increased wheeze, 
0 sore throat, 
* increased cough 
When well or stable the patients were instructed not to record any of the 
symptom letters on the diary, but when they perceived an increase over their normal, 
stable condition in symptoms they noted the corresponding letter code. There was no 
numerical grading system for each individual symptom and patients recorded 
symptom letters if a symptom was perceived as worse eg dyspnea or of new onset eg. 
a sore throat (as the latter is not usually present). For example a patient notes that he is 
developing symptoms of a Cold, and notes C, the next day he is more breathless and 
still has cold symptoms; recording A and C. The patient experienced deterioration in 
his symptoms and recorded this change as present or absent for each individual 
symptom above. Patients therefore judged if a particular symptom is worse than their 
own perceived normal level. The validated diagnostic criteria of the presence of at 
least two major or one major and one minor symptom for at least two days was then 
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used in the analysis of diary card record. Patients also recorded the time they spent 
outdoors on a daily basis as a measure of activity. 
Patients were reviewed every three months when stable, in the study clinic. 
Here a review of diaries was performed, a history taken inclusive of any change in 
medication, smoking behaviour, and of previous exacerbations not reported to the 
study team. Lung function was recorded before sampling was undertaken. Spirometric 
measurements were taken I hour after the patients' usual bronchodilator medication 
was taken inclusive of 200 ug of salbutamol via metered dose inhaler. Lung function 
measurements on all patients were taken between 0930 and 1130 hours, At least three 
serial spirometry readings were taken at each visit and the best performance recorded. 
3.5 EXACERBATIONS 
REPORTING EXACERBATIONS 
Patients were asked to contact the clinical team by telephone to arrange a clinic visit 
if their symptoms worsened. Patients were then seen within 48 hours of the call in the 
outpatient's department of the London Chest Hospital. If a patient was seen acutely at 
clinic then this was called a reported exacerbation visit. If however the exacerbation was 
diagnosed from the history or the diary card retrospectively during subsequent follow up 
then this was called an unreported exacerbation. 
DIAGNOSIS OF EXACERBAnON 
Exacerbations were identified by symptoms recorded on the diary cards, or from 
the history when patients presented to the physician: 
1. any two 'major' symptoms or one 'major' and one 'minor' symptom 
on two consecutive days 
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3. the first of the two consecutive days was taken as the day of onset of 
exacerbation 
4. symptoms present continuously for more than 5 days prior to the possible onset 
of an exacerbation were discounted. 
EXACERBAIJON TREATMENT 
The prescription of treatment for all exacerbations was at the discretion of the 
attending physician and included prednisolone and/or antibiotic therapy. Exacerbation 
treatment in the study therefore represented the usual practice of the study physician 
attending the patient or that of the primary care physician in the case of exacerbations 
treated by the patients' GP. Records were kept of the date of initiation and type of 
treatment prescribed to patients for each exacerbation, both at our clinic and also 
therapy prescribed by the patient's primary care physician. 
SEVERITY OF EXACERBATION IN TERMS OF SYMPTOMS EXPERIENCED 
The calculation of exacerbation severity in terms of symptoms experienced 
was assessed by counting up the number of individual symptoms recorded at the onset 
of an exacerbation eg. A, B 1, C= 3 symptoms or A, B 1, B2, D, E 1, E2= 6 symptoms etc. 
Symptom severity at exacerbation was calculated as the difference in total daily 
symptom count at baseline and at exacerbation onset but not from the severity of 
individual symptoms themselves as these were only recorded as increased (=I) or not 
(=0). 
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EXACERBATION TOTAL RECOVERY TIME 
This was calculated as the time from exacerbation onset for the 3-day moving 
average of the exacerbation daily symptom count to return to this baseline 
(Seemungal 2000). The use of a three-day moving average minimised the effect of 
day to day symptom variation without biasing the results. Treated recovery time was 
taken as the time between consultation and recovery. Exacerbation non-recovery was 
taken as recovery taking longer than 35 days. 
3.6 SPUTUM SAMPLING AND PROCESSING 
When sputum samples were required these were collected after lung function 
measurement, patients were asked to blow their noses and rinse their mouths out with 
water before expectorating sputum into a sterile pot to minimise oro-pharyngeal 
contamination. Patients unable to produce a sample of sputum spontaneously 
underwent sputum induction as described below. First, oxygen saturation was 
recorded (Minolta Pulsox 7; DeVilbiss Heal thcare, Middlesex, UK). This was 
continuously monitored during nebulisation with 3% saline using the DeVilbiss 
UltraNeb2000 ultrasonic nebuliser. This nebuliser produced an aerosol output of 
approximately 2 ml/minute with a mean particle size of 0.5-5 gm in diameter. After 7 
minutes of nebulization measurement spirometry was performed and nebulisation 
continued if the FEVi had not fallen by more than 20%. After a further 7 minutes the 
measurements were repeated and the procedure stopped. The collected sputum sample 
was separated from saliva by macroscopic examination using disposable plastic 
forceps and divided into two, half was taken for quantitative bacterial culture and the 
remainder processed and analyzed for inflammatory cytokines. These techniques had 
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been established and validated during previous studies by the group and are discussed 
later in this chapter. 
SPUTUM PROCESSING 
Sputum was processed within 2 hours of collection. Sputum samples containing 
25 squamous epithelial cells per low power field and > 25 leukocytes per high 
powered were accepted following processing. The weight of the total sample was 
recorded. The sputum was then separated from contaminating saliva by macroscopic 
examination using a pair of disposable plastic forceps. The selected portion of the 
sputum was placed in a pre-weighed tube and the weight of the selected portion of the 
sputum recorded. The sputum was then mixed with four times its weight of freshly 
prepared 0.1% dithiothreitol solution made by mixing the dithiothreitol powder with 
Hank's balanced salt solution (HBSS). This was vortexed for 15 seconds and then 
rocked for 15 minutes. A weight of HBSS equal to that of the sputum plus 
dithiothreitol was then added and the whole mixture was rocked for another five 
minutes. The suspension was filtered through 50 [tm nylon gauze to remove mucus 
and debris without removing any of the cells and then centrifuged at 790g (2000 rpm) 
for 10 minutes. This resulted in the formation of a cell pellet and a supernatant 
solution. The supernatant was decanted off and stored at -70'C for future analysis and 
the cell pellet was resuspended in 400-3200 [tl (depending on macroscopic estimation 
of the size of the cell pellet) of HBSS. The total cell count was determined with a 
Neubauer haemocytometer using the trypan blue exclusion method to determine cell 
viability, blue cells being counted as non-viable. The absolute number of non- 
squamous cells per gram of the original sputum sample was determined and the 
percentage of viable and non-viable cells obtained. The cell suspension was then 
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mixed with HBSS to obtain a count of 0.6-I. Ox 106 cells/ml of the suspension and 
cytospins were made using a Cytotek cytocentrifuge. The cytospin slides were stained 
with Diff-Quik to obtain differential cell counts made by counting 400 cells per slide 
(Popov 1994, Pizzichini 1996). Cytokines were measured in the supernatant samples 
using a quantitative sandwich immunoassay (R&D Systems Europe, Abingdon, Oxon, 
UK) and expressed as pg/ml of the supernatant. The supernatant itself is a tenfold 
dilution by weight of the original sputum sample minus cells (Bhowmik 2000). 
3.7 BLOOD SAMPLING AND PROCESSING 
Venous blood was taken from patients at clinic visits using standard techniques, 
samples were taken for storage of serum and plasma samples. After phlebotomy blood 
was stored on ice until centrifugation at 4'c for ten minutes. Supernatant was 
removed and divided into aliquots which were stored at -80 'c for subsequent 
analysis. The specific methology for extracting and storing PBMCs from whole blood 
is described later in the thesis. 
3.8 SPUTUM BACTERIOLOGY 
Part of the sputum sample was sent for quantitative analysis of bacterial 
colonisation, according to our previous published methodology Samples were 
processed; ten fold serial dilutions of the homogenized sample were made in Brain 
Heart infusion broth and 100[tl aliquots plated out onto the surface of a range of 
different media including blood agar, chocolate agar, MacConkey agar and cysteine 
lactose electrolyte deficient agar. These were incubated for Igh at 37 'c: in an 
atmosphere of air + 5% C02. After incubation, bacterial colonies were diluted and 
counted and sub-cultured for identification by standard methods (Barrow 1993). H. 
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influenzae and H parainfluenzae were identified and differentiated by their growth 
patterns on peptone agar on which discs containing NAD or haernin were placed 
(Unipath, UK). The number of colony forming units/g of sputum were calculated from 
the number of colonies obtained and the dilution of the sample (Barrow 1993, Patel 
2002). Potentially pathogenic micro-organisms (PPM) are bacteria known to be 
common pathogens of the respiratory tract in subjects with COPD (Streptococcus 
pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae Moraxella 
catarhalis, Staphylococcus aureus, Pseudonionas aeruginosa and other gram negative 
enteric bacteria (GNEB). 
3.9 VIRUS DETECTION: PCR TECHNIQUES 
RNA EXTRACTION AND REVERSE TRANSCRIPTION 
Total RNA was extracted from homogenised sputum samples and positive and 
negative viral controls using a standard silica-gel based kit (Qiagen, UK). Reverse 
transcription was performed using 1.25ug random hexamers (Promega, USA) and 
6.5ul nuclease-free water to each eluted sample, heated to 70c for 10 minutes and 
quenched at Oc. Followed by addition of 6ul of nuclease-free water (Promega, USA), 
10 ul of 5x RT Buffer, 5ul OAM DTT, 1.25ul IOOmM dNTPs and 40OU Superscript 
RNase H- reverse transcriptase (Invitrogen, USA) in a total volume of 95ul incubated 
at 37c for one hour. Qualitative PCR was performed using 5ul cDNA solution and 
hotstart taq polymerase in a mix containing xIO PCR buffer, 25mM M902,200uM 
dNTPs, 294 u/ml Hot Star Taq DNA Polymerase (Qiagen, UK). For all qualitative 
PCRs products were imaged using 1% agarose gel electrophoresis with ethidium. 
bromide staining and reference DNA ladder (Sigma, USA). 
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HuMAN RHINOVIRUS 
This was detected according to our previous methodology in our study of 
viruses at COPD exacerbations (Seemungal 2001). 0.5ul of each of HRV primers at 
25mM OL 26 (GCA CTT CTG TTT CCC Q and OL27 ( CGG ACA CCC AAA 
GTA G) (Oswell, UK), 25ul HotStar Taq MasterMix (Qiagen, UK) and 19ul 
nuclease-free water (Promega, USA) to a final volume of 50ul. PCR was performed 
using a Flexigene thermal cycler (Techne, UK), product size 380 bp. All the serotypes 
of picomaviruses were detected with this PCR methodology and subsequent 
sequencing of PCR product confirmed that HRV was detected. 
RESPIRATORY SYNCYTIAL VIRUS (RSV) 
A nested PCR was used similar to that used in our previous studies 
(Seemungal 2001, O'Donnell 1988) using in the first round 5ul of cDNA, 0.5ul I` 
round 25 mM primer KI (ATG TCA CGA AGG AAT CCT TGQ, and 0.5ul 25mM 
primer K2 (TAG CTC TTC ATT GTC CCT CAG Q with 25 ul HotStar Taq Master 
Mix (Promega, USA) and l9ul nuclease-free water (Promega, USA) to a final volume 
of 50ul. PCR was performed using a Flexigene thermal cycler (Techne (Cambridge) 
UK), I" round product size 360 bp. Second round; 5ul I" round product 0.5ul 2 nd 
round 25 m. M primer K3 (GAG GTC ATT GCT TAA ATG G), and 0.5ul 25m. M 
primer K4 (GCA ACA CAT GCT GAT TGT) with 25 ul HotStar Taq Master Mix 
(Promega, USA) and 19ul nuclease-free water (Promega, USA) to a final volume of 
50ul. Final product 259 bp. (van Elden 2003). 
Both RSV and HRV PCR detection assays were highly sensitive and could 
detect as few aIx 102 viral particles per ml of sputum. Figure 3.1. 
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DETEcTiON OF OTHER VIRUSES 
These were detected using established qualitative PCR techniques in the 
department of Professor Sebastian Johnston, NHLI, Imperial College, London. 
CORONAVIRUS Sputum was analysed using a nested PCR method with coronavirus- 
specific outer and inner primers for the two coronavirus types 229E and OC43. The 
copy DNA after reverse transcription will have two rounds of PCR using primers 
0637 and 0647 followed by IA and I B. (van Elden 2003). 
INFLUENZA A AND B were detected with an established PCR detection method that 
has been published (Templeton 2004). 
PARAINFLUENZA PCR was performed according to a recently published protocol 
(Templeton 2004). 
METAPNEUMOVIRUS PCR was used to detect metapneurnovirus according to a 
protocol that has been recently published (Maertzdorf 2004). 
ADENOVIRUS A PCR method was used, employing hexon-specific primers that have 
been shown to detect all 51 known adenovirus serotypes. The method has been 
adapted from a published technique (Heim 2003) and has been fully established and 
validated. 
CIILAMYDIA PNEUMONIA and MYCOPLASMA PNEUMONIA were detected using 
clinically validated PCR protocols (Cunningham 1998). 
PCR PRODUCT SEQUENCING In order to confirm and validate the PCR detection 
assay's results sequencing of both strands of selected positive PCR products using 
standard methods was performed and compared to reference strains using Clone 
Manager (Scientific and Educational Software, UK) to align the sequences. 
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PLA-TE 3.1 ETHIDIUM BROMIDE STAINED AGAROSE GEL REVEALING PCR DETECTION 
Aw 
(2N' ROUND) FOR RSV AT 259 BP ALONG WITH DNA LADDER AND NEGATIVE 
CONTROLS. 
Positive results 
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3.10 MEASURING AIRWAY AND SYSTEMIC INFLAMMATION 
Sputum and plasma inflammatory cytokines and chemokine were measured in 
the supernatant samples using a quantitative sandwich immunoassay (R&D Systems 
Europe, Abingdon, Oxon, UK) and expressed as pg/ml or ng/ml of the supernatant. 
Sputum myeloperoxidase (MPO) was also measured using ELISA (Calbiochem, 
Nottingham, UK). All assays had been previously validated during previous studies in 
our department (Bhowmik 2000, Bhowmik 2002, Seemungal 2000, Wedzicha 2000, 
Hurst 2005, Hurst 2006). 
3.11 MEASURING HEALTH RELATED OUALITY OF LIFE 
Indices of Health Related Quality Of Life (HRQOL) were obtained using the 
St. Georges Respiratory Questionnaire (SGRQ) (Jones 1991, Jones 1992). Three 
component indices were calculated using empirically derived weightings: Symptom, 
Activity and Impact scores from which a Total score was computed. Scores vary from 
0 (no disability) to 100 (maximum disability). Patients were also asked to complete 
the modified Medical Research Council (MRC) dyspnoea scale questionnaire. These 
questionnaires were completed by the patients annually at clinic visit without 
directions from the researchers. 
3.12 STATISTICAL ANALYSIS 
Normally distributed data are reported by means (SDs) and skewed data by 
medians (interquartile range [IQR]). Correlations were assessed using the Pearson or 
Spearman correlation coefficient (two tailed). Continuous variables with normal 
distributions were compared by mest, whereas those with non-normal distributions 
84 
METHODS 
were compared by the Mann-Whitney U or Wilcoxon signed ranks test. During the 
analysis, patients were divided into groups dependent on exacerbation frequency 
during the study. Patients with an exacerbation frequency that was higher or lower 
than the median were termed "frequent" or "infrequent" exacerbators, respectively 
(Seemungal 1998); p values of 0.05 or less were regarded as significant. The SPSS 
version 10.0 (SPSS Chicago, IL) statistical package and STATA-5 software (Stata 
Corporation, Texas, USA) were used for data analysis. Further statistical analyses are 
described in the appropriate chapters. 
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3.13 DisCUSSION OF STUDY METHODOLOGY 
PATTENT SELECTION 
The inclusion and exclusion criteria for the cohort and hence the studies 
described in this thesis were developed and established during the conception of the 
study. The specific criteria were developed in order to ensure that the patient cohort 
was representative of a group of patients with COPD that could exist in any clinic 
population whilst excluding those patients in whom other respiratory diseases may 
impact on the nature and interpretation of clinical and laboratory findings. 
COPD is a common condition and is likely therefore to co-exist with other 
pulmonary pathologies in any population. Indeed it has been suggested that certain 
other lung pathologies may predispose the smoker to COPD. For example the entry 
criteria into the study preclude a previous history of asthma. There has been continued 
debate in the literature about the importance of asthma or airway hyper-reactivity in 
the aetiology of COPD. The 'Dutch hypothesis' supports a relationship of asthma with 
COPD (Orie 1961). The evidence for this comes from a number of disparate studies; 
bronchial hyper-reactivity, blood cosinophilia, and serum IgE levels are higher in 
smokers compared to nonsmokers and peripheral eosinophilia was also shown to 
correlate with airway obstruction (Burrows 1980). Eosinophilic inflammation of the 
airways in patients thus has been clearly defined in a subset of COPD patients. This is 
also the group of patients who are likely to show reversibility of airway obstruction 
with therapy with corticosteroids (Brightling 2000). It is possible that by excluding 
patients with marked airway reversibility therefore that we are in fact biasing the 
study population by excluding the phenotype described above. Indeed there is 
evidence that reversibility testing in COPD is poorly reproducible (Calverley 2003), 
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however when considering the role of airway infection in COPD it is important to 
study disease population in which the contribution of other pulmonary pathologies is 
minimised as the prevalence and responses to pathogen are likely to differ between 
subjects with COPD and other diseases (Message 2004). Furthermore, patients were 
not excluded from the study on grounds of non-pulmonary co-morbidities as is the 
case in many intervention studies. Co-morbidities are common in patients with COPD 
and impact significantly on clinical outcomes (Holguin 2005) and may impact upon 
upon the natural history of COPD. Therefore, the data collected and conclusions made 
by this study can be considered generalisable to a general COPD population of similar 
disease severity but additional studies of patients with significant concurrent 
pulmonary conditions other than COPD are indicated. 
TECHNIQUES OF AIRWAY SAMPLING AND SAMPLE PROCESSING 
Any clinical study which aims to determine the role of lower airway infection 
must utilise techniques which enable the investigator to determine not only which 
pathogens are present in the lower airway but also how many are present, and what 
the effects of these pathogens on measured indices of airway inflammation are as well 
as the clinical and physiological consequences of infection. For this purpose, the 
ability to sample the lower airway to inform the researcher as to the nature of 
infection and inflammation in the lung is fundamental. Furthermore, the sampling 
techniques used must be safe, well tolerated and provide reliable and reproducible 
data which if it is not completely representative of the in vivo airway at least provides 
a close approximation. 
There is now a body of work which has established sputum sampling and 
processing as an appropriate method to achieve the aims described above. In order to 
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provide meaningful data for clinical studies, all aspects of sampling and sample 
processing must be optimised, including sample collection, sample processing and 
techniques of laboratory analysis. 
SPUTUM INDUCTION TECHNIQUES 
Whilst a significant proportion of COPD patients expectorate sputum on a 
regular basis a substantial proportion do not or only do so intermittently. The use of 
sputum induction techniques to obtain lower airway samples have been standardised 
and can aid the researcher in obtaining sputum specimens from patients with an array 
of conditions including COPD (Pin 1992). In the ERS guidelines on sputum induction 
published in 2002 (Djukanovic 2002), the section on sputum induction states that 
'The aim of sputum induction is to collect an adequate sample of secretions from 
lower airways in subjects who do not produce sputum spontaneously in order to study 
the features of airway inflammation in asthma and other respiratory disorders' 
(Paggiaro 2002) 
The technique of sputum induction has been well validated since the early 
finding that inhalation of small amounts of hypertonic saline may stimulate the 
production of airway secretions which can be collected following expectoration. The 
mechanisms underlying the production of sputum in response to inhalation of saline 
are not fully understood. However, a number of studies have confirmed that this 
technique has the potential to produce high quality, reproducible samples for analysis 
from patients with COPD (Peleman 1999, Keatings 1996). 
When considering what information is being provided by the analysis of 
induced sputum it is necessary also to determine which areas of the lung are 
providing the infective or inflammatory 'signature' contained within the sputum 
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sample obtained. A number of studies have compared the results of analysis of 
sputum samples with those of bronchoscopic sampling including washes, bronch- 
alveolar lavage and biopsies (Lensmar 1998, Pizzichini 1998, Grootendorst 1997, 
Fahy 1995, Keatings1995). These studies performed in asthmatic subjects and 
demonstrated variable relationships between eosinophil and neutrophil percentages 
between induced sputum and bronchial wash and BAL fluid. Furthermore sputum 
eosinophil counts were related to the number of eosinophils in bronchial biopsies. 
This suggests that in asthma, induced sputum techniques can produce airway samples 
that are representative of the inflammatory processes detectable by other means, 
however sputum from a small study of chronic bronchitics produced differing results, 
with closer correlations between cell numbers from different sample types only seen 
in exacerbating bronchitis. (Maestrelli 1997). In COPD, neutrophils were the 
predominant cell type in induced sputum samples from COPD subjects but not from 
bronchoscopic specimens. Furthermore sputum differential cell counts were not 
significantly related to those in wash or BAL. However levels of soluble markers such 
as eosinophil cationic protein (ECP) and interleukin-8 (IL-8) did relate to those seen 
in bronchoscopically derived specimens. (Rutgers 2000). Hence induced sputum 
would appear to be sampling a different airway component than bronchoscopic 
techniques but results between techniques are comparable especially with respect to 
measurement of soluble inflammatory markers. 
SPONTANEOUS SPUTUM; COMPARISONS WITE INDUCED SPUTUM 
A significant proportion of patients with COPD spontaneously expectorate 
sputum on a regular basis and an even higher proportion do so at acute exacerbation 
(Seemungal 2000). Early studies comparing the composition of spontaneous and 
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induced sputum in asthmatics demonstrated that both sample types contained similar 
cellular and cytokine profiles, however cell viability was lower in spontaneous 
samples (Pizzichini 1996, Bartoli 2002). This finding has been reproduced in a 
comparative study of spontaneous and induced sputum in patients from the East 
London COPD cohort (Bhowmik 1998). Here in a population of patients with 
moderate to severe COPD, FEVI, 38.2% predicted, that is nearly identical to those 
sampled in the studies described in the thesis, Bhowmik demonstrated that there was 
no significant difference in total and differential cell counts or in interleukin 8 levels 
between spontaneous and induced sputum samples. However, cell viability was lower 
in the spontaneous samples. One may conclude from this study that the use of 
spontaneous sputum is highly comparable to that of induced sputum for the 
measurement of cytokines, chemokines and cellular components but not for assays 
which rely upon cell viability. 
SPUTUM SAMPLING AND THE STUDY OF AIRWAY INFECTION 
A key feature of this thesis is the study of airway pathogens both viral and 
bacterial and their effects on airway inflammation and clinical outcomes. Hence the 
techniques utilised to sample the airway to assess airway inflammation must also be 
appropriate for assessing airway infection. A body of work exists which has validated 
the use of sputum in this role exists. A number of studies over a number of years that 
have assessed airway bacterial infection in COPD phenotypes have shown that 
sputum samples can be useful in identifying and quantifying airway pathogens 
(Brown 1954, Lapinski 1964, Smith 1976, Bartmann 1984, Hill 2000, Sethi 2002, 
Patel 2001). A number of these studies have used spontaneous sputum samples, or a 
combination of both induced and spontaneous techniques. Previous work by our 
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group has shown that both sampling techniques are comparable in estimating airway 
bacterial load and type (Patel 2000). Indeed obtaining sputum samples from patients 
with severe COPD, particularly during acute exacerbations with induction techniques 
can be difficult (see below) and therefore the utility of including analysis of 
spontaneous sputum samples allows not only additional sampling points to be 
assessed but also allows more severe patients with spontaneous sputum production to 
be included in the study. 
Any sampling technique of lower airway pathogens is, because of the relative 
anatomy, open to possible contamination by pathogens colonising or infecting the 
upper airway. Some techniques are able to minimise this by directly removing 
samples from the lower airway, for example bronchoscopic techniques, especially 
with the use of the protected specimen brush. However, bronchoscopies are not 
without associated risk to patients and are not suitable for long term cohort studies 
where repeated sampling is required or larger numbers of patients are to be followed 
up by a single researcher or during acute exacerbations. Contamination of sputum 
which must be expectorated through the upper airway by bacteria present in the naso- 
pharynx can be minimised but not prevented by the sampling techniques utilised; 
including nose blowing and mouth rinsing before expectoration. However, to 
significantly affect the results of sputum studies, large loads of upper airway bacteria 
would need to contaminate the lower airway samples obtained. Work involving direct 
sampling of upper and lower airways in our cohort has shown that the airway bacterial 
load in sputum both in the stable state and at exacerbation is several orders of 
magnitude higher than that seen in the upper airway and that the prevalence of 
potentially pathogenic micro-organisms is also significantly greater in the lower 
airway (Hurst 2005, Hurst 2006). Therefore, the effect size of upper airway 
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contamination using sputum techniques is likely to be minimal in terms of 
quantifiable parameters of infection but may impact on qualitative assays of airway 
infection such as viral PCR detection. 
SAFETY AND TOLERA13ILrrY OF SPUTUM INDUMON 
The use of sputum sampling in studies of pulmonary diseases has numerous 
advantages, not least in the tolerability and convenience of this approach in 
comparison to more invasive techniques. However, sputum induction, although 
generally well tolerated by COPD patients can cause adverse side effects and it is of 
vital importance that steps are taken to minimise risks to patients. Published 
guidelines on this technique highlight the importance of patient selection, 
premedication and careful monitoring during induction. The ERS document highlights 
the evidence that sputum induction is safe and well tolerated in asthma and mild to 
moderate COPD. (Wong 1997, de la Fuente 1998, Hunter 1999, Twaddell 1996, 
Grootendorst 1999, Fahy 1993, Vlachos-Mayer 2000). 
Whilst some studies in patients with more severe COPD have shown the 
technique to be safe and well tolerated, (Pizzichini 1998), it is well recognised that 
inhalation of nebulised saline can cause significant broncho-constriction, particularly 
at concentrations above 3% (Bickerman 1958). Pre-medication with inhaled Beta 2 
agonists can limit the induction of broncho-constriction, and is now recommended by 
established guidelines (Pizzichini 2002). However, it is apparent that bronchodilator 
therapy does not completely prevent broncho-constriction. In a previous study of 
patients from our cohort a small but significant fall in forced expiratory volume in 
one second (FEVI) of 0.098 (0.11 I)l and in forced vital capacity (FVC) was 
0.247 (0.233)l was observed (Bhowmik 1998). In other studies while the procedure 
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was well tolerated, the mean change from prebronchodilator FEVI during sputum 
induction was 8.5%, and from postbronchodilator FEVI was 10.7%, with a small 
number of the patients (I I%) experiencing a fall in FEV I from the prebronchodilator 
baseline of >20%, and a further 10 (36%) a fall of 10% (Rytila 2000). 
Therefore in patients with very severe disease (FEV I< 30% predicted) or 
during exacerbations when airway hyper-responsiveness is likely to be up-regulated 
changes of the magnitude seen during induction techniques can carry some risks and 
close patient monitoring is mandatory. A minimum standard would include 
continuous monitoring of oxygen saturation, repeated spirometry at regular intervals 
and close clinical supervision (Pizzichini 2002). Indeed during the prospective follow 
up and repeated sampling of a cohort study, particular individuals can be identified 
who react adversely to induction and excluded from further sampling in this manner. 
The induction techniques utilised in this study and outlined in the methods section 
above, were established and validated by a series of clinical researchers in previous 
studies in this group. They have proven to be safe, well tolerated and have by 
continued use of established protocols produced reproducible results which have 
allowed longitudinal follow up and analysis of cohort data over a number of years. 
SPUTUM PROCESSING METHODS 
A standardised methodology for processing sputum is necessary in order to 
produce samples which are suitable for subsequent laboratory analysis, to ensure 
maximal reproducibility and to exclude samples of poor quality. The processing 
techniques used in this study have been established and validated in a number of 
previous studies by our group (Bhowmik 1998, Bhowmik 2000, Seemungal 2000, 
Patel 2002, Patel 2004, Hurst 2004, Donaldson 2005, Hurst 2005). Indeed in order for 
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data from this cohort study to be consistent from one investigator to the next the 
techniques of sampling and processing have been standardised to ensure the validity 
of longitudinal analysis. This is reliant upon the reproducibility of techniques and of 
sample quality over time. 
There are two established methods for processing sputum for analysis, the first 
is reliant upon removing sputum plugs from the sample to minimise the dilutional 
effects of saliva on the sample the selected sputum technique (Pizzichini 1996). This 
was performed in this study using macroscopic examination and disposable plastic 
forceps. The alternative technique involves processing the entire expectorate, 
comprising sputum plus variable amounts of saliva, which may lead to variable 
dilutional effects of saliva on the sample and increases in squamous cell 
contamination (Efthiamiadis 1995). 
Once sputum was selected it was divided into a portion for bacterial analysis, 
cell counts and preservation of the liquid phase for later analysis of mediators. The 
reasons for the parallel processing of samples lie in the realisation that DTT itself can 
affect the ]measurement of mediators studied downstream of processing. Indeed 
whilst use of DTT can improve cytospin quality (Louis 1999) it may also reduce the 
detectable concentration of markers such as TNFa, LTB4 and MPO (Woolhouse 
2002). Therefore, two sub-samples were processed: one with DTT and an additional 
one wit BS and the use of subsequent aliquots dependent on the analysis required. 
The use of sputum to assess pulmonary disease processes will only give one 
aspect of the processes involved in the pathology of the disease, namely that involving 
the airway lumen. Indeed, sputum is not produced in the smallest distal airways nor in 
the alveolar compartment where significant pathology develops in patients with 
COPD (Hogg 2004). The techniques developed and utilised in this study for the 
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assessment of airway inflammation and infection in patients with moderate to severe 
COPD are however safe, well tolerated and suitable for the repetitive sampling 
required. Further studies using bronchoscopic techniques including biopsy and 
histological analysis of surgically obtained tissue samples are required to determine 
the complex relationships between pulmonary infection and inflammation throughout 
the lung and whilst these will inform on the mechanisms underlying the development 
of COPD they are of limited immediate clinical utility, thus further development of 
non-invasive sampling techniques are required to increase the value of measuring 
airway pathology in predicting physiological and clinical outcomes. 
CONCLUSION 
The methods used in this study have been established and validated for the 
follow up and investigation of infective and inflammatory parameters in patients with 
moderate to severe COPD. As in any study the limitations of the methods used will 
affect the ability to interpret the data in the context of the disease as a whole and to 
extrapolate findings to a wider population. The studies performed have been largely 
observational in nature and therefore care has been taken to limit conclusions about 
causality when appropriate. However the findings described in subsequent chapters do 
represent those from a real patient population and are not open to issues of relevance 
raised by many in vitro or animal studies. The following chapters describe the 
findings of the studies designed to address the aims outlined in chapter 2. 
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CHAPTER 4 
LOWER AIRWAY BACTERIAL 
COLONISATION, INFLAMMATION 
AND FEV I DECLINE IN PATIENTS 
WITH STABLE COPD 
A irway bacterial colonisation is an established phenomenon in COPD. 
However the majority of studies to date have not been prospective in nature 
and determining the role of bacteria in disease progression for example has not been 
possible. In this chapter, the pattems of airway bacterial colonisation over time are 
described and the relationships with inflammation and disease progression 
determined. 
4.1 INTRODUCTION 
Smoking is the most important factor in the aetiology of COPD and is known 
to cause inflammation in the lung (Di Stefano 1998). However, smokers exhibit a 
variable rate of decline in lung function, suggesting that other may contribute to the 
progression of COPD. 
Patients with stable COPD exhibit increased airway inflammation (Riise 1995, 
Keatings 1996) and the degree of airway inflammation is positively related to the 
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severity of airway obstruction with more bronchial inflammation in patients with a 
lower FEVI (Di Stefano 1998). Furthermore, higher levels of airway inflammation, as 
evidenced by high sputum neutrophil counts, were associated with a greater rate of 
decline in FEV, (Stanescu 1996). The stimulus for increasing airway inflammation as 
lung function declines has not yet been determined. 
The lower airways of healthy individuals are sterile, but bacteria have been 
isolated in significant numbers in patients with clinically stable COPD, indicating the 
presence of lower airway bacterial colonisation. (LABC) (Monso 1999, Zalacain 1999, 
Monso 1995). The presence of bacteria in the lower airway can result in a range of 
important effects on the lung, including activation of host defences with release of 
inflammatory cytokines and subsequent neutrophil recruitment, mucus hypersecretion, 
impaired mucociliary clearance, and respiratory epithelial cell damage (Murphy 
1992). Animal models of chronic bacterial infection in the lung have shown changes 
characteristic of those seen in COPD in terms of inflammatory cells, cytokine 
expression, and pathologic changes to both airways and alveoli (Vemooy 2002). 
There is evidence that airway inflammation increases with higher airway bacterial 
loads determined from quantitative sputum cultures in patients with COPD (Ilill 
2000). Thus, it has been suggested that chronic LABC contributes to progression of 
airways obstruction (Wilson 1992, Wedzicha 2000). 
Airways obstruction and in particular COPD is an established risk factor for 
cardiovascular disease (Sin 2003, Dahl 2001). In longitudinal studies severity of 
airways obstruction has been shown to be a more reliable predictor of cardiac cause 
mortality than more accepted risk factors such as serum cholesterol (Hole 1996). 
Indeed, cardiovascular disease is the commonest cause of morbidity in patients with 
COPD (Schuneman 2000, Friedman 1976). As airways obstruction develops in 
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patients with COPD, the risks of CHD increase. These are associated with elevated 
levels of inflammation-sensitive plasma proteins which are not explained by smoking 
alone (Engstrom 2002, Wedzicha 2000). 
Plasma fibrinogen and other acute phase proteins are markers of systemic 
inflammation and have been shown to be elevated in COPD patients in the stable state 
compared to a normal population (Meade 1993, Sin 2003, Engstrom 2002) and to rise 
further during acute exacerbations (Wedzicha 2000). Whilst the stimuli to airway 
inflammation such as cigarette smoking and lower airway bacterial colonisation in 
COPD patients have been described (Riise 1995, Stanescu 1996, Hill 2000), the role 
of these factors in the pathogenesis of systemic inflammation is not fully established. 
Although an analysis of baseline data from an interventional study has suggested that 
lower airway bacterial colonisation may be associated with higher levels of systemic 
inflammation (Banerjee 2004), other studies have failed to show this relationship 
(Hurst 2005). 
Fibrinogen is produced by hepatocytes in response to stimulation by systemic 
inflammatory cytokines chiefly interleukin 6 (IL-6) (Castell 1989, Gabay 1999). 
Elevated plasma fibrinogen is an established risk factor for coronary heart disease 
(CHD) (Meade 1993, Ernst 1997, Salomaa 2002). A large meta-analysis of 18 studies 
yielded an associated relative risk of CHD of 1.8 for patients with fibrinogen levels in 
the top third of baseline measurements (reference range 2.0-4.5 g/1) (Danesh 1998). In 
addition to increased risk of CHID, elevated fibrinogen levels are also associated with 
increased risk of stroke (Smith 1997) and overall mortality (Yano 2001). 
Previous studies performed to evaluate the relationship between airway 
bacterial colonisation, inflammation, and lung function have been cross-sectional in 
design and have not addressed the important relationship between these parameters 
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and effects on disease progression. Furthermore whilst lower airway bacterial 
colonisation is linked to airway inflammation in COPD its contribution to systemic 
inflammation is unclear. This section of the study addresses the hypothesis that 
bacterial colonisation leads to increased airway and systemic inflammation and thus 
contributes to the accelerated progression of airway obstruction and potentially 
additional cardiovascular morbidity. Therefore, by studying changes in airway 
bacterial load and type over time and relating these parameters of infection to indices 
of airway inflammation and decline in lung function we could inform on the role that 
bacterial colonisation may play in COPD. 
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4.2 METHODS 
The methods of patient selection, recruitment follow up and sampling are 
described in Chapter 3 of this thesis. The methods specific to the analysis described in 
this chapter are described below. 
PATIENT POPULATIONS 
The inclusion criteria and clinical and sampling methodology have been 
described in chapter 3. Seventy four patients from the COPD cohort were sampled in 
total to assess the pattern of lower airway bacterial colonisation and the analysis of 
relationships between bacterial colonisation and airway and systemic inflammation. 
Patients were followed prospectively and sampled in the stable state as described in 
Chapter 3. Of this population, thirty patients were sampled at one year after the initial 
sample for the study of the relationship between changes in bacterial colonisation and 
FEV, decline. Each patient had been clinically stable (exhcerbation-free) for at least 6 
weeks before both recruitment and sampling at the end of the study by patient 
interview and review of diary cards. Patients who suffered an exacerbation around the 
end of the study period were only sampled when they had been clear of exacerbation 
symptoms and had completed any exacerbation treatment for at least 6 weeks. 
MEASUREMENT OF LUNG FUNCTION 
Lung function was measured with a rolling seal spirometer (Sensor Medic 
Corp., Yorba Linda, California). Lung function measurements were taken in the 
morning ,I hour after the patient's usual bronchodilator medication inclusive of 200 
[tg of salbutamol via metered dose inhaler. At least three spirometry readings were 
taken at each visit, and the best performance was recorded. 
100 
STABLE STATE BACTERIOLOGY 
SPUTUM SAMPLING 
Sputum was sampled at the beginning and the end of the study. Sputum 
interleukin (IL)-6 and IL-8 levels were measured using ELISA (R&D Systems, 
Abingdon, UK). 
VENous BLOOD SAMPLING 
4.5ml of venous blood was obtained from an ante-cubital vein without vene- 
stasis into vacuum tubes with sodium citrate (0.5ml). 'Ibrombin-clottable plasma 
fibrinogen was measured in the stored serum samples by the method of Clauss (Clauss 
1957). Plasma interleukin 6 (IL-6) were measured using a standard ELISA technique 
(R&D Systems Abingdon, UK). 
QUANTITATIVE BACTERIAL ANALYSIS 
Samples were processed by using sputolysin, quantitative bacteriological 
analysis was performed as described in Chapter 3. 
STATISTICAL ANALYSIS 
Normally distributed data are reported by means (SDs) and skewed data by 
medians (interquartile range [IQR]). Correlations were assessed using the Pearson or 
Spearman correlation coefficient (two-tailed). Continuous variables with normal 
distributions were compared by mest, whereas those with non-normal distributions 
were compared by the Mann-Whitney U or Wilcoxon signed-ranks test. Repeat 
sampling allowed analysis of both intra-patient variability and inter-patient variability 
of airway bacteriology and inflammatory markers. To analyze the effects of bacterial 
colonisation independently of patient characteristics (smoking status, exacerbation 
101 
STABLE STATE BACTERIOLOGY 
frequency, and FEVI), we used using the general linear mixed model (xtreg) 
procedure in STATA-5 software (Stata Corporation, Texas, USA). These procedures 
are designed for panel (cohort) data and are particularly useful where data are 
correlated, as in repeated-measures designs and where there are complex error 
structures (Donaldson 2005). 
During the analysis, patients were divided into groups dependent on 
exacerbation frequency during the study. Patients with an exacerbation frequency that 
was higher or lower than the median were termed "frequent" or "infrequent" 
exacerbators, respectively; p values of 0.05 or less were regarded as significant. 
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4.3 RESULTS 
4.3.1 PAIIENT CHARACTERISTICS 
The baseline physiological characteristics of the 74 patients who were 
recruited for the study are summarized in Table 4.1. 
Table 4.1 Baseline Patient Characteristics 
Sampled patients (n=74) 
Median IQR 
Age (years) 67.4 62.2 to 71.4 
FEV, (1) 0.98 0.77 to 1.37 
FEV, (% predicted) 39.2 29.6 to 57.8 
FEV, (% reversibility) 7.94 0.8 to 13.1 
FVC (1) 2.41 1.86 to 2.90 
FEVt/FVC M 43.9 35.5 to 53.1 
PEF (Iftnin) 158 122 to 238 
Pa02 (kPa) 8.94 8.14 to 9.43 
Pa C02 (kPa) 5.88 5.32 to 6.29 
Smoking (years) 45 39 to 51 
Current Smokers 28 
Exacerbation frequency 2.51 1.28 to 3.83 
(per year) 
Further details of individual patient populations involved in any sub-analysis 
are included with the relevant results section. 
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4.3.2 STABLE STATE LoWER AIRWAY BACTERIAL COLONISATION IN PATIENTS V; lTli 
MODERATE TO SEVERE COPD 
SPUTUM BACTERIOLOGY 
Potentially pathogenic bacterial micro-organisms (PPMs) were identified in 
57.3 % of the initial sputum samples with the remaining 42.7 % demonstrating 
significant non-specific growth (NSG). The relative prevalence of individual bacterial 
species from all samples is illustrated in Figure 4.1. The most prevalent colonising 
bacterial organism was Haemophilus influenzae present in 19.1 % of samples. 
The overall mean airway bacterial load was 107.98(0.83) Cfu/Mj. Potentially 
pathogenic organisms (defined in chapter 3), were present at a greater bacterial load 
of io8.18(0.77) CfU/Ml compared to non-specific growth IW-67(0-")cfulml (p= 0.001) with 
a trend to a higher load in active smokers; io8.14(0.10) CfU/Ml than in ex-smokers; 
107.91(0.08) CfU/Ml (p=0.083). No significant relationship was seen between disease 
severity and airway bacterial load. 
The variation in airway bacterial load between different colonising bacteria are 
illustrated in Figure 4.2. Haemophilus inflitenzae load (108.50(0.09), p=0.004) and 
Moraxella catarrhalis load ( 108.54(0.14), p=0.033) were both present at higher bacterial 
loads than the other PPMs, with no significant difference in airway bacterial load 
identified for the other species. 
4.3.2.1 SEASONALITY OF BACTERIAL COLONISAIION 
The effects of seasonality on airway bacterial colonisation was analysed by 
comparing airway bacterial loads and relative pathogen prevalences for samples taken 
from each season: Spring (March-May), Summer (June-August), Autumn 
(September-November) and Winter ( December- February). The mean stable airway 
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bacterial load varied with season (anova p= 0.018) and was higher in the Summer 
than in other seasons Figure 4.3, whilst the variations in relative prevalence of airway 
pathogens isolated did not reach statistical significance (Figure 4.4). 
FIGURE 4.1 RELATIVE FREQUENCY OF BACTERIAL ISOLATES EXPRESSED AS A 
PERCENTAGE OF TOTAL SAMPLES IN 74 PATIENTS. 
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FIGuRE 4.2 AIRWAY BACTERIAL LOAD EXPRESSED AS LOG COLONY FORMING UNITS PER 
MILLILITRE (LOG CFU/ML) FOR DIFFERENT BACTERIAL ISOLATES FROM SPUTUM 
SAMPLES. 
* denotes significantly different airway bacterial load for particular isolate in 
comparison to load of other potentially pathogenic organisms. Haemophilus 
influenzae p=0.004, Moraxella catarrhalis p=0.033. NSG refers to Non-Specific 
bacterial Growth. 
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Figure 4.3 SEASONAL VARIATION IN AiRwAy BACTERIAL LOAD l0g cfu/ml for I 
Spring (March-May), 2 Summer (June-August), 3 Autumn (September-November), 4 
Winter ( December- February). p=0.0 18 ANOVA, for difference between seasons. 
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FIGURE 4.4 SEASONAL VARIATION IN RELATIVE PREVALENCE OF SPUTUM BACTERIAL 
ISOLATES. Spring (March-May), Summer (June-August), Autumn (September- 
November), Winter ( December- February). NS. (p>O. 12) ANOVA, for difference 
between seasons, n =74. 
Relative Prevalence of Bacterial Isolates: Spring Relative Prevalence of Bacterial Isolates: Summer 
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Key: Red = NSG, Green = Haemophilus influenzae, Blue = Streptococcus 
pneumoniae, Pink = Moraxella catarrhalis, Yellow = Gram Negative Enteric Bacteria 
(GNEB), Grey = Pseuclomonas cieruginosa. 
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4.3.3 AIRWAY INFLAMMAIION 
4.3.3.1 INDICES OF AIRWAY INFLAMMATION. 
The baseline inflammatory indices from stable state sputum samples, n= 74, 
are displayed in Table 4.2 below. 
TABLE 4.2 SPUTUM INFLAMMATORY INDICES IN STABLE STATE COPD PATIENTS n= 74. 
Cell counts expressed as total or percentage of non-squamous cells per sample 
MEDIAN IQR 
116 (pg/ml) 145.5 76.0-260.5 
118 (pg/ml) 2349 1682-3063 
106 Total cell count (x cells /g) 3.76 1.57-11.08 
Total neutrophils (x 106 cells /g) 2.38 0.52-6.23 
% Neutrophils 71.7 38.1-85.2 
Total macrophages (x 106 cells /g) 0.85 0.38-1.34 
% Macrophages 26.2 14.3-60.1 
Total eosinophils (x 106 cells 1g) 0.4 0.087-0.12 
% Eosinophils 0.88 0.43-1.81 
106 Total lymphocytes (x cells /g) 0 0-0.006 
% Lymphocytes 0 0-0.44 
4.3.3.1 AIRWAY INFLAMMAIION, BACTERIOLOGY AND PATIENT CHARACTERISTICS 
There was a positive association between higher airway bacterial loads and 
greater levels of airway inflammation in terms of sputum IL-8 (rho = 0.38, p=0.029), 
which in turn was related to total sputum (non-squamous) cell count (rho = 0.39, p= 
0.01), and neutrophil differential count (rho = 0.41, p=0.010). 
There were no significant associations between spirometric criteria of disease 
severity and sputum cell counts however, sputum IL-6 was greater in patients with 
lower percent predicted FEV, (rho= -0.347, p= 0.036). Patients with more frequent 
exacerbations had greater number of total sputum cells (rho = 0.297, p=0.04), greater 
percentage of neutrophils; (rho = 0.323, p= 0.027) and higher levels of sputum (IL-8; 
rho = 0.326, P= 0.043). 
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Airway inflammation was greater in patients colonised with Haemophilus 
influenzae and lower in those colonised with Haemophilus parainfluenzae; see figure 
4.5. 
FIGURE 4.5 VARIATION IN SpuTum IL 8 PG/ML wmi AIRWAY BACTERIAL ISOLATE. 
*= significant difference from median IL8 for all other samples (p<0.05). 
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4.3.4 AiRWAY BACTERIA AND SYSTEMIC INFLAMMATION 
4.3.4.1 PLASMA FIBRINOGEN AND INTERLEUMN 6 (IL-6) 
The mean (SD) plasma fibrinogen for all samples was 4.23 (0.84) g/l. The 
median (IQR) serum IL-6 was 6.48 (5.11-10.05) pg/ml. The plasma fibrinogen level 
was related to the IL-6 level r=0.43, p=0.001. Plasma fibrinogen was higher in 
samples from active smokers than from ex-smokers; 4.47(0.89)g/l vs 4.14 (0.79)g/l 
respectively, p=0.023,. 
There was a trend towards higher IL-6 in active smokers; 5.87 (4.94-9.3 1) 
pg/ml than ex-smokers 9.02 (5.75-12.41) pg/ml, p=0.078. Plasma fibrinogen was 
greater in patients with more severe airways disease (lower % predicted FEVI) r= 
0.238, P=0.003. 
4.3.4.2. RELATIONSIIIPS BETWEEN SpuTum BACTERIA AND PLASMA MARKERS 
The plasma fibrinogen and IL-6 levels varied with the nature of bacterial 
colonisation in the associated sputum sample; fibrinogen levels were greater in 
samples associated with colonisation with a potentially pathogenic organism; 
fibrinogen 4.35(0.89) g/l, IL-6 7.31 (5.73-12.17) pg/ml compared to those exhibiting 
non-speci ic growth; fibrinogen 4.23(0.83) g/l p=0.031, IL-6 5.4 (4.49-9.02) pg/ml, 
p =0.001. 
The plasma levels of fibrinogen and IL-6 for samples grouped by 
corresponding bacterial isolate are shown in figure 4.6. Colonisation with 
Pseudomonas aeruginosa was associated with greater systemic inflammation; 
fibrinogen 4.82(l. 04) g/l, IL-6 10.94 (6.50-14.41) pg/ml than all other PPMs; 
fibrinogen 4.16 (0.77) 9/1 p=0.036, IL-6 6.58(5.67-10.11) pg/ml p=0.003. Whereas 
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colonisation with Haemophilus parainfluenzae was associated with lower fibrinogen; 
3.68(0.47) g/l than with other PPMs; fibrinogen 4.27(0.84) g/l, p=0.039. 
IL-6 levels were related to airway bacterial load (r =0.175, p =0.035), but no relation 
between load and fibrinogen was found. The association between Pseudomonas and 
higher plasma fibrinogen remained if allowance for FEVI, bacterial load and smoking 
status was made in the regression model (regression coefficient 0.6, CI 0.21-0.99), 
p=0.003. 
In Table 4.3, the results of a multiple linear regression with fibrinogen and IL- 
6 as outcome variables are shown. The influence of colonising bacterial species on 
these plasma markers remains significant even if the possible confounders smoking 
and factors associated with disease severity, are included in the analysis. 
TABLE 4.3 MULTIPLE LINEAR REGRESSION ANALYSIS OF FACTORS ASSOCIATED WITH 
PLASMA FIBRINOGEN AND IL-6 LEVELS AS OUTCOME VARIABLES 
Fibrinogen IL-6 
Factor p Cl pp Cl 
FEV, -0.62 -1.06 to -0.17 0.007 -1.97 -0.42 to 0.25 0.081 
Smoking 0.24 -0.05 to 0.54 0.113 0.50 -0.99 to 1.99 0.508 
Bacterial Load -0.02 -0.19 to 0.15 0.813 0.38 -0.50 to 1.27 0.392 
Bacterial Species 0.08 0.0 1 to 0.14 0.021 0.38 0.07 to 0.70 0.019 
P02 0.08 -0.05 to 0.23 0.222 -0.39 -1.1 to 0.32 0.281 
PC02 -0.16 -0.31to-0.07 0.049 -0.17 -0.93toO. 59 0.656 
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4.3.4.2. AIRWAY AND SYSTEMIC INFLAMMATION 
There were no significant correlations found between airway and systemic 
inflammation. 
FIGURE 4.6. RELATIONSHIP BETWEEN PLASMA FIBRINOGEN AND INTERLEUKIN-6 (IL-6) 
in 161 blood samples from 74 patients with stable COPD. r=0.43, p=0.001. 
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FIGuRE 4.7. PLASMA FIBRINOGEN (A) AND INTERLEUKIN-6 (B) LEVELS ASSOCIATED 
VVITH DIFFERENT SPUTUM BACTERIAL ISOLATES. * denotes significantly different level 
of plasma marker from other potentially pathogenic organisms (see text for values) 
NSG refers to Non-Specific bacterial growth. 
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4.3.5 LoWER AIRWAY BACTERIAL COLONISATION AND FEV I DECLINE OVER 1 YEAR 
As an initial study into the relationship between lower airway bacterial 
colonisation and disease progression, thirty patients from the cohort who had 
previously tolerated sputum induction and who were established on optimal inhaled 
therapy, were sampled and were followed for a median (IQR) period of 1.05 (1-1.22). 
The mean (SD) FEV, for this population was 0.947 (0.329) 1, and the predicted FEV, 
was 34.8% (13.6%), with a range from 13.80 to 69.95% predicted, at the start of the 
study. Eleven of the 30 patients were current smokers at the time of recruitment and 
did not alter their smoking habits during the study. Twenty eight of the patients were 
receiving inhaled steroids with a mean (SD) dosage of 1.55 mg (0.92) beclomethasone 
equivalents; no changes to the dose of inhaled steroid occurred during this sub- study. 
The baseline data for these 30 patients did not differ significantly from that of the 
other patients in the cohort. At the first sample point, 24 patients produced sputum 
spontaneously, the remainder being induced, compared with 22 patients expectorating 
spontaneously at the second sample point. 
FEV I DECLINE 
The mean (SD) FEV, at recruitment was 0.947 (0.329) L and declined to 0.883 
(0.367) L at the end of the 1.05 (1-1.22)-year sample interval. The mean annual rate 
of decline was 57.6 (137-6) ml per year; expressed as percentage of initial FEV I, this 
equates to 6.08% of baseline FEV, decline per year. The 30 patients had a total of 86 
exacerbations during the study period, 40 (46.5 %) of which were reported to the study 
team; the remainder of the exacerbations were diagnosed from diary card review, a 
proportion of which (17.4%) had been independently reported to a general 
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practitioner. Fifty-two exacerbations received antibiotic treatment during the study. 
The median (IQR) exacerbation frequency in this study was 2.39 (1.95) exacerbations 
TABLE 4.4. CHARACTERISTICS OF 30 PATIENTS IN THE 1 YEAR STUDY OF BACTERIAL 
COLONISATION AND DECLINE IN FEV I. 
Characteristic Mean (SD) 
Number, female/male 8/22 
Age, years 66.43 (10.25) 
FEV 1, L 0.95(0.33) 
FEVI percentage predicted 34.81 (13.61) 
FVC, L 2.51(0.70) 
FEVI/FVC percentage 38.40 (10.70) 
PEF, Umin 218.07 (76.14) 
Pa02, kPa 8.55(l. 11) 
Pac02, kPa 6.20(1.00) 
Pack-years of smoking 74.3(66.5) 
Inhaled steroid dosage 1.55(0.92) 
Beclomethasone equivalent, mg/day 
per year. Patients with an exacerbation frequency higher than this median (frequent 
exacerbators) had more severe airways obstruction with a mean FEV, of 0.86 L 
compared with infrequent exacerbators with a mean FEV, of 1.07 (p = 0.05). 
BACTERIAL LOAD AND FEV , DECLINE 
All cultures of sputum samples grew significant numbers of bacteria ranging 
from 105.4 to ICP. 6 CfU MI. 
I. The mean (SD) total bacterial count at sample I was 
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ICý. 47(0.91) CfU ml-1 and rising to ICý*93(0,81) in sample 2 (p = 0.019) or a rise from 
29,512,092 cfu ml" to 85,113,804 cfu ml-1 when expressed without log 
transformation. 
Patients with an increasing airway bacterial load demonstrated a more severe 
decline in FEV, over the study period compared with patients with stable or 
decreasing airway bacterial load who exhibited less marked decline or slight 
improvement in FEVI. This relationship between FEV, decline and changes in 
bacterial load (Figure 4.7) was statistically significant in terms of absolute FEV, 
decline (r = 0.593, p=0.001) and decline expressed as a percentage of baseline FEVi 
(r = 0.633, p<0.00 1). The total bacterial count of the second sample was itself related 
to the absolute rate of decline over the study (r = 0.560, p=0.001) (Figure 4.8 ). The 
total bacterial count of the first sample was not predictive of the subsequent decline in 
FEV I over the study (r = -0.125, p=0.369). 
A linear regression analysis of the relationship between bacterial load and 
FEV, decline revealed that a 10-fold increase (101 cfu ml") in bacterial load is 
associated with an 82.4-ml decline in FEV, over the study period; the regression 
coefficient was 0.095 (95% confidence interval, 0.032-0.132) (p = 0.002). As the 
mean increase in bacterial load was from 107.47 to 107.93 CfU ml-1, this represents a 
dec ine in FEV, attributable to the airway bacterial load of 33.3 ml/year for this 
patient group. 
A multivariate regression analysis of potential factors in the observed decline 
in lung function (ml/year) was performed: regression coefficient (95% confidence 
interval), change in bacterial load (log cfu ml"I) 63.1 (34-133, p=0.003), number of 
cigarettes smoked per day -I I (- 110-890, p=0.818), exacerbation frequency -2(-270- 
220, p=0.819), and baseline FEV, 1(-2-5, p=0.368). The change in bacterial load 
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and the decline in FEV, were the strongest and the only significant relationship in this 
analysis. 
FIGURE 4.8 CORRELATION BETWEEN CHANGE IN FEVI AND CHANGE iN TOTAL 
BACTERIAL COUNT OVER STUDY PERIOD. Figure shows decline in FEV, expressed as 
millilitres of loss (negative values indicate improving lung function) against log 
change in total bacterial count (positive values indicate increasing numbers of bacteria 
over study) n=30. (r = 0.59, p=0.001). 
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Figure 4.9 CORRELATION BETwEEN RATE OF CHANGE IN FEVI OVER STUDY PERIOD 
(ADJUSTED TO MUYEAR) AND TOTAL BACTERIAL COUNT AT THE END OF THE STUDY. 
Figure shows decline in FEV, expressed as milliliters of loss (negative values indicate 
improving lung function) against log change in total bacterial count from sputum 
taken at the end of the study n=30. (r = 0.56, p=0.001). 
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BACTERIAL ISOLATES IN THE I YEAR STUDY. 
The results of the qualitative bacteriology from the 30 sputum samples taken at 
the beginning (sample 1) and the end (sample 2) of the study are shown in Figure 4.9. 
The graph illustrates the relative frequency of each bacterial isolate expressed as a 
percentage of the 30 samples at each time point. Sixteen (53.0%) and 17 (56.6%) 
patients were colonised with a potentially pathogenic organism at recruitment and 
completion of the study, respectively however bacterial colonisation was dynamic 
with changes in bacterial species identified. The remainder of patients' sputum 
produced nonspecific growth of bacteria, defined as growth of bacterial species not 
usually associated as respiratory pathogens in immunocompetent individuals such as 
Streptococcus viridans group, Neisseria spp, Corynebacterium spp, and coagulase 
negative staphylococci. The relative frequencies of individual bacterial species are as 
shown. Five and six subjects respectively displayed colonisation with more than one 
potentially pathogenic microorganisms at recruitment and completion. At each time 
point, Haenzophilus influenzae was the most prevalent individual bacterial type 
present in 9 (30%) and 7 (23.3%) patients at samples I and 2, respectively. 
The nature of bacterial colonisation was dynamic with changes in the species 
of bacterial isolate over the sample interval. Fifty percent of the subjects grew entirely 
different bacterial species at each sample point, whereas the other 50% demonstrated 
persistence of a specific bacterial species or nonspecific growth across the sampling 
interval. Patients who demonstrated changes in colonising bacterial species during the 
study exhibited higher mean bacterial loads (108*18 log cfu ml") than those who 
maintained the same species in both samples (10 7-55 log cfu ml-', p=0.03). 
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The decline in FEV, seen in the study group was significantly greater in those 
subjects with unstable bacterial type at a 102-ml (IQR 19-196, n= 18) decline in 
FEV, per year compared with a 3.6-ml (IQR-158-112, n= 12) decline per year in the 
group with persistence of one bacterial type at both time points (p = 0.017); this 
relationship with FEV, decline expressed as a percentage of baseline is illustrated in 
Figure 4.10. Changes in bacterial species were not related to the number of cigarettes 
smoked per day (rho = 0.056, p=0.767), the sputum collection method (induced or 
spontaneous) (rho = 0.012, p=0.84), the recorded exacerbation frequency (rho= 
0.149, p=0.44), or the antibiotic usage during the study (rho = 0.048, p=0.808). An 
analysis of each of the individual bacterial species and the associated lung function 
changes did not reveal any attributable significant differences in FEV, decline 
between subjects colonised with different bacterial species, although numbers in each 
subgroup were too small to draw any valid conclusions from this analysis. 
SPUTUM CYTOKINES AND FEV, DECLINE 
Sputum IL-6 and IL-8 levels were measured on all samples. The median (IQR) 
IL-6 levels were similar 114 (283) pg ml" and 51 (297) pg ml-1 in samples I and 2, 
respective y, and IL-8 levels were 3,183 (1,688) pg ml- I and 3,012 (1,684) pg ml-1 
(p=NS). Levels of sputum IL-6 and IL-8 were related to one another in each patient 
(rho = 0.378, p=0.007). The absolute changes in IL-6 between samples I and 2 
correlated with the changes in IL-8 seen between the two samples (rho = 0.542, p= 
0.011). The sputum IL-8 levels were related to pack-years of smoking; those patients 
with IL-8 higher than the median having smoked for a mean of 100 pack-years and 
those with lower IL-8 for 42 pack years (p = 0.018). Patients exhibiting a decline in 
lung function exhibited higher overall sputum median (IQR) IL-8 levels of 3 343 
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(1,592) pg ml-1 compared with those with stable or improving FEV, 2,160 (2,050) pg 
ml" (p = 0.032). Similarly, patients with a higher bacterial load (greater than the 
overall mean, sample I and 2 combined) had higher overall IL-8 levels (2,938 pg ml") 
compared with those with bacterial counts lower than the mean (2,329 pg ml- I) (P = 
0.05). There were no significant relationships between sputum IL-6 levels and 
bacterial counts or lung function decline. Similarly no significant relationships were 
seen between sputum cell counts and airway bacterial load or lung function decline in 
the I year study. 
Figure 4.10 RELATIVE FREQUENCY OF BACTERIAL ISOLATES FRom FIRST (BLACK BARS; 
N= 30) AND SECOND (HATCHED BARS; N= 30) SPUTUM SAMPLES. expressed as a 
percentage of samples. NSG = nonspecific growth. 
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FIGURE 4.11 DIFFERENCES IN FEV, DECLINE BETWEEN SUBJECTS WMI PERSISTENT (0) 
AND CHANGING (1) BACTERIAL ISOLATE. 0= Same bacterial species identified in 
sputum at beginning and end of study; I= Change in species of bacterial isolate; p 
0.017. Decline expressed as percentage of baseline FEV, (negative values indicate 
improving lung function). 
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4.3.6 ANALYSIS OF LONG TERm RELATIONSHIPS BETWEEN AIRWAY BACTERIAL 
COLONISATION AND DISEASE PROGRESSION 
The analysis shown above of the relationship between airway bacterial 
colonisation and disease progression was performed over a limited time period of one 
year. It is possible that the relationships elicited reflect reversible changes in lung 
function associated with fluctuations in airway bacteria rather than irreversible disease 
progression due to lung matrix destruction or airway remodelling. Therefore in order 
to determine if high airway bacterial loads are associated with accelerated decline in 
lung function over the longer term a retrospective analysis of the relationships 
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between FEV, decline and bacterial load was performed using data collected over the 
duration of the East London Cohort Study. This analysis included data from 148 
patients who had completed at least one year in the cohort since its inception. Over 
this time-period the cohort was maintained at between 70 and 80 patients with a 
programme of rolling recruitment and maximum of 7.3 years of data was available for 
any one patient for this analysis. The baseline characteristics of these patients at 
recruitment are shown in Table 4.4. 
Table 4.5 Baseline Initial Characteristics of the 148 COPD Patients in the analysis of 
Airway Bacteriology and FEV, Decline 
Patient Characteristic Median IQR 
Age, yr 
FEV I, L 
FEVI, % predicted 
FEVI, % reversibility 
FVC, L 
FEVI/FVC, % 
Peak expiratory flow, Urnin 
Pa02, kPa 
PaC02, kPa 
Smoking history, yr 
68.5 
0.98 
38.5 
5.45 
2.44 
42.3 
174 
9.0 
5.8 
42 
62.6 to 73.7 
0.73 to 1.30 
27.7 to 50.3 
0.00 to 12.6 
1.81 to 2.93 
33.5 to 53.1 
137 to 250 
8.23 to 9.58 
5.40 to 6.35 
32 to 50 
The annual change in FEV, over this time period was 40.2(CI 36.0 to 44-5) 
ml/yr or 1.5 (1.3 to 1.7) %FEVI predicted loss per year. The airway total bacterial 
count rose from an initial median value of 107.7(7.0-8.25) log cfu. ml at an annual rate of 
0.15 log units per year. Patients with a bacterial load greater than the median level 
demonstrated a faster decline in FEV, of an additional 0.51 (0.13 to 0.88) % FEVI 
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predicted loss per year, over and above that of 0.76 % FEVI predicted loss per year 
seen in subjects with a low bacterial load, p<0.01. 
Subjects with rapidly rising airway bacterial loads (rise in TBC above the 
median for the group) also demonstrated a faster decline in FEV, by 0.5% FEV, 
predicted loss per year, greater than those subjects with stable bacterial colonisation 
or rises below the median for the group (p=0.006). 
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4.4 DisCUSSION 
This analysis has demonstrated that lower airway bacterial colonisation is 
common in this population of COPD patients with moderate to severe disease. The 
findings confirm that higher bacterial loads are associated with greater airway 
inflammation in the stable state and for the first time demonstrate a relationship 
between airway bacterial colonisation, airway inflammation and disease progression 
in terms of FEV, decline. The data also suggests that certain pathogens particularly 
Haemophilus influenzae are present in greater numbers and are associated with 
greater levels of airway and systemic inflammation than other pathogens. 
The prevalence of lower airway bacterial colonisation in this study was high at 
57%, in comparison to some other studies of COPD patients. In previous studies, the 
prevalence of lower airway bacterial colonisation was found to be greater in subjects 
with more advanced airways obstruction (Zalacain 1999, Monso 1999). The mean 
FEVI of less than 40% predicted of our group, represents more severe COPD than the 
majority of previous studies (Sethi 2002) and may explain the higher prevalence of 
LABC found. 
The finding that the airway bacterial load was greater in the summer months is 
a novel one. Seasonality is a common phenomenon in COPD with the incidence of 
exacerbations being much higher during the winter months due to seasonal variation 
in respiratory viral infection. The relative frequency of exacerbations and therefore of 
prescribed courses of antibiotics was lower in the summer than the winter months in 
this study and this may explain the lower bacterial numbers during the summer 
months. This would suggest that airway bacterial load alone is not the key factor in 
exacerbation susceptibility but that other mechanisms are involved (Sethi 2002, 
Seemungal 2000). An alternative explanation would be that during the winter, 
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exacerbations are common due to viral infections and higher airway bacterial loads 
increase susceptibility to these. Therefore patients with higher loads in the winter are 
likely to exacerbate and hence will not be sampled in the stable state. During the 
summer months, the patients with high airway loads may be stable enough to be 
sampled in the 'stable state' and hence a confounding effect is observed. 
This work included the first longitudinal prospective study to assess directly 
the relationship between lower airway bacterial load and decline in lung function in 
patients with moderate to severe COPD. The findings demonstrate a significant 
relationship between the sputum bacterial load and disease progression in COPD, 
showing that the rate of decline of FEV, was proportional to the rise in colonising 
bacterial load over the initial 1-year study period and that this effect was still observed 
over a longer follow-up period of up to 7 years. 
Individuals who exhibited changes in the nature of bacterial colonisation, 
re- suffv, red from faster declines in lung function than those with persistence of one or 
more bacterial species. These falls in FEV, were also associated with elevated levels 
of the potent neutrophil chernoattractant IL-8. 
As discussed previously the presence of bacteria in the lower airway can 
result in a range of pathologic effects that are deleterious to lung function, including 
mucus hypersecretion and embarrassment of mucociliary clearance (Adler 1986). 
Bacteria can affect the airway epithelium directly or via the recruitment of neutrophils 
(Ras 1990, Noguera 2001) bacteria may cause release of excessive amounts of 
neutrophil derived proteases resulting in damage to airway epithelial cells. Airway 
inflammation has been shown to increase as airway obstruction worsens, but bacterial 
colonisation was not originally considered as an explanation for this finding (Di 
Stefano 1995). Bacterial colonisation has been shown to be detrimental to lung 
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function in a number of pathological conditions, including cystic fibrosis and 
bronchiectasis (Packe 1992, Angrill 2002). Previous evidence that LABC contributes 
to worsening lung function in COPD can be found in data from a study which found 
that H. influenzae colonisation was associated with increased airway inflammation in 
patients with chronic bronchitis and airflow obstruction compared with patients with 
chronic bronchitis but without airflow obstruction, where airway inflammation was 
less marked (Bresser 2000). 
The finding that higher airway bacterial loads are associated with greater 
airway inflammation in terms of sputum IL-8 levels has been shown by a number of 
groups previously, most notably in a large study of 160 patients with mixed airway 
obstructive diseases including COPD (Hill 2000). Those patients exhibiting a decline 
in FEV, during the study had higher levels of IL-8 than those with a stable or 
improving FEVI. This finding suggests a mechanistic link between airway bacterial 
load, airway inflammation, and the associated deleterious effects on FEVI. 
Our group has previously reported that some patients with COPD develop 
exacerbations frequently, year on year and this group has increased stable airway 
inflammatory cytokines (IL-6 and IL-8) compared with those with a history of 
infrequent exacerbations (Bhowmik 2000). Patients with frequent exacerbations also 
demonstrate a faster decline in FEV, than infrequent exacerbators, with exacerbations 
contributing to approximately 25% of the observed excess lung function decline seen 
in COPD (Donaldson 2002). Analysis of data from the Lung Health Study (Kanner 
2001) revealed that lower respiratory illnesses (exacerbations) in smokers are 
deleterious to FEVI and lends further support to the hypothesis that lower airway 
infection and associated inflammation contribute to lung function decline. However, 
this relationship was not significant in ex-smokers. This may appear at odds with the 
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analysis from our group; however, the Lung Health Study included patients with 
milder disease than our cohort. Therefore, in these patients with better lung function 
and preserved lung defences, airway bacterial colonisation is likely to play a lesser 
role in up-regulating inflammation and down-regulating resolution of inflammation. 
Therefore, the effects of exacerbations on disease progression are only seen in milder 
disease in active smokers. Whether this is due to direct effects of smoke on the airway 
or to effects mediated via bacteria] infection is not known. 
Previous longitudinal studies of the mechanisms of lung function decline have 
used possible surrogate markers of airway infection such as mucus hypersecretion. 
The Copenhagen City Heart Study found that chronic mucus hypersecretion was 
associated with an excess FEV, decline of 22.8 ml/year in men and 12.6 ml/year in 
women together with increased risk of hospitalization (Vestbo 1996). As bacterial 
colonisation is associated with mucous secretion (Stockley 2000), and patients with 
mucous secretion have more airway inflammation (Stanescu 1996); this again 
provides support for the role of LABC in the accelerated decline of FEVI. 
It has previously been reported that the presence of bacterial colonisation is 
directly related to exacerbation frequency, and patients with colonisation with 
Haemophilus influenzae have longer and thus more severe exacerbations (Patel 2002). 
As patients with a past history of frequent exacerbations have increased airway 
inflammation (Bhowmik 2000), the effects of lower airway bacteria on disease 
progression may be in part due to increased susceptibility to exacerbations or via 
modulation of inflammation at exacerbation. 
In this study, the relationships between FEVI decline and features of LABC 
were strongest in the analyses, which included measures of "instability" of LABC 
such as changes in bacterial load and type. It is possible that such changes generate a 
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renewed stimulus to inflammation in the airway, in turn causing a more rapid decline 
in lung function. Indeed, there is increasing evidence that bacterial colonisation is a 
highly dynamic process and that changes in bacterial type are associated with the 
etiology of exacerbations (Sethi 2002). Bacterial colonisation itself is likely to be 
affected by exacerbations and their treatment, but to what degree this is remains 
uncertain. The interrelationships between host defences and bacterial infection in the 
stable state and at exacerbation are highly complex. 
The multivariate regression analysis of the data from this study did not find a 
significant influence of active cigarette smoking on FEVI decline over I year, but this 
was apparent in the longer term follow up analysis. Indeed, although it is established 
that cigarette smoking is a risk factor for bacterial colonisation and itself leads to 
increased airway inflammation, the effects of smoking cessation on airway 
inflammation in severe COPD may not be as clearly defined as in a milder patient 
group. Indeed, study of the direct effects of smoking cessation on inflammation 
reveals that the pro-inflammatory effects of cigarette smoke may persist for several 
years, (Lapperre 2006, Rutgers 2000). In a potentially colonised COPD population 
with severe airways disease the most significant modifiable factor affecting airway 
inflammation and consequent FEV I decline may be the airway bacterial load. 
Many previous studies of lung function decline have largely been performed 
using patients diagnosed with bronchitis or airflow obstruction (Vestbo 1996, Fletcher 
1976). Therefore, understanding of the natural history of lung function decline in 
more severe COPD is based largely on an extrapolation of observations from patients 
with milder COPD. The quantitative assessment of airway bacterial load and the 
related sputum markers of inflammation suggests a threshold level of colonisation in 
the order of 105_106 CfU ml-1 above which LABC is a persisting drive to airway 
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inflammation (Hill 2000). However, the degree of airways obstruction at which the 
clinically significant effects of LABC occur and how bacterial colonisation affects the 
natural history of COPD in the longer term remains uncertain and requires further 
study. 
It is possible that the findings of changes in total bacterial count and FEV, 
may represent changes associated with unrecorded exacerbations. However, diary 
cards were used to record all changes in symptoms on a daily basis and could 
therefore be used to detect all exacerbations both reported and unreported as 
previously described (Seemungal 1998). Furthermore, direct questioning of patients at 
each study visit was used to clarify symptomology and use of rescue medication 
during the previous 3 months. Therefore, exacerbations both reported to the study 
team or primary care requiring extra medication and those unreported but recorded on 
diary cards were included in assessment of baseline status. Indeed this is a fairly 
unique strength of longitudinal studies performed using daily diary card data 
collecting as well as routine clinic follow up, other studies rely on patient recall to 
ensure stable state lung function measurements and to exclude those juxtaposed to a 
recent exacerbation. In this study, assessment of diary cards for the 6-week symptom- 
free period effectively assured that patients had returned to baseline before sampling. 
There was no identifiable relationship between the changes in FEV, observed 
and the frequency or timing of exacerbations in the one year study analysis. However, 
this study was not powered to investigate the relationship between exacerbation 
numbers and lung function decline demonstrated previously by our group (Donaldson 
2002). 
The results of this study demonstrate an association between airway bacterial 
colonisation and systemic inflammation and in particular the elevated plasma 
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fibrinogen found in patients with COPD. The finding that lower airway colonisation 
with a potentially pathogenic organism is associated with higher plasma levels of 
fibrinogen and IL-6 confirms the findings of an analysis of baseline data of a recent 
intervention study suggesting a role of airway bacteria in driving the systemic 
inflammatory response in COPD (Banerjee 2004). The finding that individual 
colonising bacterial species were associated with differing levels of plasma markers is 
a novel one. This suggests that variation in pathogen-host interaction results in a 
differential inflammatory response dependent on bacterial species. 
The factors influencing systemic inflammation such as smoking and severity 
of disease are complex and also affect the nature of bacterial colonisation itself. The 
finding therefore that the type of colonising bacteria modulated plasma fibrinogen 
even when these co-factors were included in the analysis suggests an important and 
independent role for airway bacteria in the stimulation of the systemic inflammatory 
response. 
Plasma fibrinogen is an important independent risk factor for coronary heart 
disease and stroke and a marker of systemic inflammation (Meade 1993, Ernst 1997, 
Danesh 1998, Smith 1997). The level of plasma fibrinogen is related to the severity of 
airways obstruction (Dahl 2001) in patients with COPD, suggesting that systemic 
inflammation and its associated consequences become more marked as disease 
progression occurs. In a similar manner, airway bacterial colonisation is related to 
disease severity with the prevalence of colonising PPMs greater in subjects with a 
lower FEVI (Zalacain 1999). The relationship therefore between airway bacteria and 
systemic inflammation found in this study provides a possible mechanistic link 
between these two findings. 
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Our group has previously described the changes in plasma fibrinogen and IL-6 
at acute exacerbation in a similar population of patients in our cohort (Wedzicha 
2000). Indeed a number of patients in that study were still present in the cohort four 
years later for this investigation into the role of bacterial colonisation. The initial 
study found a mean (SD) plasma fibrinogen level of 3.90 (0.67) g/1 and median (IQR) 
IL-6 of 4.3 (2.4 - 6.8) in the stable state in patients with a mean FEV, of 1.06 (0.44)1. 
Four years on, in this study plasma levels measured in an identical manner were 4.23 
(0.84) g/l and 6.48 (5.11-10.05) pg/ml respectively with a mean FEV, which had 
fallen to 0.96 (0.37)1. Thus the degree of systemic inflammation can be seen to have 
increased in association with airways disease progression in this group. This finding 
has been confirmed in a specific longitudinal analysis of changes in inflammatory 
indices in the cohort over time (Donaldson 2005). 
An increase in bacterial load was found to be associated with the rate of 
decline of FEV, in the one year study. The inter-relationship between bacterial 
colonisation, airway inflammatory markers, fibrinogen, other systemic inflammatory 
markers and disease progression remains poorly understood. Further longitudinal 
studies are required to determine the complex relationships between these factors and 
the natural history of COPD and interventions such as antibiotic therapy required to 
determine causality. 
The bacterial species which commonly colonise the lower airway of COPD 
patients, vary in their pathogenicity and ability to invade the respiratory epithelium. 
Pseudomonas aeruginosa can exist in an extraordinary range of environments and has 
evolved an array of mechanisms to evade innate and acquired immune defences. 
Secretion of specific factors such as Exo U by the Type III protein secretion system 
(Finck-Barbancon 1997) enables invasion through the respiratory epithelium and may 
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reduce the host's ability to limit the infection by this organism to remain within the 
airway itself, potentially leading to activation of systemic as well as airway 
inflammatory responses. 
In comparison, Haemophilus parainfluenzae, a less invasive and virulent 
pathogen (Middleton 2003), is associated with lower levels of plasma markers in this 
study. The level of systemic inflammatory response to other PPMs such as 
Haemophilus influenzae or Streptococcus pneumoniae was intermediate between that 
associated with colonisation with Haemophilus parainfluenzae and Pseudomonas sp. 
Haemophilus influenzae is the most prevalent colonising bacterial species in this 
patient group (Hill 2000, Patel 2002) and plays an important role in modulating the 
nature of airway inflammation (Hill 2000). However different strains of this organism 
exhibit differing degrees of pathogenicity largely related to differing abilities to 
invade the respiratory epithelium (Bandi 2001, Ahn 2002). It is plausible that different 
strains of Haemophilus influenzae and indeed other bacteria stimulate the systemic 
inflammatory response by differing degrees and further studies involving typing of 
individual bacterial species are required. 
Although plasma levels of fibrinogen and IL-6 were affected by the nature of 
colonising bacterial species min this analysis, the relationship between airway 
bacterial load and systemic inflammation was weak. The degree of neutrophilic 
airway inflammation has previously been shown to be closely related to the number of 
airway bacteria (Hill 2000), and activated neutrophils and their products play an 
important role in airway inflammation (Stanescu 1996) and have been demonstrated 
in peripheral circulation in patients with COPD (Noguera 1996, Noguera 2001, 
Noguera 2004, Koenderman 2000). The analysis of relationships in this study 
between airway bacterial load and airway IL-6 are not as close as those described for 
134 
STABLE STATE BACTERIOLOGY 
cytokines more typically associated with neutrophilic inflammation. This suggests 
that other factors apart from bacterial colonisation modulate different aspects of the 
inflammatory response in the airway. Similarly the weak relationship between airway 
and systemic inflammation in this study suggests that the relationships between the 
two compartments are complex. 
Indeed, there has been considerable recent debate about the links between 
airway and systemic inflammation in patients with COPD. It is now recognised that 
COPD is a multisystem disorder with evidence of widespread systemic inflammation 
(Agusti 2005). The clinical consequences of systemic inflammation are well described 
and include; muscle wasting and weakness, loss of fat free mass and in the most 
advanced cases cachexia (Schols 2000), in addition to the additional cardiovascular 
morbidity already discussed. The mechanisms leading to these complications are not 
fully understood. These are likely to be multifactorial and include oxidative stress 
(Rahman 1996), increased metabolic rate (Creutzberg 1998), hypoxia (Howes 1995) 
and inactivity associated with severe disease (Donaldson 2005), as well as direct 
effects of pulmonary inflammation on the systemic compartment. 
These systemic effects of COPD contribute significantly to the excessive 
morbidity and early mortality seen in this patient group and further studies are 
required to determine how airway bacteria may modulate potential mediators of these 
extra-pulmonary manifestations of COPD, such as TNF-(x (Li 1998), in a similar 
manner to fibrinogen or IL-6 as demonstrated in this study. 
There has been controversy in the literature about the possible association 
between other causes of chronic infection, elevated plasma proteins and increased risk 
of CHD (Koenig 2003). Reports that Helicobacter pylori (Murray 1995) and 
Chlamydia Pneumoniae infection (Saikku 1988) diagnosed serologically were 
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associated with increased risk of CHD and that antibiotic eradication therapy resulted 
in a lower plasma fibrinogen (Torgano 1999) contrast with meta-analyses (Danesh 
1998) and other studies (Regnstrom 1998) which contradict these conclusions 
suggesting no association between H pylori and systemic inflammation. This study, 
all be it in a distinct population of patients with moderate to severe COPD, lends 
weight to the argument that chronic infection does contribute to elevated fibrinogen 
and hence increased risk of CHD. 
Studies of patients with chronic obstructive pulmonary disease have 
demonstrated elevated levels of not only plasma fibrinogen but also C reactive 
protein, turnour necrosis factor-a and soluble cytokine receptors (Schols 1996). This 
study did not assay CRP levels and this is an obvious limitation. This molecule may 
not only be a useful marker of systemic inflammation in COPD (Mannino 2003) but 
may also be directly involved in the pathogenesis of atheromatous plaques and hence 
cardiovascular disease (Lagrand 1999, Zwaka 2001). Furthermore, CRP levels may be 
-modified with the use of cortico-steroids, as shown in a recent intervention study (Sin 
2004), although the mechanisms by which this occurs are not understood and are 
likely to be complex as this form of therapy has limited effects on airway 
inflammation (Culpitt 1999). 
The study has a number of drawbacks which warrant discussion. It has been 
performed in a group of patients with moderate to severe airways disease. It is likely 
that as airways obstruction progresses the contribution of bacteria to airway and 
systemic inflammation becomes more important and therefore the reproducibility of 
these findings in more mild disease needs to be determined. This study has 
concentrated on patients in the stable state. COPD exacerbations are an important 
stimulus to airway and systemic inflammation and whilst we have already described 
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the rise in fibrinogen at exacerbation, the role of bacterial infection in further 
stimulating airway inflammation warrants further study. 
CONCLUSIONS 
This study has demonstrated that airway bacterial colonisation may also play 
an important role in driving systemic inflammation in a group of patients with 
moderate to severe stable COPD. Plasma fibrinogen and IL-6 are modulated in a 
differential manner dependent on airway bacterial species and to a lesser extent 
bacterial load. Pseudomonas colonisation in particular is associated with heightened 
systemic inflammation and further studies to determine the whether this results in 
greater morbidity and mortality are required. If the novel findings of this study can be 
shown to relate to clinical outcomes, the concept that bacterial species differentially 
stimulate an inflammatory response may infonn on potential targets for future 
eradication studies. Such interventions could alter the natural history of this highly 
prevalent multi-system disease. 
This study has also shown that LABC is an important determinant of decline 
of lung function in this group of COPD patients with moderate to severe disease. 
These findings suggest that appropriate antimicrobial therapy in colonised patients 
may have an important therapeutic effect, offering an opportunity to alter the natural 
history of this highly prevalent disease. Studies performed over a longer period are 
required to investigate further the interactions between LABC, smoking, and 
exacerbations and their effect on the accelerated decline in lung function, which is 
characteristic of COPD. Whilst a role of airway bacterial colonisation in COPD has 
been suggested for many years, understanding of viral infection of the airway in stable 
disease is poor. The next chapter presents the findings of the studies aimed at 
determining the role of chronic viral infection in COPD. 
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CHAPTER 5 
VIRAL DETECTION, AIRWAY 
INFLAMMATION AND DISEASE 
PROGRESSION IN PATIENTS WITH 
STABLE COPD 
In the previous chapter the findings that lower airway bacterial colonisation 
was associated with airway inflammation and lung function decline 
contribute to the hypothesis that airway infection may be an important factor in 
disease progression. This chapter describes the findings of prospective studies to 
determine the prevalence and associations of respiratory viral pathogens. 
5.1 INTRODUCTION 
It has been recognised for some time that viral infection is important in the 
pathogenesis of exacerbations (Smith 1976, Smith 1980, Greenberg 2000, Seemungal 0 
2002). However, the role that viruses play in the aetiology of stable COPD remains 
uncertain. 
There is some evidence in the literature that chronic airway infection with 
viruses may play a role in the development of airways obstruction. Adenovirus, a 
DNA virus, has been detected using PCR for genomic DNA, in lungs of COPD 
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patients (Matsuse 1992) and the virus trans-activating protein (EIA) can be found in 
both airway and alveolar tissue (Elliott 1995). 
Whilst highlighting a role for adenovirus in the development of COPD studies 
to date have been cross- sectional in nature and relationships between viral infection 
and disease progression have not been demonstrated. Furthermore, a role for RNA 
viruses in the pathogenesis of COPD has been little explored. 
This chapter describes the results of prospectively sampling the cohort of well 
characterised COPD patients in the stable state to determine the nature of viral and 
atypical bacterial persistence in the lower airway and to determine the associations of 
persistence with airway inflammation and lung function decline. 
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5.2 METHODS 
The methods used in recruiting, follow-up and sampling of patients are 
common to all work in this thesis and are described in detail in Chapter 2. The work 
described in this chapter involved follow-up of 74 patients characterised in Chapter 3. 
Patients were followed up for 2.2 years for the analyses described below and were 
sampled when clinically stable, at least 6 weeks from a previous exacerbation and not 
taking oral corticosteroids. 
Sputum samples were analysed for viral and atypical pathogens using PCR 
techniques described in Chapter 3. The remainder of the sputum sample was analysed 
for inflammatory cytokines (using ELISA); interleukin-6 (IL-6) and interleukin-8 (IL-8) 
and for myeloperoxidase (MPO) using ELISA. The first sample per patient underwent 
quantitative bacterial analysis. 
PERIPHERAL BLOOD MONONUCLEAR CELL EXTRACTION 
Venous blood was taken from 27 COPD patients, randomly selected from 
cohort volunteers before the RSV PCR results were known. Peripheral blood 
mononuclear cells (PBMC) were separated from 50 - 60 ml heparinised blood by 
sedimentation on a Ficoll-Hypaque gradient. PBMCs were resuspended in 90% 
human serum and 10% dimethyl sulphoxide (DMSO) and cryo-preserved in liquid 
nitrogen. The RSV PCR status of COPD patients was unknown during the time of 
blood collection and assay. 
PBMC STIMULATION AND ELISPOT ASSAY. 
Thawed PBMC were incubated in 96-well Millipore MAHA plates pre-coated 
with anti-human IFN-y antibody I-DIK (Mabtech AB, Nacka, Sweden). Cultures 
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were performed in 200 RI RPMI 1640 with 5% human serum AB (Sigma), L- 
glutamine, penicillin and streptomycin supplements and optimal concentrations of 
antigens determined in previous experiments. Stimulation was performed with : RSV 
at moi = 5, UV -iffadiated RSV equivalent to moi =5 (inactivation was achieved by 
exposure to 1.2 joules of ultraviolet radiation in a Stratalinker 2400 Stratagene 
Europe, Amsterdam, The Netherlands). RSV A2 virus was grown in Hep-2 cells. 
Controls were culture medium without antigens, PHA (10 tig/ml) and Hep2 mock 
infected cell lysate. Whenever possible cultures were set up at 2.5 x 105 cells/ml, 
otherwise a correction factor was recorded. All cultures were set up in the same 
experiment. After 48 hours at 37 C the wells were washed, then incubated at 4C 
ovemight with l[tg/ml of biotinylated antibody clone 7-B6-1 anti human IFN-y 
(Mabtech, Nacka, Sweden), the assay was completed as previously described. Spots 
were counted using an AID ELISPOT reader, software version 3.0. Raw spot numbers 
were normalized to cell input, negative control values were subtracted (Hep-2 cells 
controls for RSV and UV irradiated RSV, medium controls for all other antigens). 
Negative values (ie: higher numbers of spots in negative controls than in antigen 
stimulation) and any sample that failed to respond to PHA positive controls were 
excluded from analysis. 
STATISTICAL ANALYSIS 
The statistical analysis in common with the other results in this thesis is 
described in Chapter 3. In summary: baseline recruitment data are presented as 
medians (inter-quartile ranges (IQR)). The annual exacerbation frequency was 
calculated by dividing the total number of exacerbations per patient by the number of 
days the patient recorded data and multiplying by 365. Normally distributed data are 
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reported by means (standard deviations, SD) and skewed data by medians (interquartile 
range, IQR). Appropriate comparative statistical tests were perforrned dependent on the 
distribution of the data. 
Specifically to analyse the associations between viral detection and lung function 
decline, I hypothesised that a greater frequency of detection of RSV in the stable airway 
is associated with greater inflammation and thus faster decline in lung function. Studies 
to date had been cross sectional in nature and hence pilot data on the periodicity of RSV 
infection was not available; a pre-detennined a cut off lin-ýt was set of 50% detection 
rate to divide patients into high and low RSV groups. The rationale behind this 
categorisation was directed at attempting to ensure adequate sample size in each 
comparator group, as no pilot data was available an a priori split at 50% detection was 
made to avoid criticisms of post hoc analysis and to try to ensure a reasonable number of 
subjects in each group. The analysis of ELISPOT data, which included a sub-population 
taken at random from the larger cohort differed as these a priori groupings resulted in a 
very small sample size in the High RSV group. As this distribution made analysis of this 
data implausible an RSV grouping of PCR positive or negative at any point in the study 
was used, which allowed for a more even number of subjects in each group. 
To analyze the effects of RSV colonisation independently of patient 
characteristics (smoking status, exacerbation frequency, bacterial load and starting 
FEVI) on decline in lung function, we used the general linear mixed model (xtreg) 
procedure in STATA-5 software (Stata Corporation, Texas, USA). These procedures 
are designed for panel (cohort) data and are particularly useful where data are 
correlated, as in repeated-measures designs and where there are complex error 
structures. Independent variables of (a) time and (b) FEV, measurement during the 
stable state, (c) whether or not the patient was persistently colonised with RSV, which 
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required 50% of their samples to be RSV positive were included in the analysis. The 
fourth independent variable (d) was an interaction tenn. obtained as the product of (a) 
and (c). Allowance for confounders was made by including whether the patient had a 
bacterial load or inflammatory marker less or greater than the cohort median, 
exacerbation frequency greater or less than the cohort median and active smoking 
status together with terms to adjust for the effect of these on FEV, decline. Also 
included in the regression model was the starting FEV, to adjust for differences in the 
rate of FEV, decline between patients with high or low starting FEVI. The magnitude 
and significance of the effect of RSV colonization on decline were unchanged with 
inclusion of one or all of these confounders. 
As multiple sputum samples were obtained during the study and the unit of analysis 
was the patient, the first sample obtained from each patient suitable for estimation of 
inflammatory cytokines was used in the analysis. p values : 50.05 were regarded as 
significant. 
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5.3 RESULTS 
Table 5.1 shows the baseline spirometric and other characteristics of 74 patients 
(45 male) who were sampled during the study. There were no differences between the 
baseline characteristics in terms of gender distribution, FEVI, FEVI% predicted, FVC, 
PEF, FEVI reversibility to beta agonists, years of smoking, current smoking status, 
exacerbation frequency of these patients and the 31 patients in the cohort who were not 
sequentially sampled (due to recruitment in the latter part of the study, use of long term 
oral steroids or intolerance of sputum induction). There were no significant differences 
in these variables between sputum producers and those requiring induction. The 74 
patients provided 241 stable sputum samples suitable for processing for analysis. Of 
these patients 16 (of whom 8 died) of the 74 patients withdrew before the end of the 
study period. 9 subjects produced I sample, 15 subjects 2 samples, 20 subjects 3 
samples, 17 subjects 4 samples, 6 subjects 5 samples, 5 subjects 6 samples and 2 subjects 
7 samples. Diary card data was collected on a mean of 656 days per person, 
(maximum possible in study being 762 days), compliance with data collection was 
thus 86%. 
5.3.1 RESPIRATORY VIRUS AND ATYPICAL BACTERIAL DETEcTiON IN STABLE COPD 
The detection rates for all respiratory viral and atypical pathogens in stable state 
samples are summarised in figure 5.1. The most commonly identified virus was RSV. 59 
of the 74 patients sampled had RSV detected in at least one stable sputum sample during 
the study. Overall RSV was detected in the stable state in 32.8% of the 241 stable 
sputum samples collected. There were no significant associations between the detection 
of one type of pathogen and another. Detection of viruses in the stable state was 
independent of time from the last exacerbation. 
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FIGuRE 5.1 PCR DETECTION RATES FOR RESPIRATORY VIRAL AND ATYPICAL 
BACTERIAL PATHOGENS iN 241 STABLE STATE SPUTUM SAMPLES FROM 74 COPD 
PATMNTS. 
35 
30 
25 
20 
15 
1 
5- 
Lam 
wod 
Z Wý, 
0 
amm9jýmým 
0 mm i: 0x> 0 zr 2-1 CL <c (D << (D 00 
:3 :3 5" M9 
(D (n * cZ W) 
(0 N3 P) 
145 
CHRONIC VIRAL INPECTION IN STA13LE COPD 
TABLE 5.1. CHARACTERISTICS OF 74 PATIENTS BY PATTERN OF RSV DETECIION 
Low RSV Pativits 
(tz=56) 
High RS V Pativits 
(n=18) 
Median IQR Median IQR P-value 
Age (years) 67.4 61.7 to 71.8 68.7 62.2 to 71.7 0.748 
FEVI (1) 0.95 0.77 to 1.37 1.09 0.73 to 1.38 0.735 
FEV, (% predicted) 39.2 29.6 to 57.8 42.9 29.0 to 59.4 0.759 
FEV, (% reversibility) 9.1 2.1 to 13.1 3.70 0.0 to 12.8 0.231 
FVC (1) 2.37 1.68 to 2.90 2.60 2.00 to 3.28 0.297 
FEVI/FVC (%) 44.1 35.5 to 53.1 41.3 26.9 to 54.7 0.696 
PEF (I/rrýin) 152 120 to 238 186 147 to 230 0.661 
P. 02 (kPa) 9.00 8.13 to 9.62 8.47 8.27 to 9.22 0.387 
Pa C02 (kPa) 5.91 5.32 to 6.31 5.81 5.32 to 6.11 0.713 
smoking (years) 46 37 to 52 42.5 39 to 50 0.555 
F, xacerbation frequency 
(per year) 
2.40 1.32 to 3.87 2.76 1.04 to 3.37 0.821 
% P-value F- 
6 
Chronic dyspnoea 44.8 52.7 0.780 
Chronic wheeze 34.3 32.4 0.211 
Chronic Cough 41.0 37.8 0.506 
Chronic sputum production 41.8 27.8 0.988 
14istory of smoking 98.2 100.0 0.568 
Smoking at recruitment 41.8 27.8 0.288 
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5.3.2 RSV DErECrION IN STABLE COPD 
Of the samples, 36.8% of winter samples (December - February), 27.1% of 
spring samples (March-May), 36.7% summer samples (June-August) and 34.0% in 
autumn (September-November) were RSV PCR positive. The incidence of RSV 
detection in stable patients showed no significant seasonality (p = 0.558). There was no 
difference in detection rates between spontaneous and induced sputum samples. 
Figure 5.2 RSV PCR Detection Rates from Stable State Sputum Samples According to 
Season of Sampling. 
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EVIDENCE FOR RSV PERSISTENCE 
To study whether detection of RSV in sputum was due to persistence of the virus 
in particular individuals or merely as a result of sporadic infection, we compared the 
predicted probability of RSV detection occurring in all samples from an individual based 
on the overall detection rate of 32.8%, to the actual prevalence of patients with RSV 
throughout the study. The probability that an individual would have RSV in 4 out of 4 
sputum samples based on a random distribution of the virus in this population is 0.0116 
or 1.16%, the actual prevalence of patients with RSV in 4 out of 4 positive samples is 
0.2 or 20% suggesting persistence in certain individuals. 
Patients were categorized a priori using their stable samples RSV status in two 
groups: 'Low RSV' in which (550% of their samples were RSV PCR positive) and 
'High RSV' (>50% of samples were positive). There were 18 patients in the High RSV 
group, and 56 patients in the Low RSV group. There was no difference in the number of 
available samples per patient between the two groups (p-value = 0.424)., or in baseline 
characteristics or the inhaled corticosteroid dosage between the two groups. See Table 
5.2. Similarly, there were no differences in exacerbation frequency between the groups; 
55% in the High RSV and 48% in the Low RSV group were frequent exacerbations, 
(with an annual rate of >= the cohort median of 2.51 (IQR 1.27 to 3.83)). 
Sequencing of both strands of 10 randomly selected RSV positive PCR 
samples confirmed homology in each case with RSV. 
5.3.3 RELATIONSHIP BETWEEN VIRUS DETECTION AND AIRWAY INFLAMMATION 
Detection of RSV was associated with higher levels of airway inflammation as 
measured by sputum IL6, EL8 and MPO. The relationships between RSV detection 
category and airway inflammatory markers are shown in Figure 5.3. Levels of individual 
airway inflammatory markers above the median were associated with a trend to faster 
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FEV, decline. Higher than median levels of IIL-6 were associated with an additional 
FEV, decline of 6.7 rnl/ýr(CI 25.3 to -11.8), IIL8 12.2rnl/ýr(30.9 to -6.4) and MPO 
6.9ml/yr (22.1 to 8.3) but these did reach significance p>O. 18 in all cases. 
TABLE 5.2 ANALYSIS OF INFLAMMATORY MARKERS wrm REspEcT To PERSISTENT 
COLONISATION wrrH RSV; cross-section regression analysis assuming a poisson 
distribution in the dependent variable to allow for repeated measures. 
Parameter Low RSV Change in 95% Cl P-value 
comparison 
in High RSV 
Group 
Sputum EL6 (pg/ml) 181 71 63 to 79 <0.001 
Sputum IL8 (pg/ml) 2571 658 629 to 686 <0.001 
MPO (ng/ml) 10.3 12.7 7.5 to 18.2 <0.001 
Plasma IL6 (pg/ml) 8.81 -1.56 -2.99 to -0.12 <0.001 
OPIER RESPIRATORY VIRUSES AND AIRWAY INFLAMMATION 
Detection of HRV was associated with higher levels of airway inflammation. 
Median sputum IL-8 level was 3177 pg/ml in HRV associated samples versus 2707 
pg/ml in non-HRV samples, (p=0.001) and median sputum IL-6 was 232.2 versus 
198.3 pg/ml, (P=0.00 I I. No significant relationships between other respiratory viruses 
and airway inflammation were found. 
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FIGURE 5.3. COMPARISON OF SPUTUM IL6 PG/ML, IL8 PG/ML AND MYELOPEROXIDASE 
LEVELS (NG/ML), FOR Low RSV AND HIGH RSV PATIENT GROUPS, p<0.001, for 
difference between groups in all cases using cross-section regression analysis assuming 
a poisson distribution in the dependent variable to allow for repeated measures. 
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5.3.4 RSV AND BACTERIAL COLONISAMN 
Total bacterial load was available for 213 of the 241 samples. The overall 
prevalence of bacterial pathogens (PPMs) was 66.1 %. The mean (SD) airway bacterial 
load was greater in the High RSV patients (io8.12(0.48) log cfu/mI, compared to Low RSV 
patients (I Cý36 (0.58)log Cfu/ml) (p =0.024). There was no significant association between 
the detection of RSV and isolation of individual bacterial pathogens, or with all potential 
pathogenic organisms as a group (p> 0.17 in all cases). 
FIGuRE 5.4 AiRwAy BACTERIAL LOAD (LOG CFU/ML) IN PATEENTS 
DicHoTomISED iNTo HIGH AND Low RSV DE-MCnON GROUPS, P--0.024. 
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5.3.5 RSV AND FEVI DECLINE 
Between the first and last RSV samples, there were 781 FEVI readings on the 74 
patients; an average of 8.37 per patient. Those in whom RSV was detected in >50% of 
samples; High RSV (n=18) showed a decline in FEV, of 101.4 ml/year (95% CI 145.8 
to 57.1) compared to 51.2 (70.8 to 31.7) ml/year in the Low RSV group (550% samples 
RSV PCR positive, n=56), the difference in rate of FEVI decline between these two 
groups was significant; p=0.01, rigure 5.4. 
Of the 56 patients in the Low RSV group, 20 (35.7%) were active smokers, and 
of the 18 patients in the High RSV group, 4 (22.2%) were active smokers. If an 
adjustment for active smoking status was made in the analysis of the relationship 
between RSV detection and FEVI decline, there remained a significantly faster decline 
in the High RSV group by an additional 47.9 ml/year (87.8 to 0.8; p =0.019) . The effect 
of smoking itself on FEVI decline was not significant (p = 0.205) in this analysis. In a 
co-variate analysis adjusting for any effects of exacerbation frequency on differences 
in rate of FEV, decline between RSV groups there remained a faster decline in the 
high RSV group by 50.6 ml/year (P=0.0 13). 
To ensure that a variation in the number of samples obtained per patient did not 
affect the relationship between RSV detection and lung function decline, a sub-group 
analysis o patients with the same number of sputum samples was made using the 
sample number of 4 per patient. The relationship between RSV detection and FEV, 
decline remained significant p=0.009, with a faster decline in FEV, of 52.2 (Cl 13.3 to 
91.3) ml/year in the high RSV group subset. 
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FIGuRE 5.5 FEV, (L) DECLINE OVER STUDY PERIOD FOR: Low RSV (550% OF SPUTUM 
SAMPLES WERE RSV PCR POSrIlVE) N= 56; 51.2 mUYR (Cl 70.8 To 31.7). HIGH 
RSV(>50% spuTum SAMPLES RSV PCR POSITIVE); N= 18; 10 1.4 miJYR (CI 145.8 To 
57.1) PATMNT GROUPS. 
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FIGURE 5.6 REGRESSION MODEL OF RSV DETEMON PATIERN AND FEV, (L) DECLINE 
OVER STUDY PMOD. Heavy lines represent decline in FEV I with standard errors for (a) 
Low RSV; (550% of sputum samples were RSV PCR Positive) n= 56; 51.2 mI/yr (SE: 
10.1; CI 70.8 to 31.7), intercept 0.97 (SE 0.42; CI 0.90 to 1.05) (continuous lines), b) 
High RSV(>50% sputum samples RSV PCR positive); n= 18; 10 1.4 ml/yr (SE 0.0 17; CI 
145.8 to 57.1) intercept 1.03 (SE 0.08; Cl 0.88 to 1.19), (interrupted lines). 
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Multivariate analysis of RSV and other factors affecting FEV, decline 
After allowance for total bacterial load, smoking status and starting FEVI, High 
RSV patients had an FEV, decline of 114.7 ml/year (95% CI 186.8 to 42.4) compared 
to the decline of 56.6 ml/year (87.0 to 26.2) seen in Low RSV patients; p<0.05 for the 
difference between the two groups. If the FEV, data was expressed as a percentage of 
the predicted FEVI, High RSV patients had a significantly faster decline of 1.94% per 
year (3.63 to 0.2) in addition to the decline of 2.1% per year (3.3 to 0.9) in Low RSV 
patients (P=0.03). If exacerbation frequency was included in the multivariate analysis, 
the faster decline in the High RSV group remained significant independent of any 
effects of exacerbations; 19.3(2.2 to 36.3) ml/year (p=0.027). A multivariate analysis 
with airway inflammation (MPO), smoking status, starting FEVI, bacterial load and 
exacerbation frequency revealed a non significant of an additional 6.9 ml/year (29.2 to - 
15.4, p---0.545) relative to the low RSV group To determine if the association between 
RSV detection and lung function decline was independent of airway inflammation, 
inflammatory markers were included in the model of analysis. The differences between 
FEV, decline in High and Low RSV groups was not independent of associations with 
airway inflammation; additional decline in High RSV group; with IL-6 as co-variate; 
42.9 ml/year (98.4 to -12.6, p--0.13), for IL-8 39.9 ml/year (95.9 to -16.0, p=0.16) and 
MPO 28.0 ml/year (79.8 to -23.8, p=0.29). 
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5.3.6 PBMC INTERFERON GAMMA RESPONSES To RSV 
The median frequency of IFN-y producing cells in response to whole live RSV 
was significantly lower in COPD patients with RSV detected in one or more sputum 
samples during the study; RSV PCR +; 60 spot forming cells compared to 215 spot 
forming cells per 106 PBMC, in patients in whom RSV was not detected in any 
sputum samples, p=0.048, see figure 3. No significant difference was observed in 
responses to UV inactivated whole RSV (Table 4). Similarly no significant difference 
in IL-4 or IL-10 responses was found between COPD patients with or without RSV 
infection (data not shown). 
TABLE 5.3 IFN-'J RESPONSES OF COPD PATIENTS To RSV AND UV-INACTIVATED RSV. 
PBMC from COPD patients characterised. for PCR detection of RSV were stimulated 
with RSV antigens and frequencies of responding cells were determined by 
ELISPOT. RSV PCR + refers to finding that sputum was PCR positive for RSV at 
least one time point for that patient. Median numbers of spot forming cells are shown 
for the two groups. Significant differences (p<0.05) are shown in bold characters. 
p value (Mann 
Stimulation RSV PCR- RSV PCR+ Whitney U) 
RSV (m. o. i. =5) 215 60 0.048 
UV-RSV (equivalent to m. o. i. =5) 266 138 0.696 
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FIGURE 5.7 IFN-y RESPONSE To RSV IN COPD PATIENTS CHARACTERISED FOR RSV 
INFECT10N BY PCR. Symbols indicate the numbers of spot forming cells per million 
PBMC in RSV PCR- (squares) and RSV PCR + (triangles) COPD patients. The 
horizontal lines and indicate medians. Y axis scale multiplied by 10-1, 
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5.4 DisCUSSION 
This is the first longitudinal prospective study to investigate the relationships 
between respiratory viral detection may play in the aetiology of inflammation and 
progression of stable COPD. The findings show that RSV RNA can be detected in the 
sputum of many COPD patients in the stable state, and its detection is associated with 
higher levels of airway inflammation, greater airway bacterial loads and an 
accelerated decline in lung function. Other respiratory viral and atypical pathogens are 
less commonly detected using the PCR assays described but when present HRV was 
associated with signals of greater airway inflammation. 
& The experimental stimulation of extracted PBMC showed that cells isolated 
from subjects with RSV detection in sputum had an attenuated interferon-y response 
to RSV stimulation, indicative of impaired T cell immunity to RSV which may 
facilitate viral persistence and explain the frequency of RSV detection. 
RSV is an established cause of acute respiratory illness in children, and RSV 
bronchiolitis is associated with the development of persistent wheeze in later 
childhood (Stein 1999). It is not clear however, whether this association is causal. 
Whilst severe RSV bronchiolitis in early life is associated with a subsequent TH-2 
type immune response it is not certain whether this is due to an existing predisposition 
to viral infection due to a pre-existing type -2 phenotype, or two to switch to a TH-2 
pattern following RSV infection. 
The classical pattern of acute infection in this childhood population is of 
marked seasonality of infection with narrow and discrete epidemics peaking during 
the month of January in the UK (Martin 1978). However what drives this marked 
seasonal pattern of infection has been postulated (Eccles 2002) but to where the virus 
lays dormant outside the RSV season is not understood. 
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RSV persistence has been demonstrated in the lungs of guinea pigs (Dakhama 
1997) and mice (Schwarze 2004) for up to 150 days after experimental infection. In 
these animal models RSV persistence was associated with continued infectivity and 
chronic airway inflammation despite an appropriate systemic humoral and T cellular 
immune response. Furthermore persistent RSV infection is well known in children 
with T cell immunodeficiency, but isolation of the virus away from acute illness has 
not been achieved in healthy humans. This may be explained by the fact that RSV 
does not usually cause persistent infection in healthy individuals or due to persistence 
of the virus in anatomically discrete or immunologically priviledged sites such as 
dendritic cells (de Graaff 2005), and neurons (Li 2006), which limit attempts to 
isolate the virus. 
Hence the role of viral infection in the actiology of airways obstruction in 
adults is not established. In the introduction the work on adenoviral persistence was 
introduced. Here a model of chronic viral infection in humans with obstructive lung 
disease has been described by one group. The concept that viral persistence or latent 
infection can result in expression of viral proteins by epithelial cells hence altering the 
cells reponse to inflammatory stimuli (Duerksen-Hughes 1989) has also been 
introduced. Not only has the adenovirus been detected but presence of high levels 
adenovirus protein expression in alveolar epithelium was associated with greater 
airway inflammation and more severe disease (Retamales 2001). 
The studies on adenovirus introduce the distinct concepts of detection of genomic 
nucleic acid detection of viral proteins and isolation of intact virus. The studies 
reported in this chapter have used sensitive PCR techniques with primers directed at 
preserved regions of the viral genome. Interpretation of PCR positive results requires 
careful consideration. Whilst these techniques are highly sensitive, a positive result 
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only confirms the presence of the appropriate fragment of the viral genome. Even 
when contamination can be excluded as a cause of a positive result using sequencing 
techniques such a result does not confirm the presence of intact virus or indeed 
actively replicating virus. It remains a possibility that PCR positive results represent 
persistence of viral RNA following an acute episode rather than ongoing or latent 
infection. However the significant relationships between detection patterns and 
inflammation and clinical outcomes that were found suggest that a phenomenon of 
infection has been identified. Furthermore our PCR technique did not distinguish 
between RSV type in this study and it is not known whether the virus isolated from an 
individual is genetically stable and representative of chronic infection rather than 
recurrent re-infection. Further studies are required to confirm the exact nature of viral 
persistence in the lower airway. 
In both acute and chronic models of infection, the key sites for RSV induced 
inflammation in the lung are the small airways. This is also the site where epithelial 
damage and increased mucous production result in small airway obstruction and 
hyperinflation in COPD (Yanai 1992) and the primary site for the persisting 
inflammation and airway obstruction which is characteristic of the disease (Ilogg 
2004, Saetta 1999). Biopsies of COPD subjects have demonstrated that the small 
airways are infiltrated with inflammatory cells, in particular CDS' cells, neutrophils 
and airway macrophages (Hogg 2004, Saetta 1999). In particular the presence of 
CDS' T cells and B lymphocytes organising into follicles, was associated with disease 
progression (Hogg 2004). The findings of this study may suggest CD8+ T cell 
populations, characteristic of COPD airway biopsies, may be recruited to the lung due 
to persistent viral infection, but an impaired immune response that is incapable of 
eliminating virus infection, permits on-going replication at low levels. 
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RSV detection was associated with heightened airway inflammation in terms of 
increased levels of IL-6, IL-8 and MPO. It is possible that RSV has direct pro- 
inflammatory effects on the airway which may contribute to faster decline in lung 
function. The observed association between RSV detection and FEV, decline 
remained significant if possible confounders such as airway bacterial load, 
exacerbation frequency, smoking status and baseline FEVI were included in the 
analysis. However, if airway inflammation was included in the covariate or 
multivariate model no significant effect of RSV on lung function independent of 
airway inflammation was seen. One explanation is that RSV, inflammation and 
decline are causally linked however it is also possible that inflammation predisposes 
the airway to viral persistence and that RSV detection is therefore an epiphenomenon. 
The direct relationship between airway inflammation and lung function decline 
was not significant in this analysis. This may be due to other non-inflammatory 
processes such as airway remodelling (Hogg 2004), effects on cellular apoptosis 
which have been demonstrated with RSV infection (Krilov 2000) or via other arms of 
the inflammatory cascade. An alternative explanation of our findings is that patients 
with more aggressive COPD and faster disease progression have impaired acquired or 
innate immune responses, allowing RSV to persist. To determine if there is causal 
role of RSV infection in disease progression and airway inflammation, it would be 
necessary to eradicate RSV with vaccines or anti-viral drugs now under development 
(Zhang 2005). 
Whilst RSV may have direct pro-inflammatory effects it is also possible that it 
acts by modulating the response of lung cells to other inflammatory stimuli, including 
bacterial lipopolysaccharide (Monick 2003) or by promoting neutrophil adhesion 
thereby augmenting lung damage (Wang 1998). Bacterial colonisation. of the lower 
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airway in patients with COPD is well described and may provide a stimulus to airway 
inflammation and disease progression as discussed in Chapter 4. The additional 
presence of RSV in the lower airway may augment bacterially driven inflammation. It 
is also possible that chronic viral infection of the lower airway occurs due to increased 
susceptibility in individuals with existing bacterial colonisation, although we found no 
direct association between the isolation of PPMs and detection of RSV. It is feasible 
therefore that eradication of airway bacteria may result in local repair and 
improvement of local defences against viral persistence. 
The relative importance of airway bacterial infection in COPD has been 
shown to increase with disease severity (Zalacain 1999). Again as discussed in the 
previous Chapter this study was performed with a group of patients with moderate to 
severe disease and therefore the findings that RSV can be detected and is associated 
with accelerated disease progression in this population may not necessarily be 
extrapolated to patients with milder disease. Further studies across the full spectrum 
of disease as well as in smoking and non-smoking controls are required to better 
understand the role of this pathogen in adults. 
Acute infection with RSV has been associated with a down regulation of the 
appropriate anti-viral immune responses seen with infection by other respiratory 
pathogens (Legg 2003) and that abrogation of these TH1 responses is associated with 
greater RSV induced inflammation (Boelen 2002). The finding of impaired IFN-y 
responses to RSV in the PBMC of COPD patients with PCR positive for the virus 
suggests that there are fewer circulating RSV specific CD8' T cells in the peripheral 
blood of these patients would suggest that viral persistence has a comparable effect on 
immune responses to that seen during acute infection. 
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The mechanisms underlying the immuno-protective effects of RSV infection 
are not understood. The switch from a predominant type 1 response may be due to 
inhibition of RSV specific effector activity as demonstrated in a murine model (Chang 
2002). This defect may occur at the level of antigen presentation and T cell activation 
as there is also evidence to support the role of dendritic cell infection in this process 
(Bartz 2003). Indeed dendritic cells have been shown to persist in the lung long after 
acute RSV infection and it is fascinating to postulate that these may be an important 
focus of viral persistence which also plays a role in orchestrating the anti-viral 
immune responses. These results on PBMC stimulation may also represent the effects 
selective recruitment of cells to the lung as a result of RSV infection, or a pre-existing 
deficiency of RSV specific CD8+ T cell mediated responses in certain individuals 
resulting in persistent RSV infection. Monitoring RSV detection by PCR in COPD 
patients over time combined with further work to elucidate the mechanisms of 
immuno-protection are required to improve understanding of this interesting field. 
The use of sputum to detect the presence of RSV in the stable state allows 
repeated sampling of patients with advanced disease that alternative techniques such 
as bronchoscopic sampling do not. The use of sputum sampling in a longitudinal 
cohort study; inevitably results in a variable number of samples obtained per patient 
and this problem is further compounded by the use of quality control in processing to 
exclude inadequate samples. However, this quality control step is a vital one as issues 
regarding sampling methodology are of great importance. Recently a study reporting 
RSV detection in less than 1% of stable state sputum samples from a population of 
112 patients with COPD (Falsey 2006). Whilst, the PCR techniques utilised were 
sensitive the patient characterisation, sputum processing and sample quality control 
were very different from those methods used in the study reported in this Chapter. 
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Whilst PCR detection assays may appear, on paper, to be highly sensitive it is 
apparent that the type of biological sample taken; sputum rather than swab, the 
rapidity of sample processing and storage and the nucleic acid extraction techniques 
used, all impact upon the likelihood of detection of RSV RNA by PCR as RNA can 
degrade rapidly at room temperature. 
This study did not examine the detection rates for RSV amongst normal 
controls, but the PCR detection techniques utilised in this study have also been used 
previously. In a number of these other studies healthy control groups have been 
studied and low detection rates have been found. Indeed we have studied adult control 
groups in two recent studies, the detection rates for RSV in both of these was zero 
(Creer 2005, Green 2002) suggesting that RSV detection in the stable state may be a 
factor in moderate to severe COPD, but not in healthy controls. 
In comparison to the detection rates only relatively low numbers of other 
respiratory pathogens were detected by PCR in this study. Whilst these findings may 
suggest that persistent infection with these other pathogens is not common in this 
patient population there are also a number of explanations why detection rates may 
underestimate the true prevalence rate. Assay sensitivity is obviously key to 
interpretation of these findings, the PCR assays used have all been demonstrated to be 
sensitive in internal validation studies of samples from subjects with acute respiratory 
illnesses. However the RSV assay used was a nested PCR and the increased 
sensitivity offered by this system over single round detection assays may be of 
importance when detecting very low copy numbers of virus associated with 
persistence rather than acute infection. It is also important to note that the cohort of 
patients studied had been vaccinated against influenza and this may have had effects 
on infection with this pathogen. The finding that no adenovirus was detectable is 
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perhaps surprising when considering the findings of the Vancouver group (Retarnales 
2001) however this work used lung tissue rather than sputum and it is quite possible 
that different pathogens play different roles in different compartments of the lung. 
When other viruses such as HRV have been detected a relationship with 
airway inflammation has been present, however the detection rates were too small to 
determine a clinical effect. 
Debate exists over the role that atypical bacterial infection may play in stable 
COPD. Some reports suggest that persistence of Chlamydia pneumoniae in peripheral 
blood mononuclear cells was both common, and associated with clinical severity of 
disease (Blasi 2002). However previous work from our group found no Chlainyclia 
using PCR analysis of induced sputum and naso-pharyngeal aspirates in the stable 
state and no associations with inflammatory indices at exacerbation (Seemungal 
2002). The data from this study therefore confirms the previous findings of our group 
but whether Chlamydia can persist in a systemic compartment has not been excluded 
by this study. 
CONCLUSION 
We have shown that respiratory syncytial virus RNA can be detected from lower 
airway samples of some patients with COPD in the stable state, with evidence of 
persistent detection in certain individuals. RSV RNA detection was associated with 
greater airway inflammation and accelerated disease progression in these patients. 
Whilst RSV is not unique as a respiratory pathogen able to modulate immune 
responses (Alvarez 2005) a combination of its prevalence in this population combined 
with its ability to modulate immune responses may indicate a role not only in 
persistent infection but also in effects on response to other pathogens. These findings 
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suggest that RSV may play a role in the natural history of stable COPD, however 
further investigation into the nature and consequences of viral persistence are required 
to confirm whether RSV is a potential therapeutic target in this important patient 
group. The strict seasonality of RSV epidemics is well known and seen in all parts of 
the globe. In some areas, cases of clinical infection are virtually unknown outside the 
winter months, and the source of winter outbreaks has not been identified. Our finding 
that RSV was present outside the RSV season in some patients with COPD therefore 
is suggestive of chronic colonisation rather than repeated re-infection, but studies to 
determine the virus isolated from an individual is genetically stable and representative 
of chronic rather than re-infection are required. 
The last two chapters have presented the findings which suggest that chronic 
infection may be important in stable disease. The role of infection in the aetiology of 
exacerbations has been studied in some detail; however these studies have focused 
largely on either viral or bacterial detection. The following chapter describes the 
finding of studies to determine the effects of each type of pathogen and co-infection at 
exacerbations of COPD. 
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CHAPTER 6 
EFFECTS OF BACTERIAL AND VIRAL 
INFECTION AT EXACERBATIONS OF 
COPD 
he findings that airway bacterial and viral infection is associated with 
increased inflammation and disease progression in patients with stable disease 
described previously are novel. This chapter presents the study of the role these 
potential co-pathogens play in modulating the nature and severity of acute 
exacerbations. 
6.1 INTRODUCTION 
It has been established that exacerbations of chronic obstructive pulmonary 
disease are characterised by increased airway (Seemungal 2000, Bhowmik 2000) and 
systemic inflammation (Wedzicha 2000), and that the marked variability in the nature 
of the inflammatory response, symptoms, clinical severity and time course of these 
events (Seemungal 2000) may be modulated by respiratory viral (Seemungal 2001, 
Seemungal 2000, Rohde 2003) and bacterial infection (Sethi 2000). However, studies 
to date have largely focused on detection of either viruses or bacteria and therefore 
interactions between these pathogens and hence the mechanisms which underlie the 
heterogeneity of exacerbations are poorly understood. 
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This study has demonstrated that bacterial pathogens are commonly identified 
in the lower airway of COPD patients in the stable state, in agreement with previously 
published work (Hill 2000, Monso 1995). The previous analysis has shown that 
airway inflammation is directly related to the number of bacteria in the lower airway 
in stable COPD and greater airway bacterial load is itself a stimulus to faster disease 
progression. Whilst it is known that airway bacterial load rises at exacerbation 
(Monso 1995) it is not known to what extent these rises modulate changes in airway 
inflammation and exacerbation severity, or what factors determine changes in 
bacterial load. 
Respiratory viruses have been implicated as important infective triggers of 
exacerbations (Seemungal 2000, Rohde 2003, Greenberg 2000) with human 
rhinovirus (HRV) being the most commonly identified viral pathogen. Our group has 
previously shown that virus associated exacerbations are longer and thus more severe 
than non-viral exacerbations (Seemungal 2000) but whether this is due to the direct 
effects of viral infection on the airway or a mechanism involving changes in lower 
airway bacteria is not known. 
Exacerbations are important clinically as they are responsible for a major 
proportion of primary care and outpatient consultations and inpatient admissions 
(Pauwels 2001). Whilst it is established that certain patients are at risk of frequent 
exacerbations (Seemungal 1998) and that the incidence of exacerbations is seasonal 
(Bhowmik 2005), the clinician remains unable to predict when a particular COPD 
patient is at risk of exacerbating. Understanding the relationships between baseline 
markers of infection and inflammation and the risk or timing of subsequent 
exacerbations would inform on the possibility of targeting treatment and potentially 
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preventing a proportion of this events and their associated morbidity and healthcare 
costs. 
Our current understanding of the inflammatory milieu in the airway of patients 
with COPD is limited to a relatively small number of studies which have concentrated 
on the measurement of a limited range of inflammatory markers related to epithelial, 
neutrophilic and lymphocytic inflammation. The assays used in this study have 
concentrated on markers which have been shown to relate to clinical outcomes and 
trigger factors. Measurement of changes in a broad spectrum of inflammatory proteins 
and peptides at exacerbation may improve our understanding of the disease process 
and also identify new targets for therapeutic interventions. 
This aspect of the study examined the hypothesis that the heterogeneity of 
inflammatory, symptomatic and physiological responses at COPD exacerbation is 
modulated by airway bacterial and viral infection and that a combination of these 
pathogens would result in greater airway and systemic inflammation and hence 
clinical and physiological indices of exacerbation severity. The analysis is in two 
parts; firstly a paired analysis of changes in exacerbation parameters compared to 
corresponding baseline values in 56 exacerbations in 39 patients. Secondly an analysis 
of 68 exacerbations in 68 patients without predated baselines. We also determined the 
relationships between stable state inflammatory markers and time to exacerbation and 
in a small sample determined the changes in an array of markers at exacerbation using 
proteornic analysis of sputum. 
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6.2 METHODS 
The cohort recruitment, follow up and sampling was performed as described 
previously. Patients were reviewed at recruitment and with their diary cards every 
three months in the study clinic to monitor compliance with data collection, record 
changes in medication and baseline lung function. Review of diary cards was utilized 
to ensure that stable sampling was performed when subjects had been clear of 
exacerbation symptoms and had completed any exacerbation treatment for at least six 
weeks. 
Patients were encouraged to report symptom changes to the study team; they 
were assessed within 24-48 hours in the study clinic by a respiratory physician prior 
to initiation of therapy for the exacerbation. The diagnosis of an exacerbation was 
based on symptomatic criteria previously validated by our group. Exacerbation 
symptoms were binary coded as present or absent and the sum of these at 
exacerbation onset was termed the symptom count, which has been validated as a 
marker of clinical severity. Lung function measurement and sputum and blood 
sampling was performed on patients prior to the initiation of exacerbation treatment. 
The treatment given was at the discretion of the attending clinician. 
Sputum was sampled if the subject met criteria for the stable state at three 
monthly review and also at presentation of exacerbation. Immediately following lung 
function measurement patients were asked to spontaneously expectorate sputum into a 
sterile container. Patients unable to produce a sample of sputum spontaneously 
underwent sputum induction. 
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6.2.1 PROTEOMIC M FMODOLOGY 
MICROARRAY MANUFACTURE 
Glass slides were cleaned with 3-cyanopropyltriethoxysilane. The slides were 
equipped with a Teflon mask, which divided the slide into sixteen 0.65 cm. diameter 
wells or circular analysis sites called subarrays (Figure 6.1). Printing was 
accomplished with a Perkin-Elmer Spot Array Enterprise non-contact arrayer 
equipped with piezoelectric tips, which dispense a droplet (-350 pL) for each 
microarray spot. Antibodies were applied at a concentration of 0.5 mg/mL at defined 
positions. Each chip was printed with sixteen copies of one type of array. A set of 
cytokines, selected for potential biological relevance, was printed with quadruplicate 
spots in each subarray. After printing, chips were inspected using light microscopy. If 
the percentage of missing spots observed was greater than 5%, then the batch failed 
and the slides were discarded immediately. For all print runs described herein, 100% 
of the antibody features and >95% of the biotin calibrators were printed. Microarray 
chips were validated in concert with a set of qualified reagents in two ways. First, 
mixtures of 1-3 different cytokines were prepared so as to provide a high intensity 
signal and applied to 14 wells of a chip (with each well being treated with a different 
mixture up to the total complement of detector antibodies) and two arrays were used 
as blank controls. 
The chips were developed and scanned and the resulting signals were 
compared to the positional map of the particular array. Second, a titration QC for all 
analytes of a specified array using known sample matrices was performed. Normal 
human serum and heparinized plasma were assayed neat or spiked with purified 
recombinant cytokines representing all analytes in the array. Spiked mixtures were 
then titrated down the subarrays of a slide from 9,000 pg/mL to 37 pg/mL of spiked 
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cytokine concentrations along with two subarrays for each un-spiked control sample. 
Thus the lower limit of sensitivity in plasma being at least 37pg/ml. The data was 
quantified and for every analyte in the array a titration curve was generated to 
examine feature intensity behavior as a function of concentration. Taken together, this 
data was used to confirm the activity of array features and reagent sets. 
ROLLING CIRCLE AMPLIFICATION (RCA) IMMUNOASSAY 
Prior to assay, the slides were removed from storage at room temperature in 
sealed containers and opened in a humidity controlled chamber (45-55%). Slides were 
blocked with Seablock (Pierce Chemical Co. ), diluted 1: 1 with PBS for Ih at 37'C in 
a humidified chamber. Following removal of the blocking solution, they were washed 
twice with PBS prior to application of sample. On each slide, control serum (Jackson 
ImmunoResearch Laboratories, Jackson, US) was applied to two subarrays, and a 
negative contro wit PBS buffer applied to two subarrays. The test samples were 
assayed on the remaining 12 subarrays. Twenty gL of the treated sample were then 
applied to each subarray. The basics of performing immunoassays with RCA signal 
amplification has been described (Schweitzer 2002) and we used SOPs derived from 
the protocols used in that study. Slides were scanned (GenePix 4000B, Axon 
Instruments Inc. ) at 10 prn resolution with a laser setting of 100% and a PMT setting 
of 550 V. Mean pixel fluorescence values were quantified using the fixed circle 
method in GenePix Pro 4.0 (Axon Instruments, US). Using proprietary software, the 
fluorescence intensity of microarray spots was analyzed for each feature and sample, 
and the resulting mean intensity values were determined. Dose-response curves for 
selected cytokines were examined, ensuring that feature intensity is above background 
and exhibiting increasing intensity with increasing analyte concentration. 
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FIGURE 6.1 SCHEMATi(, REPRESENTATION OF A SAMPLE PROTEIN MICROARRAY SLIDE 
WITH 16 SUBARRAYS. Subarrays refer to the 16 wells, or circular analysis sites, on the 
slide. Array refers to the antibody content printed in a well. Each microarray slide 
contains only one type of array. 
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STATISTICAL ANALYSIS 
The statistical analysis used for this section of the study was conventional and 
described in Chapter 3. Changes in parameters from the stable state to exacerbation 
were assessed using a paired analysis of the stable sample data taken preceding the 
exacerbation studied. p values : 50.05 were regarded as significant. In the analysis of 
changes in parameters between stable state and exacerbation, the prior stable sampling 
point closest to the subjects corresponding exacerbation was used creating a dataset of 
paired baseline and exacerbation samples for each exacerbation. The analysis of group 
data was initially adjusted for repeated measures by selecting the first exacerbation 
sampled per patient n=39, to assess the changes in measured indices from baseline to 
exacerbation. These observed changes were comparable to the larger dataset of 56 
exacerbations (in 39 patients) which was therefore used to compare individual 
exacerbation characteristics and etiologies, as in previous studies (Seemungal 2000). 
Multivariate analysis was performed using a multiple linear regression analysis. SPSS 
version 10.0 (SPSS Chicago, IL, USA) statistical package was used for data analysis. 
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6.3 RESULTS 
Table 6.1 shows the baseline characteristics of the 39 patients in the London 
COPD Cohort sampled during the study of the effects of bacterial and viral infection 
on physiological and inflammatory indices at exacerbation. Fifty six paired stable and 
exacerbation samples were obtained from 39 patients. 
Of these 39 patients, 15 were on long term oxygen therapy, all patients were 
receiving long term inhaled corticosteroids (median (IQR) dose 500 (400-1500) 
micrograms per day beclomethasone equivalents), no patients were on long term oral 
corticosteroids, and all patients received regular inhaled bronchodilators. The 
remainder of the patients did not exacerbate during the sampling period (n = 26), did 
not report an exacerbation to the study team, received antibiotic treatment before 
sampling or were unable to provide an adequate sputum sample (n =14). The sampled 
patients did not differ significantly in terms of their baseline characteristics from those 
who were not sampled. 
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TABLE 6.1 BASELINE CHARACTERISTICS OF THE 39 PATIENTS SAMPLED AT 
BASELINE AND AT EXACERBATION. 
Mean (SD) 
Age (years) 68.8(6.9) 
FEV, %Predicted 40.6(15.6) 
Pa 02 (kPa) 8.86(0.89) 
Pa C02 (kPa) 5.67(0.74) 
Median (IQR) 
Smoking (pack years) 41.0 (30-52) 
Sex (males) 60% 
Active Smokers 23% 
Chronic Sputum Producers 43% 
6.3.1 CHANGES IN LUNG FUNCTION AND INFLAMMATORY MARKERS AT 
EXACERBATION. 
Table 6.2 shows the stable and exacerbation FEVI, airway bacterial load, 
sputum IL6 and IL8 and blood 11-6 levels for all the 56 sampled exacerbations and on 
a per patient basis (n=39). In both analyses; the mean FEVI fell at exacerbation and 
the mean airway bacterial load rose significantly. Exacerbations were associated with 
increased airway inflammation in terms of sputum IL S. The rises in levels of sputum 
and serum IL6 did not reach statistical significance. 
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TABLE 6.2 FEVI, INFECTIVE AND INFLAMMATORY CHANGES FOR BASELINE (STABLE 
STATE) AND ExACERBATION. Sample Points and on a per patient basis (n=39) and for 
all 56 sampled exacerbations (n=56). 
Baseline Exacerbation p Value * 
N=39 Mean (SD) Mean (SD) 
FEV 1 (1) 0.95(0.36) 0.87(0.30) 0.012 
Bacterial Load (log cfu/ml) 7.47(0.73) 8.16(0.76) 0.001 
Median (IQR) Median (IQR) 
Sputum IL8 (pg/ml) 3647 (2930-4466) 4409. (3983-4787) 0.002 
Sputum 11-6 (pg/ml) 146.0 (20.4-246.9) 187.6 (49.9-269.1) ns 
Serum IL6 (pg/ml) 4.73 (3.34-7.07) 6.0 (4.25-13.18) ns 
N=56 Mean (SD) Mean (SD) p Value 
FEV 1 (1) 0.96(0.37) 0.89(0.32) 0.015 
Bacterial Load (log cfu/ml) 7.50(0.74) 8.09(0.76) 0.001 
Median (IQR) Median (IQR) 
Sputum IL8 (pg/ml) 3604 (2913-4390) 4288 (3991-4765) 0.005 
Sputum IL6 (pg/ml) 146.7 (29.4-233.0) 185.0 (50.0-280.0) ns 
Serum IL6 (pg/ml) 4.6 (3.1-7.1) 6.6 (4.0-11.7) ns 
Mean (SD) Mean(SD) 
Cells (xIO6)/g sputum 4.49(3.81) 13.20(13.87) ns 
% Neutrophils 64.10(24.27) 79.50(23.20) ns 
% Macrophages 19.57(22.48) 34.75(24.12) ns 
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6.3.2 AIRWAY BACTERIOLOGY AND VIROLOGY 
Airway total bacterial load rose in all samples (n=56) from I 
W. 50(0.74) log 
cfu/ml in the stable state to 108.09(0.76) log cfu/mI at exacerbation, and also rose 
significantly in data adjusted for repeated measures (n=39); 
(ICý. 47(0.73) to 108.16(0.76) 
p=0.001). The prevalence of potentially pathogenic organisms (PPM) rose from 
48.2% at baseline to 69.6% at exacerbation (n=56) with the remainder of samples 
demonstrating non-specific bacterial growth (NSG). The most frequently isolated 
organism was Haemophilus influenzae in 14.3% of stable and 37.5% of exacerbation 
samples, with Streptococcus pneumoniae in 8.9% and 14.3%, Moraxella catarrhalis 
in 7.1% and 14.3%, Haemophilus parainfluenzae in 10.7% and 0%, Staphylococcus 
aureus in 3.6% and 0%, Pseudomonas aeruginosa in 1.8% and 1.8% and GNEB in 
1.8% and 1.8%, respectively, the remainder demonstrated NSG. 
HRV PCR was positive in II out of 56 (19.6%) exacerbations and cold 
symptoms, a measure of putative viral infections, present in 18 (32.1 %). The presence 
of cold symptoms and HRV positive PCR sputum were related; continuity adjusted ý 
4.11, p =0.04. Exacerbations associated with colds were associated with a greater 
percentage fall in FEVI -14.03 (13.91) than those without colds -3.01(16.38) %, p= 
0.043. 
6.3.3 RELATIONSHIPS BETWEEN INFECTION, INFLAMMATION AND CLINICAL INDICES AT 
EXACERBATION 
Changes in airway bacterial load (n=39) were related to exacerbation severity 
in terms of changes in lung function and airway inflammation. The rise in airway 
bacterial load from baseline to exacerbation was related to the percentage fall in 
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FEVI; r=0.35, p=0.048. The magnitude of the rise in airway IL8 at exacerbation 
was related to the rise in airway bacterial load, rho = 0.37, p=0.022. 
The changes in airway and serum IL6 observed from stable state to 
exacerbation were not related to changes in bacterial load; rho = -0.76, p=0.649, rho 
= 0.144, p=0.482, respectively. However the rise in systemic inflammation was 
related to that of airway inflammation; change in sputum IL6 correlated with the 
change in serum IL6; rho = 0.435, p=0.023, n=39. 
Changes in airway and systemic markers of inflammation at exacerbation were 
modulated by existing disease severity. The observed change in sputum 11-8 at 
exacerbation per patient was inversely related to the baseline FEV, (percent of 
predicted); rho = -0.298, p=0.05, as was the change in sputum IL6; rho = -0.358, p= 
0.02 and the change in serum IL6; rho = -0.392, p=0.03. Thus patients with more 
severe COPD exhibited greater rises in inflammation at exacerbation compared with 
those with more mild disease. 
6.3.4 EFFECTS OF INDIVIDUAL PATTIOGENS AND TtIEIR INTERACTIONS 
, 
HAEMOPHILUS INFLUENZAE 
H influenzae related exacerbations were associated with higher airway 
bacterial load (n=56); 108.52 (0.39) log CfU/Ml compared to those where it was not 
isolated; ICý*85(0,81) log cfu/ml, p=0.001. There was a trend towards more severe drops 
in FEVI (expressed as a percentage of baseline); -11.91 (15.32) % with H influenzae 
present, than without -1.20 (15.09) %, p=0.057. Where 'de novo' H inflitenzae 
infection occurred (ie H influenzae present at exacerbation but not present in stable 
sample), there was again a greater exacerbation bacterial load 108.56(0.40) compared to 
where H influenzae was not isolated 167.8](0.84) log cfu/ml, p =0.001, and the 
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percentage fall in FEV, was significantly worse in this group -14.60(12.39) compared 
to the non-H influenzae exacerbations - 1.17 (15.99) %, p= 0.027. 
FIGURE 6.2 EFFECT OF AIRWAY PATHOGENS AND PATHOGEN COMBINATIONS ON 
PERCENTAGE FALL IN FEV, AT EXACERBATION. Columns represent mean values with 
error bars as standard error of mean. * represents significant (p<0.05) difference 
between this category and cold and bacterial pathogen category. n=56. 
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FIGuRE 6.3 EFFECT OF AIRWAY PATHOGENS AND PATHOGEN COMBINATIONS ON 
SYMPTOM SEVERrry. (median symptom count at exacerbation onset), columns 
represent median values, bars interquartile range * and + denote statistical significant 
(p<0.05) difference between corresponding labelled categories. n=56. *p=0.029. 
P=0.019. 
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FIGuRE 6.4. AIRWAY BACTERIAL LOAD AT EY-ACERBATION (CFU PER ML), FOR 
DIFFERENT CATEGORIES OF ISOLATED PATHOGEN. Columns represent mean values 
with error bars as standard errorof mean; All non-H influenzae PPMs ,H influenzae, 
H influenzae and HRV, H influenzae and Cold symptoms. n=56. PPM = Potentially 
Pathogenic Micro-organism 
RV = Human rhinovirus H flu = Haemophilus influenzae * represent significantly 
diffcrcnt from all PPMs catcgory. 
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The observed FEV, fall associated with colds at exacerbation was more 
marked in the presence of a lower airway bacterial pathogen; -20.3(14.81) % with 
both colds and a bacterial pathogen compared to -3.63 (5-57) % with a cold alone, p= 
0.026 or -3.13 (14.88) %, with a bacterial pathogen alone, p= 0.001. (Figure 6.2). The 
specific effect of the interaction between colds and bacterial pathogens was assessed 
with a multivariate regression analysis with the % FEV, fall at exacerbation as the 
dependent variable, the effect of the interaction was additional to the independent 
effects of each individual factor; 95% Cl - 13.13 to -2.09, p= 0.009. 
Similarly exacerbation symptoms were more severe (higher symptom count at 
exacerbation onset) in those exacerbations associated with a PPM in the presence of 
cold symptoms; 4.0 (3.0 - 4.5), compared to those exacerbations with a PPM but not 
associated with cold symptoms; 3.0 (2.0-3.0), p=0.019, or with neither a PPM nor 
cold symptoms; 3.0 (2.0-3.0), p=0.029. (Figure 6.3) 
Exacerbations associated with both Haemophilus influenzae and IIRV 
exhibited a greater bacterial load ( io8.56(0.31) VS io8.05(0.77) log cfu/mI, p=0.018) and 
serum IL6 (13.75 (10.53-16.91) vs 6.29 (3.31-9.75) pg/ml, p=0.028) than those 
without both pathogens. The exacerbation airway bacterial load associated with 
Haeinophilus influenzae and HRV compared to other PPMs is illustrated in Figure 
6.4. 
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6.3.5 ASSOCIAIIONS BETWEEN HRV AND BACTERIAL PATHOGENS 
In this further analysis we sampled 68 exacerbations in 68 patients (mean (SD) 
without corresponding baselines. Patient characteristics: age 67.8(8.22) yr, 
FEVII. 1(0.43)1, FVC 2.12(0.73)1, % predicted FEVI 44.07(15.77), pack yr history 
55.3(36.0), at exacerbation, sputum was analysed for microbiology, HRV using PCR 
and cytokines using ELISA as described previously. 
FIGURE 6.5 DETECTION RATES OF BACTERIAL PATHOGENS IN SpuTum FROM 
68 EXACERBATIONS. 
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HRV was detected in 26.5 % of patients exacerbation sputurns. Detection of 
HRV was associated with active smoking x24.0 p=0.05 and greater pack years history 
of smoking, rho=0.252, p=0.045. HRV at exacerbation was associated with isolation 
of S. pneumoniae; x24.94, p=0.02, and a trend to higher airway inflammation (IL6 
218.9(124.4-268.8) vs 113.9(42.2-283.6)pg/ml, p=0.06, figure 6.5. Exacerbations 
when S. pneumoniae was isolated from sputum exacerbations exhibited a greater drop 
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in FEV, rho=0.243, p=0.034 than those without this pathogen. No other significant 
inter-pathogen associations were present in this analysis. 
FIGURE 6.6 SPUTUM INTERLEUKIN-6 LEVELS IN EXACERBATION SAMPLES FROM 68 
COPD EXACERBATIONS n= 68, p=0.06. 
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FIGURE 6.7 ISOLATION RATES FOR STREPTOCOCCUS PNEUMONIAE IN EXACERBATIONS 
WITH AND WITHOUT HRV POSITIVE PCR n=68 p=0.02. 
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6.3.6 RELATIONSHIP BETWEEN STABLE STATE INFLAMMATION AND TiME To FIRST 
-EXACERBATION 
Stable state sputum and blood samples from120 cohort patients were taken 
and analysed in order to determine the relationship between stable state inflammation 
and the time to the next exacerbation. 
Diary cards were reviewed to ensure patients were in the stable state for at 
least six weeks prior to baseline sampling and patients were followed prospectively to 
first exacerbation- diagnosed using the standardised symptom based criteria. 
Patient baseline characteristics were typical for the East London Study. 81 
males, mean (SD) age 66 (7.64) years FEV, 1.08 (0.42) 1, FVC 2.51(0.81) 1, FEV, % 
predicted 41.1 (15.7) %. We analysed sputum (n=80) for IL-6, IL-8 and blood 
(n= 120) for IL-6 and fibrinogen. Patients completed diary cards of symptoms and 
were prospectively followed to first exacerbation. Relationships between stable state 
inflammation and time to first exacerbation after sampling were determined. 
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The median (IQR) stable state levels were: Sputum IL-6 140.7(46.8-231.6) 
ng/ml, IL-8 3430 (2046-4679) ng/ml, Serum IL-6 4.3 (2.8-5.5) ng/ml and Plasma 
Fibrinogen 3.91(3.53-4.42) g/l. Higher levels of stable state airway inflammation were 
associated with a shorter time to first exacerbation; loglo sputum IL-6; (r = -0.37, 
p=0.00 1), log Io sputum IL-8 (r = -0.56, p<0.00 1). 
A regression analysis to determine effect size revealed a sputum ILS level 
33% above the median was associated with a 26% reduction in time to next 
exacerbation. However no relationship was seen between stable state systemic 
inflammatory markers and time to exacerbation; loglo serum IL-6 (r=0.223, 
0.1450, log 10 plasma fibrinogen; (r---O. 12, p= 0.9). 
6.3.7 PROTEOMIC ANALYSIS OF SPUTUM AT BASELINE AND EXACERBATION 
A pilot study was recently performed to determine the suitability of sputum 
samples collected from patients with moderate COPD and processed using standard 
protocols, for analysis using MSI Protein arrays and to profile changes in 107 
cytokines from clinically stable state to exacerbation in five patients. 
The patients were sampled when determined to be in a clinically stable state 
and followed prospectively until they experienced an exacerbation of their symptoms, 
when confirmed clinically with review of diary cards were sampled again. All 
samples were processed in the departmental laboratory with aliquots frozen at -70 
OC 
for this analysis. Baseline and exacerbation sputum aliquots were transferred to MSI 
for protein microarray analysis as described in the methods section of this chapter. 
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TABLE 6.3 CHARACTERISTICS OF 5 BASELINE AND 5 ExACERBATION SPUTUM SAMPLES 
USED FOR PROTEIN MICROARRAY. 
Patient Sample Type TBC log cfu/ml Bacteria HRVPCR 
001 Base Line 8 H parainfluenza Negative 
001 Exacerbation 8.9 H Influenza Negative 
002 Base Line 7 NSG Negative 
002 Exacerbation 8.3 B catarrhalis Negative 
003 Base Line 9.6 H influenza Negative 
003 Exacerbation 8.7 H influenza Negative 
004 Base Line 8.3 Citrobacter sp Negative 
004 Exacerbation 9 NSG Positive 
005 Base Line 8.6 Enterobacter Negative 
005 Exacerbation 6.6 Pseudornonas Negative 
Sputum as sampled and processed is a suitable substrate for protein microarray 
analysis, all sample replicates passed quality control. 62 of the 107 (58%) analytes 
were detectable in the sputum samples assayed (Mean fluorescence intensity >1000) 
in the baseline sputum samples. 16 analytes were found to be modulated at 
exacerbation compared to matched stable samples; (GRO-beta, ICAM-3, TIMP-1, 
ENA- 78, Flt3Lig, IL-13, IL-15, IL-3, IL-4, MIP-Idelta, NT3, NT4, PARC, TARC, 
sgpl30, IGFBP-3). These results with p values are tabulated below. Table 6.4. 
Of the analytes detected a number which have been demonstrated to be 
modulated in sputum at exacerbation using larger sample populations and more 
conventional ELISA techniques did not appear to be be modulated significantly in this 
preliminary study. For example IL-8, IL-6, Gro-alpha and markers of neutrophil 
activation. This discrepancy is likely to be due to the small sample size in this study. 
Analyte intensities within each patient were highly correlated between baseline 
and exacerbation. (Coff coeff > 0.85). This suggests that variation between 
individuals is an important factor in the analyte levels detected and hence a 
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longitudinal sampling of matched baseline and exacerbation samples is a valuable 
sampling methodology 
TABLE 6.4 PROTEOMIC ANALYTES WmI EVIDENCE OF MODULATION AT 
EXACERBATION. N=5 (paired analysis). 
Analyte p-value 
Direction of change in 
exacerbated samples 
Fold change 
GROb 0.0773 increased 3.1 
ICAM3 0.0730 increased 1.5 
TIMPI 0.0387 increased 1.4 
ENA-78 0.0038 decreased 2.5 
17101, ig 0.0955 decreased 1.7 
IL-13 0.0730 decreased 1.5 
IL- 15 0.0848 decreased 1.3 
IL-3 0.0900 decreased 1.5 
IL-4 0.0744 decreased 1.6 
MIP- Id 0.0874 decreased 2.3 
NT3 0.0509 decreased 1.9 
NT4 0.0825 decreased 1.7 
PARC 0.0033 decreased 3.1 
TARC 0.0101 decreased 2.1 
sgp130 0.0639 decreased 2.0 
IGFBP-3 0.0962 decreased 1.6 
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6.4 DisCUSSION 
The results of this study show evidence of a synergistic effect between viral and 
bacterial infection in modulating the severity of symptoms, lung function changes and 
inflammation at exacerbations of COPD. The findings demonstrate that changes in 
lower airway bacterial load are associated with the variability in inflammation and 
lung function seen at exacerbation in patients with moderate to severe COPD, effects 
which were more pronounced in proven rhinoviral and putative viral infections 
associated with cold symptoms. 
These data also suggest that pathogens associated with more severe 
exacerbations such as Haeniophilus influenzae, may have greater effects on the lower 
airway and indeed on the patient as a whole due to a process which is mediated, at 
least in part via a greater stimulus to inflammation, associated with higher airway 
bacterial loads. 
Patients with more severe disease in this study demonstrated greater rises in 
airway and systemic inflammation than those with milder disease. This suggests that 
the heterogeneous nature of exacerbation severity is dependent not only upon the 
nature of infective triggers but also upon the baseline severity of disease. 
This study has been performed using the well validated technique of daily diary 
card symptom recording and analysis, to confirm both the diagnosis of exacerbations 
and also the stable state. (Bhowmik 2000, Wedzicha 2000, Seemungal 1998, 
Seemungal 2000). The study of exacerbations utilised two designs, this has allowed 
analysis of data from sampling the same patients in both stable and exacerbating 
clinical states and to describe both cross sectional analyses at exacerbation, and also 
changes from baseline and furthermore how these changes in exacerbation parameters 
were modulated by the corresponding infectious agents. 
190 
VIRAL AND BACTERIAL INFECTION AT EXACERBATIONS OF COPD 
The paired baseline- exacerbation analysis has shown that the severity of the 
fall in lung function and the rise in inflammation seen at exacerbation is related to the 
extent of the rise in airway bacterial load. A relationship between airway 
inflammation and airway bacterial load has previously been described in the stable 
state, (Hill 2000, Patel 2002, Banerjee 2004) with higher loads associated with greater 
falls in FEVI over a one year study (Wilkinson 2003). A number of previous studies 
have identified that bacterial pathogens are commonly found in the lower airway at 
exacerbation (Sethi 2000, Sethi 2002, Miravitlles 1999) with higher loads than in the 
stable state (Monso 1995). However the effect of rising numbers of bacteria on the 
nature of exacerbations has not been investigated. These findings suggest that changes 
in bacterial load may play a role in the heightened levels of airway inflammation 
characteristic of exacerbations. However, evidence for an association between 
changes in bacterial load and indices of exacerbation severity does not prove 
causality. It is possible that changes in airway bacterial load may simply be a 
secondary phenomenon to other causes of inflammation. Indeed, the findings of this 
study show that the key changes in symptoms and lung function at exacerbation were 
observed when the synergistic effects of viral and bacterial infection were found. In 
vitro and intervention studies are required to differentiate the exact contribution of a 
particular pathogen or pathogens to the inflammatory and patho-physiological 
changes at exacerbation. Indeed there has recently been established a human 
rhinoviral exposure model of COPD exacerbations (Mallia 2004). However due to the 
necessities of patient safety, only subjects with very mild disease would be suitable 
for such viral challenge experiments and the role of airway bacterial infection in such 
a population may differ greatly from that seen in more established disease. 
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Haemophilus influenzae was found in this study, as in previous studies 
(Monso 1995, Zalacain 1997) to be the most important bacterial pathogen identified 
both in terms of prevalence in the stable state and also at exacerbation, and in 
determining the airway bacterial load. Haemophilus influenzae unlike a number of 
other bacterial pathogens may colonise not only the airway but invade the respiratory 
epithelium itself. H influenzae colonisation has been shown to be a greater stimulus to 
airway inflammation than other commonly isolated pathogens (Sethi 2000, Bresser 
2000). This is in agreement with the findings of our study which demonstrate that 
Haemophilus influenzae was present in greater numbers than the other PPMs 
identified and that its presence at exacerbation was associated with more severe drops 
in FEVI. The role of less prevalent bacterial pathogens at exacerbation in particular 
their interactions with respiratory viruses requires further study; this will require a 
larger patient population or longer term follow up. 
The stimulus of newly acquired Haenzophilits influenzae at exacerbation 
provided a greater deleterious effect on FEV, than Haemophilus influenzae associated 
exacerbations in patients already colonised with this pathogen. These findings 
compliment previous work into the role that the presentation of new bacterial epitopes 
may play in stimulating the immune system. A previous study of strain changes of 
particular bacterial species play in the aetiology of exacerbations has identified the 
role that a new antigenic stimulus to the airway immune system plays in the 
pathogenesis of an exacerbation (Sethi 2001). It is feasible that acquisition of a new 
bacterial strain or type may not only provide a direct antigenic stimulus, but also 
overcome the established host-pathogen balance allowing bacterial proliferation, and 
thus a further inflammatory stimulus due to greater bacterial numbers. 
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Respiratory viral infection is an important trigger to the airway immune 
system. In our cohort of influenza vaccinated patients we have previously 
demonstrated that human rhinovirus is the most commonly isolated virus at 
exacerbation (Seemungal 2000). Rhinovirus can be isolated from lower airway 
samples and is associated with greater levels of inflammation than non viral infections 
(Seemungal 2000). Similarly we have shown that colds, a marker of putative viral 
infections (Seemungal 2000) are associated with more severe exacerbations. In this 
study systemic inflammation (serum IL6), exacerbation symptoms and lung function 
changes were all more severe when evidence for both bacterial and viral infection was 
present. It is possible that this effect may have been due to the separate additional 
inflammatory stimuli of two separate pathogens in the airway, however this 
explanation is not supported by the multivariate analysis which indicated a synergistic 
effect on lung function in addition to the individual effects of each pathogen type. 
Furthermore these exacerbations were associated with higher bacterial loads than 
when both pathogens were not present, which may suggest a synergistic interactive 
effect of viral infection which allows greater proliferation of airway bacteria. Viral 
infection therefore may impact on exacerbation severity indirectly by increasing 
bacterial load in addition to the direct effects of viral infection itself, eg heightened 
inflammation or airway hyper-responsiveness, independent of other pathogens. 
Whilst human rhinovirus is the commonest virus identified at exacerbation 
(Seemungal 2001, Rohde 2003) and hence the target of investigation in this study, a 
number of other respiratory viruses have been identified in previous studies during 
these events, for example coronavirus, influenza, parainfluenza and adenovirus 
(Rohde 2003, Seemungal 2001). The role of these other viral pathogens and 
interactions with bacterial infection requires study. Similarly as discussed previously 
193 
VIRAL AND BACTFRIAL INFECTION AT EXACERBATIONS OF COPD 
the role that atypical bacteria such as Mycoplasma and Chlamydia play at 
exacerbation remains uncertain (Blasi 2002, Seemungal 2002) and requires 
investigation. 
The mechanisms by which viral infection may facilitate airway bacterial 
growth are likely to be complex. However any disruption of the innate defences of the 
respiratory epithelium in a lower airway colonised with bacteria may unsettle a fine 
balance between host immunity and bacterial numbers. Rhinoviral infection is known 
to increase mucous production and neutrophilic inflammation (White 2003, Fraenkel 
1995). Direct evidence that rhinoviral infection increases susceptibility to bacterial 
adherence to airway epithelial cells, a key process in bacterial infection, is available 
from in-vitro studies (Ishisuka 2003). Indeed the cross-sectional analysis confirmed 
an association between infection with HRV and with Streptococcus Pneunioniae. This 
suggests that the in vitro work demonstrating up-regulation of the S pneumoniae 
cellular binding site the epithelial cell surface platelet aggregation factor receptor by 
HRV infection, may occur in vivo. However, biopsy studies would be required to 
confirm the mechanisms of bacterial adherence and how these are modulated by 
concurrent viral infection in COPD. 
The key cell surface binding site for major type HRV infection, ICAM- 1, is 
itself up-regulated by HRV infection (Papi 1999) and by bacterial colonisation (Patel 
2003). T is increase may play a key role in neutrophil elastase-mediated 
inflammation which is key process at exacerbation (Nadel 2000). Hence, by a number 
of mechanisms viral infection may alter the immune environment which may allow 
either proliferation of colonising airway bacteria or a new pathogen to infect the lower 
airway. 
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This study was performed in patients with moderate to severe COPD. The role of 
bacterial infection and therefore potential bacterial-viral interaction is likely to vary 
with disease severity and therefore prevalence of bacterial colonisation. Indeed we 
have shown that the degree of airway and systemic inflammatory response at 
exacerbation was related to baseline disease severity. This suggests that the severity 
of inflammatory response may progress with disease severity which is in agreement 
with the findings of a recent longitudinal analysis of exacerbations (Donaldson 2003). 
Further studies are required to determine if these findings can be extrapolated to 
COPD patients with milder disease. Indeed the observed heterogeneity of 
exacerbations is likely to be further modulated by the relative frequency of particular 
pathogens and hence may show seasonality. This may explain differences in 
associated cytokine responses in studies of comparable sample size (Bhowmik 2000). 
Similarly differences in the technique of sampling such asspontaneous or induced 
sputum, may affect the observed results. However, we have previously demonstrated 
that the two techniques are comparable in assessing lower airway inflammation 
(Bhowmik 1998). 
Therapy must also be considered important when considering factors modulating 
inflammatory responses. The patients sampled for this study were all receiving 
inhaled steroids both at baseline and when sampled at exacerbation. It is possible that 
the inflammatory responses observed at exacerbation were modified by effects of this 
treatment (Patel 2003). A statistical analysis of this effect was not feasible due to the 
ubiquity of inhaled steroid use in this patient group. Therefore the modulating 
influences on the nature of exacerbations are numerous. It is probable that any 
individual factor plays a contributing rather than a definitive role in detennining the 
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nature and severity of a particular exacerbation and furthermore that potential 
interactions between these factors further modulate the characteristics of these events. 
Indeed determining factors which may influence or may predict responses to 
exacerbation therapy may be of great benefit to the clinician. Therefore, analysis of 
biological, demographic and physiological indices of poor outcome requires further 
understanding and indeed is the focus for the next Chapter of this thesis. 
In a similar manner, the ability to predict when a particular patient is at high 
risk of an imminent exacerbation may allow the clinician to intervene and prevent its 
occurrence. The finding that a relationship exists between baseline inflammation and 
time to next exacerbation seen in this study may indicate that this may become 
possible at some stage. However, the relationship between stable airway inflammation 
shown and subsequent occurrence of exacerbation in this study were not strong 
enough to offer adequate predictive power to guide a clinical intervention to prevent 
exacerbations. This is particularly the case as over use of currently available therapies 
such as corticosteroids and antibiotics carry serious consequences not only for the 
patient (Walsh 2002) but also for the larger community if induction of anti-microbial 
resistance is considered (Metlay 2002). 
It is therefore important to identify new therapeutic targets for novel 
therapeutic interventions to prevent and better treat exacerbations. This preliminary 
study on 10 sputum samples has suggested that micro-array techniques may be valid 
method for the analysis of a broad range of sputum cytokines and other proteins in 
patients with COPD, however, further assay validation is required. Initial conclusions 
on modulation of individual analytes are largely speculative due to the very small 
sample size used and a number of changes in these modulated analytes have been 
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previously described in the literature eg. TIMP-1 (Mercer 2005) while others are new 
eg. ICAM-3, MIP- I delta, IL-4, IL- 13. 
However use of this technique in a larger sample of paired baseline and exacerbation 
sputa should produce highly interesting and potentially novel results. 
CONCLUSION 
The findings of these studies suggest that changes in airway bacterial load, the 
nature of the individual infective pathogens and interactions between multiple 
pathogens including bacteria and viruses and the airway modulate exacerbation 
severity. Further studies are required to improve understanding of the pathogen-host 
interactions at exacerbation and indeed also in the stable state. Manipulation of this 
complex relationship with appropriate anti-infective and anti-inflammatory therapies 
may benefit COPD patients by reducing both exacerbation severity and slowing 
progression of this highly prevalent disease. However whilst new avenues of 
therapeutic intervention are sought it is important to identify how we can improve the 
outcome of exacerbations using currently available treatments. 
Whilst this work has demonstrated that airway infection is associated with 
exacerbation severity the factors which modulate recovery from exacerbation or 
indeed responses to therapy are poorly understood. The following chapter presents the 
findings of analyses which aim to determine these parameters. 
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CHAPTER 7 
EXACERBATIONS OF COPD: 
PREDICTING AND IMPROVING 
RESPONSES To THERAPY 
I his chapter represents the findings of a two part analysis aimed at determining 
which factors determine the time course of recovery from exacerbations and 
the clinical response to therapy. The initial analysis was of a limited dataset of 
sampled exacerbations and revealed that the timing of therapy may be a key factor in 
modulating recovery. This finding is the focus of the subsequent studies into how 
exacerbation reporting behaviour affects outcome and how this behaviour may be 
modulated. 
7.1 INTRODUCTION 
Exacerbations are a frequent cause of physician consultation in primary and 
secondary care and a major cause of hospital admission (Garcia-Aymerich 2000, 
Pearson 1994, Guest 1999). Consequently management of exacerbations places a 
considerable burden on the health services both in terms of physician consultation 
time and health care costs (Grasso 1998, McGuire 2001, Sullivan 2000). Reduction in 
exacerbation frequency would have a number of benefits for patients and health 
services alike. However, currently available preventative therapies have been found to 
have only a relatively small effect (Calverley 2003, Casaburi 2002, Burge 2000). 
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Current therapies for exacerbations include oxygen, antibiotics, oral 
corticosteroids and increased bronchodilator medications. Whilst there is evidence 
that antibiotics (Anthonisen 1987) and corticosteroids (Davies 1999, Niewoehner 
1999, Aaron 2003, Thompson 1996) hasten the rate of recovery of certain 
exacerbations there is little data in the literature on the factors which predict response 
to therapy. However, patients with COPD often have poor understanding of their 
disease and symptoms, with the result that exacerbations are often not reported to 
health care professionals for treatment (Seemungal 1998). Thus, if delay in 
presentation can be shown to affect exacerbation recovery, this provides a potentially 
important issue that can be addressed in the management of COPD patients. 
The initial analysis presented in this Chapter was performed to determine 
which patient and exacerbation factors are associated with improved outcome. The 
subsequent analysis of a larger dataset of exacerbations aimed to investigate the 
hypothesis that the early presentation of the patient to the physician with an 
exacerbation would allow early intervention, reduction of exacerbation severity and 
thus potentially improve clinical outcomes such as hospital isation. 
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7.2 METHODS 
In order -to 
detennine the relationship between patient characteristics, 
exacerbation symptomology and exacerbation recovery time we initially determined 
the influence of individual characteristics on recovery time, of both peak expiratory 
now and symptoms using a non parametric correlation analysis in a sample of 57 
exacerbations reported to the study clinic. The significant associations were 
subsequently entered into a multivariate regression model. The recovery variables 
were calculated as described in Chapter 3 Methods. 
EFFECTS OF EXACERBATION REPORTING ON OUTCOMES: ANALYSIS OF COHORT DATA. 
This analysis was conducted on data collected from the entire cohort over a six 
year period. 128 patients with COPD recruited during this period, who had recorded 
daily data for I year or more, were included in the analysis. Thus data collected on daily 
symptoms and exacerbation treatment on 1099 exacerbations was included. This 
daily monitoring enabled us to investigate how exacerbation outcomes and markers of 
severity such as recovery time were affected by the timing of presentation to the 
physician for treatment. We also studied how patient and exacerbation characteristics 
influenced the patterns of health care utilisation and outcomes of therapy. 
Patient recruitment and follow up was performed as described previously. 
indices of Health Related Quality Of Life (HRQOL) were obtained using the St. 
Georges Respiratory Questionnaire (SGRQ) at the beginning of the study either at 
recruitment or during the first annual review. 
EXACERBATIONS: DEFiNmoN OF TERMS 
The diagnosis of an exacerbation was based on symptomatic criteria previously 
validated by our group (Seemungal 1998, Seemungal. 2000). Exacerbation onset was 
taken as the first day on which these symptom criteria were met. Figure 7.1 in the 
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manuscript illustrates a diagrammatic timeline of an exacerbation with a definition of 
tenns used. 
TREATMENTDELAY 
From the diary card data and treatment records, the time between exacerbation onset 
and physician consultation at which treatment was initiated, was calculated and called 
the treatment delay. 
EXACERBATION RECOVERY TME 
A total daily count of individual symptoms recorded on diary cards was 
calculated as the sum of the 7 symptoms with the presence of a symptom scored I and 
its absence 0. In order to determine recovery to baseline levels and therefore 
exacerbation recovery time a diary card symptom baseline was determined from the 
diary card for each exacerbation. The baseline symptom count was taken as the mean 
total daily symptom count over days 14 to 8 preceeding the onset of exacerbation. 
Exacerbation total recovery time was calculated as the time from exacerbation onset 
for a 3-day moving average of the total daily symptom count to return to this baseline. 
The use of a three-day moving average minimised the effect of day-to-day symptom 
variation without biasing the results. Treated recovery time was taken as the time 
between consultation and recovery. 
OMS EXPERIENCED 
Symptom severity at exacerbation was calculated as the difference between the 
average daily symptom count at baseline (days 14 to 8 preceeding the onset of 
exacerbation) and the number of symptoms at onset of exacerbation. Individual 
symptoms were recorded as increased (=1) or not (=O). 
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TREATMENT 
Patients were encouraged to report symptom changes to the study team. They 
were assessed within 24 hours in the study clinic by a respiratory physician prior to 
initiation of therapy for the exacerbation. Patients did not report all symptom changes to 
the study team, but also reported a number of these episodes to their primary care 
physician for assessment and treatment. The prescription of treatment for all 
exacerbations was at the discretion of the attending physician and included prednisolone 
and/or antibiotic therapy. Exacerbation treatment in the study therefore represented the 
usual practice of the primary care or study physician attending the patient. Records were 
kept of the date of initiation and type of treatment prescribed to patients for each 
exacerbation, both at our clinic and also therapy prescribed by the patient's primary care 
physician. 
CLASSIFICAIION OF EXACERBATTONS 
The exacerbations seen by the study clinical team or the patient's general 
practitioner were classified as "physician reported exacerbations" with those unseen by 
either GP or study clinician but recorded on diary cards termed "unreported 
exacerbations". Records of hospitalization were kept throughout the study. Additional 
detail on the diagnosis of exacerbations is available in the on-line data supplement. 
STATISTICAL ANALYSIS 
Exacerbation total recovery time was calculated as the time from exacerbation 
onset for a 3-day moving average of the total daily symptom count to return to 
baseline. Treated recovery time was taken as the time between consultation and 
recovery. Symptom severity at exacerbation was calculated as the difference in total 
daily symptom count at baseline and at exacerbation onset. 
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Assessment of the effect of delay and treatment on recovery with or without 
allowance for severity, type of treatment or non-recovery was made with a 
generalized linear model with adjustments for Poisson distribution in the dependent 
variable. Additional detail on the method for making these measurements is provided 
in an online data supplement. 
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FIGURE 7.1 SCHEMAl'Ic TIMELINE OF EXACERBATIONS AND TERMS USED IN THE' 
ANALYSIS of-JiuATMEW EFFECTS ON EXACERBATION RF(, ()vEizy. 
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7.3 RFSULTS 
7.3.1 FACTORs AFFECTING EXACERBATION RECOVERY TIME 
The baseline characteristics of the cohort patients were; mean (SD) age 68 
FEVi 1.00 (0.38)1, FEV, % predicted 41.8 (16.5), FVC 2.57 (0.93)1, Pa 02 8.8 
(0.9) kpa, Pa C02 5.5 (0.8) kpa. The relationships between clinical indices of 
exacerbation severity and exacerbation recovery time are shown in Table 7.1 below. 
TABLE 7.1 RELATIONSHIPS BETWEEN CLINICAL INDICES OF EXACERBATION SEVERITY 
AND EXACERBATION RECOVERY TIME 
Factor Symptom Recovery p PEFR Recovery p 
Time rho= Time rho= 
Age 0.373 0.019 0.294 0.069 
Smoking 0.352 0.038 0.304 0.076 
PEFR Fall 0.53 0.758 0.678 0.0001 
Symptom 0.367 0.022 0.427 0.007 
Count 
Cold 0.132 0.423 0.459 0.003 
There was also a significant relationship between the time between the onset 
of exacerbation symptoms, determined by diary card analysis, and the duration of 
exacerbation symptoms. This relationship is shown in figure 7.2. 
There were no significant relationships seen between baseline disease severity, 
airway bacterial load or pathogen type, or markers of airway inflammation (sputum 
IL6 or 11,8) and symptom or lung function recovery time. 
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A multivariate analysis of the effect of treatment delay on symptom recovery 
adjusted for age, active smoking and exacerbation symptom count, the effect of 
treatment timing remain significant (p =0.039). 
FIGURE 7.2 RELATIONSHIP BETWEEN REPORTING DELAY AND ExACERBATION 
RECOVERY TIME. rho = 0.5, p=0.004, n=57 
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7.3.2 EFFECTS OF EXACERBATION REPORTING ON OUTCOMESANALYSIS OF COHORT 
DATA. 
The physiological characteristics of the 128 (88 Male) patients at recruitment 
for the study are summarised in Table 1. The mean (SD) FEV, was 1.07 (0.43) litres 
and % predicted FEV, 40.8 (15.6) %. 115 patients took a mean (SD) daily dosage 1.2 
Ing (0.68) of inhaled steroids. 9 patients were on a mean of 4.9 (3.0) mg/day of oral 
prednisolone; 8 patients used both oral and inhaled steroids. The 128 patients in this 
study completed diary cards for a median of 925 (IQR 628 - 1520) days. 60 (46.9%) 
reported daily (chronic) dyspnoea and 65 (50.8%) daily sputum production. 
TABLE 7.2 CHARACTERISTICS OF THE 128 (88 MALE) PATIENTS IN THECOHORT STUDY 
OF RELATIONSHIPS BETWEEN EXACERBATION TiIERAPY AND OUTCOMES. 
I Mean (SD) 
Age (years) 67.3(7.6) 
FEVI (litres) 1.07 (0.43) 
FEVI % predicted 40.8(15.6) 
FVC (litres) 2.51(0.81) 
FEVI/FVC % 43.50 (0.13) 
PEF (litres/minute) 191(88) 
Pa02 (kPa) 8.93(l. 00) 
PaC02 (kPa) 5.89(0.89) 
Number of active smokers 42 
Pack years of smoking 46.6(31.4) 
Inhaled steroid dosage (mg /day) 1.21(0.68) 
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FlGuRE 7.3 REPORTING AND TREATMENT CHARACTERISTICS OF 1099 EXACERBATIONS 
RECORDED IN MIS STUDY. 
1099 Exacerbations 
658 Physician Reported Exacerbations 441 Unreported Exacerbations 
641 Treated Exacerbations (17 -Non-Treated Exacerbations 
16 Treated in Prodrome 
625 Exacerbations 
241 Antibiotics and Oral Prednisolone 
359 Antibiotics Alone 
25 Prednisolone Alone 
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ExACERBATIONS. 
During the study, the patients experienced a total of 1099 exacerbations. Of 
this total, 658 (59.9%) were reported to a physician, either a primary care physician or 
the study team. The median (IQR) number of exacerbations per patient per year was 
2.51 (1.41 to 3.75) for all 128 patients. 8 patients had no exacerbations. Of the 1099 
exacerbations, 441 (40.1%) exacerbations were diagnosed solely from review of diary 
card symptoms and were not seen by a physician. These unreported exacerbations 
were only considered in the analysis of hospitalisation and HRQOL with respect to 
reporting. The 658 remaining exacerbations were all seen by physicians but of these 
17 (2.6%) exacerbations received no additional treatment and 16 (2.4%) involved 
physician consultation in the prodromal period before formal exacerbation onset as 
defined by the diagnostic criteria. These 33 exacerbations were excluded, leaving 625 
which were analysed for the effects of physician reporting and treatment on recovery. 
summary of reporting and treatment measures is illustrated in Figure 6.2. 
Increased dyspnea was present in 63.7% of the 1099 exacerbations, increased 
sputum purulence in 26.6%, increased sputum volume in 41.3%, cold symptoms in 
29.1%, increased wheeze in 31.7%, sore throat in 13.0% and increased cough in 
30.7%. 
PHYSICIAN REPORTED EXACERBATIONS AND TREATMENT 
Figure 7.3 shows the reporting and treatment characteristics of the 
exacerbations recorded in the study. Of the 625 exacerbations which were treated with 
prescribed oral therapy, a total of 266 exacerbations were treated with oral 
corticosteroids. 600 of the exacerbations were treated with antibiotics, and of these 
241 were treated with both oral corticosteroids and antibiotics. As 93.6% of 
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exacerbations were treated with antibiotics, this precludes a meaningful statistical 
analysis of the effect of antibiotic therapy on exacerbation outcomes, as the non- 
treated group is too small. Oral prednisolone therapy hastened treated recovery by 
2.63 days (p=0.001) compared to exacerbations not treated with prednisolone. 
7.3.2.1 RELATIONSHIP BETWEEN PRESENTING SYMPTOMS AND OUTCOME 
A regression analysis of the relationship between the nature of presenting 
symptoms and the recovery time of the exacerbation was performed. The results are 
summarised in Table 7.3. The regression coefficients for each individual symptom 
recorded on diary cards correspond to the additional days recovery time to the 
regression constant of 4.8 days for this analysis. The effects on exacerbation length 
shown in the table are summative. For example an exacerbation presenting with 
symptoms of dyspnoea and sputum volume calculated using this model would take 
(4.80+2.84+1.61) 9.5 days to recover to baseline on average in this patient population. 
TABLE 7.3 REGRESSION ANALYSIS OF INDIVIDUAL EXACERBATION SYMPTOMS AND 
RECOVERY TIME. 1099 EXACERBATIONS FROM 128 PATIENTS. 
symptom 
- 
Wfect on Recovery Time if Symptom Present, days( 95%CI) 
- - 
j p, 
Dysýip noea 
ý 
ýý8 4F2.17-3.5 1) 1<0. 1 Sputum 
Purulence 
1 
0.37 (-1.06-0.31) . 281 
Sputum Volume 1.61 (0.93-2.29) j<0.00 I 
Cold 11.88 (1.13-2.64) 11<0.00 I 
heeze ", 0.23 (-0.51-0.97) ", 0.541 
Sore Throat, 
.. 
15.61 (4 45-6.77) 1<0.00 I 
Cough i- --- - U. 211 ( 0.55-0.97) ', 0.587 
(Effect on recovery time: positive = longer, negative = shorter. Regression constant = 
4.8 days, Regression coefficients are summative). 
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Exacerbations associated with increased dyspnoea and sputum volume and 
putative viral exacerbations associated with colds and sore throats took longer to 
recover than those without these symptoms and were thus more severe. 
7.3.2.2 TREATMENT DELAY AND EFFECTS ON EXACERBATION RECOVERY TiME 
The median (IQR) treatment delay (time from onset of exacerbation to the 
initiation of treatment) was 3.69 (2.00 to 5.57) days. The median exacerbation total 
recovery time was 10.7 (7.0 to 14.0) days. The median treated recovery time (time 
between the start of treatment to symptom recovery) was 6.9 (3.0 to 10.5) days. 
Figure 3 demonstrates the relationship between symptom recovery time and the delay 
between exacerbation onset and treatment. Early initiation of exacerbation therapy 
was associated with a faster recovery of exacerbation symptoms (regression 
coefficient, 95 % CI, p value) (0.42 days/day delay, 0.19 to 0.65, p< 0.00 1). 
The benefits of early physician consultation and treatment on exacerbation 
recovery time were potentially confounded by the fact that patients with more severe 
symptoms had longer exacerbations (2.68 days per symptom, 2.06 to 3.3 1, p<0.00 1) 
and also tended to report earlier (-0.28 days per symptom, -0.66 to 0.10, p=0.15). 
Following an adjustment for symptom severity by its inclusion in the 
regression model, the relationship between early treatment and faster recovery 
became more pronounced (0.52 days/day delay, 0.31 to 0.74, p<0.001). Treatment 
with oral corticosteroids could also confound the relationship if exacerbations 
reported earlier were preferentially treated with oral corticosteroids. However the 
relationship between recovery time and treatment delay remained significant if 
allowance was made for both symptom severity and the treatment with oral 
corticosteroids (0.57 days/day delay, 0.34 to 0.79, p<0.001). 
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FIGURE 7.4 EFFECT OF EARLY TREATMENT ON RECOVERY OF EXACERBATION 
symp, roms. Patient mean total recovery time (days) plotted against patient mean 
treatment delay ie time from onset of exacerbation symptoms to initiation of therapy) 
(days), in 108 patients. (Regression coefficient 0.42 day/day delay C1 0.19 to 0.65, 
P<0.00 1). 
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FACTORs AFFECTTNG PHYSICIAN CONSULTATION DELAY 
An analysis of patient characteristics with respect to mean treatment delay for 
each patient revealed that older patients received treatment earlier (rho = -0.19, p= 
0.04), however there were no observed significant relationships between treatment 
delay and baseline FEV, (rho=0.19, p=0.11), percentage predicted FEV, (rho=0.11, 
p=0.25), SGRQ Total score (rho=-0.12, p=0.21), active smoking status (rho=0.03, 
p=0.72) or baseline symptoms such as daily sputum production (rho= -0.16, p=0.08) 
or dyspnea (rho=O. 11, p=0.24). 
Table 7.4 gives the effect of a specific symptom at exacerbation onset on the 
treatment delay. Exacerbations (adjusted for repeated measures) involving worsening 
dyspnea as a presenting symptom presented earlier (regression cocfficient (days), 
95% Cl, p value) (-0.42, -0.76 to -0-08, p=0.0 16) as did those with sputum purulence 
(- 1.30, -1.60 to -0.92, P=0-00 1), wheeze (-0.59, -0.93 to -0.25, p=0.00 1) or sore throat 
(-0.78, -1.23 to -0.33, p=0.001). 
TABLE 7.4 REGRESSION ANALYSIS OF INTERACTIONS BMWEEN EXACERBATION 
SYMPTOMS AND TREATMENT DELAY FOR 625 EXACERBATIONS 
Symptom Regression Coefficient (days) p value 
(95% Confidence Interval) 
Dyspnea -0.42 (-0.76 to -0.08) 0.016 Sputum Purulence -1.26 (4.60 to -0.92) 0.001 Wheeze -0.59 (-0.93 to -0.25) 0.001 Sore Throat -0.78 (4.23 to -0.33) 0.001 Cold 0.31 (-0.05 to 0.67) 0.093 
Sputum Volume 0.02 (-0.31 to 0.34) 0.924 
Cough 0.01 (-0.34 to 0.37) 0.945 
(a negative value indicates a treatment delay shorter than those exacerbations without 
the symptom) 
213 
FACTORs AFFECTING EXACERBATION RECOVERY 
OSPrFAL OUTPAnENT PRESCRIBING. 
Patients in the study could consult either the study team or their own primary 
care physician at exacerbation. 37.6% of the physician treated exacerbations were 
seen by a general practitioner and 62.4% were seen by a member of the study team. 
Prescribing practices at exacerbation were very similar irrespective of where the 
consultation took place, with primary care physician prescribing oral corticosteroids 
in 43.8% and antibiotics in 96.2% of treated exacerbations and the study team in 
41.8% ( chi-squared, p=0.618) and 95.9% (p=0.868) respectively. 
The time to physician consultation was earlier in the primary care physician 
treated group by 0.36 days (469 to -0.04, p=0.030) however when an adjustment for 
symptom severity was made no significant differences in timing of consultation was 
found. Despite similar prescribing practices, patients reviewed by a respiratory 
specialist in the study team had a shorter recovery time than those seen in general 
practice (0-82 days, p=0.047). 
7.3.2.3 TiJE IMPORTANCE OF UNREPORTED EXACERBATIONS 
SGRO SCORES, HOSPITALISATION AND UNREPORTED EXACERBATIONS 
Not all the exacerbations experienced by a patient were reported to a physician 
for treatment. The median (IQR) percentage of physician reported exacerbations for 
the 120 patients with an exacerbation was 66.7% (50 to 83-3). Stable SGRQ scores 
were recorded on 118 of these 120 patients. Figure 7.4 illustrates the relationship 
between SGRQ total score and its components, and the percentage of physician 
treated exacerbations. Patients who had a higher percentage of their exacerbations 
seen by a physician had a better health related quality of life (lower total SGRQ 
scores) (rho=-0.22, p=0.018). This relationship was also present when considering the 
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impact (rho=-0.19, p=0.04) and activity ( rho = -0.21, p=0.02) components of the 
SGRQ score separately. 
UNREPORTED EXACERBATIONS AND RISK OF HOSPUALISATION 
During the study 6.4% of the 1099 exacerbations required hospitalization. The 
median annual unreported exacerbation rate was 0.77 per year (0.33 to 1.60) for the 
120 patients who had at least one. The annual rate for physician reported, but not 
hospitalised exacerbations, was 1.53 per year (0.86 to 2.37) and for hospitalized 
exacerbations the median rate was 0 per year (0 to 0.40). 
Of the 120 patients, those who tended not to seek treatment from their general 
practititioner or the study clinicians, at exacerbation (as measured by a high annual 
rates of unreported exacerbations) were more likely to be admitted to hospital for 
treatment of an exacerbation than those who routinely reported their exacerbations for 
treatment (rho 0.21, p=0.04). 
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FIGuRE 7.5 RELATIONSHip BETWEEN TOTAL AND COMPONENT SGRQ SCORES 
(HIGHER SCORES REPRESENT POORER HEALTH RELATED QUALITY OF LIFE) AND 
PERCENTAGE OF RECORDED EXACERBATIONS (IN QUARflLE GROUPS) THAT WERE 
REPORTED TO AND TREATED BY A PHysiciAN. The Rho and p values from Spearman's 
Rank correlations of total and component SGRQ scores with proportion of 
exacerbations treated on a per patient basis are a) Total SGRQ score rho= -0.22, 
p=0.0 18), b) Impact Score rho=-O. 19, p=0.04, c) Activity Score rho=-0.2 1, p=0.02 d) 
Symptoms Score rho=-0.13, p=0.16. Bars represent standard errors. 
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7.3.3 IMPROVING EXACERBAIION REPORTING BEHAVIOUR 
The impact of exacerbation reporting behaviour on exacerbation outcomes 
has been highlighted by the analysis presented above. It is possible therefore that 
interventions aimed at improving the timely delivery of exacerbation therapy may 
improve outcomes. However to date there have been few health care interventions 
which have been shown to improve patient reporting (Taylor 2005). We therefore 
studied a nurse lead intervention to determine if improvements in exacerbation 
reporting can be achieved within the cohort. 
COPD patients were recruited from the outpatient department and local 
primary care clinics. In the fitst winter of the study (Period I November 03-February 
04) patients were reviewed 3 monthly in the study clinic and at reported 
exacerbations, the cohort was followed through a second Winter (Period 2-November 
04-February 05) when patients were telephoned at home every 2 weeks by a 
respiratory nurse specialist, questioned about symptoms and encouraged to attend the 
study clinic if an undiagnosed exacerbation was picked up. 
RESULTS 
We studied 116 patients with COPD, mean (SD) age 70.5(24.5) yrs, FEVI 
1.25(0.55)1, FEV, % Predicted 50.4(21.8)%. 116 COPD patients had 213 
exacerbations during periods I and 2. The nurse led intervention during period 2 was 
associated with an increased reporting rate of 61.7% compared to 45.8% in period 1, p 
= 0.027. Multivariate analysis showed that reporting rates were higher during 
exacerbations associated with increased dyspnoea (OR 3.2, p=0.009), sputum 
purulence (OR 2.24, p=0.008), increased cough (OR 2.6, p=0.002) and period 2 (OR 
2.02, p=0.024). Over the two periods 31(26%) patients reported a mean of 0.55 
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exacerbations more in period 2 (p = 0.002) and patients who reported less 
exacerbations in period I were more likely to have reported more exacerbations in 
period 2 (p = 0.010). 
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7.4 DiSCUSSION 
This is the first prospective study to demonstrate the important effects of early 
treatment on COPD exacerbation outcomes. The findings show that patients who 
receive prompt therapy after the onset of their exacerbation are likely to recover more 
rapidly than those who delay reporting and thus initiation of treatment. FurthenTiore, 
patients who habitually fail to seek therapy for their exacerbations have poorer health 
related quality of life and are more likely to be hospitalised for the management of an 
exacerbation. 
This study has been performed using well-characterised patients collecting 
daily data over a number of years and has used a symptom-based definition of 
exacerbations that is well validated (Seemungal 1998, Seemungal 2000, Seemungal 
2001, Wilkinson 2003, Donaldson 2003). The collection of such prospective data 
allowed us to establish precisely the start of the exacerbation from the diary card 
entries and then the point at which therapy is commenced, in addition to in-depth 
analysis of the time-course and recovery time of the exacerbations. Our group and 
others have previously demonstrated that the recovery time of an exacerbation is an 
important measure of its severity and can be affected by various etiological factors 
such as respiratory viruses (Seemungal 2000, Seemungal 2001, Rohde 2003) and 
therapies (Anthonisen 1987, Davies 1999, Niewoehner 1999, Aaron 2003, Thompson 
1996). The delay between symptom onset and therapy and its effect on exacerbation 
outcomes has not been studied previously as most studies evaluating exacerbations 
have focused on health care utilization and therefore have missed the period between 
symptom onset and the initiation of therapy. The finding that earlier treatment 
improves exacerbation recovery has confirmed for the first time the clinical suspicion 
that treating these episodes promptly offers additional benefit to the patient. It is also 
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the first to establish the size of this effect and the role that improving exacerbation 
reporting behaviour may play in reducing morbidity. 
A possible alternative interpretation of this finding would be that patients with 
milder exacerbations seek treatment earlier and thus recover more quickly; however 
the data on the nature of symptoms at presentation demonstrates that this was not the 
case. Patients with more symptoms at exacerbation onset tended to present earlier for 
treatment and those exacerbations with more symptoms were indeed more severe as 
they took longer to recover. Therefore the milder and less symptomatic exacerbations 
were in fact presenting slightly later and when this effect is taken into account the 
benefit of early treatment became more pronounced. 
In this study we have studied exacerbations across a spectrum of exacerbation 
severities and not only those more severe exacerbations requiring hospital isation. The 
patients in this study were treated either by the dedicated study team or by their 
primary care physician and the exacerbation treatment reflected prescribing practices 
of both physician groups, which were very similar as reflected by similar exacerbation 
recovery times for both treatment groups. In the linear regression model of the effects 
of treatment delay on recovery time, allowance was made for the exacerbation 
treatment prescri e- potential bias of variation in oral antibiotic therapy was not 
apparent as over 93% of treated exacerbations received this form of therapy. The 
effect of oral prednisolone prescription was to shorten exacerbations, if the 
prescription of this treatment was included in the regression model, the key finding 
that early treatment hastens recovery time became more pronounced. 
These reported exacerbations which received treatment are in keeping with 
another definition of exacerbations recently suggested (Rodriguez Roisin 2000). 
Therefore, the findings of this study may be generalised to the COPD population 
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treated both in primary and secondary care and the validated methods used are 
suitable for future investigation into the relationships between reporting behaviour 
and exacerbation outcomes. 
Exacerbations are heterogeneous in aetiology and in the nature of presenting 
symptoms (Seemungal 2001, Patel 2002). The symptom characteristics of an 
exacerbation affected presentation of the exacerbation to the physician. Symptoms of 
increased dyspnea, sputum purulence, wheeze and sore throat were associated with 
earlier presentation, while the presence of a common cold at exacerbations was 
associated with a trend towards later presentation. The factors affecting how COPD 
patients interpret changes in their symptoms are likely to be complex including their 
understanding of COPD which is often poor (Rennard 2002), the relationship with 
disease severity, and psychological overlay in a group of patients with high levels of 
anxiety and depression (Okubadejo 1996). Further studies into the mechanisms of 
symptom recognition are required to deten-nine how to improve COPD patients' 
reporting behaviour and therefore exacerbation outcomes. These may include 
investigation of the role of patient education, self management plans and methods of 
assessing and improving compliance. 
An additional advantage of collecting daily prospective data on symptom 
changes is that episodes when patients experience an exacerbation and record their 
symptoms, but do not consult their general practitioner or a study physician, can be 
analysed. In this study of 1099 exacerbations recorded on diary cards only 658 were 
reported to a physician for treatment and these rates are in keeping with published 
clinical trials (Burge 2000). The finding that on an annual basis, patients who are less 
likely to report their exacerbations are more likely to undergo emergency hospital 
admission for treatment is an important one. These patients may be less aware of the 
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importance of the changes in their symptoms at exacerbation or indeed they may 
subjectively experience less severe symptoms for a given severity of exacerbation. 
Thus, they are less likely to seek treatment from a physician in the early stages of 
their exacerbation. Furthermore, we found that patients who had a lower proportion of 
their exacerbations treated had worse health-related quality of life, as measured by the 
St George's Respiratory Questionnaire total score, impact score and activity score 
than those patients who sought treatment for a higher proportion of exacerbations. We 
can postulate that failure to report and therefore receive treatment for exacerbations 
contributes to additional morbidity from these events and thus adversely affects 
health-related quality of life. However, it may also be the case that patients with poor 
health related quality of life are less likely to seek physician intervention for their 
exacerbation, and thus a cycle of decline in quality of life and appropriate health care 
utilisation may become established. Identification and education of the patient group 
who delay or fail to seek treatment for exacerbations in particular may increase and 
improve the rate and timing of physician consultation, reduce patient morbidity and 
the considerable burden of inpatient treatment of exacerbations on health care 
services. 
Analysis of factors that affected time to presentation of an exacerbation 
showed that older patients were likely to receive therapy earlier, but there was no 
relation between disease severity, baseline symptoms or the patient's health status. 
Adequate access to health care is important and the affect of age on presentation in 
our study suggests that the more elderly patients are receiving medical attention for 
exacerbations earlier than the younger patients in the group. This finding may be 
related to the higher degree of disability and co-morbidity in the elderly (Yohannes 
2002), causing them to recognise and report symptoms at an earlier stage. 
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This study has been performed in a population of COPD patients who were 
encouraged to report exacerbations, who were likely to have heightened awareness of 
changes in their symptoms due to the use of daily diary cards and who had improved 
access to healthcare. Therefore, the findings of this study that early treatment of 
COPD exacerbations hastens recovery time and that patients who do not report to a 
physician are more likely to be hospitalised may be an underestimation of the scale of 
these effects in the general population of patients with COPD. Indeed COPD patients 
often have a poor understanding of their disease (Rennard 2002) and often delay or 
fail to report symptom changes to their physician. To date there has been no 
significant initiatives to encourage reporting and early presentation of exacerbations 
in this patient group. 
Exacerbations of COPD are complex in their pathobiology and are markedly 
heterogeneous in the nature of presenting symptoms and clinical outcomes. Analysis 
of presenting symptoms has demonstrated that exacerbations associated with 
increased breathlessness, colds, sore throats and with increased sputum volume are 
likely to take longer to recover despite therapy than those without these symptoms. 
increased dyspnoea may be a surrogate marker for disease severity and the other 
symptoms associated with longer recovery time are known to be markers of putative 
viral infections which we have previously shown to be associated with greater 
inflammation and lung function changes. The presence of cough, wheeze and sputum 
purulence did not increase recovery time in this analysis and this may be due to the 
fact that the actiology of the processes that lead to these symptom changes; eg. 
sputum purulence due to bacterial infection responds relatively well to prescribed 
therapy ie. oral antibiotics. Greater understanding of the pathophysiology and 
223 
FACTORs AFFECTING EXACERBATION RECOVERY 
symptornatology of exacerbations may aid the development of novel therapies and 
assist the clinician in targeting treatment for these important clinical events. 
The nurse-lead intervention study has shown that regular telephone contact 
with COPD patients can improve exacerbation reporting rates and could therefore 
potentially improve outcomes and reduce hospitalisation rates. However, it must be 
ensured that regular telephone contact does not result in over reporting of trivial 
symptoms as exacerbations. Further studies of novel healthcare interventions are 
required in COPD to determine whether altering exacerbation reporting behaviour 
may influence outcomes. 
CONCLUSION 
This study has demonstrated the important finding that the early recognition of 
exacerbation symptoms and prompt treatment by a physician is beneficial to the 
recovery of the exacerbation. This result suggests that improving patient and 
physician understanding of the nature of exacerbations and the benefits of early 
treatment will improve the outcomes of therapy of exacerbations of this extremely 
prevalent disease. There is a vital role for new, more efficacious treatments for COPD 
exacerbations. However by optimising the use of existing exacerbation therapies and 
by improving patients' awareness of exacerbations and access to health care, we can 
improve the current excessive burden of morbidity and mortality resulting from 
exacerbations. 
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CHAPTER 8 
SUMMARY DisCUSSION AND AREAS 
FOR FUTuRE RESEARCH 
hiS chapter summarises the key findings of this study with particular attention 
to the original aims outlined in Chapter 2. Many of the findings 
in this thesis 
are novel and their implications have been discussed in the relevant chapter 
discussions. The key points are summarised below. This thesis concludes with some 
suggestions for future research in this area and a discussion of the possible 
implications for improving treatment for patients with COPD based upon the findings 
of this study. 
8.1 CONCLUSIONS 
The key findings of my studies are: 
* Lower airway bacterial colonisation is common in this population of patients 
with moderate to severe COPD, with isolation rates of potentially pathogenic 
organisms o 57% in the stable state with the most prevalent pathogen being 
Haemophilus influenzae. These findings are in keeping with previous studies. 
o Prospective patterns of bacterial colonisation were investigated. Colonisation 
was dynamic in nature with changes in isolation rates of particular pathogens 
225 
SUMMARY AND FUTURE RESEARCH 
but no seasonal pattern was observed. Seasonal variations in airway bacterial 
loads were seen with higher prevalence in the summer months. 
* Airway bacterial load and the degree of inflammation varied according to the 
nature of bacterial isolate in the stable state. 
e The degree of neutrophilic airway inflammation measured as sputum IL-8 
levels was related to the airway bacterial load in this population. 
9 Airway bacterial colonisation was associated with higher levels of systemic 
inflammation in terms of serum IL-6 and plasma fibrinogen. Higher levels of 
these markers were seen with the airway pathogens; Haentophilus influenzae 
and Psewlomoyzas aertiginosa. This finding suggests a possible mechanism for 
the systemic inflammation and resulting co-morbidities seen in COPD and 
thus a possible therapeutic opportunity to modulate systemic inflammation. 
9 For the first time, a relationship between airway bacterial colonisation and 
lung function decline was described. Patients with high and rising bacterial 
loads manifested a faster decline in FEV, in a I-year follow-up study. This 
finding was confirmed with an analysis of cohort data with a longer follow-up. 
* Faster decline in lung function was also associated with greater neutrophilic 
inflammation and changes in bacterial colonisation in terms of total bacterial 
load and nature of species isolated. 
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e Respiratory viruses can be detected in sputum samples from a significant 
proportion of stable COPD patients distant from any exacerbation symptoms. 
* RSV was the most prevalent viral pathogen detected in this study and present 
in approximately 1/3 of stable state samples. Patterns of RSV detection were 
highly suggestive of persistent infection and no patterns of seasonality were 
observed. Sequencing of RSV PCR products confirmed high levels of 
homology with reference RSV strains and the sequence variability observed 
precludes contamination as a cause of the findings. 
* Patients with frequent detection of RSV in stable sputum samples during a 
prospective study had higher levels of airway inflammation as measured by IL 
6, IL 8 and MPO. These patients also had higher airway bacterial loads. 
* These patients showed evidence of accelerated decline in FEV, over a two 
year follow up period. This relationship was significant independently of 
variations in baseline lung function, smoking, exacerbation frequency and 
airway bacterial colonisation but not of airway inflammation. 
* PBMCs from patients in whom RSV was detected demonstrated an impaired 
IFN-y (Th 1) response to whole RSV stimulation in an ex-vivo assay. 
e At exacerbations, evidence human rhinovirus and bacterial infection was 
common (>70% of events). Higher airway bacterial loads , higher isolation 
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rates of potentially pathogenic micro-organisms and higher detection rates of 
human rhinovirus were seen compared to the stable state. 
* The size of the rise in airway bacterial load seen at exacerbation was related to 
the severity of the episode both in terms of airway inflammation and falls in 
lung function. 
* Haemophilus influenzae isolation at exacerbation was associated with higher 
airway bacterial loads and a trend towards more severe falls in lung function. 
e Co-infection with both a bacterial pathogen and a virus was associated with 
higher airway bacterial loads, greater symptom severity and more severe falls 
in lung function suggesting a synergistic effect in modulating exacerbation 
severity. 
* There was an association with the incidence of Streptococcal and human 
rhinoviral infection at exacerbation. This confirms findings of previous 
epidemiological studies. 
9 Sputum as collected and processed using the methods described in this thesis 
is a suitable substrate for proteornic analysis using microarray techniques. This 
should allow future studies to determine the exact nature of inflammatory 
responses at exacerbation and better understand the complexity of this 
heterogeneous response. 
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e The rate of recovery from exacerbation was related to a number of variables 
including patient age, smoking status, severity of initial exacerbation 
symptoms or lung function and evidence of viral infection as cold symptoms. 
A relationship between exacerbation recovery time and the delay between the 
onset of symptoms and treatment was also found. 
9 An analysis of a large dataset of exacerbations confirmed that early treatment 
offered substantial benefit to recovery independent patient or exacerbation 
characteristics. 
* In this analysis patients who habitually fail to present for treatment at 
exacerbation exhibited poorer health-related quality of life and increased risk 
of hospitalisation. 
9 In a pilot intervention study, we demonstrated that exacerbation reporting 
behaviour can be improved by an intervention of regular patient telephone 
contact to increase reporting rates. 
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In consideration of the specific study aims outlined in chapter 2 the specific findings 
and their implications are: 
1. To prospectively determine the prevalence and chronicity of lower airway 
bacterial colonisation in a population of patients with stable COPD. 
The findings of this study confirm those of previous investigations into the 
bacteriology of the lower airway in COPD in that bacterial colonisation is a common 
phenomenon in patients with moderate to severe disease and that significant airway 
bacterial loads can be detected (107 - 108 colony forming units per ml) whilst the 
patient remains in a symptomatically stable state. The key pathogens were 
Haemophilus inflitenzae, Streptococcus pneumonia and Moraxella catarrhalis in 
keeping with previous findings. The finding of higher airway bacterial loads in the 
summer may relate to antibiotic usage in the winter season but may infer that airway 
bacterial load per se is not the primary factor in driving exacerbation susceptibility. 
2. To determine the prevalence and chronicity of lower airway viral 
colonisation in a population of patients with stable COPD. 
For the first time, direct evidence for persistence of viral pathogens in the lower 
airway of COPD patients in the stable state is available as a result of this prospective 
study. The findings confirm the previous cross-sectional analysis that RSV is present 
in a significant proportion of COPD patients. The usually marked seasonal variation 
in RSV-induced acute bronchiolitis was not present in the stable state. The detection 
patterns for RSV RNA suggest that persistent infection rather than repeated re- 
infection is detected. Further studies including sequence identification of all RSV 
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isolates would enable viral epidemiological analysis to confirm the nature of viral 
persistence. 
3. To determine the relationships between lower airway bacterial and viral 
infection on airway inflammation and disease progression in these 
patients. 
Both airway bacterial and viral (RSV and HRV) detection in the stable state was 
associated with greater levels of sputum inflammatory markers. Neutrophilic 
inflammation, a key process in the genesis of airways obstruction, was elevated in 
subjects with higher airway bacterial loads and in those in whom viruses were 
detected in the stable state. The longitudinal study design permitted analysis of the 
associations between airway infection and lung function decline. High bacterial 
loads and RSV detection were associated with faster declines in FEVI. Possible 
synergism between these effects was noted as subjects with evidence of RSV 
persistence also had higher sputum bacterial counts. However multivariate 
modelling suggested that RSV detection was an independent predictor of FEV, 
decline independent of the additional effects of bacterial colonisation. 
4. To determine the relationships between lower airway infection and 
systemic innammation. 
Airway bacterial colonisation was associated with greater levels of peripheral 
inflammation as measured by IL 6 and fibrinogen levels in plasma, particularly when 
colonisation with Haemophilus influenzae and Pseudomonas aeruginosa was 
detected. This finding may have important implications for our understanding of the 
mechanisms underlying systemic inflammation as direct relationships between airway 
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and systemic inflammation were not found in this study, as in previous studies. RSV 
detection was associated with lower systemic levels of IL 6 but not fibrinogen. RSV 
infection was also associated with depression of PBMC responses to viral stimulation. 
it is possible that suppression of lymphocytic responses is a key feature of viral 
persistence whilst neutrophilic airway responses remain upregulated. 
5. To determine the effects of lower airway bacterial and viral infection at 
exacerbations on the nature and severity of inflammation and clinical 
outcomes. 
Both bacterial and rhinoviral infection were prevalent at exacerbations with evidence 
of greater infective load than in the stable state. Greater rises in airway bacterial load 
were associated with indices of exacerbation severity as were co-infection with viral 
and bacterial pathogens. 
6. The relationship between RSV detection and responses of peripheral 
blood mononuclear cells to viral stimulation in ex-vivo assay. 
RSV detection in the stable state was associated with depressed IFN-y production by 
isolated and stimulated PBMCs from these patients. There were no observed 
differences in expression of TH2 cytokine or in IFN-y production in response to 
general stimuli or UV-inactivated virus. This suggests that RSV may be able to down- 
regulate appropriate and specific anti-viral type I responses in patients with persistent 
infection. This phenomenon has been described previously in acute illnesses and has 
been associated with increased severity of these episodes. 
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7. The relationship between exacerbation reporting behaviour and clinical 
outcomes including exacerbation recoveryg hospitalisation, and health 
related quality of life. 
A number of factors were seen to relate to the rate of recovery from exacerbation 
which is an important clinical outcome which may influence time of hospital stay or 
absence from work. The novel finding that early treatment leads to early recovery 
could have important implications for service delivery. The patients who often failed 
to seek exacerbation treatment were at increased risk of adverse outcomes such as 
hospitalisation. These findings may influence both the way we must encourage 
patients to understand their disease and consideration of inclusion of unreported 
events in any definition of COPD exacerbations 
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8.2 FUTURE RESEARCH 
This study has been largely based on the clinical observation and sampling of 
a cohort of patients with COPD. Whilst it has been carefully undertaken to address a 
particular hypothesis it has inevitably raised a number of findings and generated 
further hypotheses and research questions which warrant further consideration and 
investigation. The eventual aim of this type of clinical research is not only to enable a 
better understanding of a disease but to directly and beneficially impact on patients' 
lives by improving the range or efficacy of treatment and hence to improve clinical 
outcomes. This final section of this thesis outlines the direction future research may 
take to achieve these goals and in some cases where projects based upon the findings 
described in the previous chapters are being undertaken. 
MECHANISTIC STUDIES ON SUSCEPnBILrFY TO INFECTION 
A key question arises from consideration of this work: why are patients with 
COPD susceptible to airway infection and to the associated consequences described in 
this thesis? Since the normal lower airway is sterile, at what level or levels of the 
immune system does the susceptibility to infection lie? The immune defences of the 
airway are complex ranging from the mechanical effects of the muco-ciliary escalator, 
the integrity of the airway epithelium and the production of antimicrobial peptides to 
cellular innate responses such as macrophage-induced phagocytosis and the activity of 
toll-like receptors and other mechanisms which are poorly characterised in this 
disease. The array of adaptive immune responses is equally complex and whilst a 
number of studies hasdescribed cellular compositions in various compartments of the 
COPD lung, very little is known on the functional status of these cells. Why for 
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example are there numerous T cells present in the small airways? Are these effector 
cells and if so are they fulfilling an anti-infective or even auto-immune function? 
Clearly, detailed studies characterising the innate and adaptive immunology of 
COPD patients compared to normals are required, as are studies of differences 
between different disease phenotypes such as frequent and infrequent exacerbators. 
Our group is currently undertaking a project to investigate the role that expression of 
the main rhinovirus cell adhesion molecule, ICAM -1, plays in driving susceptibility 
to this virus and hence to exacerbation. Mechanistic as well as observational studies 
will be required to tease out the facets of the immune response peculiar to COPD and 
hopefully will identify new therapeutic targets and improve our understanding of 
airway infection as a whole. 
INTERVENTION STUDIEs AIMED AT BREAKING ITIE 'VICIOUS CIRCLE' 
The difficulty with the interpretation of observational studies is the 
determination of cause and effect. The proposed circular relationship between airway 
inflammation, compromised airway defences, airway infection and consequent up- 
regulation of inflammatory responses is described as the 'vicious circle hypothesis'. 
Clearly therefore as discussed previously the finding that airway infection is related to 
inflammation and disease progression may be an epiphenomenon. A simple way of 
breaking this cycle of inter-association would be to eradicate the infectious 
component using antibiotic therapy and deten-nine the effects on airway inflammation 
particularly targeting Haemophilus influenzae colonisation as it is associated not only 
with greater airway bacterial loads and inflammation but also with more severe 
exacerbations. Our group is currently involved in such an intervention study and if 
positive, the results may alter our practice in a similar manner to that observed in the 
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care of other diseases where airway infection is treated pro-actively such as in cystic 
fibrosis. 
FURTHER STUDIES OF COPD PA'nIOGENESIS: EARLY DISEASE 
The studies described in this work have been performed in a population of 
patients with moderate to severe COPD. Clearly the role of airway infection plays in 
milder disease may differ greatly from that described above. However, the study of 
patients with mild disease or indeed those who are yet to develop COPD would 
answer fundamental questions about the role of airway pathogens in the initial 
development of airway obstruction. It is known that only a proportion of smokers will 
develop COPD and the factors underpinning disease susceptibility have not been 
identified despite a number of genetic studies. It is possible that two environmental 
'hits' are required to develop the disease, airway infection and inhalation of toxic 
substances such as cigarette smoke. A long term, large study would be required to 
examine such a hypothesis and would perhaps not only identify the reasons why 
certain individuals are susceptible to the effects of tobacco smoke in the lung but also 
to enable targeted early intervention to prevent the onset of this progressive disease. 
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Instructions for filling in the DIARY CARDS 
EVERY DAY... 
1. After taking morning medications record the best of 3 attempts at the 
PEAK FLOW blowing test in the box on the sheet. 
2. Please record any WORSENING of symptoms from your usual daily 
level. The symptoms we are interested in are listed below, just put the 
appropriate letter in the box on the sheet. Continue recording until the 
symptom has gone away or got back to the level you consider 'normal'. 
Letter Symptom 
A increased BREATHLESSNESS. 
BI increased SPUTUM COLOUR. 
B2 increased SPUTUM AMOUNT. 
c a COLD (such as a runny or blocked nose). 
D increased WHEEZE or CHEST TIGHTNESS. 
El SORETHROAT. 
E2 increased COUGH. 
F FEVER. 
I 
If you experience a worsening in any one of these symptoms 
please phone us to arrange an assessment visit, and do this 
BEFORE starting any antibiotic or steroid tablets. The phone 
number is 
07762 038662. 
Wayomi, Tom or Ramin will have the phone and we can usually 
arrange to see you later the same day or the following morning. 
It is best to phone first-thing in the niorning. 
3. Please record any CHANGE to your usual treatment for as many days 
as it applies. Again, just put the appropriate letter in the box on the 
sheet. 
Letter Treatment 
H I am in Hospital. 
I I am taking more than usual INHALED STEROID (red / brown). 
R I needed to take extra RELIEVER (blue / green / grey / nebuliser). 
HOW MANY PUFFS? Write, eg'R3'for 3 puffs, R2'for 2 etc 
S I am taking STEROID (Prednisolone) TABLETS. 
HOW MANY TABLETS? Write, eg'S6for 6 tablets, 'S5'for 5 etc 
X I am taking ANT11310TIC TABLETS. 
PLEASE RECORD WHICH (write the name on the diary card). 
4. Finally, please estimate the time that you were out of your own home on 
the previous day. 
280 
LIST OF PROJECT PUBLICATIONS 
PAPERS 
TMA Wilkinson, JR Hurst, W Perera, M Wilks, GC Donaldson and JA Wedzicha. 
Interaction of Bacterial and Rhinoviral Infection during Chronic Obstructive 
Pulmonary Disease Exacerbations. Chest 2006; 129: 317 - 324. 
TMA. Wilkinson, GC Donaldson, S L. Johnston, P J. M. Openshaw and J A. 
Wedzicha. Respiratory Syncytial Virus, Airway Inflammation and FEV, Decline in 
Patients with COPD. Am. J. Respir. Crit. Care Med 2006 published ahead of print on 
February 2,2006 as doi: 10.1 164/rccm. 200509-14890C. 
TMA. Wilkinson, IS. Patel, M Wilks, G Donaldson and JA Wedziclia. Rclationship 
between airway bacterial load and FEVI decline in patients with COPD. Am. J. 
Respir. Crit. Care Med 2003; 167: 1090-1095. 
TMA. Wilkinson, GC Donaldson, JR Hurst, T Seemungal and JA Wedziclia. Early 
Therapy Improves Outcomes of patients with COPD. Am. J. Respir. Crit. C(ire Aled 
2004; 171: 446-452. 
281 
ABSTRACTS 
T. M. A Wilkinson, TAR Seemungal, C. Dawson, W. Perera, J. R. Hurst, G. C. 
Donaldson. J. A. Wedzicha. Improving Exacerbation Reporting Behaviour in Patients 
with Chronic Obstructive Pulmonary Disease. Thorax 2005: 60; S11, ii6g. 
T. M. A Wilkinson, W. Perera, J. R. Hurst, G. C. Donaldson. J. A. Wedzicha. 
Relationship between RSV Detection and Airway Inflammation in Patients with 
COPD. Thorax 2005: 60; S11, H85. 
T. M. A. Wilkinson, D. J. Powrie, M. Wilks, G. C. Donaldson, J. A. Wedzicha 
Associations and impact of human rhinoviral infection at exacerbations of COPD 
Eur Respir J 2005; 26: Suppl. 49,14s. 
T. M. Wilkinson, W. R. Perera, J. R. Hurst, M. Wilks, G. C. Donaldson, J. A. 
Wedzicha. Prevalence of erythromycin resistance in lower airway bacterial isolates 
from patients with stable COPD. Eur Resl)ir J 2005; 26: Suppl. 49,25 1 
T. M. A Wilkinson, P. Pala, G. C. Donaldson, P. Openshaw, J. A. Wcdziclia. RSV 
Colonisation in COPD; Clinical Consequences and Immune Responses. Proc Am 
Thorac Soc 2005. 
T. M. A Wilkinson, D. J. Powrie, G. C. Donaldson, C. M. Dawson, J. A. Wedzicha 
Spirometric Staging of COPD, a True Measure of Disease Severity? Proc Am Thorac 
Soc 2005. 
282 
TMA Wilkinson, JR Hurst, WR Perera, GC Donaldson and JA Wedzicha. 
Consequences of Respiratory Syncytial Virus Infection in Patients with COPD. 
Thorax 2004; 59 (suppl 11): ii2. 
TMA Wilkinson, JR Hurst, WR Perera, GC Donaldson and JA Wedzicha. 
Relationship between disease Severity and Airway Inflammatory Response at 
Exacerbations of COPD. Thorax 2004; 59 (suppl 11): ii59. 
TMA. Wilkinson, JR Hurst, WR Perera, GC Donaldson and JA Wedzicha. 
Exacerbations of COPD: relationship between presenting symptoms and outcome. 
Eur Respir J 2004; 24(suppl 48): 63s-64s. 
TMA Wilkinson, DJ Powrie, M Wilks, GC Donaldson and JA Wedzicha. Differential 
inflammatory effects of colonising airway bacteria in COPD. Eur Respir J 
2004; 24(suppl 48): 686s. 
TMA Wilkinson, WR Perera, M Wilks, GC Donaldson and JA Wedziclia. 
Interaction of Haernophilus influenzae and Viral Infection at COPD Exaccrbation. 
Am. J. Respir. Crit. Care Med 2004: 169; 7; A207. 
TMA Wilkinson, GC Donaldson, TAR Seemungal and JA Wedzicha. Impact of 
Reporting and Early Treatment on Outcome of COPD Exacerbations. Ain. J. ResIfir. 
Crit. Care Med 2004: 169; 7; A207. 
283 
TMA Wilkinson, GC Donaldson and JA Wedzicha. RSV: Lower Airway Colonisation 
and FEVI Decline in Patients with COPD. Am. J. Respir. Crit. Care Med 2004: 169; 
7; A274. 
TMA Wilkinson, M Wilks, GC Donaldson and JA Wedzicha. Plasma Fibrinogen and 
Airway Bacteria in Patients with COPD. Am. J. Respir. Crit. Care Med 2004: 169; 7; 
A841. 
TMA Wilkinson, GC Donaldson, JR Hurst and JA Wedzicha. Benefits of Early 
Treatment on Outcome of COPD Exacerbations. Thorax 2003; 58(Suppl 111): iii74. 
TMA Wilkinson, JR Hurst, GC Donaldson and JA Wedzicha. Physician Consultation 
and Outcomes of Treatment in Exacerbations of COPD. Eur Respir J 2003-, 
22(Suppl45): 559s. 
TMA Wilkinson, JR Hurst, GC Donaldson and JA Wedziclia. Early Treatnicnt 
Hastens Recovery of COPD Exacerbations. Eur Respir J 2003; 22 (Suppl45): 237s- 
238s. 
TMA Wilkinson, IS Patel, GC Donaldson and JA Wedzicha. Delay in Reporting 
Prolongs COPD Exacerbation Recovery. Am. J. Respir. Crit. Care Med 2003: 167: 7 
A23. 
284 
TMA Wilkinson, IS Patel, GC Donaldson and JA Wedzicha. Relationship between 
Bacterial Infection and Exacerbation Severity in Patients with COPD. Ain. J. Respir. 
Crit. Care Med 2003: 167: 7 A23. 
TMA Wilkinson, IS Patel, AC Whiley, M Wilks and JA Wedzicha. The Effect of 
Airway Bacterial Load on Exacerbation Severity in Patients with COPD. Thorax 
2002: 57: iii29 
TMA Wilkinson, IS Patel, M Wilks and JA Wedzicha. Relationship between 
bacterial load, airway inflammation and lung function decline in patients with COPD. 
Eur Respir J 2002: 20: 264s 
TMA Wilkinson, IS Patel, A. C Whiley, M Wilks and JA Wedzicha The 
relationship between bacterial colonisation and lung function decline in COPD. 
Thorax 2001: 56: iii2O. 
285 
SPOKEN PRESENTATIONS OF WORK AND AWARDS ARISING 
FROM THE RESEARCH 
SPOKEN PRESENTAIIONS 
British Thoracic Society Winter Meeting, London 2001. Spoken Presentation at 
Symposium: The relationship between bacterial colonisation and lung function 
decline in COPD. 
European Respiratory Society Annual Meeting, Stockholm 2002. Spoken 
Presentation at Symposium: Relationship between bacterial load, airway 
inflammation and lung function decline in patients with COPD. 
British Thoracic Society Winter Meeting, London 2002 Spokcn Prcscntation at 
Symposium: The Effect of Airway Bacterial Load on Exacerbation Severity in 
Patients with COPD. 
American Thoracic Society Annual Meeting, Seattle 2003 Spoken Presentation at 
Symposium: Relationship between Bacterial Infection and Exacerbation Severity in 
Patients with COPD. 
American Thoracic Society Annual Meeting, Seattle 2003 Spoken Presentation at 
Symposium: Delay in Reporting Prolongs COPD Exacerbation Recovery. 
286 
European Respiratory Society Annual Meeting, Vienna 2003. Spoken Presentation 
at Symposium: Early Treatment Hastens Recovery of COPD Exacerbations. 
American Thoracic Society Annual Meeting, Orlando 2004. Spoken Presentation at 
Symposium: Interaction of Haemophilus influenzae and Viral Infection at COPD 
Exacerbation. 
American Thoracic Society Annual Meeting, Orlando 2004. Spoken Presentation at 
Symposium: Impact of Reporting and Early Treatment on Outcome of COPD 
Exacerbations. 
European Respiratory Society Meeting, Glasgow UK, 2004. Spoken Presentation at 
Symposium: Differential inflammatory effects of colonising airway bacteria in 
COPD. 
European COPD Network Meeting, Rome 2002. Lecture: TOPD in the UK'. 
European COPD Network Meeting, Copenhagen 2003. Lecture: 'Viral and Bacterial 
Pathogenesis of COPD Exacerbations'. 
European COPD Network Meeting, Verona 2003. Lecture: 'Role of Respiratory 
Viruses in COPD Exacerbations'. 
European COPD Network Masterclass, Paris 2004. Lecture: 'Airway Pathogens in 
COPD; Passengers or New Therapeutic Targets'. 
287 
London University Microbiology MSc Course. 2004 Lecture: 'Role of Infection in 
Airways Disease'. 
British Thoracic Society Winter Meeting, London 2004: BTS/BLF Young 
Investigator of the Year Finalists Symposium. Spoken Presentation: Consequences of 
RSV Infection in Patients with Stable COPD. 
Belgian and Dutch Universities Joint Respiratory Post Graduate Meeting, 
Antwerp 2005. Spoken Presentation: The role of Airway Infection in COPD. 
NHLI/ Royal Brompton Hospital, Pharmacology of Asthma and COPI) 2005. 
Lecture: Acute Exacerbations of COPD. 
European Respiratory Society Meeting, Copenhagen, 2005. Spoken Presentation at 
Symposium: Associations and Impact of Human Rhinoviral Infection in 
Exacerbations of COPD. 
Infectious Diseases Recognised Research Group Co. Antrim, N1. Spokcn 
Presentation Role of Airway Infection in the Pathogenesis of COPD. 
288 
AWARDS FOR THE RESEARCH 
Winner 20,000 Euro Award European Respiratory Society (ERS) COPD Researcher 
of the Year 2005. 
Finalist & Runner Up British Thoracic Society Young Investigator of TheYear Award 
2004. 
European Respiratory Society (ERS) Award for Best COPD Abstract, European 
Respiratory Society Meeting, Glasgow 2004 
Winner; European Respiratory Society (ERS) United Kingdom COPD Research 
Award 2003. 
British Lung Foundation; European Respiratory Society Travel Fellowship 2003 
British Thoracic Society Travel Fellowship, European Respiratory Society meeting 
Stockholm 2002. 
European COPD Network; Nominated Member of Rising Stars Workshop Member 
2002-2004 
European COPD Network; Nominated Member of COPD Masterclass 2004. 
289 
SOURCES OF FUNDING 
The majority of the work described in this Thesis was supported by: 
An Alywen Bursary Research Fund Award, 2001 Joint Research Board St 
Bartholomew's Hospital. 
A British Lung Foundation Project Grant. 
In addition the proteornic analysis was funded by an unrestricted educational grant 
from GSK. 
The PBMC stimulation experiments were funded by Wellcome Trust Programme 
Grant No. 071381. 
290 
Airway Bacterial Load and FEV, Decline in Patients with 
Chronic Obstructive Pulmonary Disease 
Tom M. A. Wilkinson, Irem S. Patel, Mark Wilks, Gavin C. Donaldson, and jadwiga A. Wedzicha 
Academic Unit of Respiratory Medicine, St. Bartholomew's and Royal London School of Medicine, St. Bartholomew's Hospital, 
London, United Kingdom 
Chronic obstructive pulmonary disease (COPD) Is characterized by 
an accelerated decline In lung function and progressive airway in- 
flarnmation. Bacteria have been Isolated from the lower airway of 
stable COPD patients, and airway inflammation has been related 
to bacterial load and type. The relationship between bacterial colo- 
nization, airway inflammation, and lung function decline remains 
uncertain. We studied 30 patients with COPD, mean (SD) FEV, 0.947 
(0.329), 34.8% (113.6%) predicted, for 12 months. Sputum collected 
at recruitment and the end of the study was analyzed for cytokines 
and for quantitative bacteriology. The decline in FEVI was 57.6 
(137.6) ml year-'. Bacterial growth was identified in all subjects, 
with an Initial count of 107.47(091) CfU mi-I rising to 101-13(081) CfU MI-1 
at the end of the study (p = 0.019). FEVI decline was related to this 
increase In airway bacterial load (r = 0.59, p=0.001). FEVI decline 
Was greater In subjects who exhibited a change In the colonizing 
bacterial type compared with those with persistence of a single 
bacterial species over the study period (p = 0.017). Higher sputum 
interleukin (IL-8) was associated with greater declines in FEVI (p = 
0.03). Rising airway bacterial load and species changes are associ- 
ated with greater airway inflammation and accelerated decline in 
FEVI. Bacterial colonization InCOPD Isan important factor In disease 
g)rogression. 
Keywords: chronic obstructive pulmonary disease; bacterial coloniza- 
tion; FEVI decline, airway inflammation 
Chronic obstructive pulmonary disease (COPD) is character- 
ized by an accelerated and progressive decline in lung func- 
tion, which is not fully reversible (1-3). Smoking is the most 
important etiologic factor for COPD and is known to cause 
inflammation in the lung (4). However, smokers exhibit a 
variable rate of decline in lung function, suggesting that fac- 
tors such as variability in smoking behavior, susceptibility to 
cigarette smoke, and other factors such as airway inflamma- 
tion caused by bacterial colonization may contribute to the 
progression of COPD. 
Patients with stable COPD exhibit increased airway in- 
fl ammation (5,6). The degree of airway inflammation is posi- 
tively related to the severity of airway obstruction with more 
bronchial inflammation in patients with lower FEVI (4). Fur- 
thermore, higher levels of airway inflammation, as evidenced 
by high sputum neutrophil counts, were associated with a 
-cater rate of decline in FEVI (7). The stimulus for increas- 
ing airway inflammation as lung function declines has not 
yet been determined. 
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The lower airways of healthy individuals are sterile, but 
bacteria have been isolated in significant numbers in patients 
with clinically stable COPD, indicating the presence of lower 
airway bacterial colonization (LABC) (8-10). The presence 
of bacteria in the lower airway can result in a range of impor- 
tant effects on the lung, including activation of host defenses 
with release of inflammatory cytokines and subsequent neu- 
trophil recruitment, mucus hypersecretion, impaired mucocil- 
iary clearance, and respiratory epithelial cell damage (11). 
Animal models of chronic bacterial infection in the lung have 
shown changes characteristic of those seen in COII'D in terms 
of inflammatory cells, cytokinc expression, and pathologic 
changes to both airways and alveoli (12). There is evidence 
that airway inflammation increases with higher airway bacte- 
rial loads determined from quantitative sputum cultures in 
patients with COPD (13). Thus, it has been suggested that 
chronic LABC contributes to progression of airways obstruc- 
tion (14,15). 
Previous studies performed to evaluate the relationship 
between airway bacterial colonization, inflammation, and lung 
function have been cross-sectional in design and have not 
addressed the important relationship between these parame- 
ters and effects on disease progression. This study addresses 
the hypothesis that bacterial colonization leads to increased 
airway inflammation and thus contributes to the accelerated 
progression of airway obstruction. We have performed a pro- 
spectivc observational study in well-characterizcd patients 
with moderate to severe COPD to elicit the relationship be- 
tween LABC using both quantitative and qualitative microbi- 
ologic techniques and the progression of airway obstruction. 
METHODS 
Patient Selection 
Thirty patients with COPD were recruited from volunteers in the East 
London COPD cohort and gave informed consent. Ethics approval was 
obtained from the East London and City Health Authority Research 
Ethics committee. The inclusion criteria for this prospective cohort study 
have previously been published and include IFEVI of less than 70% pre- 
dicted and P2 agonist reversibility of less than 15% of baseline and/or 
200 mi. Patients were assessed clinically and with a chest radiograph at 
recruitment to ensure the absence of other significant respiratory dis- 
ease (16). Patients completed daily diary cards, for symptoms and re- 
corded peak expiratory flow. Exacerbations were diagnosed from the 
diary card data as previously described (16-18). We ensured that each 
patient had been clinically stable (exacerbation free) for at least 6 weeks 
before both recruitment and sampling at the end of the study by patient 
interview and review of diary cards. 
Patients were followed prospectively for I year. Patients who suf- 
feTed an exacerbation around the end of the study period were only 
sampled when they had been clear of exacerbation symptoms and had 
completed any exacerbation treatment for at least 6 weeks. The mean 
sampling interval (after allowance for ensuring patients were fully stable 
before the second sample point), therefore, was 1.11 years. 
Measurement of Lung Function 
Lung function was measured with a rolling seal spirometer (Sensor 
Medic Corp., Yorba Linda, California). Lung function measurements 
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TABLE 1. CHARACTERISTICS OF PATIENTS IN THE STUDY 
Characterisfic Mean (SD) 
NurTiber, female/male 8/22 
Age, years 66.43 (10.25) 
F EV, L 0.95(0.33) 
FEVi percentage predicted 34.81 (13.61) 
FVC, L 2.51 (0.70) 
FEV, /FVC percentage 38.40 (10.70) 
pEF, L/Min 218.07 (76.14) 
pao., kPa 8.55(1.11) 
paco , 
kPa 6.20(l. 00) 
,? pack-years of smoking 74.3(66.5) 
inhaled steroid dosage 1.55(0.92) 
Beclomethasone equivalent, mg/day 
were taken between 9: 30 A. m. and 11: 30 A. M., I hour after the patient's 
. 1sual bronchodilator medication 
inclusive of 200 tLg of salbutamol via 
metered dose inhaler. At least three spirometry readings were taken 
at each visit, and the 
best performance was recorded. 
Sputum Sampling 
Sputum was sampled at the beginning and the end of the study. Immedi- 
,, t, 
ly after lung function measurement, patients were asked to expecto- 
irate spontaneously sputum 
into a sterile pot. Patients unable to produce 
a , arnple of sputum spontaneously underwent sputum 
induction (17). 
Sputum samples containing less than 25 squamous epithelia] cells per 
low. powered field and more than 25 leukocytes per high-powered field 
were accepted for processing. The sample was separated from saliva, 
a nd a portion was taken and analyzed for bacteriology (19); the remain- 
tjer was processed using previously published methods 
(17,20,21) and 
arlalyzed 
forinflammatory cytokines (17,21). Sputum interleukin (IL)-6 
, Irlcj I L-8 
levels were measured using ELISA (R&D Systems, Abingdon, 
tj K) (17). Twenty of the baseline samples have been used for an analysis 
4)f the relationship 
between LABC and exacerbation frequency (22). 
(juantitative Bacterial Analysis 
Sarnples were processed by using sputolysin. Serial dilutions were made 
,, I(j cultured on appropriate media. These were incubated for 18 hours 
, It 
IVC in an atmosphere of air +5% C02. After incubation, bacterial 
colonies were enumerated and subcultured for identification by stan- 
ar(j methods (19,22). The number of colony forming units per gram tj , 
of sputum was calculated 
from the total number of colonies obtained 
,,,, 
j the dilution to give the total bacterial count for each sample ex- 
pressed in cfu ml-1. 
Statistical Analysis 
r4ormally distributed data are reported by means (SDs) and skewed 
jata by medians (interquartile range [IQRI). Correlations were assessed 
t,, iflg the 
Pearson or Spearman correlation coefficient (two tailed). 
Continuous variables with normal distributions were compared by Mest, 
, 
ýhereas those with non-normal distributions were compared by the 
Mann-Whitney U or Wilcoxon signed ranks test. 
[)uring the analysis, patients were divided into groups dependent on 
e 'gocerbation 
frequency during the study. Patients with an exacerbation 
frequency that was higher or lower than the median were termed "fre- 
,, t, ent" 
or -infrequent" exacerbators, respectively (16); p values of 0.05 
, or 
less were regarded as significant. The SPSS version 10.0 (SPSS Chi- 
cago, 
IQ statistical package was used for data analysis. An extended 
version of 
the methods is available in an online supplement. 
sEsULTS 
rpotlent Characteristics 
. rhe baseline physiologic characteristics of the 30 patients who 
,, re recruited 
for the study are summarized in Table 1. The 30 
, atients were 
followed for a median (IQR) period of 1.05 (1- 
,. 22) years to ensure all sampling data were collected in the 
, table state. 
The mean (SID) FEVI was 0.947 (0-329) L, and the 
Pred 
icted FEV, was 34.8% (13.6%), with a range from 13.80 to 
1091 
69.95% predicted. Therefore, all patients can be classified as suf- 
fering from moderate to severe COPD according to Global Ini- 
tiativc for Chronic Obstructive Lung Disease (GOLD) criteria 
(3). Eleven of the patients were current smokers at the time of 
recruitment and did not alter their smoking habits during the 
study. Twenty eight of the patients were receiving inhaled ste- 
roids mean (SD) dosage 1.55 mg (0.92) beclomethasone cquiva- 
lents; no changes to the dose of inhaled steroid occurred during 
the study. At the first sample point, 24 patients produced sputum 
spontaneously, the remainder being induced, compared with 22 
patients expectorating spontaneously at the second sample point. 
FEV, Decline 
The mean (SD) FEVI at recruitment was 0.947 (0329) L and 
declined to 0.883 (0.367) L at the end of the 1.05 (1-1.22)-year 
sample interval. The mean annualrateof decline was 57.6 (137.6) 
ml per year; expressed as percentage of initial FEVI, this equates 
to 6.08% of baseline FEVI decline per year. 
The 30 patients had a total of 86 exacerbations during the 
study period, 40 (46.5%) of which were reported to the study 
team; the remainder of the exacerbations were diagnosed from 
diary card review, a proportion of which (17.4%) had been 
independently reported to a general practitioner. Fifty-two cxac- 
erbations received antibiotic treatment during the study. The 
median (IQR) exacerbation frequency in this study was 2-19 
(1.95) exacerbations per year. Patients with an exacerbation 
frequency higher than this median (frequent cxacerbalors) had 
more severe airways obstruction with a mean FEW, of 0.86 L 
compared with infrequent cxacerbators with a mean FEVI of 
1.07 (p = 0.05). 
Quantitative Bacteriology 
All cultures of sputum samples grew significant numbers of bac- 
teria ranging from 105.4 to IWI cfu nil-'. The mean (SD) total 
bacterial count at sample I was W-I't", ") cfu nil-' and rising to 
10"'("') in sample 2 (p = 0.019) or a rise frorn 29,512,092 cfu 
nil-' to 85,113,804 cfu nil-' when expressed without log trans- 
formation. 
Bacterial Load and FEVI Decline 
Patients with an increasing airway bacterial load demonstratcd 
a more severe decline in FEVI over the study period compared 
with patients with stable or decreasing airway bacterial load who 
exhibited less marked declines or slight improvcments in FEVI. 
This relationship between FEVI decline and changes in bacterial 
load (Figure 1) was statistically significant in terms of absolute 
FEVI decline (r = 0.593, p=0.001) and decline expressed as a 
percentage of baseline FEVI (r = 0.633, p<0.001). The total 
bacterial count of the second sample was itself related to the 
absolute rate of decline over the study (r - 0.560, p-0.001) (Figure 2). The total bacterial count of the first sample was not 
predictive of the subsequent decline in FEVI over the study (r 
-0.125, p=0.369). 
A linear regression analysis of the relationship between bacte- 
rial load and FEVI decline revealed that a 10-fold increase (10' 
cfu ml-1) in bacterial load is associated with an 82.4-ml decline in FEVI over the study period; the regression coefficient was 0.095 (95% confidence interval, 0.032-0.132) (p - 0.002). As the 
mean increase in bacterial load was from 101-11 to 101-9-1 cfu ml-'. this represents a decline in FEVI attributable to the airway bacterial load of 33.3 ml/year for this patient group. A multivari- 
ate regression analysis of potential factors in the observed de- 
cline in lung function (Uyear) was performed: regression coeffi- 
cient (95% confidence interval), change in bacterial load (log 
cfu ml-1) 0.0631 (0.034-0-133, p=0.003), number of cigarettes 
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I Relative frequency of bacterial isolates from first (black bars; n= 30) and second (hotched bars, n- 30) sputum sample expressed as a 
percentage of samples. NSG = nonspecific growth. 
in the species of bacteria] isolate over the sample interval. Fifty 
, rcent 
of the subjects grew entirely different bacterial species 
, at each 
sample point, whereas the other 50% demonstrated per- 
Sisteince oa specific 
bacterial species or nonspecific growth across 
te sampling interval. Patients who demonstrated changes in col- 
Orli7ing bacterial species during the study exhibited 
higher mean 
acterial loads (10"' log cfu ml-1) than those who maintained 
the same species in both samples (10"' log cfu ml-1, p=0.03). 
The decline in FEVI seen in the study group was significantly 
,, cater 
in those subjects with unstable bacterial type at a 102 r -ml 
(, ()P, 19-196, n= 18) decline in FEVI per year compared with 
a _1.6-ml 
(. lQR -158-112, n= 12) decline per year in the group 
, ith persistence of one bacterial type at both time points 
(p = 
0.017); this relationship with FEVI decline expressed as a per- 
centagc of 
baseline is illustrated in Figure 4. Changes in bacterial 
40 
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Fi. 1ire 4. Differences 
in FEVI decline between subjects with persistent 
10) and changing 
(1) bacterial isolate. 0= Same bacterial species identi- 
%, cl jr, sputum at 
beginning and end of study; I= Change in species fie 
of bacterial 
isolate; p=0.017. Decline expressed as percentage of 
b,,, line 
FEVi (negative values indicate improving lung function). 
species were not related to the number of cigarettes smoked per 
day (rho = 0.056, p=0.767), the sputum collection method 
(induced or spontaneous) (rho = 0.012, p=0.84), the recorded 
exacerbation frequency (rho= 0.149, p-0.44). or the antibiotic 
usage during the study (rho = 0.048, p=0.808). An analysis of 
each of the individual bacterial species and the associated lung 
function changes did not reveal any attributable significant dif- 
ferenccs in FEV, decline between subjects colonized with differ- 
ent bacterial species, although numbers in each subgroup were 
too small to draw any valid conclusions from this analysis. 
Sputum Cytokines 
Sputum IL-6 and IL-8 levels were measured on all samples-Thc 
median (IQR) IL-6 levels were similar 114 (283) pg ml-' and 
51 (297) pg nil -I in samples I and 2, respectively, and I L-8 levels 
were 3,183 (1,688) pg nil-' and 3,012 (1,684) pg ml-1. Levels of 
sputum IL-6and IL-8were related toone another in each patient 
(rho = 0.378, p=0.007). The absolute changes in I L-6 between 
samples I and 2correlatcd with the changes in IL-8sccn between 
the two samples (rho = 0.542, p=0.011). The sputum IL-8 
levels were related to pack-years of smoking; those patients with 
IL-8 higher than the median having smoked for a mean of 100 
pack-years and those with lower IL-8 for 42 pack years (p - 
0.018). Patients exhibiting a decline in lung function exhibited 
higher overall sputum median (IQR) IL-8 levels 3,343 (1,592) 
pg ml-I compared with those with stable or improving FEVi 
2,160 (2,050) pg nil-' (p = 0.032). Similarly, patients with a 
higher bacterial load (greater than the overall mean, sample I 
and 2 combined) had higher overall IL-8 levels (2,938 pg ml-) 
compared with those with bacterial counts lower than the mean 
(2,329pgmi-1)(p = 0.05). Thcre were no significant relationships 
between sputum ILA levels and bacterial counts or lung function 
decline. 
NSG Haentophilus streptococcus Dranhemells Ilaemophilus plaudomonas 
influenzae pneumonia catwThalis parainfluenzae 
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DISCUSSION 
This is the first longitudinal prospective study to assess directly 
, he relationship 
between lower airway bacterial load and decline 
,n 
lung function in patients with moderate to severe COPD. We 
iave ILlernonstrated a significant relationship 
between the sputum 
aacterial 
load and disease progression in COPD, showing that the 
rate of decline of 
FEVI was proportional to the rise in colonizing 
5actcrial load over the 1-year study. Individuals who exhibited 
: banges 
in the nature of bacterial colonization suffered from 
faster declines in lung function than those with persistence of 
3ne or rnore 
bacterial species. Quantitative estimations showed 
bat subjects with higher or rising bacterial loads similarly dem- 
, nstrated greater 
declines in FEVI compared with those with 
, ower or 
decreasing airway bacterial loads. These falls in FEV, 
were also associated with elevated 
levels of the potent neutrophil 
-. hemc, attractant 
IL-8. 
lower airways of healthy nonsmoking individuals are 
although a number of studies have identified bacteria in 
te -10). 
The 
, 
lower airways of patients with stable COPD (8 
, revalence of 
LABC is increased by active smoking and with 
ýIrogressive 
airways obstruction (9,10), and as our patient group 
,, J rnore severe 
COPD, this explains the high prevalence of 
LA13C found. 
Bacterial colonisation is proinflammatory and can 
, esuli 
in a range of pathologic effects that are deleterious to lung 
C un tion, 
including mucus hypersecretion and embarrassment of 
... 1cociliary 
clearance (23,24). Bacteria can affect the airway 
ithelium directly and via the recruitment of neutrophils (25, 
with release of excessive amounts of neutrophil derived pro- 16) 
,,.,, s resulting 
in damage to airway epithelial cells (14). Airway 
r, fl. rillination 
has been shown to increase as airway obstruction 
4,. r. ens, 
but bacterial colonization was not originally considered 
Is an explanation 
for this finding (4). Bacterial colonization has 
shown to be detrimental to lung function in a number of 
)a, hologica 
conditions, including cystic fibrosis and bronchiec- 
(2,7,28). Evidence that LABC contributes to worsening 
ung 
function comes from a study that found that IL influenzae 
: 01 onization 
was associated with increased airway inflammation 
ri . tients 
with chronic bronchitis and airflow obstruction com- 
)ared 
with patients with chronic bronchitis but without airflow 
)t, struction, 
where airway inflammation was reduced (29). We 
again confirmed that higher airway bacterial load is associ- 
Ited with 
greater airway inflammation in terms of sputum IL-8 
Furthermore, patients exhibiting a decline in FEVI during 
C 
study had higher levels of IL-8 than those with a stable or 
n1proving 
FEVI. This finding suggests a mechanistic link be- 
airway bacterial load, airway inflammation, and theassoci 
'j 
Llcleterious effects on FEVI. 
, We have previously reported that some patients with COPD 
, lop 
frequent exacerbations, and this patient group has in 
:,. C, Ise(j 
stable airway inflammatory cytokines (IL-6 and IL-8) 
,,, lpaircd 
with those with a history of infrequent exacerbations 
30). patients with 
frequent exacerbations also demonstrate a 
, ter 
declineinFEV, than infrequent exacerbators, with exacer 
, tions contributing 
to approximately 25% of the observed lung 
. un, tion 
decline in COPD (31). Analysis of data from the Lung 
'alth 
Study (32) revealed that lower respiratory illnesses in 
, olccirs 
are deleterious to FEVI and lends further support to 
he hypothesis 
t at lower airway infection and associated in- 
,,, rnation 
contribute to lung function decline. 
pre, vious longitudinal studies of the mechanisms of lung func- 
ion decline 
have used possible surrogate markers of airway 
I ,, tion 
such as mucus hypersecretion. The Copenhagen City 
, cart 
Study found that chronic mucus hypersecretion was associ- 
ted with 
an excess FEVI decline of 22.8 ml/year in men and 
-2,6 , 
Vyear in women together with increased risk of hospital- 
ization (33). As bacterial colonization is associated with mucous 
secretion (34), and patients with mucous secretion have more 
airway inflammation (7); this again provides support for the role 
of LABC in the accelerated decline of FEVI. We have found 
that the presence of bacterial colonization is directly related 
to exacerbation frequency, and patients with colonization have 
longer and thus more severe exacerbations (22). As patients 
with a past history of frequent exacerbations have increased 
airway inflammation (30), the nature of stable bacterial coloniza- 
tion may be an important factor in disease progression due to 
the effect of exacerbations. 
In this study, the relationships between FEVI decline and 
features of LABC were strongest in the analyses, which included 
measures of "instability" of LABC such as changes in bacterial 
load and type. It is possible that such changes generate a renewed 
stimulus to inflammation in the airway, in turn causing a more 
rapid decline in lung function. Indeed, there is increasing evi- 
dence that bacterial colonization is a highly dynamic process 
and that changes in bacterial type are associated with the etiology 
of exacerbations (35). Bacterial colonization itself is likely to be 
affected by exacerbations and their treatment, but to what degree 
this is remains uncertain. The interrelationships between host 
defenses and bacterial infection in the stable state and at exaccr- 
bation are highly complex. We postulate that bacterial coloniza- 
tion may accelerate FEVI decline by both increasing airway 
inflammation in the clinically stable state and by affecting the 
FEVI decline due to more frequent and severe exacerbations. 
This study suggests a significant effect of bacterial colonization 
on disease progression in COPD. 
The multiviriate regression analysis of the data from this 
study did not find a significant influence of active cigarette sniok- 
ing on FEVI decline over I year. Indeed, although it is established 
that cigarette smoking is a risk factor for bacterial colonization 
and itself leads to increased airway inflammation, the effects of 
smoking cessation on airway inflammation in severe COPD may 
not be as clearly defined as in a milder patient group. In this 
colonized COPD population with severe airways disease, lower 
airway inflammation may persist despite smoking cessation (36). 
Thus, the most significant influence on airway inflammation in 
this study group and consequent FEVI decline may be the airway 
bacterial load. 
Many studies of lung function decline have largely been per- 
formed using patients diagnosed with bronchitis or airflow ob- 
struction (1,33). Therefore, understanding of the natural history 
of lung function decline in more severe COPD is based largely 
on an extrapolation of observations from patients with milder 
COPD. Quantitative assessment of airway bacterial load and 
the related sputum markers of inflammation suggestsa threshold 
level of colonisation in the order of 101-10' cfu ml-' above 
which LABC is a persisting drive to airway inflammation (13). 
However, the degree of airways obstruction at which the clini- 
cally significant effects of LABC occur and how bacterial coloni- 
zation affccts the natural history of COPD in the longer term 
remains uncertain and requires further study. 
It is possible that the findings of changes in total bacterial 
count and FEVI may represent changes associated with unrc- 
corded exacerbations. However, diary cards were used to record 
all changes in symptoms on a daily basis and could therefore be 
used to detect all exacerbations both reported and unreported 
as previously described (16). Furthermore, direct questioning of 
patients at each study visit was used to clarify symptomology 
and use of rescue medication during the previous 3 months. Therefore, exacerbations both reported to the study team or 
primary care requiring extra medication and those unreported 
but recorded on diary cards were included in assessment of 
baseline status. There was no identifiable relationship between 
V, filkins0n, Patel, Wilks, et oL: Bacteria and FEVI Decline in COPD 
the changes in FEVI observed and the frequency or timing of 
exacerbations 
in this study. However, this study was not powered 
to investigate the relationship between exacerbation numbers 
and lung function decline 
demonstrated previously by our group 
(16). Assessment of diary cards for the 6-week symptom-free 
period effectively assured that patients 
had returned to baseline 
before sampling. 
-rhis study has shown that LABC is an important determinant 
of decline of lung 
function in this group of COPD patients 
with moderate to severe disease. These findings suggest that 
appropriate antimicrobial therapy 
in colonized patients may 
have an important therapeutic effect, offering an opportunity to 
alter the natural history of this highly prevalent disease. 
Studies 
performed over a longer period are required to investigate 
fur- 
ther the interactions between LABC, smoking, and exacerba- 
tions and their effect on the accelerated decline in lung function, 
which is characteristic of COPD. 
, 4, Ck, 7owjedqment: 
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CHEST Original Research 
COPD 
Effect of Interactions Between Lower 
Airway Bacterial and Rhinoviral 
Infection in Exacerbations of COPD* 
Tom Al. A. Wilkinson, AIRCP, John R. Hurst, AfRCP, 11"ayomi R. Perera, AIRCP; 
Alark AVilks, PhD; Gavin C. Donaldson, AD, and jadwiga A. Wed-zicha, AfD 
Study objectives: The inflammatory responses and associated clinical severity of COPD exacer. 
bations are greatly variable, and the determinants of these factors are poorly understood. We 
examined the hypothesis that bacteria and viruses may modulate this heterogeneity and that 
interactions between bacterial andviral infection may affect changes in airway bacterial load and 
the clinical features and inflammatory responses of exacerbations in patients -'villi COPD. 
Design: Prospective cohort study. 
Setting: Outpatient Department, London Chest Hospital, London, UK. 
Patients: Thirty-nine patients -svith COPD. 
Measurements: We prospectively studied 56 COPD exacerbations, obtaining clinical datil and 
paired sputum and serum samples at baseline and exacerbation. Qualitative and quantitative 
microbiology, polymerase chain reaction detection for rhinovirus, and estimation of cytokine 
levels by enzyme-linked immunosorbent assay were performed. 
Results: A total of 69.6% of exacerbations were associated %vith a bacterial pathogen, mo%t 
commonly Haemophilus onfluenzae. Rhinovirus was identified in 19.6% of exacerbations. Vic rise 
in bacterial load at exacerbation correlated with the rise in sputum interleukin (1Q-8 (r = 0.37, 
p=0.022) and fall in FEVI (r = 0.35, p=0.048). Exacerbations with hoth rhinovirus and It 
influenzae had higher bacterial loads (10"' cfu/mL vs 108-o"'efulml., p=0.018) and seruni IL-6 
(13.75 pg/mL vs 6.29 pg/mL, p=0.028) than exacerbations without both pathogens. In exacer. 
bationswith both cold symptoms (a marker of putative viral infection) and a bacterial pathogen, 
the FEVI fall was greater (20.3%vs 3.6%, p=0.026) and symptom count wits higher (p = 0.019) 
than thosewith a bacterial pathogen alone. 
Conclusions: The clinical severity and inflammatory responses in COPD exacerbations are 
modulated by the nature of the infecting organism: bacterial antiviral pathogens interact to cause 
additional rises in inflammatory markers and greater exacerbation severity. 
(CHEST 2006,129: 317,32-1) 
Key words: bacteria; COPD; exacerbations; Nimses 
Abbre, dations: Cl = confidence interval; IIRV = hunian rhinmirus; IL = interleukin; IQR - interquartile range; PCR = poly-inerase chain reaction; PPNI = potentially pathogenic microorganism 
xacerbations of COPD are characterized by in- IE 
creased airway', 2 and systemic inflammation. 3 
1 lovvever, there is marked variability in the nature of 
the inflammatory response at exacerbation and thus 
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the symptoms, clinical severity, and thne course of 
these cventS. 4 Individual factors such as respiratory 
viruses-'1-7 and particular bacterial pathogens8 are 
associated with indexes of more severe exacerba- 
tions. However, interactions between indhidual 
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pathogens and the mechanisms that underlie the 
lieterogeneity of exacerbations are poorly under- 
stood. 
Bacterial pathogens are commonly identified in 
the lower airway of COPD patients in the stable 
state. '-9,10 Airway inflammation is directly related to 
tl, e number of bacteria in the lower airway in stable 
COPD, and greater airway bacterial load is itself a 
stilnulus to faster disease progression. 11 While it is 
knoNvn that airway bacterial load rises at exacerba- 
tio, 119 it is not knoNkm to what extent these rises 
Inodulate changes in airway inflanimation and exac- 
erbation severity, or what factors determine changes 
in bacterial load. 
Respiratory druses have been implicated as im- 
portant infective triggers of exacerbations, -5-7,12 with 
1,11, nan rhino%irus (IIRV) being the most commonly 
For editorial comment see page 223 
idelitified, dral pathogen. -', Virus-associated exacerba- 
tions are longer and thus more severe than nonviral 
exacerbationsý5 
but whether this is due to the direct 
effects of Niral infection on the airway or a rnecha- 
nisin invol-Ong changes in lower airway bacteria is 
not known. We examined the hypothesis that the 
licterogeneity of inflammatory, symptomatic, and 
, I, ySiologic responses at COPD exacerbation is mod- 
ulated 
by airway bacterial and Niral infection and that 
. CoInbination of these pathogens would result in 
greater aimay and systemic inflammation and hence 
clinical and physiologic indexes of exacerbation se- 
.,, erity. 
MATERIALS AND METHODS 
plitient Seleclion 
patients mith COPD , vere recruited from the outpatient 
depart ment of the Undon Chest I lospital into the East London 
CO; r) cohort. The inclusion criteria for this study have previ- 
, usly 
been publislied-6-11-1-3-11 and include a postbronchodilator 
.V<, 0% of predicted for age and height, O. -agonist revers- FF, i 
ibility < 
5% of baseline and/or < 200 mL, and a FEVI/ FVC 
ratio 
< -jo%. Patients were assessed clinically and %vith chest 
r io rap iy 
at recruitment to ensure the absence of other 
5, r1i le 
t respiratory disease. Patients were observed for this 
'Stu 
from April 2001 to July 2002. Ethics approval for the study 
%vas obtained 
from the East London and City Health Authority 
IResearcil 
Et iics committee; all patients gave written informed 
,, onsent- 
iis patient coliort bas been the subject of previous 
art cles2-6.11 
on various aspects of COPD exacerbation. 
j9iaflj Card 
31onitoting and Follmv-up 
, 4t recruitment, 
patients were tauglit how to record on diary 
card. 5 each 
morning postbrOnChodilator peak expiratory flow 
(,,,,,, -%Vright; 
Clement Clark International; Harlow, UK). Pa- 
tients recorded a change in their symptoms using a letter- 
annotated system. When well or stable, the patients were in- 
structed not to record any of the symptom letters in the diary. 
However, when they perceived an increase over their normal, 
stable condition in symptoms (major and minor, see below), they 
noted the corresponding symptom letter on their diary card. 
Therefore, the patients recorded symptom letters if a symptom 
was perceived as worse, eg, dyspnea, or of new onset, eg, a sore 
throat (as the latter is not usually present). 
Stable State 
Patients were reviewed at recruitment and with ibeir diary 
cards every 3 months in the study clinic to monitor compliance 
with data collection and to record changes in medication and 
baseline lung function. A review of diary cards was utilized to 
ensure that stable sampling was perfonned m-hen subjects had 
been clear of exacerbation s)miptoms and had completed any 
exacerbation treatment for at least 6 weeks. 
Exacerbations 
Patients were encouraged to report syniptom changes to the 
study team; they were assessm] mithin 24 to 48 li In the study 
clinic by a respiratory physician prior to initiation of therapy for 
the exacerbation. The diagnosis of all exacerbation was based oil 
syniptoniatic criteria prniously validat"I by our group. 2-11 Ali 
exacerbation was defined as the presence for at least 2 consecu- 
tive days of increase in any two jn. ýJor symptoms (dyspnea, 
sputum purulence, sputum amount) or incre-, ýse in one major and 
one ininor symptom (wheeze, sore throat, congh, symptoms of a 
common cold). Exacerbation symptoms %vere binary cod(A as 
present or absent, and the suin of these at exacerbation onset was 
terined the symptom count, mideh has been validated as a marker 
of clinical severity. 4 Lung function incasnrement and sputinn and 
blood sampling were perfornied on patients prior to the initiation 
of exacerbation treatment. 
Aleasurewnt of Lungfimclion 
Lung function was measured N%ith a rolling seal spirometer 
(SensorMedics; Yorba Linda, CA). Lung function measurements 
, vvere obtained between 9: 30 AM and 11: 30 ANI, Ih after the 
patient's usual bronchodilator medication. At least three spirom- 
etry readings were obtained at each visit, and the best perfor- 
mance was recorded. 
Sputunt and BI(x)d Sampling 
Sputum was sampled if the subject met criteria for the stable 
state at the 3-niontli review and also at presentation or exacer- bation. Immediately following lung function measurement, the 
patients were asked to spontaneously expectorate sputum into a 
sterile container. Patients unable to produce a sample of sputum 
spontaneously underwent sputum induction. " 
Once a sample was obtained, sputum plugs were separated from saliva using sterile forceps, and one third of the sputuin was 
taken and analyzed for quantitative bacteria] culture. 's Tile 
remainder was homogenized and centrifuged, and aliquots of 
supernatant were stored at - 700C for later c)1okine analy. 
SiS. 2.11.13 Sputum samples containing < Z5 squarnous epitlielill 
cells per low-power field and > 25 leuk-oc)tes per high-power field were accepted for analysis. An aliquot of phosphate- buffered saline solution-processed sputum was frozen at - 80C for subsequent RNA extraction and polymerase chain reaction (PCR). The remainder was analyzed for inflaininatory c>to- 
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Idnes-2-1 1.13 Sputum interleukin OW-6 and 11-8 levels were 
,,, eas, ured using an enzyme-linked 
immunosorbent assay (R&D 
Sy, terns; Abingdon, UK). 2 Contemporaneous blood samples 
were obtained, centrifuged at 
VC, and serum decanted mid 
stored at - 
8O'C for subsequeDt analysis of IL-6 levels using an 
enzyme-linked 
immunosorbent assay (R&D Systems). 
Q,,, ntitative Bactetial Analy. Tis 
Sa, nples were processed homogenized. Tenfold serial dilutions 
of tle ljornogenized sample were made in 
brain heart infusion 
brotli, and 100-ttL aliquots were plated out onto the surface of a 
range of 
different media, including blood agar, chocolate agar, 
Ma, conkey agar, and c)-steine lactose electrol)te-deficient agar. 
-fliese were incubated for IS to 36 h at 37C in an atmosphere of 
air + 5% carbon 
dioxide. After incubation, bacterial colonies 
were counted and subcultured 
for identification by standard 
metbods-"' Haenwphilus influenzae and HaenulAilus parainflu- 
en: -; ae were identified and 
differentiated by their groN%th patterns 
on pe . 
ptone agar on which discs containing nicotinanlide adeno- 
sine dinucleotide or 
haemin were placed (O. xoid Unipath; Bas- 
jr, gstoke, UK). The number of colony forining units per milliliter 
of sputum was calculated 
from the number of colonies obtained 
and die 
dilution of the sputum. Bacteriolog data are expressed as 
11, e total bacterial count in 
log base 10 U. Potentially pathogenic 
, nicroorganisms 
(Mls) are bacteria known to be common 
padjog"' of the respiratory tract in subjects %%ith 
COPD (Strep- 
j(), C()Cc,,. v pneunumiae, H influenzae, H Moraxella catarrhalis, 
Staj)hylococcus aureits, Pseudontonas aerviginosei, and other 
C; ran-1-negative enteric bacteria). 
, q, V, A 
E. Atraction, Reverse Treinscilption, and Picornavints FCR 
RNA extraction from the sputum was performed using a 
, t,,, clard extraction 
kit (Qiagen; Southampton, UK). Reverse 
transcription was performed using random hexamers, and picor- 
, a,, Irus 
PCR was performed as previously described. " This PCR 
,,, I, oiqije 
has been validated in the detection of rhino-drus in 
these samples using confirmatory nucleic acid sequencing. 6 
St,,, ji. 5tical Analysis 
pjorinally distributed data are reported by means and SDs and 
, ke, ved 
data are presented as medians and interquartile range 
(IQR). Correlations were assessed using the Pearson or Spear- 
correlation coefficient (two tailed), as appropriate. Contin- 
,, ous variables %vith normal 
distributions were compared by t test, 
.. 4-1jereas 
those xvith nonnormal distributions were compared by 
tl, e rlarm-Whitney 
U or NVilcoxon signed-ranks test. Changes in 
parallieters 
from the stable state to exacerbation were assessed 
,,, i, lg a paired 
analysis of the stable sample data taken preceding 
exacerbation studied; p values :s0.0.5 were regarded as 
significant, 
In the analysis of changes in parameters be veen t% 
, table state and exacerbation, 
the prior stable sampling point 
closest to 
the subjects corresponding exacerbation was used 
. ating a 
data set of paired baseline and exacerbation samples Cre 
or eacl, exacerbation. 
The analysis of group data was initially f4 
, djusted 
for repeated measures by selecting the first exacerbation 
sarnpled 
per patient (n = 39) to assess the changes in measured 
,, d,, es 
from baseline to exacerbation. These observed changes 
Comparable to die larger data set of 56 exacerbations (in 39 
its) which was therefore used to compare individual exac- patie. t characteristics and etiologies, as in previous studies. 5 erbatlo" 
,,, Itivariate analysis was performed using a multiple 
linear 
, egression 
analysis. Data analysis was performed using statistical 
soft%vare 
(SPSS version 10.0; SPSS; Chicago, IL). 
WWW. chestjoumal. 
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RESULTS 
Patient Characteristics 
Table 1 shows the baseline characteristics of the 
39 patients in the East London COPD Cohort 
sampled during the study. Fifty-six paired stable and 
exacerbation samples were obtained from 39 patients 
for this analysis. Of these 39 patients, 15 were 
receiving long-term oxygen therapy, all patients were 
receiving long-term inhaled corticosteroids (inedian, 
500 ýLg/d; IQR, 400 to 1,500 jig/d of beclomethasone 
equivalents), no patients were receiving long-tenn 
oral corticosteroids, and all patients received regular 
inhaled bronchodilators. The remainder of the pa- 
tients did not have an exacerbation during the 
sampling period (n = 26), did not report an exacer- 
bation to the study team, received antibiotic treat- 
ment before sampling, or were unable to provide an 
adequate sputum sample (n. = 14). The sampled 
patients did not differ significantly in terms of 
baseline characteristics from those who were not 
sampled (Table 1). 
Changes in Lung Function and Inflanintatonj 
Markers at Exacerbation 
Table 2 shows the stable and exacerbation FEVI, 
airway bacterial load, sputum IIA and IIA, and 
blood IIA levels for all the 56 sampled exacerba- 
tions and on a per-patient basis (n = 39). In both 
analyses, the incan FEVI fell at exacerbation and the 
mean airway bacterial load rose significantly. Exac- 
erbations %vere associated with increase(] airway in- 
flammation in ternis of sputum 11,8. The rises in 
levels of sputum and seruin ILA did not reach 
statistical significance. 
Ainvay Bactetiology 
Airway bacterial load rose in all samples (n = 56) froln 167.50 (0.74) 1 
og cfn/mL in the stable state to 
10"'-()"(0--'6) log eftt/inL at exacerbation, and also rose 
significantly in data adjusted for repeated measures 
Table I-Patient Baseline Characteristics (n = 39)* 
Manicteristics Ditta 
Age, yr 6&8 (6.0) 
FEVI % predicted 40.6(15.6) 
Pao, kPa 8.86(0.89) 
Paco2. kPa 5.67(0.74) 
Smoldng history, pack-yr 41.0 (30-52) 
Male gender, % 60 
Active smokers, % 23 
Chronic sputum producers, % 43 
*Data are presented as mean (SD) or inedian OQR) unless otherwise 
indicated. 
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-fgtble 2-FEVI, Infective and Inflammatory Changesfor Baseline (Stable State) and Exacerbation SamplePoints 
and on a Per-Patient Basis (n = 39) andfor All 56 Sampled Exacerbations (n = 56)* 
Variables Baseline Exacerbation p Valuef 
Per patient (n = 39) 
FEVI, L 0.95(0.36) 0.87(0.30) 0.012 
13acterial load, log cfu/mL 7.47 (0.7-3) 8.16(0.76) 0.001 
Sputum 11-8, pg/mL 3,647 (2,930-4,466) 4,409 (3,98.3-4, -j 87) 0.002 
Sputum IIA pg/mL 146.0 (20.4-246.9) 187.6 (49.9-260.1) 0.321-0 
Serum IL-6, pg/mL 4.73 (3.34-7.07) 6.0 (4-95-13.18) 0.22S 
ji patients (n = 56) 
FF, Vj, L 0.96(0.37) 0.69(0.32) 0.015 
13acterial load, log efu/mL 7.50(0.74) 8.09(0.76) 0.001 
Sputum 11-8, pg/mL 3,604 (2,913-4,390) 4,288 (3,991-4, T 65) 0.005 
Sputum ILA, pg/mL 146.7 (29.4-233.0) 185.0 (50.0-2SO. 0) 0.477 
Serum 11A pg/mL 4.6 (3.1-7.1) 6.6 (4.0-11.7) 0.1.36 
*Data are presented as mean (SD) or inedian OQR). 
f Statistical comparison of baseline and exacerbation. 
(" = 39) [107.47 (0.73) to 108.16 (0.76); p=0.0011. The 
I)revalence of PPNIs rose from 48.2% at baseline to 
69.6% at exacerbation (n = 56), Mth the remainder 
of samples demonstrating nonspecific bacteria] 
grc)wtli. The most frequently isolated organism was 
1I influenzae in 14.3% of stable and 37.5% of 
e, xacerbation samples, NNith S pneunwidae in 8.9% 
., lid 1.4.3%, Al catarrhalis in 7.1% an(] 14.3%, 11 
parainfluenzae in 10.7% and 0%, S aurcus in 3.6% 
aild 0%, P aeruginosa in 1.8% and 1.8%, and Gram- 
,, egative enteric bacteria in 1.8% and 1.8%, respec- 
ti, *, ely; the remainder 
demonstrated nonspecific bac- 
terial growth. 
pelationships Between Bacterial Load, Ainvay 
IIIJ7ammation, and Lung Function Changes at 
E, vacerbation 
Changes in airway bacterial load (n = 39) were 
related to exacerbation severity in terms of clianges 
i, j lung function and airway inflammation. The rise in 
airway bacteria] load from baseline to exacerbation 
was related to the percentage fall in FEV, (r = 0.35, 
P -: = 0.048). Tite magnitude of the rise in airway IL-8 
at exacerbation was related to the rise in airway 
bacterial load (p = 0.37, p=0.0"912). 
The changes in airway and serum ILA observed 
from stable state to exacerbation were not related to 
changes in bacterial load (p =-0.76, p=0.649 and 
p =-- 0.144, p=0.482, respectively). However, the 
rise in systemic inflammation was related to that of 
airway inflammation; the change in sputum 11,6 
correlated with the change in serum IL-6 (p = 0.435, 
-- 0.023, n= 39). 
Changes in airway and systemic markers of inflam- 
roation at exacerbation were modulated by existing 
disease severity. The observed change in sputum 
11,8 at exacerbation per patient was inversely related 
to the baseline FEVI (percentage of predicted) 
[p =-0.298, p=0.051, as was the change In spu- 
tum IL-6 (p =-0.358, p=0.02) and the change in 
senim 11,6 (p =-0.392,1) = 0.03). Thus, patients 
mith more severe COPD exhibited greater riscs In 
inflammation at exacerbation compared %%ith those 
N%itli more mild disease. 
Effects of Individual Pathogens and Their 
Interactions 
11 influenme: 11 hi 
, 
fluctizzac-rclated exacerbations 
were associated -vvitlk higher airway bacterial load 
]08.5210.391 log 
eft/1111 )1111), (n = 56; t c( ared to cases 
in which it was not isolated log crit/1111,; 
1) = 0.001). There \%ras a trend toward more severc 
drops in FEVI (expressed as a percentagc of basc- line): - 11.91% (SD, 15.32%) with 11 influenzae 
present, vs - 1.20 witliont 11 Influenzae (SD, 
15.09%) [p = 0.057]. NI'licre de novo 11 Influenzae 
infection occurred (ic, 11 influenzae present tit vxac- 
erbation but not present in stablc sainple), there was 
again a greater exacerbation bacterial load 
(I 0S. 5% 10.401 log efit/mL) compared to when 11 inflil- 
enzae was not isolated (10-'-" 109 efivinQ [p = 0.0011, an(] the percentage fall in FEV, \%,. is 
significantly worse in this group (- 1.1.60% [SD, 
12.39%]) compared to the non-11 influrnzae exacer. bations (- 1.17% [SD, 15.99%1) [p = 0.0271. 
HRV and Colds: 11 11V PCII findings N%-crc positivc in 11 of 56 exacerbations (19.6%); cold spnptoins, a 
measure of putative %iral infections, were present in 6 of 18 cases (32.1%). The presence of cold spnp- torns and IIRV-positivc PCII sputum were related (continuity adjusted X2 , 4.11; p=0.04). Exacerba- tions associated N%rith colds were associated with a 
greater percentage fall in FEW, (- 14.03%; SD, 
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13-91%) than those without colds (- 3.01%; SD, 
16-38%) [p = 0.0431. 
Effect of Viral and Bacterial Infections on All 
Sa, 77pled Exacerbations: The observed FEVI fall 
associated with colds at exacerbation was more 
inarked in the presence of a lower airway bacterial 
patliogen- - 20.3% (SD, 14.81%) NAth both colds 
and a bacterial pathogen, compared to - 3.63% (SD, 
5.57%) with a cold alone (p = 0.026) or - 3.13% 
(SD, 14.88%) with a bacterial pathogen alone 
(p == 0.001) [Fig 11. The specific effect of the inter- 
action between colds and bacterial pathogens was 
assessed with a multivariate regression analysis with 
tile percentage of FEVI fall at exacerbation as the 
dependent variable; the effect of the interaction was 
additional to the independent effects of each indi- 
-, idual factor (95% confidence interval [CII, - 13.13 
to - 2.09; p=0.009). 
Similarly, exacerbation symptoms were more se- 
\, ere (higher symptorn count at exacerbation onset) 
in those exacerbations associated vith a PPNI in the 
presence of cold symptoms (4.0; IQR, 3.0 to 4.5) 
compared to those \Nrith a PPNI alone (3.0; IQR, 2.0 
to 3.0) [p = 0.0191 or vrith neither a PPNI nor cold 
, yniptoms (3.0; 1QR, 2.0 to 3.0) lp = 0.029; Fig 21. 
f,: xacerbations associated \Nrith both II influenzae 
and IIRV exhibited a greater bacterial load 
( 108.56 
10.311 log cftL/inL vs 10'""' 
10.7771 log cfu/mL. 
p zz 0.018) and serum IL-6 (13.75 pg/mL; 1QR, 
10.53 to 16.91 pg/mL; vs 6.29 pg/mL; lQR, 3.31 to 
9.75 pg/m4 p=0.028) than those \Nitliotit both 
low- 
13 cc. 
F 
MCC. 
MCC. 
LjLJ 
I 
I 
ang 
+ 
lo PPM 8 No Cold Cold on$ 
Uill 
300 
U 
PPM Alone Cold & Bactedal Pedhogen 
FiGuIRE 2. Effect of airway pathogens and pathogen vombina. 
tions on ' to n severity (metlian symptom eount at exaverba. 
t 
5ý1(! "olulnms 
represent median values, bars imlic-ate JQR, 
and * and + denote statistically sipificant (1) < 0.05) differriwes 
between corresponding labehýl categories (n - 56-. 01) - OA213,. 
+p=0.019). 
pathogens. The exacerbation of airway bacterial load 
associated \\ith 11 influenzaeand MIV compared to 
other Mis is illustrated in Figure 3. 
DiSCUSSION 
The results of this study show for (lie first thne &A 
s-Piergistic effect of \iral lind bacterial hifectlom In 
and 
lao 
IN No PPM & No Cold ColdAbne 
PPM Alone Cold & BacIerial Pathogen 
r 1. Effect of ainvay pathogens and pathogen combina 
on percentage fall in FEV, at exacerbation. Columns 
ýPresent mean values with error bars as SENI *Significant ire ,0 05) difference between this category and cold and bacte- (fai 
paillogen category (n = 56). rl 
Www, chestjoumal. 
org 
FICURE 3. Airway bacteria] load at exacerbation for difreretit 
categories of isolated pathogen(n - 56). Columns represent 
inean values, %%ith error bars as SENI. IRV - rhin(Airus, 11 flu = 11 influe=1e. *Sipificanttv different from all I, PNI catego. ries. 
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modulating the severity of symptoms, lung function 
changes, and inflammation at exacerbations of 
COPD. The findings demonstrate that changes in 
lower airway bacteria] load are associated with the 
variability in inflammation and lung function seen at 
exacerbation in patients with moderate-to-severe 
COPD, effects that were more pronounced in 
proven rhinoviral and putative Aral infections. These 
data also suggest that pathogens associated with 
nlore severe exacerbations, such as II influenzae, 
may act at least in part via a greater stimulus to 
inflammation, associated with higher airway bacterial 
loads. PatientsAitli more severe disease in this study 
demonstrated greater rises in airway and systemic 
inflammation than those Aith milder disease. This 
Sliggests that the heterogeneous nature of exacerba- 
tion severity is dependent not only on the nature of 
infective triggers but also oil the baseline severity of 
di. sease. 
This study has been perforined using the well- 
validated technique of daily diary card symptoin 
recording and analysis to confirm both the diagnosis 
of exacerbations and also the stable state. 2-6-11,13,14 
-file study design has allowed us to sample the same 
patients in both clinical states and to describe not 
only cross-sectional analyses at exacerbation but also 
changes from baseline, and furthermore how these 
changes in exacerbation parameters were modulated 
by the corresponding infectious agents. 
NVe have found that that the severity of the fall in 
hing function and the rise in inflammation seen -at 
exacerbation are related to the extent of the rise in 
airway bacterial load. A relationship between airway 
inflammation and airway bacterial load has pre\i- 
ously been described in the stable state, 1,16-22 \vith 
higher loads associated with greater falls in FEV, 
over a 1-year study. " A number of previous stud- 
iess-18-l') have identified that bacterial pathogens are 
Commonly found in the lower airway at exacerbation 
with higher loads than in the stable state. 9 Ilov., ever, 
tile effect of rising numbers of bacteria oil the nature 
of exacerbations has not been investigated. These 
findings suggest that changes in bacterial load may 
play a role in the heightened levels of airway inflain- 
niation characteristic of exacerbations. However, ev- 
idence for an association between changes in bacte- 
rial load and indexes of exacerbation severity does 
not prove causality; it is possible that changes in 
airway bacterial load may simply be a secondary 
phenomenon to other causes of inflammation. In- 
deed, the findings of this study show that the key 
changes in symptoms and lung function at exacerba- 
tion were observed when the synergistic effects of 
viral and 
bacterial infection were found. In vitro and 
intervention studies are required to differentiate the 
exact contribution of a particular pathogen or patho- 
gens to the inflammatory and pathophysiologic 
clianges at exacerbation. 
11 influenzae was found in this study, as lit previous 
studies, 8.11.10 to be the most important bacterial 
pathogen identified both in terms of prevalence lit 
the stable state and at exacerbation, and lit deter- 
mining the airway bacterial load. 11 influenzae, unlike 
a number of other bacterial pathogens, may colonize 
not only the airway but the respiratory epithelium 
itself. H influenzae colonization has been shown to 
be a greater stimulus to airway inflainniation than 
other commonly isolated pathogens. 11-2-1 This is lit 
agreement with the findings of our study that dem- 
onstrate that 11 hifluenz-ae was present lit greater 
numbers than the other PPNis idcntified, and that Its 
presence at exacerbation Nvas associated , vith more 
severe drops in FEVI. The role of less prevalent 
bacterial pathogens at exacerbation, lit particular, 
their interactions %vith respiratory viruses rc(pilres 
further study. 
The stimulus of newly acquired 11 influenzae at 
exacerbation provided a 'greater deleterious efFect on 
FEV, than 11 hifluenzae-associated exacerbations lit 
patients already having colonization %vith this patho. 
gen. These findings compliment prvvions work", of 
the role that strain changes or particular bacterial 
species play lit the etiolog of exacerbations. This lkas 
identified the role that a new antigenic stimultis to 
the airway inimune system plays lit (lie pathogenesils 
of an exacerbation. It is feasible that acquisition of a 
new bacterial strain or tyi)c may not only provide it direct antigenic stinnihis but also overc-ollit. tile 
establislied host/patliogen balance alloNving bacterial 
proliferation, and thus a ftirther inflammatory stlin- 
ulus due to greater bacterial nunibvrs. To (late. 
studies to determine the possible Interactions be. 
tween viral infection and bacterial strain changes have not been perforined; these may provide infor- 
mation on the complex invellaillsins that rt, stilt lit 
triggering exacerbations. 
Respiratory viral infection is an important trigger 
to the aim%iy innnune. system. lit otir iwhort or 
influenza-vacCinated patients, we have prvviously demonstrated that 1111V is the most co, 1111joilly iso. lated vinis at exacerbation. -% 111flnovirus can be iso- lated from lower airway sainplcO and is associated 
with greater levels of inflaniniation than nonviral 
infeCtionS. 6 Similarly, -, %, c have slio%vii that colds, a 
marker of putative %iral infections, 6 are associated 
with more severe exacerbations. lit this stud , syS. ternic inflammation (serum ILA), exacertation 
symptoms, and lung function changes were nil more 
severe when evidence for both bacterial and %iral infection was present. it is possible t1int tilis ff Ct C 
may have been due to the separate additional Inflain- 
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matory stimuli of two separate pathogens in the 
airway, however, this explanation is not supported by 
the multivariate analysis that indicated a synergistic 
effect on lung function in addition to the individual 
effects of each pathogen type. Furthermore, these 
exacerbations were associated with higher bacterial 
loads than when both pathogens were not present, 
which may suggest a synergistic interactive effect of 
-oral infection which allows greater proliferation of 
airway bacteria. Viral infection therefore may impact 
on exacerbation severity indirectly by increasing 
bacterial load in addition to the direct effects of viral 
infection itself, eg, heightened inflammation or air- 
way hyperresponsiveness, independent of other 
pathogens. While IIRV is the most common virus 
identified at exacerbation-5 and hence the target of 
investigation in this study, a number of other respi- 
ratory viruses have been identified in the airway 
during these events, for example coronavirus. 5,7 The 
role of these other viral pathogens and atypical 
bacteria at exacerbation remains uncertai, 124XI and 
requires investigation. 
The mechanisms by which Aral infection may 
facilitate airway bacterial groAlli are likely to be 
complex. However, any disruption of the innate 
defenses of the respiratory epithelium in a lower 
airway colonized with bacteria may unsettle a fine 
balance between host immunity and bacterial num- 
bers. Rhinoviral infection is known to increase mu- 
cous production and neutrophilic inflammation. 26 
J)irect evidence that rhinoviral infection increases 
susceptibility to bacterial adherence to airway epi- 
thelial cells, a key process in bacterial infection, is 
available from in vitro studies. 27 Indeed, the key cell 
Surface binding site for IIRV infection, intracellular 
adhesion molecule-1, is itself up-regulated by IIRV 
infection28 and by bacterial colonization29; this in- 
crease may play a key role in neutrophil elastase- 
Inediated inflammation. -30 Hence, by a number of 
11jeclianisms, viral infection may alter the immune 
environment that may allow either proliferation of 
colonizing airway bacteria or a new pathogen to 
infect the lower airway. 
This study was performed in patients \vith moder- 
ate-to-severe COPD. The role of bacterial infection 
and therefore potential bacterial-viral interaction is 
likely to vary %rith disease severity and therefore 
prevalence of bacterial colonization. 10,18 Indeed, we 
11ave shown that the degree of airway and systemic 
inflammatory response at exacerbation was related to 
baseline disease severity. This suggests that the 
Severity of inflammatory response may progress with 
disease severity, which is in agreement with the 
findings of a longitudinal analysis3l of exacerbations. 
r-urtber studies are required to determine if these 
findings can be extrapolated to COPD patients with 
milder disease. Indeed, the obsene. d heterogeneity 
of exacerbations is likely to be further modulated by 
the relative frequency of particular pathogens and 
lience may show seasonality; this may explain differ- 
ences in associated c)tokine responses found In 
studieS2 of comparable sample size. Similarly, differ- 
ences in the technique of sampling, spontaneous or 
induced sputtim, may affect the observed results. 
However, we have preNiously demonstrated the two 
techniques are comparable in assessing lower airway 
inflammation. 13 Therapy must also be considered 
important when considering factors modulating in- 
flanimatory responses. The patients sampled for this 
study were all recehing inhaled steroids both at 
baseline and when sampled at exacerbation. It Is 
possible that the innanimatory responses observed at 
exacerbation were modified by effects of this treat- 
ment. 32 A statistical analysis of this effect was not 
feasible due to the ubiquity of hilialed steroid use in 
this patient group. Therefore, the modulating influ. 
ences on the nature of exacerbations are numerous. 
It is probable that in), individual factor plays a 
contributing rather than a definitive role In deter- 
mining the nature and severity of a particiflar exac- 
erbation, and ftirthennore that potential interactions 
between these factors further modulate the charac- 
teristics of these events. 
The findings of this study stiggest that changes in 
airwav bacterial load, the nature of the Individual 
infective pathogens, and interactions between mul. 
tiple pathogens and the ainvay modidate exacerba- 
tion severity. Further studies are required to Im- 
prove understanding of the pat I og(nd lost 
interactions at exacerbation and lnd(ýcd also In (lie 
stable state. Manipulation of this complex rclation- 
ship with appropriate anti-infective and anti-Inflam. 
matory therapies may benefit COPD pativnts by 
reducing both exacerbation severity and slowing 
progression of this highly prevalent disease. 
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Early Therapy Improves Outcomes of Exacerbations 
of Chronic Obstructive Pulmonary Disease 
Tom M. A. Wilkinson, Gavin C. Donaldson, John R. Hurst, Terence A. R. Seemungal, and Jadwiga A. Wedzicha 
Academic Unit of Respiratory Medicine, St. Bartholomew's and the Royal London School of Medicine, St. Bartholomew's Hospital, London, 
United Kingdom 
Treatment of chronic obstructive pulmonary disease (COPD) exac- 
erbations improves outcomes; however, responses to treatment are 
variable, and patients with COPD often delay presentation or fail 
to seek therapy. The impact on exacerbation outcomes, hospitaliza- 
tion, and health status of delaying or failing to seek treatment Is 
poorly understood. We studied between 1996 and 2002 a cohort 
of 128 patients with COPD, mean (SD) FEVI of 1.07 (0.43) L. Patients 
recorded respiratory symptoms daily and reported exacerbations to 
the outpatient-based study team or to their primary care physician; 
1, o99 exacerbations were recorded by the patients, of which 658 
were reported to a physician. The time between exacerbation onset 
and treatment was a median (interquartile range) of 3.69 (2.0-5.57) 
days, and the exacerbation recovery time was 10.7 (7.0-14.0) days. 
Earlier treatment was associated with a faster recovery (regression 
coefficient 0.42 days/day delay) (confidence interval, 0.19-0.65; p< 
O. ool). Patients who reported a higher proportion of exacerbations 
for treatment had better health-related quality of life than those 
patients with more untreated exacerbations (rho = -0.22, p= 
O. on). Failure to report exacerbations was associated with an in- 
creased risk of emergency hospitalization (rho = 0.21, p=0.04). 
patient recognition of exacerbation symptoms and prompt treat- 
ment improves exacerbation recovery, reduces risks of hospitaliza- 
tion, and Is associated with a better health-related quality of life. 
Keywords: chronic obstructive pulmonary disease; exacerbations; 
therapy 
Chronic obstructive pulmonary disease (COPD) is characterized 
by acceleration in the normal decline in lung function with age 
and by exacerbations. These exacerbations are associated with 
both worsening symptoms and lung function (1). The frequency 
of exacerbations has been shown to be an important determinant 
of the impaired health-related quality of life seen in COPD (2) 
and to affect decline in lung function (3,4). Exacerbations are 
a frequent cause of physician consultation in primary and second- 
ary care and a major cause of hospital admission (5-7). Conse- 
clucritly, the management of exacerbations places a considerable 
burden on the health services both in terms of physician consulta- 
tion time and healthcare costs (8-10). A reduction in exaccrba- 
tion frequency would have a number of benefits for patients and 
health services alike; however, currently available preventative 
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therapies have been found to have only a relatively small effect 
(11-13). 
Current therapies for exacerbations include antibiotics, oral 
corticosteroids, and increased bronchodilator medications. Al- 
though there is evidence that antibiotics (14) and corticosteroids 
(15-18) hasten the Tate of recovery of certain exacerbations, 
there are few data in the literature on the effects or importance 
of the timing of initiation of exacerbation treatment on outcome 
measures such as recovery time, which relates to exacerbation 
severity (1,19). We hypothesize that early presentation of the 
patient to the physician with an exacerbation would allow early 
intervention and a reduction of exacerbation severity and would 
potentially reduce disease progression; however, patients with 
COPID often have poor understanding of their disease and symp- 
toms, with the result that exacerbations are often not reported 
to healthcare professionals for treatment (2). Thus, if delay in 
presentation can be shown to affect exacerbation recovery, this 
provides a potentially important issue that can be addressed in 
the management of patients with COPD. 
In this study, we have followed prospectively 128 well- 
characterized patients with moderate to severe COPD over 6 
years from November 1996 and collected daily symptoms and 
exacerbation treatment data on 1,099 exacerbations. This daily 
monitoring enabled us to investigate how exacerbation outcomes 
and markers of severity such as recovery time were affected by 
the timing of presentation to the physician for treatment. We 
also studied how patient and exacerbation characteristics influ. 
enced the patterns of healthcare use and outcomes of therapy. 
Some of the results of these studies have been previously rc- 
ported in the form of abstracts (20,21). 
METHODS 
Patients 
This study was conducted between November 1996 and October 2(X)2. 
One hundred twenty-eight patients with COPD recruited during this 
period. who had recorded daily data for I year or more, were included 
in the analysis. Ethics approval was obtained from the East London 
and City Health Authority Research Ethics committee, and all patients 
provided written informed consent before recruitment. The inclusion 
criteria for this study have previously been published (1-3,22-24) and 
include FEVI of less than 70% predicted forage and height, 02 agonist 
reverssibility of less than 15'Yo of baseline and/or less than 2W ml, and 
an FEVI/FVCof less than 700%. This patient cohort hasbeen the subject 
of previous articles on various aspects or COPD exacerbation% (1-3, 
22-24). 
At recruitment, measurements were made or FEVI, FVC, and PEF 
by rolling seal spirometer (Sensor Medic Corp., Yorba Linda, CA), 
rcvcr%ibility to 4W tLg of inhaled salbutamol, and arterialized car lobe 
blood gases (model 278 Blood Gas Analyzer; Ciba-Corning, Medfield, 
MA). A history was takcn of smoking habits (years of smoking, ciga- 
rettes smoked per day, current smoking status). Patients gave a history 
of smoking (mean ISDI duration of 46.6131.41 pack-years, with 42 active 
smokers). Patients were asked about their stable respiratory symptoms 
and also about their long-term inhaled and oral corticosteroid use. 
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patient monitoring. Diary card records. At recruitment, patients 
were taught how to record on diary cards each morning, postbronchodi- 
lator PEF (Mini-Wright Clement Clark International Ltd., HaTIOW, 
UK). Patients recorded a change in their symptoms using a letter- 
annotated system. When well or stable, the patients were instructed 
not to record any of the symptom letters On the diary. When they 
perceived an increase over their normal, stable condition in symptoms 
dyspnea, sputum purulence or sputum volume (major symptoms), and 
colds (nasal dischargc/congestion), wheeze, sore throat, cough (minor 
symptoms), they noted the corresponding symptom letter on the diary. 
Therefore, patients record symptom letters if a symptom was perceived 
as worse, for example, dyspnea or of new onset (e. g., a sore throat) (as 
the latter is not usually present). 
The validated diagnostic criteria of the presence of at least two 
major or one major and one minor symptom for at least 2 days were 
then used in the analysis of diary card records. This method is explained 
more fully in the Mmnoi)s section of the online supplement. 
Patients were reviewed every 3 months in the study clinic when 
stable to monitor compliance with data collection, record changes in 
medication, and baseline lung function. 
Quality of life measures. Indices of Health-Related Quality of Lire 
were obtained using the St. George's Respiratory Questionnaire 
(SGRQ) at the beginning of the study either at recruitment or during 
the first annual review (25). 
Exacerbations 
J)iagnosis. Ile diagnosis of an exacerbation was based on symptomatic 
criteria previously validated by our group (1,2). An exacerbation was 
defined as the presence for at least 2 consecutive days of increase 
in any two "major" symptoms (dyspnea, sputum purulence, sputum 
amount) or increase in one "major" and one "minor"symptom (wheeze, 
sore throat, cough, symptoms of a common cold). Exacerbation onset 
was taken as the first day on which these symptom criteria were met 
(1). Figure 1 illustrates a diagrammatic timeline of an exacerbation with 
a definition of terms used. 
Treatment delay. From the diary card data and treatment records, 
the time between exacerbation onset and physician consultation at 
which treatment was initiated was calculated and called the treatment 
delay. 
Eracerbation recovery tim& A total daily count of individual symp- 
toms recorded on diary cards was calculated as the sum of the seven 
symptoms with the presence of a symptom scored I and its absence 0. 
To determine recovery to baseline levels and therefore exacerbation 
recovery time, a diary card symptom baseline was determined from the 
diary card for each exacerbation. The baseline symptom count was 
taken as the mean total daily symptom count over days 14 to 8 preceding 
exacerbation onset. Exacerbation total recovery time was calculated as 
the time from exacerbation onset for a 3-day moving average of the 
total daily symptom count to return to this baseline. The use of a 
3-day moving average minimized the effect of day-to-day symptom 
variation without biasing the results. Treated recovery time was taken 
as the time between consultation and recovery. 
Severity of exacerbation in terms of symptoms experienced Symp. 
torn severity at exacerbation was calculated as the difference between 
the average daily symptom count at baseline (Days 14 to 8 preceding 
the exacerbation onset) and the number of symptoms at exacerbation 
onset. Individual symptoms themselves were recorded as increased (1) 
or not (0) (see the online supplement for further explanation). 
Total Recovery Time 
Treatment Treated Recovery Time I prodrome Delay 
Figure 1. Schematic time- 
line of exacerbations and 
terms used in the analysis. 
Exmrbetlon Initlatlon of 
onset Treatment 
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TreatmenL Patients were encouraged to report symptom changes 
to the study team. They were assessed within 24 hours in the study 
clinic by a respiratory physician before initiation of therapy for the 
exacerbation. Patients did not report all symptom changes to the study 
team but also reported a number of these episodes to their primary 
care physician for assessment and treatment. 'Ilia prescription of treat- 
ment for all exacerbations was at the discretion or the attending physi- 
cian and included prednisolone and/or antibiotic therapy. Exacerbation 
treatment in the study therefore represented the usual practice of the 
primary care or study physician attending the patient. Records were 
kept of the date of initiation and type of treatment prescribed to patients 
for each exacerbation, both at our clinic and also for therapy prescribed 
by the patient's primary care physician. 
Classification of exacerbations. The exacerbations seen by the 
study clinical team or the patient's general practitioner were classilied 
as "physician reported exacerbations" with those unseen by either but 
recorded on diary cards termed "unreported exacerbations. " Records 
of hospitalization were kept throughout the study. Additional detail 
on the diagnosis of exacerbations is available in the online supplement. 
Statistical Analysis 
Normally distributed data are presented as mean (SD) and skewed 
data as median (interquartile range) values and associations tested by 
Spearman's correlation or chi-squared test. Ap value or less thin 0.05 
was considered statistically signilicant. 
Exacerbation total recovery time was calculated its the time from 
exacerbation onset for a 3-day moving average of the total daily symp- 
tom count to return it) baseline (1). Treated recovery time was liken 
as the time between consultation and recovery. Symptom severity at 
exacerbation was calculated as the difference in total daily symptom 
count at baseline and it exacerbation (inset. Figure I illustrates a dia. 
grammatic limeline of an exacerbation with a delinition of terms used. 
Assessment of the effect of delay and treatment oil recovery with 
or without allowance for severity, type of treatment, or nonrccovery 
was made with a generalized linear model with adjustments for Poisson 
distribution in the dependent variable. Additional detail on the method 
for making these measurements is provided in the online supplement. 
RESULTS 
Patient Characteristics 
The physiologic characteristics of the 129 (99 male) patients at 
recruitment for the study are summarized in Table 1. The mean 
(SD) FEV, was 1.07 (0.43) L, and the percentage predicted FEVI 
was 40.8 (15.6). One hundred fifteen patients took a mean (SD) 
daily dosage 1.2 mg (0.68) of inhaled steroids. Nine patients 
were on a mean of 4.9 (3.0) mg/day of oral prcdnisolone; eight 
patients used both oral and inhaled steroids. The 128 patients 
in this study completed diary cards for a median of 925 (inter- 
quartile range, 628-1,520) days. Sixty (46.9%) reported daily 
(chronic) dyspnca and 65 (50.9%) daily sputum production. 
TABLE 1. Characteristics of the 128 (88 male) patients 
In this study 
Age, yr 67.3(7.6) 
FEV,, L 1.07(0.43) 
FEVj% predicted 40.8(15.6) 
FVC, L 2.51(0.81) 
FEVI/FVC % 43.50 (0.13) 
PEF, L/min 191 (88) 
Pao., kPa 8.93(l. 00) 
Paco, kPa 5.89(0.89) 
Number of active smokers 42 
Pack years of smoking 46.6(31.4) 
Inhaled steroid dosage, mg/day 1.21 (0.68) 
Data are expressed as mean (SD). 
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Exacerbations 
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During the study, the patients experienced a total of 1,099 exac- 
erbations. Of this total, 658 (59.9%) were reported to a physician, 
either a primary care physician or the study team. The median 
(interquartile range) number of exacerbations per patient per 
year was 2.51 (1.41 to 3.75) for all 128 patients. Eight patients 
had no exacerbations. Of the 1,099 exacerbations, 441 (40.1 %) 
were diagnosed solely from review of diary card symptoms 
and were not seen by a physician. These unreported exacerba- 
tions were only considered in the analysis of hospitalization 
and Indices of Health-Related Quality of Life with respect to 
reporting. The 658 remaining exacerbations were all seen by 
physicians; however, of these, 17 (2.6%) exacerbations received 
no additional treatment, and 16 (2.4%) involved physician con- 
. sultation 
in the prodromal period before formal exacerbation 
onset, as defined by the diagnostic criteria. These 33 exacerba- 
tions were excluded, leaving 625 that were analyzed for the 
effects of physician reporting and treatment on recovery. A 
summary of reporting and treatment measures is illustrated in 
Figure 2. 
I ncreased dyspnea was present in 63.7% of the 1,099 exacer- 
t)ations, increased sputum purulence in 26.6%, increased sputum 
volume in 41.3%, cold symptoms in 29.1 %, increased wheeze in 
31.7%, sore throat in 13.0%, and increased cough in 30.7%. 
physician-Reported Exacerbations and Treatment 
, ri, racerbation therapy. 
Figure 2 shows the reporting and treat- 
Ment characteristics of the exacerbations recorded in the study. 
of the 625 exacerbations that were treated with prescribed oral 
therapy, a total of 266 exacerbations were treated with oral 
corticosteroids. Six hundred of the exacerbations were treated 
with antibiotics, and of these, 241 were treated with both oral 
Corticosteroids and antibiotics. As 93.6% of exacerbations were 
treated with antibiotics, this precludes a meaningful statistical 
', nalysis 
of the effect of antibiotic therapy on exacerbation out- 
comes, as the nontreated group is too small. Oral prednisolone 
therapy hastened treated recovery by 2.63 days (p = 0.001) 
compared with exacerbations not treated with prcdnisolone. 
Effect of consultation delay and treatment on recovery time. 
The median (interquartile range) treatment delay (time from 
the onset of exacerbation to the initiation of treatment) was 3.69 
(2-00 to 5.57) days. The median exacerbation total recovery time 
was 10.7 (7.0 to 14-0) days. The median treated recovery time 
1099 Exacerbations 
(time between the start of treatment to symptom recovery) was 
6.9 (3.0 to 10.5) days. Figure 3 demonstrates the relationship 
between symptom recovery time and the delay between cxaccr- 
bation onset and treatment. Early initiation of exacerbation 
therapy was associated with a faster recovery of exacerbation 
symptoms (regression coefficient, 95% confidence interval, p 
value) (0.42 days/day delay, 0.19 to 0.65, p< 00M). 
The benefits of early physician consultation and treatment 
on exacerbation recovery time were potentially confounded by 
the fact that patients with more severe symptoms had longer 
exacerbations (2.69 days per symptom, 2.06 to 3.31, p<0.001) 
and also tended to report earlier (-0.28 days per symptom, 
-0.66 to 0.10, p=0.15). After an adjustment for symptom 
severity by its inclusion in the regression model, the relationship 
between early treatment and faster recovery became more pro- 
nounced (0.52 days/day delay, 0.31 to 0.74, p<0.001). Treatment 
with oral corticosteroids could also confound the relationship if 
exacerbations reported earlier were preferentially treated with 
oral corticosteroids; however, the relationship between recovery 
time and treatment delay remained significant if allowance was 
made for both symptom severity and the treatment with oral 
corticosteroids (0.57 days/day delay, 0.34 to 0.79, p< 00H). 
Factors affecting physician consultation delay. An analysis 
of patient characteristics with respect to mean treatment delay 
for each patient revealed that older patients received treatment 
earlier (rho = -0.19, p=0.04); however, there were no observed 
significant relationships between treatment delay and baseline 
FEVI (rho = 0.19, p=0.11), percentage predicted FEVI (rho - 
0.11, p=0.25), SGRQ total score (rho = -0.12, p=0.21), active 
smoking status (rho = 0.03, p=0.72), or baseline symptoms such 
as daily sputum production (rho = -0.16, p=0.08) or dyspnca 
(rho = 0.11, p=0.24). 
Table 2 gives the effect of a specific symptom at exacerbation 
onset on the treatment delay. Exacerbations (adjusted for re- 
peated measures) involving worsening dyspnca as a presenting 
symptom presented earlier (regression coefficient [days], 95% 
confidence interval, p value) (-0.42, -0.76 to -0.08, p-0.016) 
as did those with sputum purulence (-1.30, -1.60 to -0.92, 
p=0.00I), wheeze (-0.59, -0.93 to -0.25, p= 00M), or sore 
throat (-0.78, -1.23 to -0.33, p= RUH). 
Family physician versus hospital outpatient prescribing. Pa- 
ticrits in the study could consult either the study team or their 
own primary care physician at exacerbation; 37.6% of the 
L! 7ý siclan Reported Exacerbations 441 Unreported Exacerbations 
641 Treated Exacerbatlons-ý (17 Non-Treated Exacerbations 
Treated In Prodrome 
625 Exacerbaflons 
241 Anbbioks and Oral Prednisolone 
359 AnUbioUcs Alone 
Figure 2. Reporting and treatment characteristics of 
1,099 exacerbations recorded in this study. 
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Figure 3. Effect of early treatment on recovery of exacerbation symp- 
toms. Patient mean total recovery time (days) plotted against the patient 
mean treatment delay (i. e., time from onset of exacerbation symptoms 
to initiation of therapy) (days) in 108 patients (regression coefficient 
0.42 day/day delay, confidence interval, 0.19 to 0.65; p<0.001). 
physician-treated exacerbations were seen by a general prac- 
titioner, and 62.4% were seen by a member of the study team. 
Prescribing practices at exacerbation were very similar irrcspcc- 
tive of where the consultation took place, with the primary care 
physician prescribing oral corticosteroids in 43.8% and antibiot- 
ics in 96.2% of treated exacerbations and the study team in 41.8% 
(chi-squared, p=0.618) and 95.9% (p = 0.868), respectively. 
The time to physician consultation was earlier in the primary 
care physician-treated group by 0.36 days (-0.69 to -0.04, p= 
0.030); however, when an adjustment for symptom severity was 
made, no significant differences in timing of consultation were 
found. Despite similar prescribing practices, patients reviewed 
by a respiratory specialist in the study team had a shorter recov- 
ery time than those seen in general practice (0.82 days, p 
(). W). 
SGRQ Scores, Hospitalization, and Unreported Exacerbations 
Untreated exacerbations and SGRQ scores. Not all of the exac- 
erbations experienced by a patient were reported to a physician 
for treatment. The median (interquartile range) percentage of 
physician-reported exacerbations for the 120 patients with an 
exacerbation was 66.7% (50 to 83.3%). Stable SGRQ scores 
were recorded on 118 of these 120 patients. Figure 4 illustrates 
the relationship between SGRQ total score and its components, 
and the percentage of physician-treated exacerbations. Patients 
who had a higher percentage of their exacerbations seen by a 
physician had a better health-related quality of life (lower total 
TABLE 2. REGRESSION ANALYSIS OF INTERACTIONS 
BETWEEN EXACERBATION SYMPTOMS AND TREATMENT 
DELAY FOR 625 EXACERBATIONS 
symptom Regression Coefficient (days) (95% CO p Value 
Dyspnea -0.42 (-0.76 to -0.08) 0.016 
Sputum purulence -1.26 (-1.60 to -0.92) 0.001 
Wheeze -0.59 (-0.93 to -0.25) 0.001 
Sore throat -0.78 (-1.23 to -0.33) 0.001 
Cold 0.31 (-0.05 to 0.67) 0.093 
Sputum volume 0.02 (-0.31 to 0.34) 0.924 
Cough 0.01 (-0.34 to 0.37) 0.945 
Definition of abbreviation: Cl - confidence interval. 
A negative value indicates a treatment delay shorter than those exacerbations 
without the symptom. 
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SGRQ scores) (rho = -0.22, p=0.018). This relationship was 
also present when considering the impact (rho = -0-19, p= 
0.04) and activity (rho = -0.21, p=0.02) components of the 
SGRQ score separately. 
Unreported exacerbations and risk of hospitalization. Dur- 
ing the study, 6.4% of the 1,099 exacerbations required hospital- 
ization. The median annual unreported exacerbation rate was 
0.77 per year (0.33 to 1.60) for the 120 patients who had at least 
one. The annual rate for physician-reported but not hospitalized 
exacerbations was 1.53 per year (0.86 to 2.37), and for hospital- 
ized exacerbations the median rate was 0 per year (0 to 0.40). 
Of the 120 patients, those who tended not to seek treatment 
from their general practitioner or the study clinicians at exacer- 
bation (as measured by high annual rates of unreported exacer- 
bations) were more likely to be admitted to the hospital for 
treatment of an exacerbation than those who routinely reported 
their exacerbations for treatment (rho = 0.21, p=0.04). 
DISCUSSION 
This is the first prospective study to demonstrate the important 
effects of early treatment on COPD exacerbation outcomes. The 
findings show that patients who receive prompt therapy after 
the onset of their exacerbation arc likely to recover more rapidly 
than those who delay reporting and thus initiation of treatment. 
Furthermore, patients who habitually fail to seek therapy for 
their exacerbations have poorer health-relatcd quality of life 
and are more likely to be hospitalized for the management of 
an exacerbation. 
This study has been performed using well characterized pa- 
tients collecting daily data over a number of years and has used a 
symptom-based definition of exacerbations that is well validatcd 
(1-3,22-24). The collection of such prospective data allowed us 
to establish precisely the start of the exacerbation from the diary 
card entries and then the point at which therapy is commenced, 
in addition to in-depth analysis of the time course and recovery 
time of the exacerbations. Our group and others have previously 
demonstrated that the recovery time of an exacerbation is an 
important measure of its severity and can be affected by various 
etiologic factors such as respiratory viruses (22,26,27) and 
therapies (14-19). The delay between symptom onset and thcr- 
apy and its effect on exacerbation outcomes has not been studied 
previously, as most studies evaluating exacerbations have fo- 
cused on healthcare use and therefore have missed the period 
between symptom onsctand the initiation of therapy. The finding 
that earlier treatment improves exacerbation recovery has con- 
firmcd for the first time the clinical suspicion that treating these 
episodes promptly offers additional bcncrit to the patient. It is 
also the first to establish the size of this effect and the role that 
improving exacerbation reporting behavior may play in reducing 
morbidity. 
A possible alternative interpretation of this finding would be 
that patients with milder exacerbations seek treatment earlier 
and thus recover more quickly; however, the data on the nature 
of symptoms at presentation demonstrate that this was not the 
case. Patients with more symptoms at exacerbation onset tended 
to present earlier for treatment, and those exacerbations with 
more symptoms were indeed more severe, as they took longer 
to recover. Therefore, the milder and less symptomatic exacerba- 
tions were in fact presenting slightly later, and when this effect 
is taken into account, the benefit of early treatment became 
more pronounced. 
In this study, we have studied exacerbations across a spectrum 
of exacerbation severities and not only those more severe exacer- 
bations requiring hospitalization. The patients in this study were 
treated either by the dedicated study team or by their primary care 
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physician, and the exacerbation treatment reflected prescribing 
practices of both physician groups, which were very similar, as 
(coected by similar exacerbation recovery times for both treat- 
I. ncnt groups. In the linear regression model of the effects of 
treatment delay on recovery time, allowance was made for the 
exacerbation treatment prescribed. A potential bias of variation 
in oral antibiotic therapy was not apparent, as over 93% of 
treated exacerbations received this form of therapy. The effect 
of oral prednisolone prescription was to shorten exacerbations; 
if the prescription of this treatment was included in the regression 
friodel, the key finding that early treatment hastens recovery 
time became more pronounced. 
These reported exacerbations that received treatment are in 
ýeeping with another definition of exacerbations recently sug- 
gested (28). Therefore, the findings of this study may be general- 
ized to the COPD population treated both in primary and 
ýecondary care, and the validated methods used are suitable 
for future investigation into the relationships between reporting 
t)chavior and exacerbation outcomes. 
Exacerbations are heterogeneous in etiology and in the na- 
ture of presenting symptoms (22,29). The symptom charactcris- 
tics of an exacerbation affected presentation of the exacerbation 
to the physician. Symptoms of increased dyspnea, sputum puru- 
lencc, wheeze, and sore throat were associated with earlier 
presentation, whereas the presence of a common cold at exacer- 
bations was associated with a trend toward later presentation. 
The factors affecting how patients with COPD interpret changes 
in their symptoms are likely to be complex, including their under- 
standing of COPD, which is often poor (30), the relationship 
with disease severity, and psychologic overlay in a group of 
patients with high levels of anxiety and depression (31). Further 
studies into the mechanisms of symptom recognition are re- 
quired to determine how to improve the reporting behavior of 
patients with COPD and therefore exacerbation outcomes. 
These may include investigation of the role of patient education, 
self. management plans, and methods of assessing and improving 
compliance. 
An additional advantage of collecting daily prospective data 
on symptom changes is that episodes when patients experience 
an exacerbation and record their symptoms but do not consult 
their general practitioner or a study physician can be analyzed. 
Figure 4. Relationship between total and component St. 
George's Respiratory Questionnaire (SGRQ) scores (higher 
scores represent poorer health-related quality of life) and 
percentage of recorded exacerbations (in quartile groups) 
that were reported to and treated by a physician. The rho 
and p values from Spearman's Rank correlations of total and 
component SGRQ scores with proportion of exacerbations 
treated on a per patient basis are (a) total SGRQ score, 
rho = -0.22, p=0.018; (b) Impact score, rho - -0.19, 
p=0.04; (c) activity score, rho -0.21, p-0.02; (d) 
symptoms score, rho - -0.13, p 0.16. The bars repre- 
sent SEs. 
In this study of 1,099 exacerbations recorded on diary cards, 
only 658 were reported to a physician for treatment, and these 
rates are in keeping with published clinical trials (13). The finding 
that on an annual basis patients whoarc less likely to report their 
exacerbations arc more likely to undergo emergency hospital 
admission for treatment is an important one. These patients may 
be less aware of the importance of the changes in their symptoms 
at exacerbation, or indeed, they may subjectively experience less 
severe symptoms for a given severity of exacerbation. Thus, they 
are less likely to seek treatment from a physician in the early 
stages of their exacerbation, which may prevent the need for 
hospitalization. Furthermore, we found that patients who had a 
lower proportion of their exacerbations treated had worse 
health-rclated quality of life, as measured by the SGRQ total 
score, impact score, and activity score. than those patients who 
sought treatment for a higher proportion of exacerbations. We 
can postulate that failure to report and therefore receive treat- 
ment for exacerbations contributes to additional morbidity from 
these events and thus adversely affects heilth-related quality of 
life. However, it may also be the case that patients with poor 
hcalth-rclated quality of life arc less likely to seek physician 
intervention for their exacerbation, and thus, a cycle of decline 
in quality of life and appropriate healthcare use may become 
established. Identification and education of the patient group 
who delay or fail to seek treatment for exacerbations in particular 
may increase and improve the rate and timing of physician con- 
sultation reduce patient morbidity and the considerable burden 
of inpatient treatment of exacerbations on healthcare services. 
Analysis of factors that affected time to presentation of an 
exacerbation showed that older patients were likely to receive 
therapy earlier, but there was no relationship between disease 
severity, baseline symptoms, or the patient's health status. Ade- 
quate access to healthcare is important, and the affect of age on 
presentation in our study suggests that the older patients are 
receiving medical attention for exacerbations earlier than the 
younger patients in the group. This finding may be related to 
the higher degree of disability and comorbidity in the older 
population (32), causing them to recognize and report symptoms 
at an earlier stage. 
This study has been performed in a population of patients 
with COPD who were encouraged to report exacerbations, who 
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were likely to have heightened awareness of changes in their 
symptoms because of the use of daily diary cards, and who had 
improved access to healthcare. Therefore, the findings of this 
study that early treatment of COPD exacerbations hasten recov- 
ery time and that patients who do not report to a physician are 
more likely to be hospitalized may be an underestimation of the 
scale of these effects in the general population of patients with 
COPD. Indeed, patients with COPD often have a poor under- 
standing of their disease (30) and often delay or fail to report 
symptom changes to their physician. To date, there have been 
no significant initiatives to encourage reporting and early presen- 
tation of exacerbations in this patient group. 
This study has demonstrated the important finding that the 
early recognition of exacerbation symptoms and prompt treat- 
ment by a physician is beneficial to the recovery of the exacerba- 
tion. This result suggests that improving patient and physician 
understanding of the nature of exacerbations and the benefits 
of early treatment will improve the outcomes of therapy of 
exacerbations of this extremely prevalent disease. There is a 
vital role for new, more efficacious treatments for COPD exacer- 
bations. However, by optimizing the use of existing exacerbation 
therapies and by improving patients' awareness of exacerbations 
and access to healthcare, we can improve the current excessive 
burden of exacerbation-related morbidity and mortality. 
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Decline in Patients 
Pulmonary Disease 
A0 irway Inflammation, 
with Chronic Obstructive 
Tom M. A. Wilkinson, Gavin C. Donaldson, Sebastian L. Johnston, Peter 1. M. Openshaw, and 
jadwiga A. Wedzicha 
Academic Unit of Respiratory Medicine, University College London; and Department of Respiratory Medicine, National Heart and 
Lung Institute, Imperial College, London, United Kingdom 
Background. Respiratory syncytial virus (RSV) Is increasingly recog- 
nized as an important pathogen in adults with cardiopulmonary 
disease. It has been associated with acute exacerbations of chronic 
obstructive pulmonary disease (COPD); however, it has also been 
detected in the lower airway in the stable state, but the conse- 
quences of RSV in stable disease have not previously been deter. 
mined. We therefore studied the consequences of RSV persistence 
in adults with COPD and its eff ect on airway inflammation and lung 
function decline. 
Methods: A total of 241 sputum samples from 74 patients with COPD 
(FEVi% predicted, 39.2%, Interquartile range, 29. &-57.8%) were 
collected quarterly in the stable state over 2 yr. RSV was detected 
by polymerase chain reaction (PCR), quantitative microbiology was 
performed, and inflammatory cytokines were quantified by ELISA. 
pesults: RSV RNA was detected in 32.8% of sputum samples. Patients 
in whom RSV was more frequently detected (> 50% of samples 
RSV PCR-positive, n= 18) had higher airway Inflammation and 
faster FEVI decline over the study (101.4 ml/yr 195% confidence 
interval, 57.1-145.8]) compared with those with less frequent de- 
tection of RSV (n = 56; 51.2 ml/yr [31.7-70.8]; p=0.01). The 
observed relationship between RSV detection and accelerated lung 
function decline was Independent of smoking status, exacerbation 
frequency, and lower airway bacterial load. 
Conclusions: Persistent RSV detection in patients with COPD Is asso- 
ciated with airway Inflammation and accelerated decline in FEVI. 
Chronic RSV infection may be a novel therapeutic target to alter 
the natural history of COPD. 
Keywords: chronic obstructive pulmonary disease, respiratory syncytial 
virus; FEV, decline 
Chronic obstructive pulmonary disease (COPD) is a major and 
growing cause of ill health and death Worldwide. The Global 
Burden of Disease Study predicts that it will rise to being the 
third commonest cause of death by 2020 (1). Although cigarette 
smoking is the major cause, evidence exists that chronic lung infec- 
tion may sustain inflammation in the small airways and lung paren- 
chyrna, leading to accelerated and progressive loss of lung function 
characteristic of COPD (2-4). There is some evidence that 
chronic airway infection with adenovirus may play a role in the 
development of airway obstruction, but studies have been cross- 
sectional in nature and relationships between viral infection and 
disease progression have not been demonstrated (5). Further- 
more, a role for RNA viruses in the pathogenesis of COPD has 
been little explored. 
Respiratory syncytial virus (RSV) is a negative-strand RNA 
virus of the Pararmyxoviridac family, genus 11neumoviriss, and 
is the major cause of acute lower respiratory tract infections in 
young children, where it occurs in winter epidemics but is rarely 
identified in the summer (6,7). Human RSV has no animal 
reservoir and the source of these winter epidemics remains un- 
known. Recent studies have also identified RSV as an important 
pathogen in the elderly (K-10) and in adults with cardiopulmo- 
nary disease (8,11). 
We have previously detected RSV in nasopharyngeal samples 
from patients with COPD in a cross-sectional study (12). Al- 
though the other cornmonly detected respiratory viral pathogens, 
such as human rhinovirus, were much more prevalent at exacer- 
bation than in the stable state, RSV was detected at similar 
rates regardless of whether the patient was stable or having an 
exacerbation (12). Using quantitative polymerasc chain reaction 
(PCR), these findings have been confirmed in patients with stable 
COPD and at exacerbation, with low viral loads identified in 
comparison to those seen in children with seasonal bronchiolitis 
(13). liowcvcr, longitudinal studies to determine whether RSV 
is able to persist in the lower airways of patients with stable 
COPD are lacking and the clinical consequences of RSV persis- 
tence have not been determined. 
We therefore prospectively studied a cohort or patients with 
wcll-characterized COPD with repetitive sampling in the stable 
state to determine the nature of RSV persistence in the lower 
airway. We investigated the effects of RSV persistence on lung 
function decline and airway inflammation and investigated inter- 
actions with lower airway bacterial colonization. Sonic results 
of this study have previously been reported in the form of abstracts 
(14,15). 
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METHODS 
Patient Selection 
Patients with COPD were recruited from outpatient clinics into our 
COPD cohort. Ethics approval for the study was obtained from the 
East London and City Health Authority Research Ethics committee, 
all patients gave written, informed consent. I'he inclusion criteria for 
this study have previously been published (2,12,16-2o) and include 
FEVI of less than 70% predicted for age and height, p, -agonist revers- 
ibility of less than 15% of baseline and/or less than 2(X) ml, and an 
FEVI/FVC of less than 70'Yo. Work from this cohort has been published 
in a number of previous studies (2.4,12,16-20). Additional information 
is included in the online supplement. 
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Diary Card Monitoring and Follow-up 
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At recruitment, patients were taught how to record post-bronchodilator 
PEF on diary cards each morning (Mini-Wright, Clement Clark Interna- 
tional Ltd, Harlow, UK). 
Patients were reviewed at recruitment and with their diary cards 
every 3 mo in the study clinic to monitor compliance with data collec- 
tion, record changes in medication, and baseline lung function. Review 
of diary cards was used to ensure that stable sampling was performed, 
when subjects had been clear of exacerbation symptoms and had com- 
pletcd any exacerbation treatment for at least 6 wk. 
Measurement of Lung Function 
Lung function was measured with a rolling sea] spirometer (Sensor 
Medic Corp., Yorba Linda, CA). Lung function measurements were 
taken between 9: 30 and 11: 30 A. %t., 1h after the patient's usual bron- 
chodilator medication. At least three spirometry readings were taken 
at each visit and the best performance recorded. 
sputum Sampling 
Sputum was sampled if the subject met criteria for the stable state at 
three monthly reviews. Additional detail on the sampling and processing 
methods is provided in the online supplement. An aliquot of phosphate- 
buffered saline-processed sputum was frozen at -80'C for subsequent 
RNA extraction. I'he remainder was analyzed for inflammatory cyto- 
kines using ELISA (2,16,19), sputum interIcukin 6 (IL-6) and IL-8 
(R&D Systems. Abingdon, IJK) (2), and myeloperoxidase (MPO; ENID 
ilioscicnces. San Diego. CA). 
Quantitative Bacterial Analysis 
Samples were processed by using sputolysin; serial dilutions were made 
and cultured on appropriate media. These were incubated for Is h at 
37'C in an atmosphere of air plus 5% C02. After incubation, bacteria] 
colonies were enumerated and subcultured for identification by stan- 
dard methods (21). The number of colony forming units per gram of 
sputum was calculated frorn the total number of colonies obtained and 
the dilution to give the total bacterial count for each sample expressed 
in colony forming units per milliliter (cfu ml-'). 
RNA Extraction, Reverse Transcription, RSV PCR, and 
Product Sequencing 
RNA extraction from the sputum was performed using a standard 
extraction kit (Oiagen, CraAley, UK). Reverse transcription was per- 
formed using random hexamers, and nested RSV virus PCR was per. 
formed as previously described (12) using taq polymerase. Positive and 
negative controls were run with all samples analyzed. A random sample 
of the PCR product from RSV-positive sputa was taken and both 
strands sequenced using a standard dye terminator method. These were 
Compared with a reference RSV strain using Clone Manager (Scientific 
and Educational Software. Cary. NQ to align the sequences. Additional 
detail on the methods is provided in the online supplement. 
Statistical Analysis 
Baseline recruitment data are presented as medians (interquartile 
ranges 11ORsl). The annual exacerbation frequency was calculated by 
dividing the total number of exacerbations per patient by the number 
of days the patient recorded data and multiplying by 365. Normally 
distributed data are reported by means (SD) and skewed data by medi- 
ans (IOR). Appropriate comparative statistical tests were performed 
dependent on the distribution of the data. 
We hypothesized that a greater frequency of detection of RSV in 
the stable airway is associated with greater inflammation and thus faster 
decline in lung function. Studies to date had been cro%s-sectional in 
nature and hence pilot data on the periodicity of RSV infection were 
not available', we therefore predetermined a cut-off limit of 50% detec- 
tion rate to divide patients into high and low RSV groups. To analyze 
the effects of RSV colonization independently of patient characteristics 
(s , moking status, exacerbation 
frequency, bacterial load, and starting 
FEVj) on decline in lung function, we used the general linear mixed 
model (xtreg) procedure in STATA-5 software (Stala Corporation, 
College Station, TX). These procedures are designed for panel (cohort) 
data and are particularly useful where data are correlated, as in 
repeated-measures designs and where there are complex error struc- 
tures (4). We included as independent variables (a) time and (h) FEVI 
measurement during the stable state, as two of four independent vari- 
ables. The third variable was whether or not the patient was persistently 
colonized with RSV, which required 50% of their samples to be RSV 
positive. The fourth independent variable (d) was an interaction term 
obtained as the product of a and c. Allowance for confounders, was made 
by including whether the patient had a bacterial load or intlammatory 
marker less or greater than the cobort median, exacerbation frequency 
greater or less than the cobort median, and active smoking status to- 
gether with terms to adjust for the effect of these on FEVI decline. 
Also included in the regression model was the starting FEVI to adjust 
for differences in the rate of FEVI decline between patients with high 
or low starting FEVI. The magnitude and significance of the effect of 
RSV colonization on decline were unchanged with inclusion of one or 
all of these confounders. 
As multiple sputum samples were obtained during the study and 
the unit of analysis was the patient, the first sample obtained from each 
patient suitable for estimation of inflammatory cytokines was used in 
the analysis. p Values of 0.05 or less were regarded as significant. 
RESULTS 
Patient Characteristics 
Table I shows the baseline spirometric and other characteristics 
of 74 patients (45 male) who were sampled during the study. 
There were no differences between the baseline characteristics 
in terms of sex distribution, FEVI, FEVI% predicted, FVC, PER 
reversibility, years of smoking, current smoking status, exacerba- 
tion frequency of these patients and the 31 patients in the cohort 
who were not sequentially sampled (due to recruitment in the 
latter part of the study, use of long-ICTIII oral steroids, or intoler- 
ance of sputum induction). There were no significant differences 
in these variables between sputum producers and those requiring 
sputum induction. The 74 patients provided 241 stable sputurn 
samples suitable for processing for analysis. Of these patients, 
16 (of whom 8 died) of the 74 patients withdrew before the end 
of the study period. Diary card data were collectcd on a mean 
of 656 d/person (maximum possible in study, 762 d); compliance 
with data collection was thus 86%. 
Patterns of RSV Detection 
Fifty-nine of the 74 patients sampled had RSV detected in at 
least one stable sputum sample during the study. Overall RSV 
was detected in the stable state in 32.8% of the 241 stable sputum 
samples collected. Sequencing of both strands of 11) randomly 
TABLE 1. CHARACTERISTICS OF THE 74 PATIENTS WITH 
CHRONIC OBSTRUCTIVE PULMONARY DISEASE, MEASURED 
AT RECRUITMENT 
Sampled Patients (n - 74) 
Median IQR 
Age, yr 67.4 62.2-71.4 
FEV,, L 0.98 0.77-1.37 
FEVI, % predicted 39.2 29.6-57.8 
FEV,, % reversibility 7.94 0.8-13.1 
FVC, L 2.41 1,86-2.90 
FEVI/FVC, % 43.9 3S. 5-53.1 
PEF, L/min 158 122-238 
Pa., kPa 8.94 8.14-9.43 
Paco, kPa 5.88 5.32-6.29 
Smoking, yr 45 39-SI 
Inhaled corticosteroid dose, mg/d* 1000 500-2,000 
Exacerbation frequency, per yr 2.51 1.28-3.83 
Definition of abbreviation; lQR - interquartile range. 
* Beclomethasone equivalents. 
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selected RSV-positive PCR samples confirmed homology in each 
case with RSV. 
Of the samples, 36.8% of winter samples (Dcccmbcr- 
February), 27.1% of spring samples (MaTch-May), 36.7% of 
summer samples (June-August), and 34.0% of autumn samples 
(September-November) were RSV PCR positive. The incidence 
of RSV detection in stable patients showed no significant season- 
ality (P = 0.558). There was no difference in detection rates 
between spontaneous and induced sputum samples. 
Evidence for RSV Persistence 
To study whether detection of RSV in sputum was due to peTSiS- 
tence of the virus in particular individuals or merely as a result 
of Sporadic infection, we compared the predicted probability of 
RSV detection occurring in all samples from an individual based 
on the overall detection rate of 32.8%, to the actual prevalence 
of patients with RSV throughout the study. The probability that 
an individual would have RSV in four of four sputum samples 
based on a random distribution of the Virus in this population 
is 0.0116, or 1.16%; the actual prevalence of patients with RSV 
in four of four positive samples is 0.2, or 20%, suggesting persis- 
tence in certain individuals. 
Patients were categorized a priori using their stable-sample 
p, SV status in two groups: "low RSW (in which -_ 50% of their 
samples were RSV PCR positive) and "high RSV*' (in which > 
50% of samples were positive). There were 18 patients in the 
high RSV group and 56 patients in the low RSV group. There 
was no difference in the number of available samples per patient 
between the two groups (p value = 0.424), or in baseline charac- 
teristics or the inhaled corticosteroid dosage between the two 
groups (see Table 2). Similarly, there were no differences in 
exacerbation frequency between the groups; 55% in the high 
RSV and 48% in the low RSV group were frequent exaccrba- 
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tions (with an annual rate of ; -- the cohort median of 2.51 [IQR, 
1.27-3.83]). 
RSV Detection and FEV, Decline 
Between the first and last RSV samples, there were 781 FEV, 
readings on the 74 patients, an average of 8.37 per patient. For 
those in whom RSV was detected in more than 50% of samples; 
the high RSV group (n = 19) showed a decline in FEVI of 101 A 
ml/yr (95% confidence interval JCIJ, 57.1-145.8) compared with 
51.2 (31.7-70.8) milyr in the low RSV group (z. 50% samples 
were RSV PCR positive, n= 56). The difference in rate of FEV, 
decline between these two groups was significant (p = 0.01; 
Figure 1). 
Of the 56 patients in the low RSV group, 20 (35.7%) were 
active smokers, and of the 18 patients in the high RSV group, 
4 (22.2%) were active smokers. If an adjustment for active smok- 
ing status was made in the analysis or the relationship between 
RSV detection and FEV, decline, there remained a significantly 
faster decline in the high RSV group by an additional 47.9 ml/yr 
(0. "7.8; p=0.019). The effect of smoking itself oil FEVI 
decline was not significant (p = 0.205) in this analysis. In a 
covariate analysis adjusting for any effects of exacerbation frc. 
qucncy on differences in rate of FEV, decline between RSV 
groups, there remained a faster decline in tile high RSV group 
by 50.6 mi/yr (p = 0.013). 
To ensure that variation in the number of samples obtained 
per patient did not affect the relationship between RSV detec- 
tion and lung function decline, a subgroup analysis of patients 
with the same number of sputum samples was made using the 
sample number of four per patient. The relationship between 
RSV detection and FEVI decline remained significant (p = 
0. (X)9), with a faster decline in FEVI of 52.2 (Cl, 13.3-91.3) ml/yr 
in the high RSV group subset. 
TABLE 2. CHARACTERISTICS OF THE 74 PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE AS CHARACTERIZED BY PATTERN OF RESPIRATORY SYNCYTIAL VIRUS DETECTION 
BY POLYMERASE CHAIN REACTION 
Low RSV Patients* (n - 56) 
Median IQR 
High RSV P 
Median 
atients* (n - 18) 
IQR 
P Value 
(Wilcoxon) 
Age, yr 67.4 61.7-71.8 68.7 62.2-71.7 0.748 
FEVI, L 0.95 0.77-1.37 1.09 0.73-1.38 0.735 
FEVI, % predicted 39.2 29.6-57.8 42.9 29.0-59.4 0.759 
FEVI, % reversibility 9.1 2.1-13.1 3.70 0.0-12.8 0.231 
FVC, L 2.37 1.68-2.90 2.60 2.00-3.28 0.297 
FEV, /FVC, % 44.1 35.5-53.1 41.3 26.9-54.7 0.696 
PEF, L/min 152 120-238 186 147-230 0.661 
Pao, kPa 9.00 8.13-9.62 8.47 8.27-9.22 0.387 
Paco, kPa 5.91 S. 32-6.311 5.81 5.32-6.11 0.713 
Smoking, yr 46 37-52 42.5 39-50 O. S53 
Inhaled corticosteroid dose, mg/dt 1000 500-1,800 1000 600-2,000 0.600 
Exacerbation frequency, per yr 2.40 1.32-3.87 2.76 1.04-3.37 0.821 
% % p Value XI Sex, males 60 60.8 0.976 
Chronic dyspnea 44.8 52.7 0.780 
Chronic wheeze 34.3 32.4 0.211 
Chronic cough 41.0 37.8 0.506 
Chronic sputum production 41.8 27.8 0.988 
History of smoking 98.2 100.0 0.568 
Smoking at recruitment 41.8 27.8 0.288 
For definition of abbreviation, see Table 1. 
* Low RSV defined as e. 50% of sputum samples were RSV polymerase chain reaction (PCR) negative, and high RSV as > 50% 
sputum samples were RSV PCR positive. 
I Beclomethasone equivalents. 
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Figure 1. Relationship between respiratory syncytial virus (RSV) detec- 
tion pattern and FEVI decline over study period. Heavy lines represent 
decline in FEVI with standard errors (SEs) for (1) low RSV (, c- 50% of 
sputum samples were RSV polymerase chain reaction [PCR] positive; 
n= 56; 51.2 ml/yr, SE, 10.1; confidence interval [CI], 31.7-70.8), 
intercept 0.97 (SE, 0.42; Cl, 0.90-1.05; continuous lines), and (2) high 
RSV (> 50% sputum samples, RSV PCR positive; n= 18; 101.4 ml/yr, 
SE, 0.017; Cl, 57.1-145.8), intercept 1.03 (SE, 0.08; Cl, 0.88-1.19; 
dashed lines). 
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Airway Bacteria and RSV 
Total bacterial load was available for 213 of tile 241 samples. 
The overall prevalence of bacterial pathogens (PPMs) was 
66.1 %. The mean (SD) airway bacterial load was greater in the 
high RSV patients (109.121(IA81 log cfu/ml), compared with low RSV 
patients (1()-'61("'Ilog cfu/ml; p=0.024). There was no significant 
association between the detection of RSV and isolation of indi- 
vidual PPMs, or with all potential pathogenic organisms as a 
group (p > 0.17 in all cases). 
Figure 2. Comparison of sputum interleukin 6 (IL-6; pg/ml), IL-8 (pgl 
ml), and myeloperoxiclase levels (ng/ml) for low RSV and high RSV 
patient groups (p < 0.001, for difference between groups In all cases 
using cross-sectional regression analysis assuming a Polsson distribution 
in the dependent variable to allow for repeated measures). Sputum IL-6 
(182 [178-185] and 253 1244-261 ] pg/ml), IL-8 (2,571 [2,558-2,585] 
and 3,229 [3,197-3,262) pg1ml), myeloperoxiclase (10.3 17.5-13.2] 
and 23.0 [16.7-29.3] ng/ml) for low RSV and high RSV patient groups, 
respectively. 
Airway Inflammatory Markers and RSV Persistence 
Detection of RSV was associated with higher levels of airway 
inflammation as measured by sputum IL, 6, IL-8, and MPO (p < 
(). (X)l in all cases). The relationships between RSV detection cite- 
gory and airway inflammatory markers are shown in Figure 2. 
Levels of individual airway inflammatory markers above the 
median Were associated with a trend to faster FEVI decline. 
Ifigh levels of IL-6 were associated with additional FEVI decline 
of 6.7 milyr (Cl, 1 U&-25.3), with high IL-8; 12.2 ml/yr (-6.4-30.9) 
and with high M PO 6.9 mllyr (8.3-22.1), but these did not reach 
significance (p > 0.18 in all cases). To determine if the association 
between RSV detection and lung function decline was indepen- 
dent of airway inflammation, inflammatory markers were in- 
cluded in tile model of analysis. The differences between FEVI 
decline in high and low RSV groups were not statistically inde- 
pendent of associations with airway inflammation. Additional 
decline in high RSV group with IL-6 as a covariate: 42.9 ml/yr 
(-12.6-98.4, p=0.13); for IL-8,39.9 mllyr (-16.0-95.9, p 
0.16); and for MPO, 28.0 mllyr (-23.8-79.8, p=0.29). 
Multivariate Analysis of RSV and Other Factors 
Affecting FEV, Decline 
After allowance for total bacterial load, smoking status, and 
starting FEVI, high RSV patients had an FEVI decline of 114.7 
MI/yr (95% Cl, 42.4-186.8) compared with the decline of 56.6 
MI/yr (26.2-87-0) seen in low RSV patients (p < 0.05 for the 
difference between the two groups). If the FEVI data were ex- 
pressed as a percentage of the predicted FEVI, high RSV patients 
had a significantly faster decline of 1.94%/yr (0.2-3.63) in addi- 
tion to the decline of 2.1 'Yo/yr (0.9-3.3) in low RSV patients (p = 
0.03). If exacerbation frequency was included in the multivariatc 
analysis, the faster decline in the high RSV group remained 
significant independent of any effects of exacerbations (19.3 [2-2- 
36.31 ml/yr, p=0.027). A multivariate analysis with airway 
inflammation (MPO), smoking status, starting FEV,, bacterial 
load, and exacerbation frequency revealed a nonsignificant find- 
ing of an additional 6.9-ml/yr FEVI decline (-15.4-29.2, p 
0.545) relative to the low RSV group. 
DISCUSSION 
This is the first longitudinal prospective study to investigate the 
role that RSV may play in the etiology and progression of stable 
COPD. We show that RSV RNA can be detected in the sputum 
of many patients with COPD in the stable state, and its detection 
is associated with higher levels of airway inflammation, greater 
airway bacterial loads, and an accelerated decline in lung 
function. 
RSV is an established cause of acute respiratory illness in 
children, and RSV bronchiolitis is associated with the develop- 
ment of persistent wheeze in later childhood (22); however, it 
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is not clear whether this association is causal. The role of viral 
infection in the etiology of airway obstruction in adults is even 
less well established. In a different setting, Retamales and col- 
leagues reported that adenovirus EI A Protein was expressed in 
respiratory epithelial cells in patients with emphysema, and that 
the quantity of EI A expression correlated with disease severity 
and inflammatory cell numbers (5). However, to date, longitudi- 
nal studies to determine the role of latent viral infection in 
COPD disease progression have been lacking. The data from 
this study suggest that RSV may play a role in the pathogenesis 
of airway inflammation and subsequent deterioration in lung 
function in adults with COPD. 
Persistent RSV infection is well known in children with T- 
cell immunodeficiency, and has been demonstrated in the lungs 
of guinea pigs (23) and mice (24) for up to 150 d after experimental 
infection. In these animal models, RSV persistence was associated 
with continued infectivity and chronic airway inflammation despite 
an appropriate systemic humoral (23,24) and T-cellular immune 
response (24). 
In both acute and chronic models of infection, the key sites 
for RSV-induced inflammation in the lung are the small airways, 
in which epithelia] damage and increased mucous production 
result in small airway obstruction and hyperinflation (25). It is 
of note that the small airways are also the primary Site for 
the persisting inflammation and airway obstruction, which are 
characteristic of COPD (26,27). Biopsies of subjects with COPD 
have demonstrated that the small airways are infiltrated with 
inflammatory cells, in particular CDS' cells, neutrophils, and 
airway macrophages (27,28). In particular, the presence of CD8' 
T cells and B lymphocytes organizing into follicles was associated 
with disease progression (27). The findings of this study may sug- 
gcst CD8-'T-cell populations, characteristic of COPD airway biop- 
sies, may be, recruited to the lung due to persistent viral infection, 
but an impaired immune response that is incapable of eliminating 
virus infection permits ongoing replication at low levels. 
RSV detection was associated with heightened airway in- 
flammation in terms of increased levels of IL-6, IL-8, and MPO. 
it is possible that RSV has direct proinflammatory effects on 
the airway, which may contribute to faster decline in lung func- 
tion. The observed association between RSV detection and FEVI 
decline remained significant if possible confounders such as air- 
way bacterial load, exacerbation frequency, smoking status, and 
baseline FEV, were included in the analysis. However, if airway 
inflammation was included in the covariate or multivariate 
model, no sipificant effect of RSV on lung function independent 
of airway inflammation was seen. One explanation is that RSV, 
inflammation, and decline are causally linked; however, it is 
also possible that inflammation predisposes the airway to viral 
persistence and that RSV detection is therefore an epiphenome- 
non. The direct relationship between airway inflammation and 
lung function decline was not significant in this analysis. This 
may be due to other noninflammatory processes such as airway 
remodeling (27) and effects on cellular apoptosis (29) or via 
other arms of the inflammatory cascade (30). Ilowevcr, over a 
longer follow-up period in a similar patient population, direct 
relationships between lung function decline and airway inflam- 
mation have been demonstrated (4), and therefore a similar 
relationship may have been found with prolongation of the follow- 
up period of this study. An alternative explanation of our findings 
is that patients with more aggressive COPD and faster disease 
progression have impaired acquired Or innate immune responses, 
allowing RSV to persist. To determine the causal role of RSV 
infection, one would need to attempt to eradicate RSV with 
vaccines or antiviral drugs now under development. 
Although RSV may have proinflammatory effects, it is also 
possible that it acts by modulating the response of lung cells to 
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other inflammatory stimuli, including bacteria] lipopolysaccha- 
ride (31), or by promoting neutrophil adhesion, thereby aug- 
menting lung damage (32). Bacterial colonization of the lower 
airway in patients with COPD is well described (2,3,33,34) 
and provides a stimulus to airway inflammation and disease 
progression (2). The additional presence of RSV in the lower 
airway may augment bacterially driven inflammation. It is also 
possible that chronic viral infection of the lower airway occurs 
due to increased susceptibility in individuals with existing bactc- 
rial colonization, although we found no direct association be- 
tween the isolation of PPMs and detection of RSV. It is feasible 
therefore (hat eradication of airway bacteria may result in local 
repair and improvement of local defenses against viral persistence. 
The relative importance of airway bacterial infection in 
COPD has been shown to increase with disease severity (34). 
This study was performed with a group of patients with moderate 
to severe disease and therefore the findings that RSV can be 
detected and is associated with accelerated disease progression 
in this population may not necessarily be extrapolated to patients 
with milder disease. Further studies across the full spectrum of 
disease as well as in smoking and nonsmoking control subjects 
are required to better understand the role of this pathogen in 
adults. 
The use of sputum to detect the presence of RSV in the 
stable state allows repeated sampling of patients with advanced 
disease, which alternative techniques, such as bronchoscopic 
sampling, do not manage. The use of sputum sampling in a 
longitudinal cohort study inevitably results in a variable number 
of samples obtained per patient, and this problem is further 
compounded by the use of quality control in processing to ex- 
clude inadequate samples. However. this quality-confrol step 
is a vital one, because variations in sampling methodology are 
likely to be responsible for the differences in detection of RSV 
in patients with stable COPD seen in one study to the next (13, 
35). Although PCR detection assays may appear, on paper. to 
be highly sensitive, it is apparent that the type of biological 
sample taken (sputum rather than swab), the rapidity of sample 
processing and storage, and the nucleic acid extraction tech. 
niques used all impact on the likelihood of detection of RSV 
RNA by PCR (35). 
The use of highly sensitive PCR assays may detect viral nu- 
cleic acids; however, this does equate to detection of intact and 
pathogenic virus. Furthermore, our PCR technique did not dis- 
tinguish between RSV type in this study and it is not known 
whether the virus isolated from an individual is genetically stable 
and representative of chronic infection rather than recurrent 
reinfection. Further studies arc required to confirm the exact 
nature of viral persistence in the lower airway of patients with 
COPD. 
This study did not examine the detection rates for RSV among 
normal control subjects, but the PCR detection techniques used 
in this study have also been used previously. In a number of 
there other studies, healthy control groups have been studied 
and low detection rates have been found. Indeed, we have stud- 
ied adult control groups in two recent studies; the detection rates 
for RSV in both of these was zero (36,37), suggesting that RSV 
detection in the stable state may be a factor in patients with 
moderate to severe COPD, but not in healthy control subjects. 
In conclusion, we have shown that RSV RNA can be detected 
from lower airway samples of some patients with COPD in 
the stable state, with evidence of Persistent detection in certain 
individuals. RSV RNA detection was associated with greater 
airway inflammation and accelerated disease progression in 
these patients. These findings suggest that RSV may play a Tole 
in the natural history of stable COPD. I lowevcr, further investi- 
gation into the nature and consequences of viral persistence are 
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required to confirm whether RSV is a potential therapeutic tar- 
get in this important patient group. 
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